Datasets:
bio-datasets
/
bigbio-ner-merged

Dataset card Data Studio Files
xet
Community
answer
stringlengths
1
16.1k
id
stringlengths
7
56
instruction
stringlengths
106
72.6k
ner_tags
list
text
stringlengths
5
72.4k
tokens
list
types
list
Zementpenetration is an umlsterm, Femur is an umlsterm, Praeparationstechnik is an umlsterm, Knochenlagerspuelung is an umlsterm, Blasenspritze is an umlsterm, Zementapplikation is an umlsterm, Druckzementierung is an umlsterm, Prothesentypen is an umlsterm, Bildanalyse is an umlsterm, Zementapplikation is an umlsterm, Druckbeaufschlagung is an umlsterm, Zements is an umlsterm, Blasenspritze is an umlsterm, Knochenzements is an umlsterm, Verwendung is an umlsterm, Druckzementierung is an umlsterm, Blasenspritzenspuelung is an umlsterm, Prothesentyp is an umlsterm, Verwendung is an umlsterm, Knochenzement is an umlsterm, Knochenlager is an umlsterm, Druckzementierung is an umlsterm, Zementverzahnung is an umlsterm, Komplikationen is an umlsterm
DerOrthopaede.00290260.ger.abstr_task0
Sentence: Das Ziel dieser Studie war zu untersuchen , inwieweit unterschiedliche Zementiertechniken Einfluss auf die Zementpenetration in das spongioese Lager am koxalen Femur haben . An 60 linken humanen Leichenfemora wurden mit standardisierter Praeparationstechnik zementierte Femurkomponenten implantiert . Vier verschiedene Zementiergruppen wurden randomisiert . Je nach Gruppe erfolgte die Knochenlagerspuelung mit Jetlavage oder Blasenspritze , sowie die Zementapplikation mit oder ohne Druckzementierung ( " pressurising " ) ; 5 verschiedene Prothesentypen wurden implantiert . Alle Praeparate wurden in 2 Ebenen geroentgt und in 2-cm-Abstaenden horizontale Saegeschnitte angefertigt . Von den Schnitten wurden Mikroradiogramme erstellt und diese hinsichtlich unterschiedlicher Penetrationstiefe mittels Bildanalyse morphometrisch ausgewertet . In einer Zusatzstudie ohne Stielimplantation erfolgte standardisiert an 11 humanen Femurpaaren nach retrograder Zementapplikation die Druckbeaufschlagung des Zements mit einer konstanten Kraft von 3000 N. Dabei unterschieden sich die praeparierten Femurpaare lediglich hinsichtlich Spuelart ( 1000 ml Jetlavage vs. 1000 ml Blasenspritze ) . Die Auswertung wurde analog zum Hauptversuch durchgefuehrt . Den groessten Einfluss auf die Penetrationstiefe des Knochenzements in die Spongiosa hatten im Hauptversuch die Verwendung der Jetlavage ( p = 0,027 ) und die Druckzementierung ( p = 0,003 ) . Bei dichter Spongiosa war der Unterschied zwischen Jetlavage und Blasenspritzenspuelung staerker ausgepraegt . Im Zusatzversuch zeigte die Jetlavage ebenfalls eine signifikante Verbesserung der Penetrationstiefe ( p 0,001 ) . Unterschiede in Abhaengigkeit vom Prothesentyp konnten nicht nachgewiesen werden . Die Verwendung der Jetlavage hat wesentlichen Einfluss auf die Penetrationstiefe von Knochenzement in das Knochenlager und sollte in der zementierten Hueftendoprothetik als unverzichtbar angesehen werden . Die Druckzementierung fuehrt ebenfalls zu verbesserter Zementverzahnung , sollte jedoch im Hinblick auf moegliche Knochenmarksausschwemmungen und resultierende thromboembolische Komplikationen nur in Kombination mit der Jetlavage angewandt werden . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Das Ziel dieser Studie war zu untersuchen , inwieweit unterschiedliche Zementiertechniken Einfluss auf die Zementpenetration in das spongioese Lager am koxalen Femur haben . An 60 linken humanen Leichenfemora wurden mit standardisierter Praeparationstechnik zementierte Femurkomponenten implantiert . Vier verschiedene Zementiergruppen wurden randomisiert . Je nach Gruppe erfolgte die Knochenlagerspuelung mit Jetlavage oder Blasenspritze , sowie die Zementapplikation mit oder ohne Druckzementierung ( " pressurising " ) ; 5 verschiedene Prothesentypen wurden implantiert . Alle Praeparate wurden in 2 Ebenen geroentgt und in 2-cm-Abstaenden horizontale Saegeschnitte angefertigt . Von den Schnitten wurden Mikroradiogramme erstellt und diese hinsichtlich unterschiedlicher Penetrationstiefe mittels Bildanalyse morphometrisch ausgewertet . In einer Zusatzstudie ohne Stielimplantation erfolgte standardisiert an 11 humanen Femurpaaren nach retrograder Zementapplikation die Druckbeaufschlagung des Zements mit einer konstanten Kraft von 3000 N. Dabei unterschieden sich die praeparierten Femurpaare lediglich hinsichtlich Spuelart ( 1000 ml Jetlavage vs. 1000 ml Blasenspritze ) . Die Auswertung wurde analog zum Hauptversuch durchgefuehrt . Den groessten Einfluss auf die Penetrationstiefe des Knochenzements in die Spongiosa hatten im Hauptversuch die Verwendung der Jetlavage ( p = 0,027 ) und die Druckzementierung ( p = 0,003 ) . Bei dichter Spongiosa war der Unterschied zwischen Jetlavage und Blasenspritzenspuelung staerker ausgepraegt . Im Zusatzversuch zeigte die Jetlavage ebenfalls eine signifikante Verbesserung der Penetrationstiefe ( p 0,001 ) . Unterschiede in Abhaengigkeit vom Prothesentyp konnten nicht nachgewiesen werden . Die Verwendung der Jetlavage hat wesentlichen Einfluss auf die Penetrationstiefe von Knochenzement in das Knochenlager und sollte in der zementierten Hueftendoprothetik als unverzichtbar angesehen werden . Die Druckzementierung fuehrt ebenfalls zu verbesserter Zementverzahnung , sollte jedoch im Hinblick auf moegliche Knochenmarksausschwemmungen und resultierende thromboembolische Komplikationen nur in Kombination mit der Jetlavage angewandt werden .
[ "Das", "Ziel", "dieser", "Studie", "war", "zu", "untersuchen", ",", "inwieweit", "unterschiedliche", "Zementiertechniken", "Einfluss", "auf", "die", "Zementpenetration", "in", "das", "spongioese", "Lager", "am", "koxalen", "Femur", "haben", ".", "An", "60", "linken", "humanen", "Leichenfemora", "wurden", "mit", "standardisierter", "Praeparationstechnik", "zementierte", "Femurkomponenten", "implantiert", ".", "Vier", "verschiedene", "Zementiergruppen", "wurden", "randomisiert", ".", "Je", "nach", "Gruppe", "erfolgte", "die", "Knochenlagerspuelung", "mit", "Jetlavage", "oder", "Blasenspritze", ",", "sowie", "die", "Zementapplikation", "mit", "oder", "ohne", "Druckzementierung", "(", "\"", "pressurising", "\"", ")", ";", "5", "verschiedene", "Prothesentypen", "wurden", "implantiert", ".", "Alle", "Praeparate", "wurden", "in", "2", "Ebenen", "geroentgt", "und", "in", "2-cm", "-", "Abstaenden", "horizontale", "Saegeschnitte", "angefertigt", ".", "Von", "den", "Schnitten", "wurden", "Mikroradiogramme", "erstellt", "und", "diese", "hinsichtlich", "unterschiedlicher", "Penetrationstiefe", "mittels", "Bildanalyse", "morphometrisch", "ausgewertet", ".", "In", "einer", "Zusatzstudie", "ohne", "Stielimplantation", "erfolgte", "standardisiert", "an", "11", "humanen", "Femurpaaren", "nach", "retrograder", "Zementapplikation", "die", "Druckbeaufschlagung", "des", "Zements", "mit", "einer", "konstanten", "Kraft", "von", "3000", "N.", "Dabei", "unterschieden", "sich", "die", "praeparierten", "Femurpaare", "lediglich", "hinsichtlich", "Spuelart", "(", "1000", "ml", "Jetlavage", "vs", ".", "1000", "ml", "Blasenspritze", ")", ".", "Die", "Auswertung", "wurde", "analog", "zum", "Hauptversuch", "durchgefuehrt", ".", "Den", "groessten", "Einfluss", "auf", "die", "Penetrationstiefe", "des", "Knochenzements", "in", "die", "Spongiosa", "hatten", "im", "Hauptversuch", "die", "Verwendung", "der", "Jetlavage", "(", "p", "=", "0,027", ")", "und", "die", "Druckzementierung", "(", "p", "=", "0,003", ")", ".", "Bei", "dichter", "Spongiosa", "war", "der", "Unterschied", "zwischen", "Jetlavage", "und", "Blasenspritzenspuelung", "staerker", "ausgepraegt", ".", "Im", "Zusatzversuch", "zeigte", "die", "Jetlavage", "ebenfalls", "eine", "signifikante", "Verbesserung", "der", "Penetrationstiefe", "(", "p", "0,001", ")", ".", "Unterschiede", "in", "Abhaengigkeit", "vom", "Prothesentyp", "konnten", "nicht", "nachgewiesen", "werden", ".", "Die", "Verwendung", "der", "Jetlavage", "hat", "wesentlichen", "Einfluss", "auf", "die", "Penetrationstiefe", "von", "Knochenzement", "in", "das", "Knochenlager", "und", "sollte", "in", "der", "zementierten", "Hueftendoprothetik", "als", "unverzichtbar", "angesehen", "werden", ".", "Die", "Druckzementierung", "fuehrt", "ebenfalls", "zu", "verbesserter", "Zementverzahnung", ",", "sollte", "jedoch", "im", "Hinblick", "auf", "moegliche", "Knochenmarksausschwemmungen", "und", "resultierende", "thromboembolische", "Komplikationen", "nur", "in", "Kombination", "mit", "der", "Jetlavage", "angewandt", "werden", "." ]
[ "umlsterm" ]
Zementpenetration is an umlsterm, Femur is an umlsterm, Praeparationstechnik is an umlsterm, Knochenlagerspuelung is an umlsterm, Blasenspritze is an umlsterm, Zementapplikation is an umlsterm, Druckzementierung is an umlsterm, Prothesentypen is an umlsterm, Bildanalyse is an umlsterm, Zementapplikation is an umlsterm, Druckbeaufschlagung is an umlsterm, Zements is an umlsterm, Blasenspritze is an umlsterm, Knochenzements is an umlsterm, Verwendung is an umlsterm, Druckzementierung is an umlsterm, Blasenspritzenspuelung is an umlsterm, Prothesentyp is an umlsterm, Verwendung is an umlsterm, Knochenzement is an umlsterm, Knochenlager is an umlsterm, Druckzementierung is an umlsterm, Zementverzahnung is an umlsterm, Komplikationen is an umlsterm
DerOrthopaede.00290260.ger.abstr_task1
Sentence: Das Ziel dieser Studie war zu untersuchen , inwieweit unterschiedliche Zementiertechniken Einfluss auf die Zementpenetration in das spongioese Lager am koxalen Femur haben . An 60 linken humanen Leichenfemora wurden mit standardisierter Praeparationstechnik zementierte Femurkomponenten implantiert . Vier verschiedene Zementiergruppen wurden randomisiert . Je nach Gruppe erfolgte die Knochenlagerspuelung mit Jetlavage oder Blasenspritze , sowie die Zementapplikation mit oder ohne Druckzementierung ( " pressurising " ) ; 5 verschiedene Prothesentypen wurden implantiert . Alle Praeparate wurden in 2 Ebenen geroentgt und in 2-cm-Abstaenden horizontale Saegeschnitte angefertigt . Von den Schnitten wurden Mikroradiogramme erstellt und diese hinsichtlich unterschiedlicher Penetrationstiefe mittels Bildanalyse morphometrisch ausgewertet . In einer Zusatzstudie ohne Stielimplantation erfolgte standardisiert an 11 humanen Femurpaaren nach retrograder Zementapplikation die Druckbeaufschlagung des Zements mit einer konstanten Kraft von 3000 N. Dabei unterschieden sich die praeparierten Femurpaare lediglich hinsichtlich Spuelart ( 1000 ml Jetlavage vs. 1000 ml Blasenspritze ) . Die Auswertung wurde analog zum Hauptversuch durchgefuehrt . Den groessten Einfluss auf die Penetrationstiefe des Knochenzements in die Spongiosa hatten im Hauptversuch die Verwendung der Jetlavage ( p = 0,027 ) und die Druckzementierung ( p = 0,003 ) . Bei dichter Spongiosa war der Unterschied zwischen Jetlavage und Blasenspritzenspuelung staerker ausgepraegt . Im Zusatzversuch zeigte die Jetlavage ebenfalls eine signifikante Verbesserung der Penetrationstiefe ( p 0,001 ) . Unterschiede in Abhaengigkeit vom Prothesentyp konnten nicht nachgewiesen werden . Die Verwendung der Jetlavage hat wesentlichen Einfluss auf die Penetrationstiefe von Knochenzement in das Knochenlager und sollte in der zementierten Hueftendoprothetik als unverzichtbar angesehen werden . Die Druckzementierung fuehrt ebenfalls zu verbesserter Zementverzahnung , sollte jedoch im Hinblick auf moegliche Knochenmarksausschwemmungen und resultierende thromboembolische Komplikationen nur in Kombination mit der Jetlavage angewandt werden . Instructions: please typing these entity words according to sentence: Zementpenetration, Femur, Praeparationstechnik, Knochenlagerspuelung, Blasenspritze, Zementapplikation, Druckzementierung, Prothesentypen, Bildanalyse, Zementapplikation, Druckbeaufschlagung, Zements, Blasenspritze, Knochenzements, Verwendung, Druckzementierung, Blasenspritzenspuelung, Prothesentyp, Verwendung, Knochenzement, Knochenlager, Druckzementierung, Zementverzahnung, Komplikationen Options: umlsterm
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Das Ziel dieser Studie war zu untersuchen , inwieweit unterschiedliche Zementiertechniken Einfluss auf die Zementpenetration in das spongioese Lager am koxalen Femur haben . An 60 linken humanen Leichenfemora wurden mit standardisierter Praeparationstechnik zementierte Femurkomponenten implantiert . Vier verschiedene Zementiergruppen wurden randomisiert . Je nach Gruppe erfolgte die Knochenlagerspuelung mit Jetlavage oder Blasenspritze , sowie die Zementapplikation mit oder ohne Druckzementierung ( " pressurising " ) ; 5 verschiedene Prothesentypen wurden implantiert . Alle Praeparate wurden in 2 Ebenen geroentgt und in 2-cm-Abstaenden horizontale Saegeschnitte angefertigt . Von den Schnitten wurden Mikroradiogramme erstellt und diese hinsichtlich unterschiedlicher Penetrationstiefe mittels Bildanalyse morphometrisch ausgewertet . In einer Zusatzstudie ohne Stielimplantation erfolgte standardisiert an 11 humanen Femurpaaren nach retrograder Zementapplikation die Druckbeaufschlagung des Zements mit einer konstanten Kraft von 3000 N. Dabei unterschieden sich die praeparierten Femurpaare lediglich hinsichtlich Spuelart ( 1000 ml Jetlavage vs. 1000 ml Blasenspritze ) . Die Auswertung wurde analog zum Hauptversuch durchgefuehrt . Den groessten Einfluss auf die Penetrationstiefe des Knochenzements in die Spongiosa hatten im Hauptversuch die Verwendung der Jetlavage ( p = 0,027 ) und die Druckzementierung ( p = 0,003 ) . Bei dichter Spongiosa war der Unterschied zwischen Jetlavage und Blasenspritzenspuelung staerker ausgepraegt . Im Zusatzversuch zeigte die Jetlavage ebenfalls eine signifikante Verbesserung der Penetrationstiefe ( p 0,001 ) . Unterschiede in Abhaengigkeit vom Prothesentyp konnten nicht nachgewiesen werden . Die Verwendung der Jetlavage hat wesentlichen Einfluss auf die Penetrationstiefe von Knochenzement in das Knochenlager und sollte in der zementierten Hueftendoprothetik als unverzichtbar angesehen werden . Die Druckzementierung fuehrt ebenfalls zu verbesserter Zementverzahnung , sollte jedoch im Hinblick auf moegliche Knochenmarksausschwemmungen und resultierende thromboembolische Komplikationen nur in Kombination mit der Jetlavage angewandt werden .
[ "Das", "Ziel", "dieser", "Studie", "war", "zu", "untersuchen", ",", "inwieweit", "unterschiedliche", "Zementiertechniken", "Einfluss", "auf", "die", "Zementpenetration", "in", "das", "spongioese", "Lager", "am", "koxalen", "Femur", "haben", ".", "An", "60", "linken", "humanen", "Leichenfemora", "wurden", "mit", "standardisierter", "Praeparationstechnik", "zementierte", "Femurkomponenten", "implantiert", ".", "Vier", "verschiedene", "Zementiergruppen", "wurden", "randomisiert", ".", "Je", "nach", "Gruppe", "erfolgte", "die", "Knochenlagerspuelung", "mit", "Jetlavage", "oder", "Blasenspritze", ",", "sowie", "die", "Zementapplikation", "mit", "oder", "ohne", "Druckzementierung", "(", "\"", "pressurising", "\"", ")", ";", "5", "verschiedene", "Prothesentypen", "wurden", "implantiert", ".", "Alle", "Praeparate", "wurden", "in", "2", "Ebenen", "geroentgt", "und", "in", "2-cm", "-", "Abstaenden", "horizontale", "Saegeschnitte", "angefertigt", ".", "Von", "den", "Schnitten", "wurden", "Mikroradiogramme", "erstellt", "und", "diese", "hinsichtlich", "unterschiedlicher", "Penetrationstiefe", "mittels", "Bildanalyse", "morphometrisch", "ausgewertet", ".", "In", "einer", "Zusatzstudie", "ohne", "Stielimplantation", "erfolgte", "standardisiert", "an", "11", "humanen", "Femurpaaren", "nach", "retrograder", "Zementapplikation", "die", "Druckbeaufschlagung", "des", "Zements", "mit", "einer", "konstanten", "Kraft", "von", "3000", "N.", "Dabei", "unterschieden", "sich", "die", "praeparierten", "Femurpaare", "lediglich", "hinsichtlich", "Spuelart", "(", "1000", "ml", "Jetlavage", "vs", ".", "1000", "ml", "Blasenspritze", ")", ".", "Die", "Auswertung", "wurde", "analog", "zum", "Hauptversuch", "durchgefuehrt", ".", "Den", "groessten", "Einfluss", "auf", "die", "Penetrationstiefe", "des", "Knochenzements", "in", "die", "Spongiosa", "hatten", "im", "Hauptversuch", "die", "Verwendung", "der", "Jetlavage", "(", "p", "=", "0,027", ")", "und", "die", "Druckzementierung", "(", "p", "=", "0,003", ")", ".", "Bei", "dichter", "Spongiosa", "war", "der", "Unterschied", "zwischen", "Jetlavage", "und", "Blasenspritzenspuelung", "staerker", "ausgepraegt", ".", "Im", "Zusatzversuch", "zeigte", "die", "Jetlavage", "ebenfalls", "eine", "signifikante", "Verbesserung", "der", "Penetrationstiefe", "(", "p", "0,001", ")", ".", "Unterschiede", "in", "Abhaengigkeit", "vom", "Prothesentyp", "konnten", "nicht", "nachgewiesen", "werden", ".", "Die", "Verwendung", "der", "Jetlavage", "hat", "wesentlichen", "Einfluss", "auf", "die", "Penetrationstiefe", "von", "Knochenzement", "in", "das", "Knochenlager", "und", "sollte", "in", "der", "zementierten", "Hueftendoprothetik", "als", "unverzichtbar", "angesehen", "werden", ".", "Die", "Druckzementierung", "fuehrt", "ebenfalls", "zu", "verbesserter", "Zementverzahnung", ",", "sollte", "jedoch", "im", "Hinblick", "auf", "moegliche", "Knochenmarksausschwemmungen", "und", "resultierende", "thromboembolische", "Komplikationen", "nur", "in", "Kombination", "mit", "der", "Jetlavage", "angewandt", "werden", "." ]
[ "umlsterm" ]
Zementpenetration, Femur, Praeparationstechnik, Knochenlagerspuelung, Blasenspritze, Zementapplikation, Druckzementierung, Prothesentypen, Bildanalyse, Zementapplikation, Druckbeaufschlagung, Zements, Blasenspritze, Knochenzements, Verwendung, Druckzementierung, Blasenspritzenspuelung, Prothesentyp, Verwendung, Knochenzement, Knochenlager, Druckzementierung, Zementverzahnung, Komplikationen
DerOrthopaede.00290260.ger.abstr_task2
Sentence: Das Ziel dieser Studie war zu untersuchen , inwieweit unterschiedliche Zementiertechniken Einfluss auf die Zementpenetration in das spongioese Lager am koxalen Femur haben . An 60 linken humanen Leichenfemora wurden mit standardisierter Praeparationstechnik zementierte Femurkomponenten implantiert . Vier verschiedene Zementiergruppen wurden randomisiert . Je nach Gruppe erfolgte die Knochenlagerspuelung mit Jetlavage oder Blasenspritze , sowie die Zementapplikation mit oder ohne Druckzementierung ( " pressurising " ) ; 5 verschiedene Prothesentypen wurden implantiert . Alle Praeparate wurden in 2 Ebenen geroentgt und in 2-cm-Abstaenden horizontale Saegeschnitte angefertigt . Von den Schnitten wurden Mikroradiogramme erstellt und diese hinsichtlich unterschiedlicher Penetrationstiefe mittels Bildanalyse morphometrisch ausgewertet . In einer Zusatzstudie ohne Stielimplantation erfolgte standardisiert an 11 humanen Femurpaaren nach retrograder Zementapplikation die Druckbeaufschlagung des Zements mit einer konstanten Kraft von 3000 N. Dabei unterschieden sich die praeparierten Femurpaare lediglich hinsichtlich Spuelart ( 1000 ml Jetlavage vs. 1000 ml Blasenspritze ) . Die Auswertung wurde analog zum Hauptversuch durchgefuehrt . Den groessten Einfluss auf die Penetrationstiefe des Knochenzements in die Spongiosa hatten im Hauptversuch die Verwendung der Jetlavage ( p = 0,027 ) und die Druckzementierung ( p = 0,003 ) . Bei dichter Spongiosa war der Unterschied zwischen Jetlavage und Blasenspritzenspuelung staerker ausgepraegt . Im Zusatzversuch zeigte die Jetlavage ebenfalls eine signifikante Verbesserung der Penetrationstiefe ( p 0,001 ) . Unterschiede in Abhaengigkeit vom Prothesentyp konnten nicht nachgewiesen werden . Die Verwendung der Jetlavage hat wesentlichen Einfluss auf die Penetrationstiefe von Knochenzement in das Knochenlager und sollte in der zementierten Hueftendoprothetik als unverzichtbar angesehen werden . Die Druckzementierung fuehrt ebenfalls zu verbesserter Zementverzahnung , sollte jedoch im Hinblick auf moegliche Knochenmarksausschwemmungen und resultierende thromboembolische Komplikationen nur in Kombination mit der Jetlavage angewandt werden . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Das Ziel dieser Studie war zu untersuchen , inwieweit unterschiedliche Zementiertechniken Einfluss auf die Zementpenetration in das spongioese Lager am koxalen Femur haben . An 60 linken humanen Leichenfemora wurden mit standardisierter Praeparationstechnik zementierte Femurkomponenten implantiert . Vier verschiedene Zementiergruppen wurden randomisiert . Je nach Gruppe erfolgte die Knochenlagerspuelung mit Jetlavage oder Blasenspritze , sowie die Zementapplikation mit oder ohne Druckzementierung ( " pressurising " ) ; 5 verschiedene Prothesentypen wurden implantiert . Alle Praeparate wurden in 2 Ebenen geroentgt und in 2-cm-Abstaenden horizontale Saegeschnitte angefertigt . Von den Schnitten wurden Mikroradiogramme erstellt und diese hinsichtlich unterschiedlicher Penetrationstiefe mittels Bildanalyse morphometrisch ausgewertet . In einer Zusatzstudie ohne Stielimplantation erfolgte standardisiert an 11 humanen Femurpaaren nach retrograder Zementapplikation die Druckbeaufschlagung des Zements mit einer konstanten Kraft von 3000 N. Dabei unterschieden sich die praeparierten Femurpaare lediglich hinsichtlich Spuelart ( 1000 ml Jetlavage vs. 1000 ml Blasenspritze ) . Die Auswertung wurde analog zum Hauptversuch durchgefuehrt . Den groessten Einfluss auf die Penetrationstiefe des Knochenzements in die Spongiosa hatten im Hauptversuch die Verwendung der Jetlavage ( p = 0,027 ) und die Druckzementierung ( p = 0,003 ) . Bei dichter Spongiosa war der Unterschied zwischen Jetlavage und Blasenspritzenspuelung staerker ausgepraegt . Im Zusatzversuch zeigte die Jetlavage ebenfalls eine signifikante Verbesserung der Penetrationstiefe ( p 0,001 ) . Unterschiede in Abhaengigkeit vom Prothesentyp konnten nicht nachgewiesen werden . Die Verwendung der Jetlavage hat wesentlichen Einfluss auf die Penetrationstiefe von Knochenzement in das Knochenlager und sollte in der zementierten Hueftendoprothetik als unverzichtbar angesehen werden . Die Druckzementierung fuehrt ebenfalls zu verbesserter Zementverzahnung , sollte jedoch im Hinblick auf moegliche Knochenmarksausschwemmungen und resultierende thromboembolische Komplikationen nur in Kombination mit der Jetlavage angewandt werden .
[ "Das", "Ziel", "dieser", "Studie", "war", "zu", "untersuchen", ",", "inwieweit", "unterschiedliche", "Zementiertechniken", "Einfluss", "auf", "die", "Zementpenetration", "in", "das", "spongioese", "Lager", "am", "koxalen", "Femur", "haben", ".", "An", "60", "linken", "humanen", "Leichenfemora", "wurden", "mit", "standardisierter", "Praeparationstechnik", "zementierte", "Femurkomponenten", "implantiert", ".", "Vier", "verschiedene", "Zementiergruppen", "wurden", "randomisiert", ".", "Je", "nach", "Gruppe", "erfolgte", "die", "Knochenlagerspuelung", "mit", "Jetlavage", "oder", "Blasenspritze", ",", "sowie", "die", "Zementapplikation", "mit", "oder", "ohne", "Druckzementierung", "(", "\"", "pressurising", "\"", ")", ";", "5", "verschiedene", "Prothesentypen", "wurden", "implantiert", ".", "Alle", "Praeparate", "wurden", "in", "2", "Ebenen", "geroentgt", "und", "in", "2-cm", "-", "Abstaenden", "horizontale", "Saegeschnitte", "angefertigt", ".", "Von", "den", "Schnitten", "wurden", "Mikroradiogramme", "erstellt", "und", "diese", "hinsichtlich", "unterschiedlicher", "Penetrationstiefe", "mittels", "Bildanalyse", "morphometrisch", "ausgewertet", ".", "In", "einer", "Zusatzstudie", "ohne", "Stielimplantation", "erfolgte", "standardisiert", "an", "11", "humanen", "Femurpaaren", "nach", "retrograder", "Zementapplikation", "die", "Druckbeaufschlagung", "des", "Zements", "mit", "einer", "konstanten", "Kraft", "von", "3000", "N.", "Dabei", "unterschieden", "sich", "die", "praeparierten", "Femurpaare", "lediglich", "hinsichtlich", "Spuelart", "(", "1000", "ml", "Jetlavage", "vs", ".", "1000", "ml", "Blasenspritze", ")", ".", "Die", "Auswertung", "wurde", "analog", "zum", "Hauptversuch", "durchgefuehrt", ".", "Den", "groessten", "Einfluss", "auf", "die", "Penetrationstiefe", "des", "Knochenzements", "in", "die", "Spongiosa", "hatten", "im", "Hauptversuch", "die", "Verwendung", "der", "Jetlavage", "(", "p", "=", "0,027", ")", "und", "die", "Druckzementierung", "(", "p", "=", "0,003", ")", ".", "Bei", "dichter", "Spongiosa", "war", "der", "Unterschied", "zwischen", "Jetlavage", "und", "Blasenspritzenspuelung", "staerker", "ausgepraegt", ".", "Im", "Zusatzversuch", "zeigte", "die", "Jetlavage", "ebenfalls", "eine", "signifikante", "Verbesserung", "der", "Penetrationstiefe", "(", "p", "0,001", ")", ".", "Unterschiede", "in", "Abhaengigkeit", "vom", "Prothesentyp", "konnten", "nicht", "nachgewiesen", "werden", ".", "Die", "Verwendung", "der", "Jetlavage", "hat", "wesentlichen", "Einfluss", "auf", "die", "Penetrationstiefe", "von", "Knochenzement", "in", "das", "Knochenlager", "und", "sollte", "in", "der", "zementierten", "Hueftendoprothetik", "als", "unverzichtbar", "angesehen", "werden", ".", "Die", "Druckzementierung", "fuehrt", "ebenfalls", "zu", "verbesserter", "Zementverzahnung", ",", "sollte", "jedoch", "im", "Hinblick", "auf", "moegliche", "Knochenmarksausschwemmungen", "und", "resultierende", "thromboembolische", "Komplikationen", "nur", "in", "Kombination", "mit", "der", "Jetlavage", "angewandt", "werden", "." ]
[ "umlsterm" ]
patients is an umlsterm, gastroesophageal reflux disease is an umlsterm, fundoplication is an umlsterm, Dysphagia is an umlsterm, belch is an umlsterm, gas is an umlsterm, syndrome is an umlsterm, sequelae is an umlsterm, fundoplication is an umlsterm, frequency is an umlsterm, symptoms is an umlsterm, fundoplication is an umlsterm, Nissen fundoplication is an umlsterm, gastric fundus is an umlsterm, procedure is an umlsterm, displacement is an umlsterm, reoperation is an umlsterm, fundoplication is an umlsterm, gastroesophageal reflux disease is an umlsterm, hiatal hernia is an umlsterm, esophageal is an umlsterm, esophageal motility disorders is an umlsterm, anatomic is an umlsterm, abnormalities is an umlsterm, endoscopy is an umlsterm, barium is an umlsterm, manometry is an umlsterm, techniques is an umlsterm, repairs is an umlsterm, Nissen fundoplication is an umlsterm, Collis gastroplasty is an umlsterm, Nissen operation is an umlsterm, fundoplications is an umlsterm, repair is an umlsterm, fundoplication is an umlsterm, prosthesis is an umlsterm
DerChirurg.80690141.eng.abstr_task0
Sentence: In over 80 % of patients with gastroesophageal reflux disease , the Nissen antireflux fundoplication gives good long-term results . Dysphagia , inability to belch or vomit as well as the gas bloat syndrome are possible sequelae after fundoplication . The frequency of these symptoms could be reduced by modification of the original Nissen-Rossetti fundoplication into the so-called " floppy " Nissen fundoplication , a short and loose wrap of mobilized gastric fundus . Failures of the antireflux procedure are mainly due to disruption or displacement of the wrap with the telescope phenomenon . Here , reoperation with refashioning of the original wrap may lead to same functional results like a primary fundoplication . Technical alternatives may selectively be chosen , when gastroesophageal reflux disease is complicated by fixated hiatal hernia , esophageal shortening , or serious esophageal motility disorders . Such specific anatomic or functional abnormalities are detected by preoperative endoscopy , barium swallow , 24-h pH monitoring , and manometry . Alternative techniques are mainly transthoracic repairs , including the Nissen fundoplication , Collis gastroplasty , and the Belsey Mark IV . Modifications of the 360 ° Nissen operation are partial fundoplications like the Hill repair and the Toupet dorsal fundoplication . Because of a high failure rate in the long-term follow-up , application of the ligamentum teres cardiopexy and of the Angelchik prosthesis is not recommended . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]
In over 80 % of patients with gastroesophageal reflux disease , the Nissen antireflux fundoplication gives good long-term results . Dysphagia , inability to belch or vomit as well as the gas bloat syndrome are possible sequelae after fundoplication . The frequency of these symptoms could be reduced by modification of the original Nissen-Rossetti fundoplication into the so-called " floppy " Nissen fundoplication , a short and loose wrap of mobilized gastric fundus . Failures of the antireflux procedure are mainly due to disruption or displacement of the wrap with the telescope phenomenon . Here , reoperation with refashioning of the original wrap may lead to same functional results like a primary fundoplication . Technical alternatives may selectively be chosen , when gastroesophageal reflux disease is complicated by fixated hiatal hernia , esophageal shortening , or serious esophageal motility disorders . Such specific anatomic or functional abnormalities are detected by preoperative endoscopy , barium swallow , 24-h pH monitoring , and manometry . Alternative techniques are mainly transthoracic repairs , including the Nissen fundoplication , Collis gastroplasty , and the Belsey Mark IV . Modifications of the 360 ° Nissen operation are partial fundoplications like the Hill repair and the Toupet dorsal fundoplication . Because of a high failure rate in the long-term follow-up , application of the ligamentum teres cardiopexy and of the Angelchik prosthesis is not recommended .
[ "In", "over", "80", "%", "of", "patients", "with", "gastroesophageal", "reflux", "disease", ",", "the", "Nissen", "antireflux", "fundoplication", "gives", "good", "long", "-", "term", "results", ".", "Dysphagia", ",", "inability", "to", "belch", "or", "vomit", "as", "well", "as", "the", "gas", "bloat", "syndrome", "are", "possible", "sequelae", "after", "fundoplication", ".", "The", "frequency", "of", "these", "symptoms", "could", "be", "reduced", "by", "modification", "of", "the", "original", "Nissen", "-", "Rossetti", "fundoplication", "into", "the", "so", "-", "called", "\"", "floppy", "\"", "Nissen", "fundoplication", ",", "a", "short", "and", "loose", "wrap", "of", "mobilized", "gastric", "fundus", ".", "Failures", "of", "the", "antireflux", "procedure", "are", "mainly", "due", "to", "disruption", "or", "displacement", "of", "the", "wrap", "with", "the", "telescope", "phenomenon", ".", "Here", ",", "reoperation", "with", "refashioning", "of", "the", "original", "wrap", "may", "lead", "to", "same", "functional", "results", "like", "a", "primary", "fundoplication", ".", "Technical", "alternatives", "may", "selectively", "be", "chosen", ",", "when", "gastroesophageal", "reflux", "disease", "is", "complicated", "by", "fixated", "hiatal", "hernia", ",", "esophageal", "shortening", ",", "or", "serious", "esophageal", "motility", "disorders", ".", "Such", "specific", "anatomic", "or", "functional", "abnormalities", "are", "detected", "by", "preoperative", "endoscopy", ",", "barium", "swallow", ",", "24-h", "pH", "monitoring", ",", "and", "manometry", ".", "Alternative", "techniques", "are", "mainly", "transthoracic", "repairs", ",", "including", "the", "Nissen", "fundoplication", ",", "Collis", "gastroplasty", ",", "and", "the", "Belsey", "Mark", "IV", ".", "Modifications", "of", "the", "360", "°", "Nissen", "operation", "are", "partial", "fundoplications", "like", "the", "Hill", "repair", "and", "the", "Toupet", "dorsal", "fundoplication", ".", "Because", "of", "a", "high", "failure", "rate", "in", "the", "long", "-", "term", "follow", "-", "up", ",", "application", "of", "the", "ligamentum", "teres", "cardiopexy", "and", "of", "the", "Angelchik", "prosthesis", "is", "not", "recommended", "." ]
[ "umlsterm" ]
patients is an umlsterm, gastroesophageal reflux disease is an umlsterm, fundoplication is an umlsterm, Dysphagia is an umlsterm, belch is an umlsterm, gas is an umlsterm, syndrome is an umlsterm, sequelae is an umlsterm, fundoplication is an umlsterm, frequency is an umlsterm, symptoms is an umlsterm, fundoplication is an umlsterm, Nissen fundoplication is an umlsterm, gastric fundus is an umlsterm, procedure is an umlsterm, displacement is an umlsterm, reoperation is an umlsterm, fundoplication is an umlsterm, gastroesophageal reflux disease is an umlsterm, hiatal hernia is an umlsterm, esophageal is an umlsterm, esophageal motility disorders is an umlsterm, anatomic is an umlsterm, abnormalities is an umlsterm, endoscopy is an umlsterm, barium is an umlsterm, manometry is an umlsterm, techniques is an umlsterm, repairs is an umlsterm, Nissen fundoplication is an umlsterm, Collis gastroplasty is an umlsterm, Nissen operation is an umlsterm, fundoplications is an umlsterm, repair is an umlsterm, fundoplication is an umlsterm, prosthesis is an umlsterm
DerChirurg.80690141.eng.abstr_task1
Sentence: In over 80 % of patients with gastroesophageal reflux disease , the Nissen antireflux fundoplication gives good long-term results . Dysphagia , inability to belch or vomit as well as the gas bloat syndrome are possible sequelae after fundoplication . The frequency of these symptoms could be reduced by modification of the original Nissen-Rossetti fundoplication into the so-called " floppy " Nissen fundoplication , a short and loose wrap of mobilized gastric fundus . Failures of the antireflux procedure are mainly due to disruption or displacement of the wrap with the telescope phenomenon . Here , reoperation with refashioning of the original wrap may lead to same functional results like a primary fundoplication . Technical alternatives may selectively be chosen , when gastroesophageal reflux disease is complicated by fixated hiatal hernia , esophageal shortening , or serious esophageal motility disorders . Such specific anatomic or functional abnormalities are detected by preoperative endoscopy , barium swallow , 24-h pH monitoring , and manometry . Alternative techniques are mainly transthoracic repairs , including the Nissen fundoplication , Collis gastroplasty , and the Belsey Mark IV . Modifications of the 360 ° Nissen operation are partial fundoplications like the Hill repair and the Toupet dorsal fundoplication . Because of a high failure rate in the long-term follow-up , application of the ligamentum teres cardiopexy and of the Angelchik prosthesis is not recommended . Instructions: please typing these entity words according to sentence: patients, gastroesophageal reflux disease, fundoplication, Dysphagia, belch, gas, syndrome, sequelae, fundoplication, frequency, symptoms, fundoplication, Nissen fundoplication, gastric fundus, procedure, displacement, reoperation, fundoplication, gastroesophageal reflux disease, hiatal hernia, esophageal, esophageal motility disorders, anatomic, abnormalities, endoscopy, barium, manometry, techniques, repairs, Nissen fundoplication, Collis gastroplasty, Nissen operation, fundoplications, repair, fundoplication, prosthesis Options: umlsterm
[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]
In over 80 % of patients with gastroesophageal reflux disease , the Nissen antireflux fundoplication gives good long-term results . Dysphagia , inability to belch or vomit as well as the gas bloat syndrome are possible sequelae after fundoplication . The frequency of these symptoms could be reduced by modification of the original Nissen-Rossetti fundoplication into the so-called " floppy " Nissen fundoplication , a short and loose wrap of mobilized gastric fundus . Failures of the antireflux procedure are mainly due to disruption or displacement of the wrap with the telescope phenomenon . Here , reoperation with refashioning of the original wrap may lead to same functional results like a primary fundoplication . Technical alternatives may selectively be chosen , when gastroesophageal reflux disease is complicated by fixated hiatal hernia , esophageal shortening , or serious esophageal motility disorders . Such specific anatomic or functional abnormalities are detected by preoperative endoscopy , barium swallow , 24-h pH monitoring , and manometry . Alternative techniques are mainly transthoracic repairs , including the Nissen fundoplication , Collis gastroplasty , and the Belsey Mark IV . Modifications of the 360 ° Nissen operation are partial fundoplications like the Hill repair and the Toupet dorsal fundoplication . Because of a high failure rate in the long-term follow-up , application of the ligamentum teres cardiopexy and of the Angelchik prosthesis is not recommended .
[ "In", "over", "80", "%", "of", "patients", "with", "gastroesophageal", "reflux", "disease", ",", "the", "Nissen", "antireflux", "fundoplication", "gives", "good", "long", "-", "term", "results", ".", "Dysphagia", ",", "inability", "to", "belch", "or", "vomit", "as", "well", "as", "the", "gas", "bloat", "syndrome", "are", "possible", "sequelae", "after", "fundoplication", ".", "The", "frequency", "of", "these", "symptoms", "could", "be", "reduced", "by", "modification", "of", "the", "original", "Nissen", "-", "Rossetti", "fundoplication", "into", "the", "so", "-", "called", "\"", "floppy", "\"", "Nissen", "fundoplication", ",", "a", "short", "and", "loose", "wrap", "of", "mobilized", "gastric", "fundus", ".", "Failures", "of", "the", "antireflux", "procedure", "are", "mainly", "due", "to", "disruption", "or", "displacement", "of", "the", "wrap", "with", "the", "telescope", "phenomenon", ".", "Here", ",", "reoperation", "with", "refashioning", "of", "the", "original", "wrap", "may", "lead", "to", "same", "functional", "results", "like", "a", "primary", "fundoplication", ".", "Technical", "alternatives", "may", "selectively", "be", "chosen", ",", "when", "gastroesophageal", "reflux", "disease", "is", "complicated", "by", "fixated", "hiatal", "hernia", ",", "esophageal", "shortening", ",", "or", "serious", "esophageal", "motility", "disorders", ".", "Such", "specific", "anatomic", "or", "functional", "abnormalities", "are", "detected", "by", "preoperative", "endoscopy", ",", "barium", "swallow", ",", "24-h", "pH", "monitoring", ",", "and", "manometry", ".", "Alternative", "techniques", "are", "mainly", "transthoracic", "repairs", ",", "including", "the", "Nissen", "fundoplication", ",", "Collis", "gastroplasty", ",", "and", "the", "Belsey", "Mark", "IV", ".", "Modifications", "of", "the", "360", "°", "Nissen", "operation", "are", "partial", "fundoplications", "like", "the", "Hill", "repair", "and", "the", "Toupet", "dorsal", "fundoplication", ".", "Because", "of", "a", "high", "failure", "rate", "in", "the", "long", "-", "term", "follow", "-", "up", ",", "application", "of", "the", "ligamentum", "teres", "cardiopexy", "and", "of", "the", "Angelchik", "prosthesis", "is", "not", "recommended", "." ]
[ "umlsterm" ]
patients, gastroesophageal reflux disease, fundoplication, Dysphagia, belch, gas, syndrome, sequelae, fundoplication, frequency, symptoms, fundoplication, Nissen fundoplication, gastric fundus, procedure, displacement, reoperation, fundoplication, gastroesophageal reflux disease, hiatal hernia, esophageal, esophageal motility disorders, anatomic, abnormalities, endoscopy, barium, manometry, techniques, repairs, Nissen fundoplication, Collis gastroplasty, Nissen operation, fundoplications, repair, fundoplication, prosthesis
DerChirurg.80690141.eng.abstr_task2
Sentence: In over 80 % of patients with gastroesophageal reflux disease , the Nissen antireflux fundoplication gives good long-term results . Dysphagia , inability to belch or vomit as well as the gas bloat syndrome are possible sequelae after fundoplication . The frequency of these symptoms could be reduced by modification of the original Nissen-Rossetti fundoplication into the so-called " floppy " Nissen fundoplication , a short and loose wrap of mobilized gastric fundus . Failures of the antireflux procedure are mainly due to disruption or displacement of the wrap with the telescope phenomenon . Here , reoperation with refashioning of the original wrap may lead to same functional results like a primary fundoplication . Technical alternatives may selectively be chosen , when gastroesophageal reflux disease is complicated by fixated hiatal hernia , esophageal shortening , or serious esophageal motility disorders . Such specific anatomic or functional abnormalities are detected by preoperative endoscopy , barium swallow , 24-h pH monitoring , and manometry . Alternative techniques are mainly transthoracic repairs , including the Nissen fundoplication , Collis gastroplasty , and the Belsey Mark IV . Modifications of the 360 ° Nissen operation are partial fundoplications like the Hill repair and the Toupet dorsal fundoplication . Because of a high failure rate in the long-term follow-up , application of the ligamentum teres cardiopexy and of the Angelchik prosthesis is not recommended . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]
In over 80 % of patients with gastroesophageal reflux disease , the Nissen antireflux fundoplication gives good long-term results . Dysphagia , inability to belch or vomit as well as the gas bloat syndrome are possible sequelae after fundoplication . The frequency of these symptoms could be reduced by modification of the original Nissen-Rossetti fundoplication into the so-called " floppy " Nissen fundoplication , a short and loose wrap of mobilized gastric fundus . Failures of the antireflux procedure are mainly due to disruption or displacement of the wrap with the telescope phenomenon . Here , reoperation with refashioning of the original wrap may lead to same functional results like a primary fundoplication . Technical alternatives may selectively be chosen , when gastroesophageal reflux disease is complicated by fixated hiatal hernia , esophageal shortening , or serious esophageal motility disorders . Such specific anatomic or functional abnormalities are detected by preoperative endoscopy , barium swallow , 24-h pH monitoring , and manometry . Alternative techniques are mainly transthoracic repairs , including the Nissen fundoplication , Collis gastroplasty , and the Belsey Mark IV . Modifications of the 360 ° Nissen operation are partial fundoplications like the Hill repair and the Toupet dorsal fundoplication . Because of a high failure rate in the long-term follow-up , application of the ligamentum teres cardiopexy and of the Angelchik prosthesis is not recommended .
[ "In", "over", "80", "%", "of", "patients", "with", "gastroesophageal", "reflux", "disease", ",", "the", "Nissen", "antireflux", "fundoplication", "gives", "good", "long", "-", "term", "results", ".", "Dysphagia", ",", "inability", "to", "belch", "or", "vomit", "as", "well", "as", "the", "gas", "bloat", "syndrome", "are", "possible", "sequelae", "after", "fundoplication", ".", "The", "frequency", "of", "these", "symptoms", "could", "be", "reduced", "by", "modification", "of", "the", "original", "Nissen", "-", "Rossetti", "fundoplication", "into", "the", "so", "-", "called", "\"", "floppy", "\"", "Nissen", "fundoplication", ",", "a", "short", "and", "loose", "wrap", "of", "mobilized", "gastric", "fundus", ".", "Failures", "of", "the", "antireflux", "procedure", "are", "mainly", "due", "to", "disruption", "or", "displacement", "of", "the", "wrap", "with", "the", "telescope", "phenomenon", ".", "Here", ",", "reoperation", "with", "refashioning", "of", "the", "original", "wrap", "may", "lead", "to", "same", "functional", "results", "like", "a", "primary", "fundoplication", ".", "Technical", "alternatives", "may", "selectively", "be", "chosen", ",", "when", "gastroesophageal", "reflux", "disease", "is", "complicated", "by", "fixated", "hiatal", "hernia", ",", "esophageal", "shortening", ",", "or", "serious", "esophageal", "motility", "disorders", ".", "Such", "specific", "anatomic", "or", "functional", "abnormalities", "are", "detected", "by", "preoperative", "endoscopy", ",", "barium", "swallow", ",", "24-h", "pH", "monitoring", ",", "and", "manometry", ".", "Alternative", "techniques", "are", "mainly", "transthoracic", "repairs", ",", "including", "the", "Nissen", "fundoplication", ",", "Collis", "gastroplasty", ",", "and", "the", "Belsey", "Mark", "IV", ".", "Modifications", "of", "the", "360", "°", "Nissen", "operation", "are", "partial", "fundoplications", "like", "the", "Hill", "repair", "and", "the", "Toupet", "dorsal", "fundoplication", ".", "Because", "of", "a", "high", "failure", "rate", "in", "the", "long", "-", "term", "follow", "-", "up", ",", "application", "of", "the", "ligamentum", "teres", "cardiopexy", "and", "of", "the", "Angelchik", "prosthesis", "is", "not", "recommended", "." ]
[ "umlsterm" ]
serum albumin is a protein, BSA is a protein, poly(3-hydroxybutyrate - co-3-hydroxyvalerate is a compound, poly(lactide - co - glycolide is a compound, PLGA is a compound, PLGA is a compound
DS.d161_task0
Sentence: To determine the capabilities of previously used microsphere scaffold to deliver growth factors simultaneously, this work investigated a long-term (about three months) release of bovine serum albumin (BSA) from microsphere scaffolds fabricated by using two different polymers, poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV, 8% PHV), poly(lactide-co-glycolide) acid (PLGA, 5050) and a blend of PLGA and PHBV. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "I-compound", "I-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "I-compound", "I-compound", "I-compound", "I-compound", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O" ]
To determine the capabilities of previously used microsphere scaffold to deliver growth factors simultaneously, this work investigated a long-term (about three months) release of bovine serum albumin (BSA) from microsphere scaffolds fabricated by using two different polymers, poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV, 8% PHV), poly(lactide-co-glycolide) acid (PLGA, 5050) and a blend of PLGA and PHBV.
[ "To", "determine", "the", "capabilities", "of", "previously", "used", "microsphere", "scaffold", "to", "deliver", "growth", "factors", "simultaneously", ",", "this", "work", "investigated", "a", "long", "-", "term", "(", "about", "three", "months", ")", "release", "of", "bovine", "serum", "albumin", "(", "BSA", ")", "from", "microsphere", "scaffolds", "fabricated", "by", "using", "two", "different", "polymers", ",", "poly(3-hydroxybutyrate", "-", "co-3-hydroxyvalerate", ")", "(", "PHBV", ",", "8", "%", "PHV", ")", ",", "poly(lactide", "-", "co", "-", "glycolide", ")", "acid", "(", "PLGA", ",", "5050", ")", "and", "a", "blend", "of", "PLGA", "and", "PHBV", "." ]
[ "compound", "protein" ]
serum albumin is a protein, BSA is a protein, poly(3-hydroxybutyrate - co-3-hydroxyvalerate is a compound, poly(lactide - co - glycolide is a compound, PLGA is a compound, PLGA is a compound
DS.d161_task1
Sentence: To determine the capabilities of previously used microsphere scaffold to deliver growth factors simultaneously, this work investigated a long-term (about three months) release of bovine serum albumin (BSA) from microsphere scaffolds fabricated by using two different polymers, poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV, 8% PHV), poly(lactide-co-glycolide) acid (PLGA, 5050) and a blend of PLGA and PHBV. Instructions: please typing these entity words according to sentence: serum albumin, BSA, poly(3-hydroxybutyrate - co-3-hydroxyvalerate, poly(lactide - co - glycolide, PLGA, PLGA Options: compound, protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "I-compound", "I-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "I-compound", "I-compound", "I-compound", "I-compound", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O" ]
To determine the capabilities of previously used microsphere scaffold to deliver growth factors simultaneously, this work investigated a long-term (about three months) release of bovine serum albumin (BSA) from microsphere scaffolds fabricated by using two different polymers, poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV, 8% PHV), poly(lactide-co-glycolide) acid (PLGA, 5050) and a blend of PLGA and PHBV.
[ "To", "determine", "the", "capabilities", "of", "previously", "used", "microsphere", "scaffold", "to", "deliver", "growth", "factors", "simultaneously", ",", "this", "work", "investigated", "a", "long", "-", "term", "(", "about", "three", "months", ")", "release", "of", "bovine", "serum", "albumin", "(", "BSA", ")", "from", "microsphere", "scaffolds", "fabricated", "by", "using", "two", "different", "polymers", ",", "poly(3-hydroxybutyrate", "-", "co-3-hydroxyvalerate", ")", "(", "PHBV", ",", "8", "%", "PHV", ")", ",", "poly(lactide", "-", "co", "-", "glycolide", ")", "acid", "(", "PLGA", ",", "5050", ")", "and", "a", "blend", "of", "PLGA", "and", "PHBV", "." ]
[ "compound", "protein" ]
serum albumin, BSA, poly(3-hydroxybutyrate - co-3-hydroxyvalerate, poly(lactide - co - glycolide, PLGA, PLGA
DS.d161_task2
Sentence: To determine the capabilities of previously used microsphere scaffold to deliver growth factors simultaneously, this work investigated a long-term (about three months) release of bovine serum albumin (BSA) from microsphere scaffolds fabricated by using two different polymers, poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV, 8% PHV), poly(lactide-co-glycolide) acid (PLGA, 5050) and a blend of PLGA and PHBV. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "I-compound", "I-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-compound", "I-compound", "I-compound", "I-compound", "I-compound", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O" ]
To determine the capabilities of previously used microsphere scaffold to deliver growth factors simultaneously, this work investigated a long-term (about three months) release of bovine serum albumin (BSA) from microsphere scaffolds fabricated by using two different polymers, poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV, 8% PHV), poly(lactide-co-glycolide) acid (PLGA, 5050) and a blend of PLGA and PHBV.
[ "To", "determine", "the", "capabilities", "of", "previously", "used", "microsphere", "scaffold", "to", "deliver", "growth", "factors", "simultaneously", ",", "this", "work", "investigated", "a", "long", "-", "term", "(", "about", "three", "months", ")", "release", "of", "bovine", "serum", "albumin", "(", "BSA", ")", "from", "microsphere", "scaffolds", "fabricated", "by", "using", "two", "different", "polymers", ",", "poly(3-hydroxybutyrate", "-", "co-3-hydroxyvalerate", ")", "(", "PHBV", ",", "8", "%", "PHV", ")", ",", "poly(lactide", "-", "co", "-", "glycolide", ")", "acid", "(", "PLGA", ",", "5050", ")", "and", "a", "blend", "of", "PLGA", "and", "PHBV", "." ]
[ "compound", "protein" ]
clinically significant is a Qualifier, disease is a Condition, disorder is a Condition, recent is a Temporal, < 3 months is a Temporal, cardiovascular event is a Condition, Type 1 diabetes is a Condition, maturity onset diabetes of the young is a Condition, secondary diabetes is a Condition, diabetes insipidus is a Condition, Unstable / rapidly progressing is a Scope, renal disease is a Condition, estimated Glomerular Filtration Rate is a Measurement, < 60 mL / min is a Value, Cockcroft - Gault formula is a Qualifier, Clinically significant is a Qualifier, out of range values is a Value, alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) or alkaline phosphatase ( ALP ) is a Scope, Contraindications is a Condition, dapagliflozin is a Drug, antidiabetic drugs is a Drug, other than is a Negation, metformin is a Drug, within 3 months prior to screening is a Temporal, Weight gain or loss is a Scope, > 5 kg is a Value, in the last 3 months is a Temporal, ongoing is a Temporal, weight - loss diet is a Observation, hypocaloric diet is a Observation, weight loss agents is a Drug, History is a Observation, drug abuse or alcohol abuse is a Scope, in the past 12 months is a Temporal, Plasma donation is a Procedure, within one month of screening is a Temporal, blood donation / blood loss > 500 mL is a Scope, within 3 months prior to screening or during the study is a Scope, Anemia is a Condition, Hemoglobin ( Hb ) < 115 g / L ( 7.1 mM ) in women and < 120 g / L ( 7.5 mM ) in men is a Scope, anti - coagulant treatment is a Procedure, heparin is a Drug, warfarin is a Drug, platelet inhibitors is a Drug, thrombin is a Drug, factor X inhibitors is a Drug, oral glucocorticoids , anti - estrogens or other medications is a Scope, markedly influence insulin sensitivity is a Qualifier, loop diuretics is a Drug, Regular is a Multiplier, smoking is a Observation, regular is a Multiplier, nicotine is a Drug, Central nervous system aneurysm clip is a Device, Implanted neural stimulator is a Device, cardiac pacemaker is a Device, defibrillator is a Device, Cochlear implant is a Device, Metal containing is a Qualifier, corpora aliena in the eye is a Device
NCT03338855_exc_task0
Sentence: Involvement in the planning and conduct of the study (applies to both AstraZeneca staff and staff at third party vendor or at the investigational sites). Previous enrolment in the present study or participation in another clinical study with an investigational product during the last 3 months or as judged by the Investigator. History of or presence of any clinically significant disease or disorder including a recent (< 3 months) cardiovascular event which, in the opinion of the Investigator, may either put the patient at risk because of participation in the study or influence the results or the patient's ability to participate in the study. Clinical diagnosis of Type 1 diabetes, maturity onset diabetes of the young, secondary diabetes or diabetes insipidus. Unstable/rapidly progressing renal disease or estimated Glomerular Filtration Rate < 60 mL/min (Cockcroft-Gault formula). Clinically significant out of range values of serum levels of either alanine aminotransferase (ALT), aspartate aminotransferase (AST) or alkaline phosphatase (ALP) in the Investigator's opinion. Contraindications to dapagliflozin according to the local label. Use of antidiabetic drugs other than metformin within 3 months prior to screening. Weight gain or loss > 5 kg in the last 3 months, ongoing weight-loss diet (hypocaloric diet) or use of weight loss agents. History of drug abuse or alcohol abuse in the past 12 months. Any clinically significant abnormalities in clinical chemistry, hematology or urinalysis or other condition the Investigator believes would interfere with the patient's ability to provide informed consent, comply with study instructions, or which might confound the interpretation of the study results or put the patient at undue risk. Plasma donation within one month of screening or any blood donation/blood loss > 500 mL within 3 months prior to screening or during the study. Anemia defined as Hemoglobin (Hb) < 115 g/L (7.1 mM) in women and < 120 g/L (7.5 mM) in men. Use of anti-coagulant treatment such as heparin, warfarin, platelet inhibitors, thrombin and factor X inhibitors. Use of medication such as oral glucocorticoids, anti-estrogens or other medications that are known to markedly influence insulin sensitivity. Use of loop diuretics. Regular smoking and other regular nicotine use. Central nervous system aneurysm clip Implanted neural stimulator Implanted cardiac pacemaker of defibrillator Cochlear implant Metal containing corpora aliena in the eye or brain. Patients, who do not want to be informed about unexpected medical findings, or do not wish that their physician be informed about coincidental findings, cannot participate in the study. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Temporal, Condition, Qualifier, Value, Observation, Multiplier, Procedure, Negation, Scope, Measurement, Device, Drug
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Qualifier", "I-Qualifier", "B-Condition", "O", "B-Condition", "O", "O", "B-Temporal", "O", "B-Temporal", "I-Temporal", "I-Temporal", "O", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Condition", "I-Condition", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "O", "O", "O", "B-Qualifier", "I-Qualifier", "B-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "O", "B-Drug", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Drug", "I-Drug", "B-Negation", "I-Negation", "B-Drug", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Value", "I-Value", "I-Value", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Temporal", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "O", "B-Observation", "I-Observation", "O", "O", "O", "O", "B-Drug", "I-Drug", "I-Drug", "O", "O", "B-Observation", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Condition", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "B-Drug", "O", "B-Drug", "O", "B-Drug", "I-Drug", "O", "B-Drug", "O", "B-Drug", "I-Drug", "I-Drug", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "O", "O", "O", "O", "B-Drug", "I-Drug", "O", "O", "B-Multiplier", "B-Observation", "O", "O", "B-Multiplier", "B-Drug", "O", "O", "O", "B-Device", "I-Device", "I-Device", "I-Device", "I-Device", "O", "B-Device", "I-Device", "I-Device", "O", "O", "B-Device", "I-Device", "O", "B-Device", "O", "B-Device", "I-Device", "O", "B-Qualifier", "I-Qualifier", "B-Device", "I-Device", "I-Device", "I-Device", "I-Device", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Involvement in the planning and conduct of the study (applies to both AstraZeneca staff and staff at third party vendor or at the investigational sites). Previous enrolment in the present study or participation in another clinical study with an investigational product during the last 3 months or as judged by the Investigator. History of or presence of any clinically significant disease or disorder including a recent (< 3 months) cardiovascular event which, in the opinion of the Investigator, may either put the patient at risk because of participation in the study or influence the results or the patient's ability to participate in the study. Clinical diagnosis of Type 1 diabetes, maturity onset diabetes of the young, secondary diabetes or diabetes insipidus. Unstable/rapidly progressing renal disease or estimated Glomerular Filtration Rate < 60 mL/min (Cockcroft-Gault formula). Clinically significant out of range values of serum levels of either alanine aminotransferase (ALT), aspartate aminotransferase (AST) or alkaline phosphatase (ALP) in the Investigator's opinion. Contraindications to dapagliflozin according to the local label. Use of antidiabetic drugs other than metformin within 3 months prior to screening. Weight gain or loss > 5 kg in the last 3 months, ongoing weight-loss diet (hypocaloric diet) or use of weight loss agents. History of drug abuse or alcohol abuse in the past 12 months. Any clinically significant abnormalities in clinical chemistry, hematology or urinalysis or other condition the Investigator believes would interfere with the patient's ability to provide informed consent, comply with study instructions, or which might confound the interpretation of the study results or put the patient at undue risk. Plasma donation within one month of screening or any blood donation/blood loss > 500 mL within 3 months prior to screening or during the study. Anemia defined as Hemoglobin (Hb) < 115 g/L (7.1 mM) in women and < 120 g/L (7.5 mM) in men. Use of anti-coagulant treatment such as heparin, warfarin, platelet inhibitors, thrombin and factor X inhibitors. Use of medication such as oral glucocorticoids, anti-estrogens or other medications that are known to markedly influence insulin sensitivity. Use of loop diuretics. Regular smoking and other regular nicotine use. Central nervous system aneurysm clip Implanted neural stimulator Implanted cardiac pacemaker of defibrillator Cochlear implant Metal containing corpora aliena in the eye or brain. Patients, who do not want to be informed about unexpected medical findings, or do not wish that their physician be informed about coincidental findings, cannot participate in the study.
[ "Involvement", "in", "the", "planning", "and", "conduct", "of", "the", "study", "(", "applies", "to", "both", "AstraZeneca", "staff", "and", "staff", "at", "third", "party", "vendor", "or", "at", "the", "investigational", "sites", ")", ".", "\n", "Previous", "enrolment", "in", "the", "present", "study", "or", "participation", "in", "another", "clinical", "study", "with", "an", "investigational", "product", "during", "the", "last", "3", "months", "or", "as", "judged", "by", "the", "Investigator", ".", "\n", "History", "of", "or", "presence", "of", "any", "clinically", "significant", "disease", "or", "disorder", "including", "a", "recent", "(", "<", "3", "months", ")", "cardiovascular", "event", "which", ",", "in", "the", "opinion", "of", "the", "Investigator", ",", "may", "either", "put", "the", "patient", "at", "risk", "because", "of", "participation", "in", "the", "study", "or", "influence", "the", "results", "or", "the", "patient", "'s", "ability", "to", "participate", "in", "the", "study", ".", "\n", "Clinical", "diagnosis", "of", "Type", "1", "diabetes", ",", "maturity", "onset", "diabetes", "of", "the", "young", ",", "secondary", "diabetes", "or", "diabetes", "insipidus", ".", "\n", "Unstable", "/", "rapidly", "progressing", "renal", "disease", "or", "estimated", "Glomerular", "Filtration", "Rate", "<", "60", "mL", "/", "min", "(", "Cockcroft", "-", "Gault", "formula", ")", ".", "\n", "Clinically", "significant", "out", "of", "range", "values", "of", "serum", "levels", "of", "either", "alanine", "aminotransferase", "(", "ALT", ")", ",", "aspartate", "aminotransferase", "(", "AST", ")", "or", "alkaline", "phosphatase", "(", "ALP", ")", "in", "the", "Investigator", "'s", "opinion", ".", "\n", "Contraindications", "to", "dapagliflozin", "according", "to", "the", "local", "label", ".", "\n", "Use", "of", "antidiabetic", "drugs", "other", "than", "metformin", "within", "3", "months", "prior", "to", "screening", ".", "\n", "Weight", "gain", "or", "loss", ">", "5", "kg", "in", "the", "last", "3", "months", ",", "ongoing", "weight", "-", "loss", "diet", "(", "hypocaloric", "diet", ")", "or", "use", "of", "weight", "loss", "agents", ".", "\n", "History", "of", "drug", "abuse", "or", "alcohol", "abuse", "in", "the", "past", "12", "months", ".", "\n", "Any", "clinically", "significant", "abnormalities", "in", "clinical", "chemistry", ",", "hematology", "or", "urinalysis", "or", "other", "condition", "the", "Investigator", "believes", "would", "interfere", "with", "the", "patient", "'s", "ability", "to", "provide", "informed", "consent", ",", "comply", "with", "study", "instructions", ",", "or", "which", "might", "confound", "the", "interpretation", "of", "the", "study", "results", "or", "put", "the", "patient", "at", "undue", "risk", ".", "\n", "Plasma", "donation", "within", "one", "month", "of", "screening", "or", "any", "blood", "donation", "/", "blood", "loss", ">", "500", "mL", "within", "3", "months", "prior", "to", "screening", "or", "during", "the", "study", ".", "\n", "Anemia", "defined", "as", "Hemoglobin", "(", "Hb", ")", "<", "115", "g", "/", "L", "(", "7.1", "mM", ")", "in", "women", "and", "<", "120", "g", "/", "L", "(", "7.5", "mM", ")", "in", "men", ".", "\n", "Use", "of", "anti", "-", "coagulant", "treatment", "such", "as", "heparin", ",", "warfarin", ",", "platelet", "inhibitors", ",", "thrombin", "and", "factor", "X", "inhibitors", ".", "\n", "Use", "of", "medication", "such", "as", "oral", "glucocorticoids", ",", "anti", "-", "estrogens", "or", "other", "medications", "that", "are", "known", "to", "markedly", "influence", "insulin", "sensitivity", ".", "\n", "Use", "of", "loop", "diuretics", ".", "\n", "Regular", "smoking", "and", "other", "regular", "nicotine", "use", ".", "\n", "Central", "nervous", "system", "aneurysm", "clip", "\n", "Implanted", "neural", "stimulator", "\n", "Implanted", "cardiac", "pacemaker", "of", "defibrillator", "\n", "Cochlear", "implant", "\n", "Metal", "containing", "corpora", "aliena", "in", "the", "eye", "or", "brain", ".", "\n", "Patients", ",", "who", "do", "not", "want", "to", "be", "informed", "about", "unexpected", "medical", "findings", ",", "or", "do", "not", "wish", "that", "their", "physician", "be", "informed", "about", "coincidental", "findings", ",", "cannot", "participate", "in", "the", "study", ".", "\n" ]
[ "Scope", "Qualifier", "Condition", "Measurement", "Device", "Temporal", "Procedure", "Drug", "Value", "Observation", "Negation", "Reference_point", "Multiplier", "Person" ]
clinically significant is a Qualifier, disease is a Condition, disorder is a Condition, recent is a Temporal, < 3 months is a Temporal, cardiovascular event is a Condition, Type 1 diabetes is a Condition, maturity onset diabetes of the young is a Condition, secondary diabetes is a Condition, diabetes insipidus is a Condition, Unstable / rapidly progressing is a Scope, renal disease is a Condition, estimated Glomerular Filtration Rate is a Measurement, < 60 mL / min is a Value, Cockcroft - Gault formula is a Qualifier, Clinically significant is a Qualifier, out of range values is a Value, alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) or alkaline phosphatase ( ALP ) is a Scope, Contraindications is a Condition, dapagliflozin is a Drug, antidiabetic drugs is a Drug, other than is a Negation, metformin is a Drug, within 3 months prior to screening is a Temporal, Weight gain or loss is a Scope, > 5 kg is a Value, in the last 3 months is a Temporal, ongoing is a Temporal, weight - loss diet is a Observation, hypocaloric diet is a Observation, weight loss agents is a Drug, History is a Observation, drug abuse or alcohol abuse is a Scope, in the past 12 months is a Temporal, Plasma donation is a Procedure, within one month of screening is a Temporal, blood donation / blood loss > 500 mL is a Scope, within 3 months prior to screening or during the study is a Scope, Anemia is a Condition, Hemoglobin ( Hb ) < 115 g / L ( 7.1 mM ) in women and < 120 g / L ( 7.5 mM ) in men is a Scope, anti - coagulant treatment is a Procedure, heparin is a Drug, warfarin is a Drug, platelet inhibitors is a Drug, thrombin is a Drug, factor X inhibitors is a Drug, oral glucocorticoids , anti - estrogens or other medications is a Scope, markedly influence insulin sensitivity is a Qualifier, loop diuretics is a Drug, Regular is a Multiplier, smoking is a Observation, regular is a Multiplier, nicotine is a Drug, Central nervous system aneurysm clip is a Device, Implanted neural stimulator is a Device, cardiac pacemaker is a Device, defibrillator is a Device, Cochlear implant is a Device, Metal containing is a Qualifier, corpora aliena in the eye is a Device
NCT03338855_exc_task1
Sentence: Involvement in the planning and conduct of the study (applies to both AstraZeneca staff and staff at third party vendor or at the investigational sites). Previous enrolment in the present study or participation in another clinical study with an investigational product during the last 3 months or as judged by the Investigator. History of or presence of any clinically significant disease or disorder including a recent (< 3 months) cardiovascular event which, in the opinion of the Investigator, may either put the patient at risk because of participation in the study or influence the results or the patient's ability to participate in the study. Clinical diagnosis of Type 1 diabetes, maturity onset diabetes of the young, secondary diabetes or diabetes insipidus. Unstable/rapidly progressing renal disease or estimated Glomerular Filtration Rate < 60 mL/min (Cockcroft-Gault formula). Clinically significant out of range values of serum levels of either alanine aminotransferase (ALT), aspartate aminotransferase (AST) or alkaline phosphatase (ALP) in the Investigator's opinion. Contraindications to dapagliflozin according to the local label. Use of antidiabetic drugs other than metformin within 3 months prior to screening. Weight gain or loss > 5 kg in the last 3 months, ongoing weight-loss diet (hypocaloric diet) or use of weight loss agents. History of drug abuse or alcohol abuse in the past 12 months. Any clinically significant abnormalities in clinical chemistry, hematology or urinalysis or other condition the Investigator believes would interfere with the patient's ability to provide informed consent, comply with study instructions, or which might confound the interpretation of the study results or put the patient at undue risk. Plasma donation within one month of screening or any blood donation/blood loss > 500 mL within 3 months prior to screening or during the study. Anemia defined as Hemoglobin (Hb) < 115 g/L (7.1 mM) in women and < 120 g/L (7.5 mM) in men. Use of anti-coagulant treatment such as heparin, warfarin, platelet inhibitors, thrombin and factor X inhibitors. Use of medication such as oral glucocorticoids, anti-estrogens or other medications that are known to markedly influence insulin sensitivity. Use of loop diuretics. Regular smoking and other regular nicotine use. Central nervous system aneurysm clip Implanted neural stimulator Implanted cardiac pacemaker of defibrillator Cochlear implant Metal containing corpora aliena in the eye or brain. Patients, who do not want to be informed about unexpected medical findings, or do not wish that their physician be informed about coincidental findings, cannot participate in the study. Instructions: please typing these entity words according to sentence: clinically significant, disease, disorder, recent, < 3 months, cardiovascular event, Type 1 diabetes, maturity onset diabetes of the young, secondary diabetes, diabetes insipidus, Unstable / rapidly progressing, renal disease, estimated Glomerular Filtration Rate, < 60 mL / min, Cockcroft - Gault formula, Clinically significant, out of range values, alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) or alkaline phosphatase ( ALP ), Contraindications, dapagliflozin, antidiabetic drugs, other than, metformin, within 3 months prior to screening, Weight gain or loss, > 5 kg, in the last 3 months, ongoing, weight - loss diet, hypocaloric diet, weight loss agents, History, drug abuse or alcohol abuse, in the past 12 months, Plasma donation, within one month of screening, blood donation / blood loss > 500 mL, within 3 months prior to screening or during the study, Anemia, Hemoglobin ( Hb ) < 115 g / L ( 7.1 mM ) in women and < 120 g / L ( 7.5 mM ) in men, anti - coagulant treatment, heparin, warfarin, platelet inhibitors, thrombin, factor X inhibitors, oral glucocorticoids , anti - estrogens or other medications, markedly influence insulin sensitivity, loop diuretics, Regular, smoking, regular, nicotine, Central nervous system aneurysm clip, Implanted neural stimulator, cardiac pacemaker, defibrillator, Cochlear implant, Metal containing, corpora aliena in the eye Options: Temporal, Condition, Qualifier, Value, Observation, Multiplier, Procedure, Negation, Scope, Measurement, Device, Drug
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Qualifier", "I-Qualifier", "B-Condition", "O", "B-Condition", "O", "O", "B-Temporal", "O", "B-Temporal", "I-Temporal", "I-Temporal", "O", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Condition", "I-Condition", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "O", "O", "O", "B-Qualifier", "I-Qualifier", "B-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "O", "B-Drug", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Drug", "I-Drug", "B-Negation", "I-Negation", "B-Drug", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Value", "I-Value", "I-Value", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Temporal", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "O", "B-Observation", "I-Observation", "O", "O", "O", "O", "B-Drug", "I-Drug", "I-Drug", "O", "O", "B-Observation", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Condition", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "B-Drug", "O", "B-Drug", "O", "B-Drug", "I-Drug", "O", "B-Drug", "O", "B-Drug", "I-Drug", "I-Drug", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "O", "O", "O", "O", "B-Drug", "I-Drug", "O", "O", "B-Multiplier", "B-Observation", "O", "O", "B-Multiplier", "B-Drug", "O", "O", "O", "B-Device", "I-Device", "I-Device", "I-Device", "I-Device", "O", "B-Device", "I-Device", "I-Device", "O", "O", "B-Device", "I-Device", "O", "B-Device", "O", "B-Device", "I-Device", "O", "B-Qualifier", "I-Qualifier", "B-Device", "I-Device", "I-Device", "I-Device", "I-Device", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Involvement in the planning and conduct of the study (applies to both AstraZeneca staff and staff at third party vendor or at the investigational sites). Previous enrolment in the present study or participation in another clinical study with an investigational product during the last 3 months or as judged by the Investigator. History of or presence of any clinically significant disease or disorder including a recent (< 3 months) cardiovascular event which, in the opinion of the Investigator, may either put the patient at risk because of participation in the study or influence the results or the patient's ability to participate in the study. Clinical diagnosis of Type 1 diabetes, maturity onset diabetes of the young, secondary diabetes or diabetes insipidus. Unstable/rapidly progressing renal disease or estimated Glomerular Filtration Rate < 60 mL/min (Cockcroft-Gault formula). Clinically significant out of range values of serum levels of either alanine aminotransferase (ALT), aspartate aminotransferase (AST) or alkaline phosphatase (ALP) in the Investigator's opinion. Contraindications to dapagliflozin according to the local label. Use of antidiabetic drugs other than metformin within 3 months prior to screening. Weight gain or loss > 5 kg in the last 3 months, ongoing weight-loss diet (hypocaloric diet) or use of weight loss agents. History of drug abuse or alcohol abuse in the past 12 months. Any clinically significant abnormalities in clinical chemistry, hematology or urinalysis or other condition the Investigator believes would interfere with the patient's ability to provide informed consent, comply with study instructions, or which might confound the interpretation of the study results or put the patient at undue risk. Plasma donation within one month of screening or any blood donation/blood loss > 500 mL within 3 months prior to screening or during the study. Anemia defined as Hemoglobin (Hb) < 115 g/L (7.1 mM) in women and < 120 g/L (7.5 mM) in men. Use of anti-coagulant treatment such as heparin, warfarin, platelet inhibitors, thrombin and factor X inhibitors. Use of medication such as oral glucocorticoids, anti-estrogens or other medications that are known to markedly influence insulin sensitivity. Use of loop diuretics. Regular smoking and other regular nicotine use. Central nervous system aneurysm clip Implanted neural stimulator Implanted cardiac pacemaker of defibrillator Cochlear implant Metal containing corpora aliena in the eye or brain. Patients, who do not want to be informed about unexpected medical findings, or do not wish that their physician be informed about coincidental findings, cannot participate in the study.
[ "Involvement", "in", "the", "planning", "and", "conduct", "of", "the", "study", "(", "applies", "to", "both", "AstraZeneca", "staff", "and", "staff", "at", "third", "party", "vendor", "or", "at", "the", "investigational", "sites", ")", ".", "\n", "Previous", "enrolment", "in", "the", "present", "study", "or", "participation", "in", "another", "clinical", "study", "with", "an", "investigational", "product", "during", "the", "last", "3", "months", "or", "as", "judged", "by", "the", "Investigator", ".", "\n", "History", "of", "or", "presence", "of", "any", "clinically", "significant", "disease", "or", "disorder", "including", "a", "recent", "(", "<", "3", "months", ")", "cardiovascular", "event", "which", ",", "in", "the", "opinion", "of", "the", "Investigator", ",", "may", "either", "put", "the", "patient", "at", "risk", "because", "of", "participation", "in", "the", "study", "or", "influence", "the", "results", "or", "the", "patient", "'s", "ability", "to", "participate", "in", "the", "study", ".", "\n", "Clinical", "diagnosis", "of", "Type", "1", "diabetes", ",", "maturity", "onset", "diabetes", "of", "the", "young", ",", "secondary", "diabetes", "or", "diabetes", "insipidus", ".", "\n", "Unstable", "/", "rapidly", "progressing", "renal", "disease", "or", "estimated", "Glomerular", "Filtration", "Rate", "<", "60", "mL", "/", "min", "(", "Cockcroft", "-", "Gault", "formula", ")", ".", "\n", "Clinically", "significant", "out", "of", "range", "values", "of", "serum", "levels", "of", "either", "alanine", "aminotransferase", "(", "ALT", ")", ",", "aspartate", "aminotransferase", "(", "AST", ")", "or", "alkaline", "phosphatase", "(", "ALP", ")", "in", "the", "Investigator", "'s", "opinion", ".", "\n", "Contraindications", "to", "dapagliflozin", "according", "to", "the", "local", "label", ".", "\n", "Use", "of", "antidiabetic", "drugs", "other", "than", "metformin", "within", "3", "months", "prior", "to", "screening", ".", "\n", "Weight", "gain", "or", "loss", ">", "5", "kg", "in", "the", "last", "3", "months", ",", "ongoing", "weight", "-", "loss", "diet", "(", "hypocaloric", "diet", ")", "or", "use", "of", "weight", "loss", "agents", ".", "\n", "History", "of", "drug", "abuse", "or", "alcohol", "abuse", "in", "the", "past", "12", "months", ".", "\n", "Any", "clinically", "significant", "abnormalities", "in", "clinical", "chemistry", ",", "hematology", "or", "urinalysis", "or", "other", "condition", "the", "Investigator", "believes", "would", "interfere", "with", "the", "patient", "'s", "ability", "to", "provide", "informed", "consent", ",", "comply", "with", "study", "instructions", ",", "or", "which", "might", "confound", "the", "interpretation", "of", "the", "study", "results", "or", "put", "the", "patient", "at", "undue", "risk", ".", "\n", "Plasma", "donation", "within", "one", "month", "of", "screening", "or", "any", "blood", "donation", "/", "blood", "loss", ">", "500", "mL", "within", "3", "months", "prior", "to", "screening", "or", "during", "the", "study", ".", "\n", "Anemia", "defined", "as", "Hemoglobin", "(", "Hb", ")", "<", "115", "g", "/", "L", "(", "7.1", "mM", ")", "in", "women", "and", "<", "120", "g", "/", "L", "(", "7.5", "mM", ")", "in", "men", ".", "\n", "Use", "of", "anti", "-", "coagulant", "treatment", "such", "as", "heparin", ",", "warfarin", ",", "platelet", "inhibitors", ",", "thrombin", "and", "factor", "X", "inhibitors", ".", "\n", "Use", "of", "medication", "such", "as", "oral", "glucocorticoids", ",", "anti", "-", "estrogens", "or", "other", "medications", "that", "are", "known", "to", "markedly", "influence", "insulin", "sensitivity", ".", "\n", "Use", "of", "loop", "diuretics", ".", "\n", "Regular", "smoking", "and", "other", "regular", "nicotine", "use", ".", "\n", "Central", "nervous", "system", "aneurysm", "clip", "\n", "Implanted", "neural", "stimulator", "\n", "Implanted", "cardiac", "pacemaker", "of", "defibrillator", "\n", "Cochlear", "implant", "\n", "Metal", "containing", "corpora", "aliena", "in", "the", "eye", "or", "brain", ".", "\n", "Patients", ",", "who", "do", "not", "want", "to", "be", "informed", "about", "unexpected", "medical", "findings", ",", "or", "do", "not", "wish", "that", "their", "physician", "be", "informed", "about", "coincidental", "findings", ",", "cannot", "participate", "in", "the", "study", ".", "\n" ]
[ "Scope", "Qualifier", "Condition", "Measurement", "Device", "Temporal", "Procedure", "Drug", "Value", "Observation", "Negation", "Reference_point", "Multiplier", "Person" ]
clinically significant, disease, disorder, recent, < 3 months, cardiovascular event, Type 1 diabetes, maturity onset diabetes of the young, secondary diabetes, diabetes insipidus, Unstable / rapidly progressing, renal disease, estimated Glomerular Filtration Rate, < 60 mL / min, Cockcroft - Gault formula, Clinically significant, out of range values, alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) or alkaline phosphatase ( ALP ), Contraindications, dapagliflozin, antidiabetic drugs, other than, metformin, within 3 months prior to screening, Weight gain or loss, > 5 kg, in the last 3 months, ongoing, weight - loss diet, hypocaloric diet, weight loss agents, History, drug abuse or alcohol abuse, in the past 12 months, Plasma donation, within one month of screening, blood donation / blood loss > 500 mL, within 3 months prior to screening or during the study, Anemia, Hemoglobin ( Hb ) < 115 g / L ( 7.1 mM ) in women and < 120 g / L ( 7.5 mM ) in men, anti - coagulant treatment, heparin, warfarin, platelet inhibitors, thrombin, factor X inhibitors, oral glucocorticoids , anti - estrogens or other medications, markedly influence insulin sensitivity, loop diuretics, Regular, smoking, regular, nicotine, Central nervous system aneurysm clip, Implanted neural stimulator, cardiac pacemaker, defibrillator, Cochlear implant, Metal containing, corpora aliena in the eye
NCT03338855_exc_task2
Sentence: Involvement in the planning and conduct of the study (applies to both AstraZeneca staff and staff at third party vendor or at the investigational sites). Previous enrolment in the present study or participation in another clinical study with an investigational product during the last 3 months or as judged by the Investigator. History of or presence of any clinically significant disease or disorder including a recent (< 3 months) cardiovascular event which, in the opinion of the Investigator, may either put the patient at risk because of participation in the study or influence the results or the patient's ability to participate in the study. Clinical diagnosis of Type 1 diabetes, maturity onset diabetes of the young, secondary diabetes or diabetes insipidus. Unstable/rapidly progressing renal disease or estimated Glomerular Filtration Rate < 60 mL/min (Cockcroft-Gault formula). Clinically significant out of range values of serum levels of either alanine aminotransferase (ALT), aspartate aminotransferase (AST) or alkaline phosphatase (ALP) in the Investigator's opinion. Contraindications to dapagliflozin according to the local label. Use of antidiabetic drugs other than metformin within 3 months prior to screening. Weight gain or loss > 5 kg in the last 3 months, ongoing weight-loss diet (hypocaloric diet) or use of weight loss agents. History of drug abuse or alcohol abuse in the past 12 months. Any clinically significant abnormalities in clinical chemistry, hematology or urinalysis or other condition the Investigator believes would interfere with the patient's ability to provide informed consent, comply with study instructions, or which might confound the interpretation of the study results or put the patient at undue risk. Plasma donation within one month of screening or any blood donation/blood loss > 500 mL within 3 months prior to screening or during the study. Anemia defined as Hemoglobin (Hb) < 115 g/L (7.1 mM) in women and < 120 g/L (7.5 mM) in men. Use of anti-coagulant treatment such as heparin, warfarin, platelet inhibitors, thrombin and factor X inhibitors. Use of medication such as oral glucocorticoids, anti-estrogens or other medications that are known to markedly influence insulin sensitivity. Use of loop diuretics. Regular smoking and other regular nicotine use. Central nervous system aneurysm clip Implanted neural stimulator Implanted cardiac pacemaker of defibrillator Cochlear implant Metal containing corpora aliena in the eye or brain. Patients, who do not want to be informed about unexpected medical findings, or do not wish that their physician be informed about coincidental findings, cannot participate in the study. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Qualifier", "I-Qualifier", "B-Condition", "O", "B-Condition", "O", "O", "B-Temporal", "O", "B-Temporal", "I-Temporal", "I-Temporal", "O", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "I-Condition", "I-Condition", "I-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "O", "B-Condition", "I-Condition", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Condition", "I-Condition", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "O", "O", "O", "B-Qualifier", "I-Qualifier", "B-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "O", "B-Drug", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Drug", "I-Drug", "B-Negation", "I-Negation", "B-Drug", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Value", "I-Value", "I-Value", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Temporal", "B-Observation", "I-Observation", "I-Observation", "I-Observation", "O", "B-Observation", "I-Observation", "O", "O", "O", "O", "B-Drug", "I-Drug", "I-Drug", "O", "O", "B-Observation", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "B-Condition", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "B-Drug", "O", "B-Drug", "O", "B-Drug", "I-Drug", "O", "B-Drug", "O", "B-Drug", "I-Drug", "I-Drug", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "B-Qualifier", "I-Qualifier", "I-Qualifier", "I-Qualifier", "O", "O", "O", "O", "B-Drug", "I-Drug", "O", "O", "B-Multiplier", "B-Observation", "O", "O", "B-Multiplier", "B-Drug", "O", "O", "O", "B-Device", "I-Device", "I-Device", "I-Device", "I-Device", "O", "B-Device", "I-Device", "I-Device", "O", "O", "B-Device", "I-Device", "O", "B-Device", "O", "B-Device", "I-Device", "O", "B-Qualifier", "I-Qualifier", "B-Device", "I-Device", "I-Device", "I-Device", "I-Device", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Involvement in the planning and conduct of the study (applies to both AstraZeneca staff and staff at third party vendor or at the investigational sites). Previous enrolment in the present study or participation in another clinical study with an investigational product during the last 3 months or as judged by the Investigator. History of or presence of any clinically significant disease or disorder including a recent (< 3 months) cardiovascular event which, in the opinion of the Investigator, may either put the patient at risk because of participation in the study or influence the results or the patient's ability to participate in the study. Clinical diagnosis of Type 1 diabetes, maturity onset diabetes of the young, secondary diabetes or diabetes insipidus. Unstable/rapidly progressing renal disease or estimated Glomerular Filtration Rate < 60 mL/min (Cockcroft-Gault formula). Clinically significant out of range values of serum levels of either alanine aminotransferase (ALT), aspartate aminotransferase (AST) or alkaline phosphatase (ALP) in the Investigator's opinion. Contraindications to dapagliflozin according to the local label. Use of antidiabetic drugs other than metformin within 3 months prior to screening. Weight gain or loss > 5 kg in the last 3 months, ongoing weight-loss diet (hypocaloric diet) or use of weight loss agents. History of drug abuse or alcohol abuse in the past 12 months. Any clinically significant abnormalities in clinical chemistry, hematology or urinalysis or other condition the Investigator believes would interfere with the patient's ability to provide informed consent, comply with study instructions, or which might confound the interpretation of the study results or put the patient at undue risk. Plasma donation within one month of screening or any blood donation/blood loss > 500 mL within 3 months prior to screening or during the study. Anemia defined as Hemoglobin (Hb) < 115 g/L (7.1 mM) in women and < 120 g/L (7.5 mM) in men. Use of anti-coagulant treatment such as heparin, warfarin, platelet inhibitors, thrombin and factor X inhibitors. Use of medication such as oral glucocorticoids, anti-estrogens or other medications that are known to markedly influence insulin sensitivity. Use of loop diuretics. Regular smoking and other regular nicotine use. Central nervous system aneurysm clip Implanted neural stimulator Implanted cardiac pacemaker of defibrillator Cochlear implant Metal containing corpora aliena in the eye or brain. Patients, who do not want to be informed about unexpected medical findings, or do not wish that their physician be informed about coincidental findings, cannot participate in the study.
[ "Involvement", "in", "the", "planning", "and", "conduct", "of", "the", "study", "(", "applies", "to", "both", "AstraZeneca", "staff", "and", "staff", "at", "third", "party", "vendor", "or", "at", "the", "investigational", "sites", ")", ".", "\n", "Previous", "enrolment", "in", "the", "present", "study", "or", "participation", "in", "another", "clinical", "study", "with", "an", "investigational", "product", "during", "the", "last", "3", "months", "or", "as", "judged", "by", "the", "Investigator", ".", "\n", "History", "of", "or", "presence", "of", "any", "clinically", "significant", "disease", "or", "disorder", "including", "a", "recent", "(", "<", "3", "months", ")", "cardiovascular", "event", "which", ",", "in", "the", "opinion", "of", "the", "Investigator", ",", "may", "either", "put", "the", "patient", "at", "risk", "because", "of", "participation", "in", "the", "study", "or", "influence", "the", "results", "or", "the", "patient", "'s", "ability", "to", "participate", "in", "the", "study", ".", "\n", "Clinical", "diagnosis", "of", "Type", "1", "diabetes", ",", "maturity", "onset", "diabetes", "of", "the", "young", ",", "secondary", "diabetes", "or", "diabetes", "insipidus", ".", "\n", "Unstable", "/", "rapidly", "progressing", "renal", "disease", "or", "estimated", "Glomerular", "Filtration", "Rate", "<", "60", "mL", "/", "min", "(", "Cockcroft", "-", "Gault", "formula", ")", ".", "\n", "Clinically", "significant", "out", "of", "range", "values", "of", "serum", "levels", "of", "either", "alanine", "aminotransferase", "(", "ALT", ")", ",", "aspartate", "aminotransferase", "(", "AST", ")", "or", "alkaline", "phosphatase", "(", "ALP", ")", "in", "the", "Investigator", "'s", "opinion", ".", "\n", "Contraindications", "to", "dapagliflozin", "according", "to", "the", "local", "label", ".", "\n", "Use", "of", "antidiabetic", "drugs", "other", "than", "metformin", "within", "3", "months", "prior", "to", "screening", ".", "\n", "Weight", "gain", "or", "loss", ">", "5", "kg", "in", "the", "last", "3", "months", ",", "ongoing", "weight", "-", "loss", "diet", "(", "hypocaloric", "diet", ")", "or", "use", "of", "weight", "loss", "agents", ".", "\n", "History", "of", "drug", "abuse", "or", "alcohol", "abuse", "in", "the", "past", "12", "months", ".", "\n", "Any", "clinically", "significant", "abnormalities", "in", "clinical", "chemistry", ",", "hematology", "or", "urinalysis", "or", "other", "condition", "the", "Investigator", "believes", "would", "interfere", "with", "the", "patient", "'s", "ability", "to", "provide", "informed", "consent", ",", "comply", "with", "study", "instructions", ",", "or", "which", "might", "confound", "the", "interpretation", "of", "the", "study", "results", "or", "put", "the", "patient", "at", "undue", "risk", ".", "\n", "Plasma", "donation", "within", "one", "month", "of", "screening", "or", "any", "blood", "donation", "/", "blood", "loss", ">", "500", "mL", "within", "3", "months", "prior", "to", "screening", "or", "during", "the", "study", ".", "\n", "Anemia", "defined", "as", "Hemoglobin", "(", "Hb", ")", "<", "115", "g", "/", "L", "(", "7.1", "mM", ")", "in", "women", "and", "<", "120", "g", "/", "L", "(", "7.5", "mM", ")", "in", "men", ".", "\n", "Use", "of", "anti", "-", "coagulant", "treatment", "such", "as", "heparin", ",", "warfarin", ",", "platelet", "inhibitors", ",", "thrombin", "and", "factor", "X", "inhibitors", ".", "\n", "Use", "of", "medication", "such", "as", "oral", "glucocorticoids", ",", "anti", "-", "estrogens", "or", "other", "medications", "that", "are", "known", "to", "markedly", "influence", "insulin", "sensitivity", ".", "\n", "Use", "of", "loop", "diuretics", ".", "\n", "Regular", "smoking", "and", "other", "regular", "nicotine", "use", ".", "\n", "Central", "nervous", "system", "aneurysm", "clip", "\n", "Implanted", "neural", "stimulator", "\n", "Implanted", "cardiac", "pacemaker", "of", "defibrillator", "\n", "Cochlear", "implant", "\n", "Metal", "containing", "corpora", "aliena", "in", "the", "eye", "or", "brain", ".", "\n", "Patients", ",", "who", "do", "not", "want", "to", "be", "informed", "about", "unexpected", "medical", "findings", ",", "or", "do", "not", "wish", "that", "their", "physician", "be", "informed", "about", "coincidental", "findings", ",", "cannot", "participate", "in", "the", "study", ".", "\n" ]
[ "Scope", "Qualifier", "Condition", "Measurement", "Device", "Temporal", "Procedure", "Drug", "Value", "Observation", "Negation", "Reference_point", "Multiplier", "Person" ]
disease is an umlsterm, disorder is an umlsterm, triad is an umlsterm, ulcers is an umlsterm, central nervous system is an umlsterm, brain stem is an umlsterm, brain is an umlsterm, ganglia is an umlsterm, Caucasian is an umlsterm, disease is an umlsterm, HLA is an umlsterm, uveitis is an umlsterm, therapy is an umlsterm, diagnosis is an umlsterm, time is an umlsterm, MRI is an umlsterm, brain stem is an umlsterm, Gd - DTPA is an umlsterm, inflammation is an umlsterm
ZfuerRheumatologie.70560031.eng.abstr_task0
Sentence: Behçet's disease is a chronic inflammatory disorder characterized by the triad of oral and genital ulcers and ocular lesions . One of the most life-threatening manifestations results from involvement of the central nervous system , presenting as necrotising meningo-encephalitis , most typically affecting the brain stem , internal capsula and basal brain ganglia . We report on a young Caucasian mate with Behçet's disease ( HLA B51+) and recurrent uveitis , who presented with acute neurologic involvement under CyA therapy 5 years after first diagnosis . At the time of admission MRI showed two high intensity lesions in the brain stem on T1 weighted images enhanced with Gd-DTPA , reflecting active inflammation . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O" ]
Behçet's disease is a chronic inflammatory disorder characterized by the triad of oral and genital ulcers and ocular lesions . One of the most life-threatening manifestations results from involvement of the central nervous system , presenting as necrotising meningo-encephalitis , most typically affecting the brain stem , internal capsula and basal brain ganglia . We report on a young Caucasian mate with Behçet's disease ( HLA B51+) and recurrent uveitis , who presented with acute neurologic involvement under CyA therapy 5 years after first diagnosis . At the time of admission MRI showed two high intensity lesions in the brain stem on T1 weighted images enhanced with Gd-DTPA , reflecting active inflammation .
[ "Behçet", "'s", "disease", "is", "a", "chronic", "inflammatory", "disorder", "characterized", "by", "the", "triad", "of", "oral", "and", "genital", "ulcers", "and", "ocular", "lesions", ".", "One", "of", "the", "most", "life", "-", "threatening", "manifestations", "results", "from", "involvement", "of", "the", "central", "nervous", "system", ",", "presenting", "as", "necrotising", "meningo", "-", "encephalitis", ",", "most", "typically", "affecting", "the", "brain", "stem", ",", "internal", "capsula", "and", "basal", "brain", "ganglia", ".", "We", "report", "on", "a", "young", "Caucasian", "mate", "with", "Behçet", "'s", "disease", "(", "HLA", "B51", "+", ")", "and", "recurrent", "uveitis", ",", "who", "presented", "with", "acute", "neurologic", "involvement", "under", "CyA", "therapy", "5", "years", "after", "first", "diagnosis", ".", "At", "the", "time", "of", "admission", "MRI", "showed", "two", "high", "intensity", "lesions", "in", "the", "brain", "stem", "on", "T1", "weighted", "images", "enhanced", "with", "Gd", "-", "DTPA", ",", "reflecting", "active", "inflammation", "." ]
[ "umlsterm" ]
disease is an umlsterm, disorder is an umlsterm, triad is an umlsterm, ulcers is an umlsterm, central nervous system is an umlsterm, brain stem is an umlsterm, brain is an umlsterm, ganglia is an umlsterm, Caucasian is an umlsterm, disease is an umlsterm, HLA is an umlsterm, uveitis is an umlsterm, therapy is an umlsterm, diagnosis is an umlsterm, time is an umlsterm, MRI is an umlsterm, brain stem is an umlsterm, Gd - DTPA is an umlsterm, inflammation is an umlsterm
ZfuerRheumatologie.70560031.eng.abstr_task1
Sentence: Behçet's disease is a chronic inflammatory disorder characterized by the triad of oral and genital ulcers and ocular lesions . One of the most life-threatening manifestations results from involvement of the central nervous system , presenting as necrotising meningo-encephalitis , most typically affecting the brain stem , internal capsula and basal brain ganglia . We report on a young Caucasian mate with Behçet's disease ( HLA B51+) and recurrent uveitis , who presented with acute neurologic involvement under CyA therapy 5 years after first diagnosis . At the time of admission MRI showed two high intensity lesions in the brain stem on T1 weighted images enhanced with Gd-DTPA , reflecting active inflammation . Instructions: please typing these entity words according to sentence: disease, disorder, triad, ulcers, central nervous system, brain stem, brain, ganglia, Caucasian, disease, HLA, uveitis, therapy, diagnosis, time, MRI, brain stem, Gd - DTPA, inflammation Options: umlsterm
[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O" ]
Behçet's disease is a chronic inflammatory disorder characterized by the triad of oral and genital ulcers and ocular lesions . One of the most life-threatening manifestations results from involvement of the central nervous system , presenting as necrotising meningo-encephalitis , most typically affecting the brain stem , internal capsula and basal brain ganglia . We report on a young Caucasian mate with Behçet's disease ( HLA B51+) and recurrent uveitis , who presented with acute neurologic involvement under CyA therapy 5 years after first diagnosis . At the time of admission MRI showed two high intensity lesions in the brain stem on T1 weighted images enhanced with Gd-DTPA , reflecting active inflammation .
[ "Behçet", "'s", "disease", "is", "a", "chronic", "inflammatory", "disorder", "characterized", "by", "the", "triad", "of", "oral", "and", "genital", "ulcers", "and", "ocular", "lesions", ".", "One", "of", "the", "most", "life", "-", "threatening", "manifestations", "results", "from", "involvement", "of", "the", "central", "nervous", "system", ",", "presenting", "as", "necrotising", "meningo", "-", "encephalitis", ",", "most", "typically", "affecting", "the", "brain", "stem", ",", "internal", "capsula", "and", "basal", "brain", "ganglia", ".", "We", "report", "on", "a", "young", "Caucasian", "mate", "with", "Behçet", "'s", "disease", "(", "HLA", "B51", "+", ")", "and", "recurrent", "uveitis", ",", "who", "presented", "with", "acute", "neurologic", "involvement", "under", "CyA", "therapy", "5", "years", "after", "first", "diagnosis", ".", "At", "the", "time", "of", "admission", "MRI", "showed", "two", "high", "intensity", "lesions", "in", "the", "brain", "stem", "on", "T1", "weighted", "images", "enhanced", "with", "Gd", "-", "DTPA", ",", "reflecting", "active", "inflammation", "." ]
[ "umlsterm" ]
disease, disorder, triad, ulcers, central nervous system, brain stem, brain, ganglia, Caucasian, disease, HLA, uveitis, therapy, diagnosis, time, MRI, brain stem, Gd - DTPA, inflammation
ZfuerRheumatologie.70560031.eng.abstr_task2
Sentence: Behçet's disease is a chronic inflammatory disorder characterized by the triad of oral and genital ulcers and ocular lesions . One of the most life-threatening manifestations results from involvement of the central nervous system , presenting as necrotising meningo-encephalitis , most typically affecting the brain stem , internal capsula and basal brain ganglia . We report on a young Caucasian mate with Behçet's disease ( HLA B51+) and recurrent uveitis , who presented with acute neurologic involvement under CyA therapy 5 years after first diagnosis . At the time of admission MRI showed two high intensity lesions in the brain stem on T1 weighted images enhanced with Gd-DTPA , reflecting active inflammation . Instructions: please extract entity words from the input sentence
[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O" ]
Behçet's disease is a chronic inflammatory disorder characterized by the triad of oral and genital ulcers and ocular lesions . One of the most life-threatening manifestations results from involvement of the central nervous system , presenting as necrotising meningo-encephalitis , most typically affecting the brain stem , internal capsula and basal brain ganglia . We report on a young Caucasian mate with Behçet's disease ( HLA B51+) and recurrent uveitis , who presented with acute neurologic involvement under CyA therapy 5 years after first diagnosis . At the time of admission MRI showed two high intensity lesions in the brain stem on T1 weighted images enhanced with Gd-DTPA , reflecting active inflammation .
[ "Behçet", "'s", "disease", "is", "a", "chronic", "inflammatory", "disorder", "characterized", "by", "the", "triad", "of", "oral", "and", "genital", "ulcers", "and", "ocular", "lesions", ".", "One", "of", "the", "most", "life", "-", "threatening", "manifestations", "results", "from", "involvement", "of", "the", "central", "nervous", "system", ",", "presenting", "as", "necrotising", "meningo", "-", "encephalitis", ",", "most", "typically", "affecting", "the", "brain", "stem", ",", "internal", "capsula", "and", "basal", "brain", "ganglia", ".", "We", "report", "on", "a", "young", "Caucasian", "mate", "with", "Behçet", "'s", "disease", "(", "HLA", "B51", "+", ")", "and", "recurrent", "uveitis", ",", "who", "presented", "with", "acute", "neurologic", "involvement", "under", "CyA", "therapy", "5", "years", "after", "first", "diagnosis", ".", "At", "the", "time", "of", "admission", "MRI", "showed", "two", "high", "intensity", "lesions", "in", "the", "brain", "stem", "on", "T1", "weighted", "images", "enhanced", "with", "Gd", "-", "DTPA", ",", "reflecting", "active", "inflammation", "." ]
[ "umlsterm" ]
trauma is an umlsterm, shoulder is an umlsterm, knee joint is an umlsterm, injuries is an umlsterm, ligaments is an umlsterm, capsule is an umlsterm, fractures is an umlsterm, Anterior is an umlsterm, shoulder dislocation is an umlsterm, repair is an umlsterm, torn is an umlsterm, therapy is an umlsterm, choice is an umlsterm, ruptures is an umlsterm, collateral ligaments is an umlsterm, knee is an umlsterm, torn is an umlsterm, anterior cruciate ligament is an umlsterm, knee joint is an umlsterm, muscle is an umlsterm, exercises is an umlsterm, grafting is an umlsterm, techniques is an umlsterm, injuries is an umlsterm
Trauma+Berufskrankheit.0002s376.eng.abstr_task0
Sentence: Indirect trauma to the shoulder and knee joint often results in injuries to the ligaments and the capsule , and more rarely in fractures . Anterior shoulder dislocation is common . Over the last few years arthroscopic repair of the torn labrum has become established as the therapy of choice . Isolated ruptures of the collateral ligaments of the knee can be treated functionally . A torn anterior cruciate ligament of the knee joint can be compensated by the quadriceps muscle if this is adequately prepared by special exercises . Chronic or combined instabilities should be treated surgically by ACI grafting techniques . Menisceal injuries are treated arthroscopically . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]
Indirect trauma to the shoulder and knee joint often results in injuries to the ligaments and the capsule , and more rarely in fractures . Anterior shoulder dislocation is common . Over the last few years arthroscopic repair of the torn labrum has become established as the therapy of choice . Isolated ruptures of the collateral ligaments of the knee can be treated functionally . A torn anterior cruciate ligament of the knee joint can be compensated by the quadriceps muscle if this is adequately prepared by special exercises . Chronic or combined instabilities should be treated surgically by ACI grafting techniques . Menisceal injuries are treated arthroscopically .
[ "Indirect", "trauma", "to", "the", "shoulder", "and", "knee", "joint", "often", "results", "in", "injuries", "to", "the", "ligaments", "and", "the", "capsule", ",", "and", "more", "rarely", "in", "fractures", ".", "Anterior", "shoulder", "dislocation", "is", "common", ".", "Over", "the", "last", "few", "years", "arthroscopic", "repair", "of", "the", "torn", "labrum", "has", "become", "established", "as", "the", "therapy", "of", "choice", ".", "Isolated", "ruptures", "of", "the", "collateral", "ligaments", "of", "the", "knee", "can", "be", "treated", "functionally", ".", "A", "torn", "anterior", "cruciate", "ligament", "of", "the", "knee", "joint", "can", "be", "compensated", "by", "the", "quadriceps", "muscle", "if", "this", "is", "adequately", "prepared", "by", "special", "exercises", ".", "Chronic", "or", "combined", "instabilities", "should", "be", "treated", "surgically", "by", "ACI", "grafting", "techniques", ".", "Menisceal", "injuries", "are", "treated", "arthroscopically", "." ]
[ "umlsterm" ]
trauma is an umlsterm, shoulder is an umlsterm, knee joint is an umlsterm, injuries is an umlsterm, ligaments is an umlsterm, capsule is an umlsterm, fractures is an umlsterm, Anterior is an umlsterm, shoulder dislocation is an umlsterm, repair is an umlsterm, torn is an umlsterm, therapy is an umlsterm, choice is an umlsterm, ruptures is an umlsterm, collateral ligaments is an umlsterm, knee is an umlsterm, torn is an umlsterm, anterior cruciate ligament is an umlsterm, knee joint is an umlsterm, muscle is an umlsterm, exercises is an umlsterm, grafting is an umlsterm, techniques is an umlsterm, injuries is an umlsterm
Trauma+Berufskrankheit.0002s376.eng.abstr_task1
Sentence: Indirect trauma to the shoulder and knee joint often results in injuries to the ligaments and the capsule , and more rarely in fractures . Anterior shoulder dislocation is common . Over the last few years arthroscopic repair of the torn labrum has become established as the therapy of choice . Isolated ruptures of the collateral ligaments of the knee can be treated functionally . A torn anterior cruciate ligament of the knee joint can be compensated by the quadriceps muscle if this is adequately prepared by special exercises . Chronic or combined instabilities should be treated surgically by ACI grafting techniques . Menisceal injuries are treated arthroscopically . Instructions: please typing these entity words according to sentence: trauma, shoulder, knee joint, injuries, ligaments, capsule, fractures, Anterior, shoulder dislocation, repair, torn, therapy, choice, ruptures, collateral ligaments, knee, torn, anterior cruciate ligament, knee joint, muscle, exercises, grafting, techniques, injuries Options: umlsterm
[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]
Indirect trauma to the shoulder and knee joint often results in injuries to the ligaments and the capsule , and more rarely in fractures . Anterior shoulder dislocation is common . Over the last few years arthroscopic repair of the torn labrum has become established as the therapy of choice . Isolated ruptures of the collateral ligaments of the knee can be treated functionally . A torn anterior cruciate ligament of the knee joint can be compensated by the quadriceps muscle if this is adequately prepared by special exercises . Chronic or combined instabilities should be treated surgically by ACI grafting techniques . Menisceal injuries are treated arthroscopically .
[ "Indirect", "trauma", "to", "the", "shoulder", "and", "knee", "joint", "often", "results", "in", "injuries", "to", "the", "ligaments", "and", "the", "capsule", ",", "and", "more", "rarely", "in", "fractures", ".", "Anterior", "shoulder", "dislocation", "is", "common", ".", "Over", "the", "last", "few", "years", "arthroscopic", "repair", "of", "the", "torn", "labrum", "has", "become", "established", "as", "the", "therapy", "of", "choice", ".", "Isolated", "ruptures", "of", "the", "collateral", "ligaments", "of", "the", "knee", "can", "be", "treated", "functionally", ".", "A", "torn", "anterior", "cruciate", "ligament", "of", "the", "knee", "joint", "can", "be", "compensated", "by", "the", "quadriceps", "muscle", "if", "this", "is", "adequately", "prepared", "by", "special", "exercises", ".", "Chronic", "or", "combined", "instabilities", "should", "be", "treated", "surgically", "by", "ACI", "grafting", "techniques", ".", "Menisceal", "injuries", "are", "treated", "arthroscopically", "." ]
[ "umlsterm" ]
trauma, shoulder, knee joint, injuries, ligaments, capsule, fractures, Anterior, shoulder dislocation, repair, torn, therapy, choice, ruptures, collateral ligaments, knee, torn, anterior cruciate ligament, knee joint, muscle, exercises, grafting, techniques, injuries
Trauma+Berufskrankheit.0002s376.eng.abstr_task2
Sentence: Indirect trauma to the shoulder and knee joint often results in injuries to the ligaments and the capsule , and more rarely in fractures . Anterior shoulder dislocation is common . Over the last few years arthroscopic repair of the torn labrum has become established as the therapy of choice . Isolated ruptures of the collateral ligaments of the knee can be treated functionally . A torn anterior cruciate ligament of the knee joint can be compensated by the quadriceps muscle if this is adequately prepared by special exercises . Chronic or combined instabilities should be treated surgically by ACI grafting techniques . Menisceal injuries are treated arthroscopically . Instructions: please extract entity words from the input sentence
[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]
Indirect trauma to the shoulder and knee joint often results in injuries to the ligaments and the capsule , and more rarely in fractures . Anterior shoulder dislocation is common . Over the last few years arthroscopic repair of the torn labrum has become established as the therapy of choice . Isolated ruptures of the collateral ligaments of the knee can be treated functionally . A torn anterior cruciate ligament of the knee joint can be compensated by the quadriceps muscle if this is adequately prepared by special exercises . Chronic or combined instabilities should be treated surgically by ACI grafting techniques . Menisceal injuries are treated arthroscopically .
[ "Indirect", "trauma", "to", "the", "shoulder", "and", "knee", "joint", "often", "results", "in", "injuries", "to", "the", "ligaments", "and", "the", "capsule", ",", "and", "more", "rarely", "in", "fractures", ".", "Anterior", "shoulder", "dislocation", "is", "common", ".", "Over", "the", "last", "few", "years", "arthroscopic", "repair", "of", "the", "torn", "labrum", "has", "become", "established", "as", "the", "therapy", "of", "choice", ".", "Isolated", "ruptures", "of", "the", "collateral", "ligaments", "of", "the", "knee", "can", "be", "treated", "functionally", ".", "A", "torn", "anterior", "cruciate", "ligament", "of", "the", "knee", "joint", "can", "be", "compensated", "by", "the", "quadriceps", "muscle", "if", "this", "is", "adequately", "prepared", "by", "special", "exercises", ".", "Chronic", "or", "combined", "instabilities", "should", "be", "treated", "surgically", "by", "ACI", "grafting", "techniques", ".", "Menisceal", "injuries", "are", "treated", "arthroscopically", "." ]
[ "umlsterm" ]
Oct-1 is a Protein, Oct-2 is a Protein, Oct-2A is a Protein, Oct-1 is a Protein, Oct-1 is a Protein, Oct-2A is a Protein, Oct-1 is a Protein, Oct-2A is a Protein, Oct-1 is a Protein, Oct-2A is a Protein, Oct-1 is a Protein, Oct-2A is a Protein, N - Oct-3 is a Protein, Oct-2A is a Protein, N - Oct-3 is a Protein
2216722_task0
Sentence: Astrocytes and glioblastoma cells express novel octamer-DNA binding proteins distinct from the ubiquitous Oct-1 and B cell type Oct-2 proteins. The 'octamer' sequence, ATGCAAAT or its complement ATTTGCAT, is a key element for the transcriptional regulation of immunoglobulin genes in B-lymphocytes as well as a number of housekeeping genes in all cell types. In lymphocytes, the octamer-binding protein Oct-2A and variants thereof are thought to contribute to the B-cell specific gene expression, while the ubiquitous protein Oct-1 seems to control general octamer site-dependent transcription. Various other genes, for example interleukin-1 and MHC class II genes, contain an octamer sequence in the promoter and are expressed in cells of both the immune and nervous systems. This prompted us to analyze the octamer-binding proteins in the latter cells. Using the electrophoretic mobility shift assay, at least six novel octamer binding proteins were detected in nuclear extracts of cultured mouse astrocytes. These proteins are differentially expressed in human glioblastoma and neuroblastoma cell lines. The nervous system-derived (N-Oct) proteins bound to the octamer DNA sequence in a manner which is indistinguishable from the Oct-1 and Oct-2A proteins. The relationship of the N-Oct proteins to Oct-1 and Oct-2A was analyzed by proteolytic clipping bandshift assays and by their reactivity towards antisera raised against recombinant Oct-1 and Oct-2A proteins. On the basis of these assays, all N-Oct-factors were found to be distinct from the ubiquitous Oct-1 and the lymphoid-specific Oct-2A proteins. In melanoma cells that contain the N-Oct-3 factor, a transfected lymphocyte-specific promoter was neither activated nor was it repressed upon contransfection with an Oct-2A expression vector. We therefore speculate that N-Oct-3 and other N-Oct factors have a specific role in gene expression in cells of the nervous system. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Astrocytes and glioblastoma cells express novel octamer-DNA binding proteins distinct from the ubiquitous Oct-1 and B cell type Oct-2 proteins. The 'octamer' sequence, ATGCAAAT or its complement ATTTGCAT, is a key element for the transcriptional regulation of immunoglobulin genes in B-lymphocytes as well as a number of housekeeping genes in all cell types. In lymphocytes, the octamer-binding protein Oct-2A and variants thereof are thought to contribute to the B-cell specific gene expression, while the ubiquitous protein Oct-1 seems to control general octamer site-dependent transcription. Various other genes, for example interleukin-1 and MHC class II genes, contain an octamer sequence in the promoter and are expressed in cells of both the immune and nervous systems. This prompted us to analyze the octamer-binding proteins in the latter cells. Using the electrophoretic mobility shift assay, at least six novel octamer binding proteins were detected in nuclear extracts of cultured mouse astrocytes. These proteins are differentially expressed in human glioblastoma and neuroblastoma cell lines. The nervous system-derived (N-Oct) proteins bound to the octamer DNA sequence in a manner which is indistinguishable from the Oct-1 and Oct-2A proteins. The relationship of the N-Oct proteins to Oct-1 and Oct-2A was analyzed by proteolytic clipping bandshift assays and by their reactivity towards antisera raised against recombinant Oct-1 and Oct-2A proteins. On the basis of these assays, all N-Oct-factors were found to be distinct from the ubiquitous Oct-1 and the lymphoid-specific Oct-2A proteins. In melanoma cells that contain the N-Oct-3 factor, a transfected lymphocyte-specific promoter was neither activated nor was it repressed upon contransfection with an Oct-2A expression vector. We therefore speculate that N-Oct-3 and other N-Oct factors have a specific role in gene expression in cells of the nervous system.
[ "Astrocytes", "and", "glioblastoma", "cells", "express", "novel", "octamer", "-", "DNA", "binding", "proteins", "distinct", "from", "the", "ubiquitous", "Oct-1", "and", "B", "cell", "type", "Oct-2", "proteins", ".", "\n", "The", "'", "octamer", "'", "sequence", ",", "ATGCAAAT", "or", "its", "complement", "ATTTGCAT", ",", "is", "a", "key", "element", "for", "the", "transcriptional", "regulation", "of", "immunoglobulin", "genes", "in", "B", "-", "lymphocytes", "as", "well", "as", "a", "number", "of", "housekeeping", "genes", "in", "all", "cell", "types", ".", "In", "lymphocytes", ",", "the", "octamer", "-", "binding", "protein", "Oct-2A", "and", "variants", "thereof", "are", "thought", "to", "contribute", "to", "the", "B", "-", "cell", "specific", "gene", "expression", ",", "while", "the", "ubiquitous", "protein", "Oct-1", "seems", "to", "control", "general", "octamer", "site", "-", "dependent", "transcription", ".", "Various", "other", "genes", ",", "for", "example", "interleukin-1", "and", "MHC", "class", "II", "genes", ",", "contain", "an", "octamer", "sequence", "in", "the", "promoter", "and", "are", "expressed", "in", "cells", "of", "both", "the", "immune", "and", "nervous", "systems", ".", "This", "prompted", "us", "to", "analyze", "the", "octamer", "-", "binding", "proteins", "in", "the", "latter", "cells", ".", "Using", "the", "electrophoretic", "mobility", "shift", "assay", ",", "at", "least", "six", "novel", "octamer", "binding", "proteins", "were", "detected", "in", "nuclear", "extracts", "of", "cultured", "mouse", "astrocytes", ".", "These", "proteins", "are", "differentially", "expressed", "in", "human", "glioblastoma", "and", "neuroblastoma", "cell", "lines", ".", "The", "nervous", "system", "-", "derived", "(", "N", "-", "Oct", ")", "proteins", "bound", "to", "the", "octamer", "DNA", "sequence", "in", "a", "manner", "which", "is", "indistinguishable", "from", "the", "Oct-1", "and", "Oct-2A", "proteins", ".", "The", "relationship", "of", "the", "N", "-", "Oct", "proteins", "to", "Oct-1", "and", "Oct-2A", "was", "analyzed", "by", "proteolytic", "clipping", "bandshift", "assays", "and", "by", "their", "reactivity", "towards", "antisera", "raised", "against", "recombinant", "Oct-1", "and", "Oct-2A", "proteins", ".", "On", "the", "basis", "of", "these", "assays", ",", "all", "N", "-", "Oct", "-", "factors", "were", "found", "to", "be", "distinct", "from", "the", "ubiquitous", "Oct-1", "and", "the", "lymphoid", "-", "specific", "Oct-2A", "proteins", ".", "In", "melanoma", "cells", "that", "contain", "the", "N", "-", "Oct-3", "factor", ",", "a", "transfected", "lymphocyte", "-", "specific", "promoter", "was", "neither", "activated", "nor", "was", "it", "repressed", "upon", "contransfection", "with", "an", "Oct-2A", "expression", "vector", ".", "We", "therefore", "speculate", "that", "N", "-", "Oct-3", "and", "other", "N", "-", "Oct", "factors", "have", "a", "specific", "role", "in", "gene", "expression", "in", "cells", "of", "the", "nervous", "system", "." ]
[ "Protein" ]
Oct-1 is a Protein, Oct-2 is a Protein, Oct-2A is a Protein, Oct-1 is a Protein, Oct-1 is a Protein, Oct-2A is a Protein, Oct-1 is a Protein, Oct-2A is a Protein, Oct-1 is a Protein, Oct-2A is a Protein, Oct-1 is a Protein, Oct-2A is a Protein, N - Oct-3 is a Protein, Oct-2A is a Protein, N - Oct-3 is a Protein
2216722_task1
Sentence: Astrocytes and glioblastoma cells express novel octamer-DNA binding proteins distinct from the ubiquitous Oct-1 and B cell type Oct-2 proteins. The 'octamer' sequence, ATGCAAAT or its complement ATTTGCAT, is a key element for the transcriptional regulation of immunoglobulin genes in B-lymphocytes as well as a number of housekeeping genes in all cell types. In lymphocytes, the octamer-binding protein Oct-2A and variants thereof are thought to contribute to the B-cell specific gene expression, while the ubiquitous protein Oct-1 seems to control general octamer site-dependent transcription. Various other genes, for example interleukin-1 and MHC class II genes, contain an octamer sequence in the promoter and are expressed in cells of both the immune and nervous systems. This prompted us to analyze the octamer-binding proteins in the latter cells. Using the electrophoretic mobility shift assay, at least six novel octamer binding proteins were detected in nuclear extracts of cultured mouse astrocytes. These proteins are differentially expressed in human glioblastoma and neuroblastoma cell lines. The nervous system-derived (N-Oct) proteins bound to the octamer DNA sequence in a manner which is indistinguishable from the Oct-1 and Oct-2A proteins. The relationship of the N-Oct proteins to Oct-1 and Oct-2A was analyzed by proteolytic clipping bandshift assays and by their reactivity towards antisera raised against recombinant Oct-1 and Oct-2A proteins. On the basis of these assays, all N-Oct-factors were found to be distinct from the ubiquitous Oct-1 and the lymphoid-specific Oct-2A proteins. In melanoma cells that contain the N-Oct-3 factor, a transfected lymphocyte-specific promoter was neither activated nor was it repressed upon contransfection with an Oct-2A expression vector. We therefore speculate that N-Oct-3 and other N-Oct factors have a specific role in gene expression in cells of the nervous system. Instructions: please typing these entity words according to sentence: Oct-1, Oct-2, Oct-2A, Oct-1, Oct-1, Oct-2A, Oct-1, Oct-2A, Oct-1, Oct-2A, Oct-1, Oct-2A, N - Oct-3, Oct-2A, N - Oct-3 Options: Protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Astrocytes and glioblastoma cells express novel octamer-DNA binding proteins distinct from the ubiquitous Oct-1 and B cell type Oct-2 proteins. The 'octamer' sequence, ATGCAAAT or its complement ATTTGCAT, is a key element for the transcriptional regulation of immunoglobulin genes in B-lymphocytes as well as a number of housekeeping genes in all cell types. In lymphocytes, the octamer-binding protein Oct-2A and variants thereof are thought to contribute to the B-cell specific gene expression, while the ubiquitous protein Oct-1 seems to control general octamer site-dependent transcription. Various other genes, for example interleukin-1 and MHC class II genes, contain an octamer sequence in the promoter and are expressed in cells of both the immune and nervous systems. This prompted us to analyze the octamer-binding proteins in the latter cells. Using the electrophoretic mobility shift assay, at least six novel octamer binding proteins were detected in nuclear extracts of cultured mouse astrocytes. These proteins are differentially expressed in human glioblastoma and neuroblastoma cell lines. The nervous system-derived (N-Oct) proteins bound to the octamer DNA sequence in a manner which is indistinguishable from the Oct-1 and Oct-2A proteins. The relationship of the N-Oct proteins to Oct-1 and Oct-2A was analyzed by proteolytic clipping bandshift assays and by their reactivity towards antisera raised against recombinant Oct-1 and Oct-2A proteins. On the basis of these assays, all N-Oct-factors were found to be distinct from the ubiquitous Oct-1 and the lymphoid-specific Oct-2A proteins. In melanoma cells that contain the N-Oct-3 factor, a transfected lymphocyte-specific promoter was neither activated nor was it repressed upon contransfection with an Oct-2A expression vector. We therefore speculate that N-Oct-3 and other N-Oct factors have a specific role in gene expression in cells of the nervous system.
[ "Astrocytes", "and", "glioblastoma", "cells", "express", "novel", "octamer", "-", "DNA", "binding", "proteins", "distinct", "from", "the", "ubiquitous", "Oct-1", "and", "B", "cell", "type", "Oct-2", "proteins", ".", "\n", "The", "'", "octamer", "'", "sequence", ",", "ATGCAAAT", "or", "its", "complement", "ATTTGCAT", ",", "is", "a", "key", "element", "for", "the", "transcriptional", "regulation", "of", "immunoglobulin", "genes", "in", "B", "-", "lymphocytes", "as", "well", "as", "a", "number", "of", "housekeeping", "genes", "in", "all", "cell", "types", ".", "In", "lymphocytes", ",", "the", "octamer", "-", "binding", "protein", "Oct-2A", "and", "variants", "thereof", "are", "thought", "to", "contribute", "to", "the", "B", "-", "cell", "specific", "gene", "expression", ",", "while", "the", "ubiquitous", "protein", "Oct-1", "seems", "to", "control", "general", "octamer", "site", "-", "dependent", "transcription", ".", "Various", "other", "genes", ",", "for", "example", "interleukin-1", "and", "MHC", "class", "II", "genes", ",", "contain", "an", "octamer", "sequence", "in", "the", "promoter", "and", "are", "expressed", "in", "cells", "of", "both", "the", "immune", "and", "nervous", "systems", ".", "This", "prompted", "us", "to", "analyze", "the", "octamer", "-", "binding", "proteins", "in", "the", "latter", "cells", ".", "Using", "the", "electrophoretic", "mobility", "shift", "assay", ",", "at", "least", "six", "novel", "octamer", "binding", "proteins", "were", "detected", "in", "nuclear", "extracts", "of", "cultured", "mouse", "astrocytes", ".", "These", "proteins", "are", "differentially", "expressed", "in", "human", "glioblastoma", "and", "neuroblastoma", "cell", "lines", ".", "The", "nervous", "system", "-", "derived", "(", "N", "-", "Oct", ")", "proteins", "bound", "to", "the", "octamer", "DNA", "sequence", "in", "a", "manner", "which", "is", "indistinguishable", "from", "the", "Oct-1", "and", "Oct-2A", "proteins", ".", "The", "relationship", "of", "the", "N", "-", "Oct", "proteins", "to", "Oct-1", "and", "Oct-2A", "was", "analyzed", "by", "proteolytic", "clipping", "bandshift", "assays", "and", "by", "their", "reactivity", "towards", "antisera", "raised", "against", "recombinant", "Oct-1", "and", "Oct-2A", "proteins", ".", "On", "the", "basis", "of", "these", "assays", ",", "all", "N", "-", "Oct", "-", "factors", "were", "found", "to", "be", "distinct", "from", "the", "ubiquitous", "Oct-1", "and", "the", "lymphoid", "-", "specific", "Oct-2A", "proteins", ".", "In", "melanoma", "cells", "that", "contain", "the", "N", "-", "Oct-3", "factor", ",", "a", "transfected", "lymphocyte", "-", "specific", "promoter", "was", "neither", "activated", "nor", "was", "it", "repressed", "upon", "contransfection", "with", "an", "Oct-2A", "expression", "vector", ".", "We", "therefore", "speculate", "that", "N", "-", "Oct-3", "and", "other", "N", "-", "Oct", "factors", "have", "a", "specific", "role", "in", "gene", "expression", "in", "cells", "of", "the", "nervous", "system", "." ]
[ "Protein" ]
Oct-1, Oct-2, Oct-2A, Oct-1, Oct-1, Oct-2A, Oct-1, Oct-2A, Oct-1, Oct-2A, Oct-1, Oct-2A, N - Oct-3, Oct-2A, N - Oct-3
2216722_task2
Sentence: Astrocytes and glioblastoma cells express novel octamer-DNA binding proteins distinct from the ubiquitous Oct-1 and B cell type Oct-2 proteins. The 'octamer' sequence, ATGCAAAT or its complement ATTTGCAT, is a key element for the transcriptional regulation of immunoglobulin genes in B-lymphocytes as well as a number of housekeeping genes in all cell types. In lymphocytes, the octamer-binding protein Oct-2A and variants thereof are thought to contribute to the B-cell specific gene expression, while the ubiquitous protein Oct-1 seems to control general octamer site-dependent transcription. Various other genes, for example interleukin-1 and MHC class II genes, contain an octamer sequence in the promoter and are expressed in cells of both the immune and nervous systems. This prompted us to analyze the octamer-binding proteins in the latter cells. Using the electrophoretic mobility shift assay, at least six novel octamer binding proteins were detected in nuclear extracts of cultured mouse astrocytes. These proteins are differentially expressed in human glioblastoma and neuroblastoma cell lines. The nervous system-derived (N-Oct) proteins bound to the octamer DNA sequence in a manner which is indistinguishable from the Oct-1 and Oct-2A proteins. The relationship of the N-Oct proteins to Oct-1 and Oct-2A was analyzed by proteolytic clipping bandshift assays and by their reactivity towards antisera raised against recombinant Oct-1 and Oct-2A proteins. On the basis of these assays, all N-Oct-factors were found to be distinct from the ubiquitous Oct-1 and the lymphoid-specific Oct-2A proteins. In melanoma cells that contain the N-Oct-3 factor, a transfected lymphocyte-specific promoter was neither activated nor was it repressed upon contransfection with an Oct-2A expression vector. We therefore speculate that N-Oct-3 and other N-Oct factors have a specific role in gene expression in cells of the nervous system. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Astrocytes and glioblastoma cells express novel octamer-DNA binding proteins distinct from the ubiquitous Oct-1 and B cell type Oct-2 proteins. The 'octamer' sequence, ATGCAAAT or its complement ATTTGCAT, is a key element for the transcriptional regulation of immunoglobulin genes in B-lymphocytes as well as a number of housekeeping genes in all cell types. In lymphocytes, the octamer-binding protein Oct-2A and variants thereof are thought to contribute to the B-cell specific gene expression, while the ubiquitous protein Oct-1 seems to control general octamer site-dependent transcription. Various other genes, for example interleukin-1 and MHC class II genes, contain an octamer sequence in the promoter and are expressed in cells of both the immune and nervous systems. This prompted us to analyze the octamer-binding proteins in the latter cells. Using the electrophoretic mobility shift assay, at least six novel octamer binding proteins were detected in nuclear extracts of cultured mouse astrocytes. These proteins are differentially expressed in human glioblastoma and neuroblastoma cell lines. The nervous system-derived (N-Oct) proteins bound to the octamer DNA sequence in a manner which is indistinguishable from the Oct-1 and Oct-2A proteins. The relationship of the N-Oct proteins to Oct-1 and Oct-2A was analyzed by proteolytic clipping bandshift assays and by their reactivity towards antisera raised against recombinant Oct-1 and Oct-2A proteins. On the basis of these assays, all N-Oct-factors were found to be distinct from the ubiquitous Oct-1 and the lymphoid-specific Oct-2A proteins. In melanoma cells that contain the N-Oct-3 factor, a transfected lymphocyte-specific promoter was neither activated nor was it repressed upon contransfection with an Oct-2A expression vector. We therefore speculate that N-Oct-3 and other N-Oct factors have a specific role in gene expression in cells of the nervous system.
[ "Astrocytes", "and", "glioblastoma", "cells", "express", "novel", "octamer", "-", "DNA", "binding", "proteins", "distinct", "from", "the", "ubiquitous", "Oct-1", "and", "B", "cell", "type", "Oct-2", "proteins", ".", "\n", "The", "'", "octamer", "'", "sequence", ",", "ATGCAAAT", "or", "its", "complement", "ATTTGCAT", ",", "is", "a", "key", "element", "for", "the", "transcriptional", "regulation", "of", "immunoglobulin", "genes", "in", "B", "-", "lymphocytes", "as", "well", "as", "a", "number", "of", "housekeeping", "genes", "in", "all", "cell", "types", ".", "In", "lymphocytes", ",", "the", "octamer", "-", "binding", "protein", "Oct-2A", "and", "variants", "thereof", "are", "thought", "to", "contribute", "to", "the", "B", "-", "cell", "specific", "gene", "expression", ",", "while", "the", "ubiquitous", "protein", "Oct-1", "seems", "to", "control", "general", "octamer", "site", "-", "dependent", "transcription", ".", "Various", "other", "genes", ",", "for", "example", "interleukin-1", "and", "MHC", "class", "II", "genes", ",", "contain", "an", "octamer", "sequence", "in", "the", "promoter", "and", "are", "expressed", "in", "cells", "of", "both", "the", "immune", "and", "nervous", "systems", ".", "This", "prompted", "us", "to", "analyze", "the", "octamer", "-", "binding", "proteins", "in", "the", "latter", "cells", ".", "Using", "the", "electrophoretic", "mobility", "shift", "assay", ",", "at", "least", "six", "novel", "octamer", "binding", "proteins", "were", "detected", "in", "nuclear", "extracts", "of", "cultured", "mouse", "astrocytes", ".", "These", "proteins", "are", "differentially", "expressed", "in", "human", "glioblastoma", "and", "neuroblastoma", "cell", "lines", ".", "The", "nervous", "system", "-", "derived", "(", "N", "-", "Oct", ")", "proteins", "bound", "to", "the", "octamer", "DNA", "sequence", "in", "a", "manner", "which", "is", "indistinguishable", "from", "the", "Oct-1", "and", "Oct-2A", "proteins", ".", "The", "relationship", "of", "the", "N", "-", "Oct", "proteins", "to", "Oct-1", "and", "Oct-2A", "was", "analyzed", "by", "proteolytic", "clipping", "bandshift", "assays", "and", "by", "their", "reactivity", "towards", "antisera", "raised", "against", "recombinant", "Oct-1", "and", "Oct-2A", "proteins", ".", "On", "the", "basis", "of", "these", "assays", ",", "all", "N", "-", "Oct", "-", "factors", "were", "found", "to", "be", "distinct", "from", "the", "ubiquitous", "Oct-1", "and", "the", "lymphoid", "-", "specific", "Oct-2A", "proteins", ".", "In", "melanoma", "cells", "that", "contain", "the", "N", "-", "Oct-3", "factor", ",", "a", "transfected", "lymphocyte", "-", "specific", "promoter", "was", "neither", "activated", "nor", "was", "it", "repressed", "upon", "contransfection", "with", "an", "Oct-2A", "expression", "vector", ".", "We", "therefore", "speculate", "that", "N", "-", "Oct-3", "and", "other", "N", "-", "Oct", "factors", "have", "a", "specific", "role", "in", "gene", "expression", "in", "cells", "of", "the", "nervous", "system", "." ]
[ "Protein" ]
incidence is an umlsterm, arrhythmias is an umlsterm, patients is an umlsterm, hypertension is an umlsterm, times is an umlsterm, risk is an umlsterm, left ventricular hypertrophy is an umlsterm, LVH is an umlsterm, left ventricular function is an umlsterm, LVH is an umlsterm, incidence is an umlsterm, criteria is an umlsterm, patients is an umlsterm, risk is an umlsterm, hypertension is an umlsterm, muscle is an umlsterm, index is an umlsterm, ventricular tachycardias is an umlsterm, life is an umlsterm, arrhythmias is an umlsterm
ZfuerKardiologie.0089iii36.eng.abstr_task0
Sentence: The incidence of supraventricular and ventricular arrhythmias in patients with arterial hypertension is up to 96% and is about 10 times higher than in normotensives . Predictors for an increased ventricular arrhythmogenic risk are left ventricular hypertrophy ( LVH ) , impaired left ventricular function with enlarged enddiastolic and endsystolic volumes as well as late potentials which in case of LVH increased from a 7% to 18% incidence . Especially the Simson criteria fQRS and RMS seem to characterize patients at risk . In addition a longer duration of hypertension in conjunction with a higher muscle mass index and a larger amount of couplets and non-sustained ventricular tachycardias , documented by Holter recording , are determinants of life threatening arrhythmias . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]
The incidence of supraventricular and ventricular arrhythmias in patients with arterial hypertension is up to 96% and is about 10 times higher than in normotensives . Predictors for an increased ventricular arrhythmogenic risk are left ventricular hypertrophy ( LVH ) , impaired left ventricular function with enlarged enddiastolic and endsystolic volumes as well as late potentials which in case of LVH increased from a 7% to 18% incidence . Especially the Simson criteria fQRS and RMS seem to characterize patients at risk . In addition a longer duration of hypertension in conjunction with a higher muscle mass index and a larger amount of couplets and non-sustained ventricular tachycardias , documented by Holter recording , are determinants of life threatening arrhythmias .
[ "The", "incidence", "of", "supraventricular", "and", "ventricular", "arrhythmias", "in", "patients", "with", "arterial", "hypertension", "is", "up", "to", "96", "%", "and", "is", "about", "10", "times", "higher", "than", "in", "normotensives", ".", "Predictors", "for", "an", "increased", "ventricular", "arrhythmogenic", "risk", "are", "left", "ventricular", "hypertrophy", "(", "LVH", ")", ",", "impaired", "left", "ventricular", "function", "with", "enlarged", "enddiastolic", "and", "endsystolic", "volumes", "as", "well", "as", "late", "potentials", "which", "in", "case", "of", "LVH", "increased", "from", "a", "7", "%", "to", "18", "%", "incidence", ".", "Especially", "the", "Simson", "criteria", "fQRS", "and", "RMS", "seem", "to", "characterize", "patients", "at", "risk", ".", "In", "addition", "a", "longer", "duration", "of", "hypertension", "in", "conjunction", "with", "a", "higher", "muscle", "mass", "index", "and", "a", "larger", "amount", "of", "couplets", "and", "non", "-", "sustained", "ventricular", "tachycardias", ",", "documented", "by", "Holter", "recording", ",", "are", "determinants", "of", "life", "threatening", "arrhythmias", "." ]
[ "umlsterm" ]
incidence is an umlsterm, arrhythmias is an umlsterm, patients is an umlsterm, hypertension is an umlsterm, times is an umlsterm, risk is an umlsterm, left ventricular hypertrophy is an umlsterm, LVH is an umlsterm, left ventricular function is an umlsterm, LVH is an umlsterm, incidence is an umlsterm, criteria is an umlsterm, patients is an umlsterm, risk is an umlsterm, hypertension is an umlsterm, muscle is an umlsterm, index is an umlsterm, ventricular tachycardias is an umlsterm, life is an umlsterm, arrhythmias is an umlsterm
ZfuerKardiologie.0089iii36.eng.abstr_task1
Sentence: The incidence of supraventricular and ventricular arrhythmias in patients with arterial hypertension is up to 96% and is about 10 times higher than in normotensives . Predictors for an increased ventricular arrhythmogenic risk are left ventricular hypertrophy ( LVH ) , impaired left ventricular function with enlarged enddiastolic and endsystolic volumes as well as late potentials which in case of LVH increased from a 7% to 18% incidence . Especially the Simson criteria fQRS and RMS seem to characterize patients at risk . In addition a longer duration of hypertension in conjunction with a higher muscle mass index and a larger amount of couplets and non-sustained ventricular tachycardias , documented by Holter recording , are determinants of life threatening arrhythmias . Instructions: please typing these entity words according to sentence: incidence, arrhythmias, patients, hypertension, times, risk, left ventricular hypertrophy, LVH, left ventricular function, LVH, incidence, criteria, patients, risk, hypertension, muscle, index, ventricular tachycardias, life, arrhythmias Options: umlsterm
[ "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]
The incidence of supraventricular and ventricular arrhythmias in patients with arterial hypertension is up to 96% and is about 10 times higher than in normotensives . Predictors for an increased ventricular arrhythmogenic risk are left ventricular hypertrophy ( LVH ) , impaired left ventricular function with enlarged enddiastolic and endsystolic volumes as well as late potentials which in case of LVH increased from a 7% to 18% incidence . Especially the Simson criteria fQRS and RMS seem to characterize patients at risk . In addition a longer duration of hypertension in conjunction with a higher muscle mass index and a larger amount of couplets and non-sustained ventricular tachycardias , documented by Holter recording , are determinants of life threatening arrhythmias .
[ "The", "incidence", "of", "supraventricular", "and", "ventricular", "arrhythmias", "in", "patients", "with", "arterial", "hypertension", "is", "up", "to", "96", "%", "and", "is", "about", "10", "times", "higher", "than", "in", "normotensives", ".", "Predictors", "for", "an", "increased", "ventricular", "arrhythmogenic", "risk", "are", "left", "ventricular", "hypertrophy", "(", "LVH", ")", ",", "impaired", "left", "ventricular", "function", "with", "enlarged", "enddiastolic", "and", "endsystolic", "volumes", "as", "well", "as", "late", "potentials", "which", "in", "case", "of", "LVH", "increased", "from", "a", "7", "%", "to", "18", "%", "incidence", ".", "Especially", "the", "Simson", "criteria", "fQRS", "and", "RMS", "seem", "to", "characterize", "patients", "at", "risk", ".", "In", "addition", "a", "longer", "duration", "of", "hypertension", "in", "conjunction", "with", "a", "higher", "muscle", "mass", "index", "and", "a", "larger", "amount", "of", "couplets", "and", "non", "-", "sustained", "ventricular", "tachycardias", ",", "documented", "by", "Holter", "recording", ",", "are", "determinants", "of", "life", "threatening", "arrhythmias", "." ]
[ "umlsterm" ]
incidence, arrhythmias, patients, hypertension, times, risk, left ventricular hypertrophy, LVH, left ventricular function, LVH, incidence, criteria, patients, risk, hypertension, muscle, index, ventricular tachycardias, life, arrhythmias
ZfuerKardiologie.0089iii36.eng.abstr_task2
Sentence: The incidence of supraventricular and ventricular arrhythmias in patients with arterial hypertension is up to 96% and is about 10 times higher than in normotensives . Predictors for an increased ventricular arrhythmogenic risk are left ventricular hypertrophy ( LVH ) , impaired left ventricular function with enlarged enddiastolic and endsystolic volumes as well as late potentials which in case of LVH increased from a 7% to 18% incidence . Especially the Simson criteria fQRS and RMS seem to characterize patients at risk . In addition a longer duration of hypertension in conjunction with a higher muscle mass index and a larger amount of couplets and non-sustained ventricular tachycardias , documented by Holter recording , are determinants of life threatening arrhythmias . Instructions: please extract entity words from the input sentence
[ "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]
The incidence of supraventricular and ventricular arrhythmias in patients with arterial hypertension is up to 96% and is about 10 times higher than in normotensives . Predictors for an increased ventricular arrhythmogenic risk are left ventricular hypertrophy ( LVH ) , impaired left ventricular function with enlarged enddiastolic and endsystolic volumes as well as late potentials which in case of LVH increased from a 7% to 18% incidence . Especially the Simson criteria fQRS and RMS seem to characterize patients at risk . In addition a longer duration of hypertension in conjunction with a higher muscle mass index and a larger amount of couplets and non-sustained ventricular tachycardias , documented by Holter recording , are determinants of life threatening arrhythmias .
[ "The", "incidence", "of", "supraventricular", "and", "ventricular", "arrhythmias", "in", "patients", "with", "arterial", "hypertension", "is", "up", "to", "96", "%", "and", "is", "about", "10", "times", "higher", "than", "in", "normotensives", ".", "Predictors", "for", "an", "increased", "ventricular", "arrhythmogenic", "risk", "are", "left", "ventricular", "hypertrophy", "(", "LVH", ")", ",", "impaired", "left", "ventricular", "function", "with", "enlarged", "enddiastolic", "and", "endsystolic", "volumes", "as", "well", "as", "late", "potentials", "which", "in", "case", "of", "LVH", "increased", "from", "a", "7", "%", "to", "18", "%", "incidence", ".", "Especially", "the", "Simson", "criteria", "fQRS", "and", "RMS", "seem", "to", "characterize", "patients", "at", "risk", ".", "In", "addition", "a", "longer", "duration", "of", "hypertension", "in", "conjunction", "with", "a", "higher", "muscle", "mass", "index", "and", "a", "larger", "amount", "of", "couplets", "and", "non", "-", "sustained", "ventricular", "tachycardias", ",", "documented", "by", "Holter", "recording", ",", "are", "determinants", "of", "life", "threatening", "arrhythmias", "." ]
[ "umlsterm" ]
complications is an umlsterm, patients is an umlsterm, multiple injuries is an umlsterm, release is an umlsterm, mediators is an umlsterm, trauma is an umlsterm, syndrome is an umlsterm, SIRS is an umlsterm, multisystem organ failure is an umlsterm, mortality is an umlsterm, development is an umlsterm, multiple organ failure is an umlsterm, trauma is an umlsterm, dysfunction is an umlsterm, manuscript is an umlsterm, trauma is an umlsterm, research is an umlsterm, evaluation is an umlsterm, findings is an umlsterm, trauma is an umlsterm, patients is an umlsterm, role is an umlsterm, cytokines is an umlsterm, development is an umlsterm, SIRS is an umlsterm, immunology is an umlsterm, dysfunction is an umlsterm, trauma is an umlsterm, therapeutic is an umlsterm, efforts is an umlsterm
DerChirurg.70681066.eng.abstr_task0
Sentence: Immunologial complications frequently occur during the clinical course in patients with multiple injuries . The increased release of pro-inflammatory mediators during the immunological response to trauma may lead to the systemic inflammatory response syndrome ( SIRS ) and furthermore , to multisystem organ failure ( MOF ) , which is associated with a mortality of up to 80% . The development of multiple organ failure following major trauma is associated with remote organ failure , the dysfunction of organs which were not initially affected by the traum . This manuscript reviews recent data in experimental trauma research and offers a more detailed evaluation of the immunological findings in trauma patients . In particular , the role of pro- and anti-inflammatory cytokines in the development or SIRS , MOF and ROF is discussed . Despite the enormous progress in clinical immunology and the available data on trauma-induced immune dysfunction , a large number of questions still remain to be answered before the immunological alterations following severe trauma can be beneficially influenced by immunomodulatory therapeutic efforts . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O" ]
Immunologial complications frequently occur during the clinical course in patients with multiple injuries . The increased release of pro-inflammatory mediators during the immunological response to trauma may lead to the systemic inflammatory response syndrome ( SIRS ) and furthermore , to multisystem organ failure ( MOF ) , which is associated with a mortality of up to 80% . The development of multiple organ failure following major trauma is associated with remote organ failure , the dysfunction of organs which were not initially affected by the traum . This manuscript reviews recent data in experimental trauma research and offers a more detailed evaluation of the immunological findings in trauma patients . In particular , the role of pro- and anti-inflammatory cytokines in the development or SIRS , MOF and ROF is discussed . Despite the enormous progress in clinical immunology and the available data on trauma-induced immune dysfunction , a large number of questions still remain to be answered before the immunological alterations following severe trauma can be beneficially influenced by immunomodulatory therapeutic efforts .
[ "Immunologial", "complications", "frequently", "occur", "during", "the", "clinical", "course", "in", "patients", "with", "multiple", "injuries", ".", "The", "increased", "release", "of", "pro", "-", "inflammatory", "mediators", "during", "the", "immunological", "response", "to", "trauma", "may", "lead", "to", "the", "systemic", "inflammatory", "response", "syndrome", "(", "SIRS", ")", "and", "furthermore", ",", "to", "multisystem", "organ", "failure", "(", "MOF", ")", ",", "which", "is", "associated", "with", "a", "mortality", "of", "up", "to", "80", "%", ".", "The", "development", "of", "multiple", "organ", "failure", "following", "major", "trauma", "is", "associated", "with", "remote", "organ", "failure", ",", "the", "dysfunction", "of", "organs", "which", "were", "not", "initially", "affected", "by", "the", "traum", ".", "This", "manuscript", "reviews", "recent", "data", "in", "experimental", "trauma", "research", "and", "offers", "a", "more", "detailed", "evaluation", "of", "the", "immunological", "findings", "in", "trauma", "patients", ".", "In", "particular", ",", "the", "role", "of", "pro-", "and", "anti", "-", "inflammatory", "cytokines", "in", "the", "development", "or", "SIRS", ",", "MOF", "and", "ROF", "is", "discussed", ".", "Despite", "the", "enormous", "progress", "in", "clinical", "immunology", "and", "the", "available", "data", "on", "trauma", "-", "induced", "immune", "dysfunction", ",", "a", "large", "number", "of", "questions", "still", "remain", "to", "be", "answered", "before", "the", "immunological", "alterations", "following", "severe", "trauma", "can", "be", "beneficially", "influenced", "by", "immunomodulatory", "therapeutic", "efforts", "." ]
[ "umlsterm" ]
complications is an umlsterm, patients is an umlsterm, multiple injuries is an umlsterm, release is an umlsterm, mediators is an umlsterm, trauma is an umlsterm, syndrome is an umlsterm, SIRS is an umlsterm, multisystem organ failure is an umlsterm, mortality is an umlsterm, development is an umlsterm, multiple organ failure is an umlsterm, trauma is an umlsterm, dysfunction is an umlsterm, manuscript is an umlsterm, trauma is an umlsterm, research is an umlsterm, evaluation is an umlsterm, findings is an umlsterm, trauma is an umlsterm, patients is an umlsterm, role is an umlsterm, cytokines is an umlsterm, development is an umlsterm, SIRS is an umlsterm, immunology is an umlsterm, dysfunction is an umlsterm, trauma is an umlsterm, therapeutic is an umlsterm, efforts is an umlsterm
DerChirurg.70681066.eng.abstr_task1
Sentence: Immunologial complications frequently occur during the clinical course in patients with multiple injuries . The increased release of pro-inflammatory mediators during the immunological response to trauma may lead to the systemic inflammatory response syndrome ( SIRS ) and furthermore , to multisystem organ failure ( MOF ) , which is associated with a mortality of up to 80% . The development of multiple organ failure following major trauma is associated with remote organ failure , the dysfunction of organs which were not initially affected by the traum . This manuscript reviews recent data in experimental trauma research and offers a more detailed evaluation of the immunological findings in trauma patients . In particular , the role of pro- and anti-inflammatory cytokines in the development or SIRS , MOF and ROF is discussed . Despite the enormous progress in clinical immunology and the available data on trauma-induced immune dysfunction , a large number of questions still remain to be answered before the immunological alterations following severe trauma can be beneficially influenced by immunomodulatory therapeutic efforts . Instructions: please typing these entity words according to sentence: complications, patients, multiple injuries, release, mediators, trauma, syndrome, SIRS, multisystem organ failure, mortality, development, multiple organ failure, trauma, dysfunction, manuscript, trauma, research, evaluation, findings, trauma, patients, role, cytokines, development, SIRS, immunology, dysfunction, trauma, therapeutic, efforts Options: umlsterm
[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O" ]
Immunologial complications frequently occur during the clinical course in patients with multiple injuries . The increased release of pro-inflammatory mediators during the immunological response to trauma may lead to the systemic inflammatory response syndrome ( SIRS ) and furthermore , to multisystem organ failure ( MOF ) , which is associated with a mortality of up to 80% . The development of multiple organ failure following major trauma is associated with remote organ failure , the dysfunction of organs which were not initially affected by the traum . This manuscript reviews recent data in experimental trauma research and offers a more detailed evaluation of the immunological findings in trauma patients . In particular , the role of pro- and anti-inflammatory cytokines in the development or SIRS , MOF and ROF is discussed . Despite the enormous progress in clinical immunology and the available data on trauma-induced immune dysfunction , a large number of questions still remain to be answered before the immunological alterations following severe trauma can be beneficially influenced by immunomodulatory therapeutic efforts .
[ "Immunologial", "complications", "frequently", "occur", "during", "the", "clinical", "course", "in", "patients", "with", "multiple", "injuries", ".", "The", "increased", "release", "of", "pro", "-", "inflammatory", "mediators", "during", "the", "immunological", "response", "to", "trauma", "may", "lead", "to", "the", "systemic", "inflammatory", "response", "syndrome", "(", "SIRS", ")", "and", "furthermore", ",", "to", "multisystem", "organ", "failure", "(", "MOF", ")", ",", "which", "is", "associated", "with", "a", "mortality", "of", "up", "to", "80", "%", ".", "The", "development", "of", "multiple", "organ", "failure", "following", "major", "trauma", "is", "associated", "with", "remote", "organ", "failure", ",", "the", "dysfunction", "of", "organs", "which", "were", "not", "initially", "affected", "by", "the", "traum", ".", "This", "manuscript", "reviews", "recent", "data", "in", "experimental", "trauma", "research", "and", "offers", "a", "more", "detailed", "evaluation", "of", "the", "immunological", "findings", "in", "trauma", "patients", ".", "In", "particular", ",", "the", "role", "of", "pro-", "and", "anti", "-", "inflammatory", "cytokines", "in", "the", "development", "or", "SIRS", ",", "MOF", "and", "ROF", "is", "discussed", ".", "Despite", "the", "enormous", "progress", "in", "clinical", "immunology", "and", "the", "available", "data", "on", "trauma", "-", "induced", "immune", "dysfunction", ",", "a", "large", "number", "of", "questions", "still", "remain", "to", "be", "answered", "before", "the", "immunological", "alterations", "following", "severe", "trauma", "can", "be", "beneficially", "influenced", "by", "immunomodulatory", "therapeutic", "efforts", "." ]
[ "umlsterm" ]
complications, patients, multiple injuries, release, mediators, trauma, syndrome, SIRS, multisystem organ failure, mortality, development, multiple organ failure, trauma, dysfunction, manuscript, trauma, research, evaluation, findings, trauma, patients, role, cytokines, development, SIRS, immunology, dysfunction, trauma, therapeutic, efforts
DerChirurg.70681066.eng.abstr_task2
Sentence: Immunologial complications frequently occur during the clinical course in patients with multiple injuries . The increased release of pro-inflammatory mediators during the immunological response to trauma may lead to the systemic inflammatory response syndrome ( SIRS ) and furthermore , to multisystem organ failure ( MOF ) , which is associated with a mortality of up to 80% . The development of multiple organ failure following major trauma is associated with remote organ failure , the dysfunction of organs which were not initially affected by the traum . This manuscript reviews recent data in experimental trauma research and offers a more detailed evaluation of the immunological findings in trauma patients . In particular , the role of pro- and anti-inflammatory cytokines in the development or SIRS , MOF and ROF is discussed . Despite the enormous progress in clinical immunology and the available data on trauma-induced immune dysfunction , a large number of questions still remain to be answered before the immunological alterations following severe trauma can be beneficially influenced by immunomodulatory therapeutic efforts . Instructions: please extract entity words from the input sentence
[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O" ]
Immunologial complications frequently occur during the clinical course in patients with multiple injuries . The increased release of pro-inflammatory mediators during the immunological response to trauma may lead to the systemic inflammatory response syndrome ( SIRS ) and furthermore , to multisystem organ failure ( MOF ) , which is associated with a mortality of up to 80% . The development of multiple organ failure following major trauma is associated with remote organ failure , the dysfunction of organs which were not initially affected by the traum . This manuscript reviews recent data in experimental trauma research and offers a more detailed evaluation of the immunological findings in trauma patients . In particular , the role of pro- and anti-inflammatory cytokines in the development or SIRS , MOF and ROF is discussed . Despite the enormous progress in clinical immunology and the available data on trauma-induced immune dysfunction , a large number of questions still remain to be answered before the immunological alterations following severe trauma can be beneficially influenced by immunomodulatory therapeutic efforts .
[ "Immunologial", "complications", "frequently", "occur", "during", "the", "clinical", "course", "in", "patients", "with", "multiple", "injuries", ".", "The", "increased", "release", "of", "pro", "-", "inflammatory", "mediators", "during", "the", "immunological", "response", "to", "trauma", "may", "lead", "to", "the", "systemic", "inflammatory", "response", "syndrome", "(", "SIRS", ")", "and", "furthermore", ",", "to", "multisystem", "organ", "failure", "(", "MOF", ")", ",", "which", "is", "associated", "with", "a", "mortality", "of", "up", "to", "80", "%", ".", "The", "development", "of", "multiple", "organ", "failure", "following", "major", "trauma", "is", "associated", "with", "remote", "organ", "failure", ",", "the", "dysfunction", "of", "organs", "which", "were", "not", "initially", "affected", "by", "the", "traum", ".", "This", "manuscript", "reviews", "recent", "data", "in", "experimental", "trauma", "research", "and", "offers", "a", "more", "detailed", "evaluation", "of", "the", "immunological", "findings", "in", "trauma", "patients", ".", "In", "particular", ",", "the", "role", "of", "pro-", "and", "anti", "-", "inflammatory", "cytokines", "in", "the", "development", "or", "SIRS", ",", "MOF", "and", "ROF", "is", "discussed", ".", "Despite", "the", "enormous", "progress", "in", "clinical", "immunology", "and", "the", "available", "data", "on", "trauma", "-", "induced", "immune", "dysfunction", ",", "a", "large", "number", "of", "questions", "still", "remain", "to", "be", "answered", "before", "the", "immunological", "alterations", "following", "severe", "trauma", "can", "be", "beneficially", "influenced", "by", "immunomodulatory", "therapeutic", "efforts", "." ]
[ "umlsterm" ]
Embolie is an umlsterm, Cholesterinembolie is an umlsterm, Diagnose is an umlsterm, Cholesterinembolie is an umlsterm, Komplikation is an umlsterm, Atherosklerose is an umlsterm, Aorta is an umlsterm, Echokardiographie is an umlsterm, Routinemethode is an umlsterm, Embolien is an umlsterm, Aorta is an umlsterm, Embolien is an umlsterm, Assoziation is an umlsterm, Aortenbogen is an umlsterm, Embolien is an umlsterm, Patienten is an umlsterm, Patientenjahr is an umlsterm, Aortenbogen is an umlsterm, Embolien is an umlsterm, Embolie is an umlsterm, Atherosklerose is an umlsterm, Aorta is an umlsterm, Komplikationen is an umlsterm, Aorta is an umlsterm, Therapie is an umlsterm, Patienten is an umlsterm, Atherosklerose is an umlsterm, Aorta is an umlsterm, Embolierezidive is an umlsterm
ZfuerKardiologie.80870789.ger.abstr_task0
Sentence: Die athero-arterielle Embolie ist ein bereits frueh beschriebenes Phaenomen . Der histologische Nachweis von Cholesterinkristallen in kleinen Endstrombahnarterien praegte den Begriff der Cholesterinembolie . Wegen des sehr variablen klinischen Bildes und der nur invasiv oder post mortem zu sichernden Diagnose galt die Cholesterinembolie als seltene Komplikation einer schweren Atherosklerose der Aorta . Mit Etablierung der transoesophagealen Echokardiographie als Routinemethode bei der Abklaerung arterieller Embolien wurden Plaques in der Aorta als Quelle anderweitig nicht erklaerbarer Embolien erkannt . Querschnittsstudien belegten eine unabhaengige Assoziation zwischen komplexen Plaques im Aortenbogen und arteriellen Embolien . Kritische Laesionen waren Plaques mit einer Dicke von mindestens 4-5 Millimetern oder beweglichen thrombotischen Auflagerungen . In Laengsschnittsstudien betrug das Embolierisiko bei Patienten mit diesen Laesionen mehr als 10% pro Patientenjahr . Pathologische Studien bestaetigten konsistent die Bedeutung komplexer und ulzerativer Plaques im Aortenbogen als unabhaengigen Risikofaktor fuer arterielle Embolien . Neben der spontanen Embolie ist die Atherosklerose der proximalen Aorta Ursache fuer embolische Komplikationen bei operativen Eingriffen oder Katheterisierungen der Aorta . Die Wirksamkeit einer praeventiven Therapie wurde bisher nicht systematisch untersucht . Bei Patienten mit einer besonderen Variante der Atherosklerose in der Aorta mit gestielten und beweglichen Thromben , die von umschriebenen Plaques ausgehen , erwiesen sich Antikoagulanzien als wirksam . Embolierezidive konnten verhindert und eine Regression der Thromben beobachtet werden . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Die athero-arterielle Embolie ist ein bereits frueh beschriebenes Phaenomen . Der histologische Nachweis von Cholesterinkristallen in kleinen Endstrombahnarterien praegte den Begriff der Cholesterinembolie . Wegen des sehr variablen klinischen Bildes und der nur invasiv oder post mortem zu sichernden Diagnose galt die Cholesterinembolie als seltene Komplikation einer schweren Atherosklerose der Aorta . Mit Etablierung der transoesophagealen Echokardiographie als Routinemethode bei der Abklaerung arterieller Embolien wurden Plaques in der Aorta als Quelle anderweitig nicht erklaerbarer Embolien erkannt . Querschnittsstudien belegten eine unabhaengige Assoziation zwischen komplexen Plaques im Aortenbogen und arteriellen Embolien . Kritische Laesionen waren Plaques mit einer Dicke von mindestens 4-5 Millimetern oder beweglichen thrombotischen Auflagerungen . In Laengsschnittsstudien betrug das Embolierisiko bei Patienten mit diesen Laesionen mehr als 10% pro Patientenjahr . Pathologische Studien bestaetigten konsistent die Bedeutung komplexer und ulzerativer Plaques im Aortenbogen als unabhaengigen Risikofaktor fuer arterielle Embolien . Neben der spontanen Embolie ist die Atherosklerose der proximalen Aorta Ursache fuer embolische Komplikationen bei operativen Eingriffen oder Katheterisierungen der Aorta . Die Wirksamkeit einer praeventiven Therapie wurde bisher nicht systematisch untersucht . Bei Patienten mit einer besonderen Variante der Atherosklerose in der Aorta mit gestielten und beweglichen Thromben , die von umschriebenen Plaques ausgehen , erwiesen sich Antikoagulanzien als wirksam . Embolierezidive konnten verhindert und eine Regression der Thromben beobachtet werden .
[ "Die", "athero", "-", "arterielle", "Embolie", "ist", "ein", "bereits", "frueh", "beschriebenes", "Phaenomen", ".", "Der", "histologische", "Nachweis", "von", "Cholesterinkristallen", "in", "kleinen", "Endstrombahnarterien", "praegte", "den", "Begriff", "der", "Cholesterinembolie", ".", "Wegen", "des", "sehr", "variablen", "klinischen", "Bildes", "und", "der", "nur", "invasiv", "oder", "post", "mortem", "zu", "sichernden", "Diagnose", "galt", "die", "Cholesterinembolie", "als", "seltene", "Komplikation", "einer", "schweren", "Atherosklerose", "der", "Aorta", ".", "Mit", "Etablierung", "der", "transoesophagealen", "Echokardiographie", "als", "Routinemethode", "bei", "der", "Abklaerung", "arterieller", "Embolien", "wurden", "Plaques", "in", "der", "Aorta", "als", "Quelle", "anderweitig", "nicht", "erklaerbarer", "Embolien", "erkannt", ".", "Querschnittsstudien", "belegten", "eine", "unabhaengige", "Assoziation", "zwischen", "komplexen", "Plaques", "im", "Aortenbogen", "und", "arteriellen", "Embolien", ".", "Kritische", "Laesionen", "waren", "Plaques", "mit", "einer", "Dicke", "von", "mindestens", "4", "-", "5", "Millimetern", "oder", "beweglichen", "thrombotischen", "Auflagerungen", ".", "In", "Laengsschnittsstudien", "betrug", "das", "Embolierisiko", "bei", "Patienten", "mit", "diesen", "Laesionen", "mehr", "als", "10", "%", "pro", "Patientenjahr", ".", "Pathologische", "Studien", "bestaetigten", "konsistent", "die", "Bedeutung", "komplexer", "und", "ulzerativer", "Plaques", "im", "Aortenbogen", "als", "unabhaengigen", "Risikofaktor", "fuer", "arterielle", "Embolien", ".", "Neben", "der", "spontanen", "Embolie", "ist", "die", "Atherosklerose", "der", "proximalen", "Aorta", "Ursache", "fuer", "embolische", "Komplikationen", "bei", "operativen", "Eingriffen", "oder", "Katheterisierungen", "der", "Aorta", ".", "Die", "Wirksamkeit", "einer", "praeventiven", "Therapie", "wurde", "bisher", "nicht", "systematisch", "untersucht", ".", "Bei", "Patienten", "mit", "einer", "besonderen", "Variante", "der", "Atherosklerose", "in", "der", "Aorta", "mit", "gestielten", "und", "beweglichen", "Thromben", ",", "die", "von", "umschriebenen", "Plaques", "ausgehen", ",", "erwiesen", "sich", "Antikoagulanzien", "als", "wirksam", ".", "Embolierezidive", "konnten", "verhindert", "und", "eine", "Regression", "der", "Thromben", "beobachtet", "werden", "." ]
[ "umlsterm" ]
Embolie is an umlsterm, Cholesterinembolie is an umlsterm, Diagnose is an umlsterm, Cholesterinembolie is an umlsterm, Komplikation is an umlsterm, Atherosklerose is an umlsterm, Aorta is an umlsterm, Echokardiographie is an umlsterm, Routinemethode is an umlsterm, Embolien is an umlsterm, Aorta is an umlsterm, Embolien is an umlsterm, Assoziation is an umlsterm, Aortenbogen is an umlsterm, Embolien is an umlsterm, Patienten is an umlsterm, Patientenjahr is an umlsterm, Aortenbogen is an umlsterm, Embolien is an umlsterm, Embolie is an umlsterm, Atherosklerose is an umlsterm, Aorta is an umlsterm, Komplikationen is an umlsterm, Aorta is an umlsterm, Therapie is an umlsterm, Patienten is an umlsterm, Atherosklerose is an umlsterm, Aorta is an umlsterm, Embolierezidive is an umlsterm
ZfuerKardiologie.80870789.ger.abstr_task1
Sentence: Die athero-arterielle Embolie ist ein bereits frueh beschriebenes Phaenomen . Der histologische Nachweis von Cholesterinkristallen in kleinen Endstrombahnarterien praegte den Begriff der Cholesterinembolie . Wegen des sehr variablen klinischen Bildes und der nur invasiv oder post mortem zu sichernden Diagnose galt die Cholesterinembolie als seltene Komplikation einer schweren Atherosklerose der Aorta . Mit Etablierung der transoesophagealen Echokardiographie als Routinemethode bei der Abklaerung arterieller Embolien wurden Plaques in der Aorta als Quelle anderweitig nicht erklaerbarer Embolien erkannt . Querschnittsstudien belegten eine unabhaengige Assoziation zwischen komplexen Plaques im Aortenbogen und arteriellen Embolien . Kritische Laesionen waren Plaques mit einer Dicke von mindestens 4-5 Millimetern oder beweglichen thrombotischen Auflagerungen . In Laengsschnittsstudien betrug das Embolierisiko bei Patienten mit diesen Laesionen mehr als 10% pro Patientenjahr . Pathologische Studien bestaetigten konsistent die Bedeutung komplexer und ulzerativer Plaques im Aortenbogen als unabhaengigen Risikofaktor fuer arterielle Embolien . Neben der spontanen Embolie ist die Atherosklerose der proximalen Aorta Ursache fuer embolische Komplikationen bei operativen Eingriffen oder Katheterisierungen der Aorta . Die Wirksamkeit einer praeventiven Therapie wurde bisher nicht systematisch untersucht . Bei Patienten mit einer besonderen Variante der Atherosklerose in der Aorta mit gestielten und beweglichen Thromben , die von umschriebenen Plaques ausgehen , erwiesen sich Antikoagulanzien als wirksam . Embolierezidive konnten verhindert und eine Regression der Thromben beobachtet werden . Instructions: please typing these entity words according to sentence: Embolie, Cholesterinembolie, Diagnose, Cholesterinembolie, Komplikation, Atherosklerose, Aorta, Echokardiographie, Routinemethode, Embolien, Aorta, Embolien, Assoziation, Aortenbogen, Embolien, Patienten, Patientenjahr, Aortenbogen, Embolien, Embolie, Atherosklerose, Aorta, Komplikationen, Aorta, Therapie, Patienten, Atherosklerose, Aorta, Embolierezidive Options: umlsterm
[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Die athero-arterielle Embolie ist ein bereits frueh beschriebenes Phaenomen . Der histologische Nachweis von Cholesterinkristallen in kleinen Endstrombahnarterien praegte den Begriff der Cholesterinembolie . Wegen des sehr variablen klinischen Bildes und der nur invasiv oder post mortem zu sichernden Diagnose galt die Cholesterinembolie als seltene Komplikation einer schweren Atherosklerose der Aorta . Mit Etablierung der transoesophagealen Echokardiographie als Routinemethode bei der Abklaerung arterieller Embolien wurden Plaques in der Aorta als Quelle anderweitig nicht erklaerbarer Embolien erkannt . Querschnittsstudien belegten eine unabhaengige Assoziation zwischen komplexen Plaques im Aortenbogen und arteriellen Embolien . Kritische Laesionen waren Plaques mit einer Dicke von mindestens 4-5 Millimetern oder beweglichen thrombotischen Auflagerungen . In Laengsschnittsstudien betrug das Embolierisiko bei Patienten mit diesen Laesionen mehr als 10% pro Patientenjahr . Pathologische Studien bestaetigten konsistent die Bedeutung komplexer und ulzerativer Plaques im Aortenbogen als unabhaengigen Risikofaktor fuer arterielle Embolien . Neben der spontanen Embolie ist die Atherosklerose der proximalen Aorta Ursache fuer embolische Komplikationen bei operativen Eingriffen oder Katheterisierungen der Aorta . Die Wirksamkeit einer praeventiven Therapie wurde bisher nicht systematisch untersucht . Bei Patienten mit einer besonderen Variante der Atherosklerose in der Aorta mit gestielten und beweglichen Thromben , die von umschriebenen Plaques ausgehen , erwiesen sich Antikoagulanzien als wirksam . Embolierezidive konnten verhindert und eine Regression der Thromben beobachtet werden .
[ "Die", "athero", "-", "arterielle", "Embolie", "ist", "ein", "bereits", "frueh", "beschriebenes", "Phaenomen", ".", "Der", "histologische", "Nachweis", "von", "Cholesterinkristallen", "in", "kleinen", "Endstrombahnarterien", "praegte", "den", "Begriff", "der", "Cholesterinembolie", ".", "Wegen", "des", "sehr", "variablen", "klinischen", "Bildes", "und", "der", "nur", "invasiv", "oder", "post", "mortem", "zu", "sichernden", "Diagnose", "galt", "die", "Cholesterinembolie", "als", "seltene", "Komplikation", "einer", "schweren", "Atherosklerose", "der", "Aorta", ".", "Mit", "Etablierung", "der", "transoesophagealen", "Echokardiographie", "als", "Routinemethode", "bei", "der", "Abklaerung", "arterieller", "Embolien", "wurden", "Plaques", "in", "der", "Aorta", "als", "Quelle", "anderweitig", "nicht", "erklaerbarer", "Embolien", "erkannt", ".", "Querschnittsstudien", "belegten", "eine", "unabhaengige", "Assoziation", "zwischen", "komplexen", "Plaques", "im", "Aortenbogen", "und", "arteriellen", "Embolien", ".", "Kritische", "Laesionen", "waren", "Plaques", "mit", "einer", "Dicke", "von", "mindestens", "4", "-", "5", "Millimetern", "oder", "beweglichen", "thrombotischen", "Auflagerungen", ".", "In", "Laengsschnittsstudien", "betrug", "das", "Embolierisiko", "bei", "Patienten", "mit", "diesen", "Laesionen", "mehr", "als", "10", "%", "pro", "Patientenjahr", ".", "Pathologische", "Studien", "bestaetigten", "konsistent", "die", "Bedeutung", "komplexer", "und", "ulzerativer", "Plaques", "im", "Aortenbogen", "als", "unabhaengigen", "Risikofaktor", "fuer", "arterielle", "Embolien", ".", "Neben", "der", "spontanen", "Embolie", "ist", "die", "Atherosklerose", "der", "proximalen", "Aorta", "Ursache", "fuer", "embolische", "Komplikationen", "bei", "operativen", "Eingriffen", "oder", "Katheterisierungen", "der", "Aorta", ".", "Die", "Wirksamkeit", "einer", "praeventiven", "Therapie", "wurde", "bisher", "nicht", "systematisch", "untersucht", ".", "Bei", "Patienten", "mit", "einer", "besonderen", "Variante", "der", "Atherosklerose", "in", "der", "Aorta", "mit", "gestielten", "und", "beweglichen", "Thromben", ",", "die", "von", "umschriebenen", "Plaques", "ausgehen", ",", "erwiesen", "sich", "Antikoagulanzien", "als", "wirksam", ".", "Embolierezidive", "konnten", "verhindert", "und", "eine", "Regression", "der", "Thromben", "beobachtet", "werden", "." ]
[ "umlsterm" ]
Embolie, Cholesterinembolie, Diagnose, Cholesterinembolie, Komplikation, Atherosklerose, Aorta, Echokardiographie, Routinemethode, Embolien, Aorta, Embolien, Assoziation, Aortenbogen, Embolien, Patienten, Patientenjahr, Aortenbogen, Embolien, Embolie, Atherosklerose, Aorta, Komplikationen, Aorta, Therapie, Patienten, Atherosklerose, Aorta, Embolierezidive
ZfuerKardiologie.80870789.ger.abstr_task2
Sentence: Die athero-arterielle Embolie ist ein bereits frueh beschriebenes Phaenomen . Der histologische Nachweis von Cholesterinkristallen in kleinen Endstrombahnarterien praegte den Begriff der Cholesterinembolie . Wegen des sehr variablen klinischen Bildes und der nur invasiv oder post mortem zu sichernden Diagnose galt die Cholesterinembolie als seltene Komplikation einer schweren Atherosklerose der Aorta . Mit Etablierung der transoesophagealen Echokardiographie als Routinemethode bei der Abklaerung arterieller Embolien wurden Plaques in der Aorta als Quelle anderweitig nicht erklaerbarer Embolien erkannt . Querschnittsstudien belegten eine unabhaengige Assoziation zwischen komplexen Plaques im Aortenbogen und arteriellen Embolien . Kritische Laesionen waren Plaques mit einer Dicke von mindestens 4-5 Millimetern oder beweglichen thrombotischen Auflagerungen . In Laengsschnittsstudien betrug das Embolierisiko bei Patienten mit diesen Laesionen mehr als 10% pro Patientenjahr . Pathologische Studien bestaetigten konsistent die Bedeutung komplexer und ulzerativer Plaques im Aortenbogen als unabhaengigen Risikofaktor fuer arterielle Embolien . Neben der spontanen Embolie ist die Atherosklerose der proximalen Aorta Ursache fuer embolische Komplikationen bei operativen Eingriffen oder Katheterisierungen der Aorta . Die Wirksamkeit einer praeventiven Therapie wurde bisher nicht systematisch untersucht . Bei Patienten mit einer besonderen Variante der Atherosklerose in der Aorta mit gestielten und beweglichen Thromben , die von umschriebenen Plaques ausgehen , erwiesen sich Antikoagulanzien als wirksam . Embolierezidive konnten verhindert und eine Regression der Thromben beobachtet werden . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Die athero-arterielle Embolie ist ein bereits frueh beschriebenes Phaenomen . Der histologische Nachweis von Cholesterinkristallen in kleinen Endstrombahnarterien praegte den Begriff der Cholesterinembolie . Wegen des sehr variablen klinischen Bildes und der nur invasiv oder post mortem zu sichernden Diagnose galt die Cholesterinembolie als seltene Komplikation einer schweren Atherosklerose der Aorta . Mit Etablierung der transoesophagealen Echokardiographie als Routinemethode bei der Abklaerung arterieller Embolien wurden Plaques in der Aorta als Quelle anderweitig nicht erklaerbarer Embolien erkannt . Querschnittsstudien belegten eine unabhaengige Assoziation zwischen komplexen Plaques im Aortenbogen und arteriellen Embolien . Kritische Laesionen waren Plaques mit einer Dicke von mindestens 4-5 Millimetern oder beweglichen thrombotischen Auflagerungen . In Laengsschnittsstudien betrug das Embolierisiko bei Patienten mit diesen Laesionen mehr als 10% pro Patientenjahr . Pathologische Studien bestaetigten konsistent die Bedeutung komplexer und ulzerativer Plaques im Aortenbogen als unabhaengigen Risikofaktor fuer arterielle Embolien . Neben der spontanen Embolie ist die Atherosklerose der proximalen Aorta Ursache fuer embolische Komplikationen bei operativen Eingriffen oder Katheterisierungen der Aorta . Die Wirksamkeit einer praeventiven Therapie wurde bisher nicht systematisch untersucht . Bei Patienten mit einer besonderen Variante der Atherosklerose in der Aorta mit gestielten und beweglichen Thromben , die von umschriebenen Plaques ausgehen , erwiesen sich Antikoagulanzien als wirksam . Embolierezidive konnten verhindert und eine Regression der Thromben beobachtet werden .
[ "Die", "athero", "-", "arterielle", "Embolie", "ist", "ein", "bereits", "frueh", "beschriebenes", "Phaenomen", ".", "Der", "histologische", "Nachweis", "von", "Cholesterinkristallen", "in", "kleinen", "Endstrombahnarterien", "praegte", "den", "Begriff", "der", "Cholesterinembolie", ".", "Wegen", "des", "sehr", "variablen", "klinischen", "Bildes", "und", "der", "nur", "invasiv", "oder", "post", "mortem", "zu", "sichernden", "Diagnose", "galt", "die", "Cholesterinembolie", "als", "seltene", "Komplikation", "einer", "schweren", "Atherosklerose", "der", "Aorta", ".", "Mit", "Etablierung", "der", "transoesophagealen", "Echokardiographie", "als", "Routinemethode", "bei", "der", "Abklaerung", "arterieller", "Embolien", "wurden", "Plaques", "in", "der", "Aorta", "als", "Quelle", "anderweitig", "nicht", "erklaerbarer", "Embolien", "erkannt", ".", "Querschnittsstudien", "belegten", "eine", "unabhaengige", "Assoziation", "zwischen", "komplexen", "Plaques", "im", "Aortenbogen", "und", "arteriellen", "Embolien", ".", "Kritische", "Laesionen", "waren", "Plaques", "mit", "einer", "Dicke", "von", "mindestens", "4", "-", "5", "Millimetern", "oder", "beweglichen", "thrombotischen", "Auflagerungen", ".", "In", "Laengsschnittsstudien", "betrug", "das", "Embolierisiko", "bei", "Patienten", "mit", "diesen", "Laesionen", "mehr", "als", "10", "%", "pro", "Patientenjahr", ".", "Pathologische", "Studien", "bestaetigten", "konsistent", "die", "Bedeutung", "komplexer", "und", "ulzerativer", "Plaques", "im", "Aortenbogen", "als", "unabhaengigen", "Risikofaktor", "fuer", "arterielle", "Embolien", ".", "Neben", "der", "spontanen", "Embolie", "ist", "die", "Atherosklerose", "der", "proximalen", "Aorta", "Ursache", "fuer", "embolische", "Komplikationen", "bei", "operativen", "Eingriffen", "oder", "Katheterisierungen", "der", "Aorta", ".", "Die", "Wirksamkeit", "einer", "praeventiven", "Therapie", "wurde", "bisher", "nicht", "systematisch", "untersucht", ".", "Bei", "Patienten", "mit", "einer", "besonderen", "Variante", "der", "Atherosklerose", "in", "der", "Aorta", "mit", "gestielten", "und", "beweglichen", "Thromben", ",", "die", "von", "umschriebenen", "Plaques", "ausgehen", ",", "erwiesen", "sich", "Antikoagulanzien", "als", "wirksam", ".", "Embolierezidive", "konnten", "verhindert", "und", "eine", "Regression", "der", "Thromben", "beobachtet", "werden", "." ]
[ "umlsterm" ]
ribosomal protein S3 is a GENE-N, TRAF2 is a GENE-N
23188828_task0
Sentence: Phosphorylation of ribosomal protein S3 and antiapoptotic TRAF2 protein mediates radioresistance in non-small cell lung cancer cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N
[ "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Phosphorylation of ribosomal protein S3 and antiapoptotic TRAF2 protein mediates radioresistance in non-small cell lung cancer cells.
[ "Phosphorylation", "of", "ribosomal", "protein", "S3", "and", "antiapoptotic", "TRAF2", "protein", "mediates", "radioresistance", "in", "non", "-", "small", "cell", "lung", "cancer", "cells", "." ]
[ "GENE-N", "CHEMICAL" ]
ribosomal protein S3 is a GENE-N, TRAF2 is a GENE-N
23188828_task1
Sentence: Phosphorylation of ribosomal protein S3 and antiapoptotic TRAF2 protein mediates radioresistance in non-small cell lung cancer cells. Instructions: please typing these entity words according to sentence: ribosomal protein S3, TRAF2 Options: GENE-N
[ "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Phosphorylation of ribosomal protein S3 and antiapoptotic TRAF2 protein mediates radioresistance in non-small cell lung cancer cells.
[ "Phosphorylation", "of", "ribosomal", "protein", "S3", "and", "antiapoptotic", "TRAF2", "protein", "mediates", "radioresistance", "in", "non", "-", "small", "cell", "lung", "cancer", "cells", "." ]
[ "GENE-N", "CHEMICAL" ]
ribosomal protein S3, TRAF2
23188828_task2
Sentence: Phosphorylation of ribosomal protein S3 and antiapoptotic TRAF2 protein mediates radioresistance in non-small cell lung cancer cells. Instructions: please extract entity words from the input sentence
[ "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Phosphorylation of ribosomal protein S3 and antiapoptotic TRAF2 protein mediates radioresistance in non-small cell lung cancer cells.
[ "Phosphorylation", "of", "ribosomal", "protein", "S3", "and", "antiapoptotic", "TRAF2", "protein", "mediates", "radioresistance", "in", "non", "-", "small", "cell", "lung", "cancer", "cells", "." ]
[ "GENE-N", "CHEMICAL" ]
interferon beta is a Protein, NF - kappa B is a Entity, interferon beta is a Protein, IFN - beta is a Protein, regulatory element is a Entity, enhanson domains is a Entity, promoter is a Entity, DNA is a Entity, IFN - beta is a Protein, positive regulatory domain ( PRD ) II is a Entity, DNA is a Entity, tetrahexamer sequence is a Entity, PRDI domain is a Entity, IRF-1 is a Protein, ISGF2 is a Protein, IFN beta promoter deletions is a Entity, upstream of the PRDII element is a Entity, promoter is a Entity, IFN - beta is a Protein, promoter is a Entity, elements is a Entity, IFN - beta is a Protein, IFN - beta is a Protein
395_task0
Sentence: Stimulation of interferon beta gene transcription in vitro by purified NF-kappa B and a novel TH protein. The human interferon beta (IFN-beta) regulatory element consists of multiple enhanson domains which are targets for transcription factors involved in inducible expression of the promoter. To further characterize the protein-DNA interactions mediating IFN-beta induction, positive regulatory domain (PRD) II binding proteins were purified from phorbol ester induced Jurkat T-cells and from IFN primed, cycloheximide/polyinosinic-polycytidylic acid treated HeLa S3 cells. From HeLa cells, two major proteins of 52 and 45 kilodaltons (kD) copurified with DNA binding activity, whereas from T-cells, four proteins--a major protein of 52 kD and three minor proteins of 82, 67, and 43-47 kD--were purified. Also, an induction specific DNA binding protein was purified from HeLa cells that interacted with the (AAGTGA)4 tetrahexamer sequence and the PRDI domain. This protein is immunologically distinct from IRF-1/ISGF2. Uninduced or Sendai virus induced HeLa extracts were used to examine transcription in vitro using a series of IFN beta promoter deletions. Deletions upstream of the PRDII element increased transcription in the uninduced extract, indicating predominantly negative regulation of the promoter. A 2-4-fold increase in IFN-beta promoter transcription was observed in Sendai virus induced extracts, and deletion of PRDI and PRDII elements decreased this induced level of transcription. When purified PRDII and tetrahexamer binding proteins were added to the induced extract, a 4-fold increase in transcription was observed. These experiments demonstrate that it is possible to modulate IFN-beta transcription in vitro but indicate that additional proteins may be required to fully activate IFN-beta transcription. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein
[ "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Entity", "I-Entity", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O" ]
Stimulation of interferon beta gene transcription in vitro by purified NF-kappa B and a novel TH protein. The human interferon beta (IFN-beta) regulatory element consists of multiple enhanson domains which are targets for transcription factors involved in inducible expression of the promoter. To further characterize the protein-DNA interactions mediating IFN-beta induction, positive regulatory domain (PRD) II binding proteins were purified from phorbol ester induced Jurkat T-cells and from IFN primed, cycloheximide/polyinosinic-polycytidylic acid treated HeLa S3 cells. From HeLa cells, two major proteins of 52 and 45 kilodaltons (kD) copurified with DNA binding activity, whereas from T-cells, four proteins--a major protein of 52 kD and three minor proteins of 82, 67, and 43-47 kD--were purified. Also, an induction specific DNA binding protein was purified from HeLa cells that interacted with the (AAGTGA)4 tetrahexamer sequence and the PRDI domain. This protein is immunologically distinct from IRF-1/ISGF2. Uninduced or Sendai virus induced HeLa extracts were used to examine transcription in vitro using a series of IFN beta promoter deletions. Deletions upstream of the PRDII element increased transcription in the uninduced extract, indicating predominantly negative regulation of the promoter. A 2-4-fold increase in IFN-beta promoter transcription was observed in Sendai virus induced extracts, and deletion of PRDI and PRDII elements decreased this induced level of transcription. When purified PRDII and tetrahexamer binding proteins were added to the induced extract, a 4-fold increase in transcription was observed. These experiments demonstrate that it is possible to modulate IFN-beta transcription in vitro but indicate that additional proteins may be required to fully activate IFN-beta transcription.
[ "Stimulation", "of", "interferon", "beta", "gene", "transcription", "in", "vitro", "by", "purified", "NF", "-", "kappa", "B", "and", "a", "novel", "TH", "protein", ".", "\n", "The", "human", "interferon", "beta", "(", "IFN", "-", "beta", ")", "regulatory", "element", "consists", "of", "multiple", "enhanson", "domains", "which", "are", "targets", "for", "transcription", "factors", "involved", "in", "inducible", "expression", "of", "the", "promoter", ".", "To", "further", "characterize", "the", "protein", "-", "DNA", "interactions", "mediating", "IFN", "-", "beta", "induction", ",", "positive", "regulatory", "domain", "(", "PRD", ")", "II", "binding", "proteins", "were", "purified", "from", "phorbol", "ester", "induced", "Jurkat", "T", "-", "cells", "and", "from", "IFN", "primed", ",", "cycloheximide", "/", "polyinosinic", "-", "polycytidylic", "acid", "treated", "HeLa", "S3", "cells", ".", "From", "HeLa", "cells", ",", "two", "major", "proteins", "of", "52", "and", "45", "kilodaltons", "(", "kD", ")", "copurified", "with", "DNA", "binding", "activity", ",", "whereas", "from", "T", "-", "cells", ",", "four", "proteins", "--", "a", "major", "protein", "of", "52", "kD", "and", "three", "minor", "proteins", "of", "82", ",", "67", ",", "and", "43", "-", "47", "kD", "--", "were", "purified", ".", "Also", ",", "an", "induction", "specific", "DNA", "binding", "protein", "was", "purified", "from", "HeLa", "cells", "that", "interacted", "with", "the", "(", "AAGTGA)4", "tetrahexamer", "sequence", "and", "the", "PRDI", "domain", ".", "This", "protein", "is", "immunologically", "distinct", "from", "IRF-1", "/", "ISGF2", ".", "Uninduced", "or", "Sendai", "virus", "induced", "HeLa", "extracts", "were", "used", "to", "examine", "transcription", "in", "vitro", "using", "a", "series", "of", "IFN", "beta", "promoter", "deletions", ".", "Deletions", "upstream", "of", "the", "PRDII", "element", "increased", "transcription", "in", "the", "uninduced", "extract", ",", "indicating", "predominantly", "negative", "regulation", "of", "the", "promoter", ".", "A", "2", "-", "4-fold", "increase", "in", "IFN", "-", "beta", "promoter", "transcription", "was", "observed", "in", "Sendai", "virus", "induced", "extracts", ",", "and", "deletion", "of", "PRDI", "and", "PRDII", "elements", "decreased", "this", "induced", "level", "of", "transcription", ".", "When", "purified", "PRDII", "and", "tetrahexamer", "binding", "proteins", "were", "added", "to", "the", "induced", "extract", ",", "a", "4-fold", "increase", "in", "transcription", "was", "observed", ".", "These", "experiments", "demonstrate", "that", "it", "is", "possible", "to", "modulate", "IFN", "-", "beta", "transcription", "in", "vitro", "but", "indicate", "that", "additional", "proteins", "may", "be", "required", "to", "fully", "activate", "IFN", "-", "beta", "transcription", ".", "\n" ]
[ "Entity", "Protein" ]
interferon beta is a Protein, NF - kappa B is a Entity, interferon beta is a Protein, IFN - beta is a Protein, regulatory element is a Entity, enhanson domains is a Entity, promoter is a Entity, DNA is a Entity, IFN - beta is a Protein, positive regulatory domain ( PRD ) II is a Entity, DNA is a Entity, tetrahexamer sequence is a Entity, PRDI domain is a Entity, IRF-1 is a Protein, ISGF2 is a Protein, IFN beta promoter deletions is a Entity, upstream of the PRDII element is a Entity, promoter is a Entity, IFN - beta is a Protein, promoter is a Entity, elements is a Entity, IFN - beta is a Protein, IFN - beta is a Protein
395_task1
Sentence: Stimulation of interferon beta gene transcription in vitro by purified NF-kappa B and a novel TH protein. The human interferon beta (IFN-beta) regulatory element consists of multiple enhanson domains which are targets for transcription factors involved in inducible expression of the promoter. To further characterize the protein-DNA interactions mediating IFN-beta induction, positive regulatory domain (PRD) II binding proteins were purified from phorbol ester induced Jurkat T-cells and from IFN primed, cycloheximide/polyinosinic-polycytidylic acid treated HeLa S3 cells. From HeLa cells, two major proteins of 52 and 45 kilodaltons (kD) copurified with DNA binding activity, whereas from T-cells, four proteins--a major protein of 52 kD and three minor proteins of 82, 67, and 43-47 kD--were purified. Also, an induction specific DNA binding protein was purified from HeLa cells that interacted with the (AAGTGA)4 tetrahexamer sequence and the PRDI domain. This protein is immunologically distinct from IRF-1/ISGF2. Uninduced or Sendai virus induced HeLa extracts were used to examine transcription in vitro using a series of IFN beta promoter deletions. Deletions upstream of the PRDII element increased transcription in the uninduced extract, indicating predominantly negative regulation of the promoter. A 2-4-fold increase in IFN-beta promoter transcription was observed in Sendai virus induced extracts, and deletion of PRDI and PRDII elements decreased this induced level of transcription. When purified PRDII and tetrahexamer binding proteins were added to the induced extract, a 4-fold increase in transcription was observed. These experiments demonstrate that it is possible to modulate IFN-beta transcription in vitro but indicate that additional proteins may be required to fully activate IFN-beta transcription. Instructions: please typing these entity words according to sentence: interferon beta, NF - kappa B, interferon beta, IFN - beta, regulatory element, enhanson domains, promoter, DNA, IFN - beta, positive regulatory domain ( PRD ) II, DNA, tetrahexamer sequence, PRDI domain, IRF-1, ISGF2, IFN beta promoter deletions, upstream of the PRDII element, promoter, IFN - beta, promoter, elements, IFN - beta, IFN - beta Options: Entity, Protein
[ "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Entity", "I-Entity", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O" ]
Stimulation of interferon beta gene transcription in vitro by purified NF-kappa B and a novel TH protein. The human interferon beta (IFN-beta) regulatory element consists of multiple enhanson domains which are targets for transcription factors involved in inducible expression of the promoter. To further characterize the protein-DNA interactions mediating IFN-beta induction, positive regulatory domain (PRD) II binding proteins were purified from phorbol ester induced Jurkat T-cells and from IFN primed, cycloheximide/polyinosinic-polycytidylic acid treated HeLa S3 cells. From HeLa cells, two major proteins of 52 and 45 kilodaltons (kD) copurified with DNA binding activity, whereas from T-cells, four proteins--a major protein of 52 kD and three minor proteins of 82, 67, and 43-47 kD--were purified. Also, an induction specific DNA binding protein was purified from HeLa cells that interacted with the (AAGTGA)4 tetrahexamer sequence and the PRDI domain. This protein is immunologically distinct from IRF-1/ISGF2. Uninduced or Sendai virus induced HeLa extracts were used to examine transcription in vitro using a series of IFN beta promoter deletions. Deletions upstream of the PRDII element increased transcription in the uninduced extract, indicating predominantly negative regulation of the promoter. A 2-4-fold increase in IFN-beta promoter transcription was observed in Sendai virus induced extracts, and deletion of PRDI and PRDII elements decreased this induced level of transcription. When purified PRDII and tetrahexamer binding proteins were added to the induced extract, a 4-fold increase in transcription was observed. These experiments demonstrate that it is possible to modulate IFN-beta transcription in vitro but indicate that additional proteins may be required to fully activate IFN-beta transcription.
[ "Stimulation", "of", "interferon", "beta", "gene", "transcription", "in", "vitro", "by", "purified", "NF", "-", "kappa", "B", "and", "a", "novel", "TH", "protein", ".", "\n", "The", "human", "interferon", "beta", "(", "IFN", "-", "beta", ")", "regulatory", "element", "consists", "of", "multiple", "enhanson", "domains", "which", "are", "targets", "for", "transcription", "factors", "involved", "in", "inducible", "expression", "of", "the", "promoter", ".", "To", "further", "characterize", "the", "protein", "-", "DNA", "interactions", "mediating", "IFN", "-", "beta", "induction", ",", "positive", "regulatory", "domain", "(", "PRD", ")", "II", "binding", "proteins", "were", "purified", "from", "phorbol", "ester", "induced", "Jurkat", "T", "-", "cells", "and", "from", "IFN", "primed", ",", "cycloheximide", "/", "polyinosinic", "-", "polycytidylic", "acid", "treated", "HeLa", "S3", "cells", ".", "From", "HeLa", "cells", ",", "two", "major", "proteins", "of", "52", "and", "45", "kilodaltons", "(", "kD", ")", "copurified", "with", "DNA", "binding", "activity", ",", "whereas", "from", "T", "-", "cells", ",", "four", "proteins", "--", "a", "major", "protein", "of", "52", "kD", "and", "three", "minor", "proteins", "of", "82", ",", "67", ",", "and", "43", "-", "47", "kD", "--", "were", "purified", ".", "Also", ",", "an", "induction", "specific", "DNA", "binding", "protein", "was", "purified", "from", "HeLa", "cells", "that", "interacted", "with", "the", "(", "AAGTGA)4", "tetrahexamer", "sequence", "and", "the", "PRDI", "domain", ".", "This", "protein", "is", "immunologically", "distinct", "from", "IRF-1", "/", "ISGF2", ".", "Uninduced", "or", "Sendai", "virus", "induced", "HeLa", "extracts", "were", "used", "to", "examine", "transcription", "in", "vitro", "using", "a", "series", "of", "IFN", "beta", "promoter", "deletions", ".", "Deletions", "upstream", "of", "the", "PRDII", "element", "increased", "transcription", "in", "the", "uninduced", "extract", ",", "indicating", "predominantly", "negative", "regulation", "of", "the", "promoter", ".", "A", "2", "-", "4-fold", "increase", "in", "IFN", "-", "beta", "promoter", "transcription", "was", "observed", "in", "Sendai", "virus", "induced", "extracts", ",", "and", "deletion", "of", "PRDI", "and", "PRDII", "elements", "decreased", "this", "induced", "level", "of", "transcription", ".", "When", "purified", "PRDII", "and", "tetrahexamer", "binding", "proteins", "were", "added", "to", "the", "induced", "extract", ",", "a", "4-fold", "increase", "in", "transcription", "was", "observed", ".", "These", "experiments", "demonstrate", "that", "it", "is", "possible", "to", "modulate", "IFN", "-", "beta", "transcription", "in", "vitro", "but", "indicate", "that", "additional", "proteins", "may", "be", "required", "to", "fully", "activate", "IFN", "-", "beta", "transcription", ".", "\n" ]
[ "Entity", "Protein" ]
interferon beta, NF - kappa B, interferon beta, IFN - beta, regulatory element, enhanson domains, promoter, DNA, IFN - beta, positive regulatory domain ( PRD ) II, DNA, tetrahexamer sequence, PRDI domain, IRF-1, ISGF2, IFN beta promoter deletions, upstream of the PRDII element, promoter, IFN - beta, promoter, elements, IFN - beta, IFN - beta
395_task2
Sentence: Stimulation of interferon beta gene transcription in vitro by purified NF-kappa B and a novel TH protein. The human interferon beta (IFN-beta) regulatory element consists of multiple enhanson domains which are targets for transcription factors involved in inducible expression of the promoter. To further characterize the protein-DNA interactions mediating IFN-beta induction, positive regulatory domain (PRD) II binding proteins were purified from phorbol ester induced Jurkat T-cells and from IFN primed, cycloheximide/polyinosinic-polycytidylic acid treated HeLa S3 cells. From HeLa cells, two major proteins of 52 and 45 kilodaltons (kD) copurified with DNA binding activity, whereas from T-cells, four proteins--a major protein of 52 kD and three minor proteins of 82, 67, and 43-47 kD--were purified. Also, an induction specific DNA binding protein was purified from HeLa cells that interacted with the (AAGTGA)4 tetrahexamer sequence and the PRDI domain. This protein is immunologically distinct from IRF-1/ISGF2. Uninduced or Sendai virus induced HeLa extracts were used to examine transcription in vitro using a series of IFN beta promoter deletions. Deletions upstream of the PRDII element increased transcription in the uninduced extract, indicating predominantly negative regulation of the promoter. A 2-4-fold increase in IFN-beta promoter transcription was observed in Sendai virus induced extracts, and deletion of PRDI and PRDII elements decreased this induced level of transcription. When purified PRDII and tetrahexamer binding proteins were added to the induced extract, a 4-fold increase in transcription was observed. These experiments demonstrate that it is possible to modulate IFN-beta transcription in vitro but indicate that additional proteins may be required to fully activate IFN-beta transcription. Instructions: please extract entity words from the input sentence
[ "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "B-Protein", "I-Protein", "I-Protein", "O", "B-Entity", "I-Entity", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "O", "O", "B-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O" ]
Stimulation of interferon beta gene transcription in vitro by purified NF-kappa B and a novel TH protein. The human interferon beta (IFN-beta) regulatory element consists of multiple enhanson domains which are targets for transcription factors involved in inducible expression of the promoter. To further characterize the protein-DNA interactions mediating IFN-beta induction, positive regulatory domain (PRD) II binding proteins were purified from phorbol ester induced Jurkat T-cells and from IFN primed, cycloheximide/polyinosinic-polycytidylic acid treated HeLa S3 cells. From HeLa cells, two major proteins of 52 and 45 kilodaltons (kD) copurified with DNA binding activity, whereas from T-cells, four proteins--a major protein of 52 kD and three minor proteins of 82, 67, and 43-47 kD--were purified. Also, an induction specific DNA binding protein was purified from HeLa cells that interacted with the (AAGTGA)4 tetrahexamer sequence and the PRDI domain. This protein is immunologically distinct from IRF-1/ISGF2. Uninduced or Sendai virus induced HeLa extracts were used to examine transcription in vitro using a series of IFN beta promoter deletions. Deletions upstream of the PRDII element increased transcription in the uninduced extract, indicating predominantly negative regulation of the promoter. A 2-4-fold increase in IFN-beta promoter transcription was observed in Sendai virus induced extracts, and deletion of PRDI and PRDII elements decreased this induced level of transcription. When purified PRDII and tetrahexamer binding proteins were added to the induced extract, a 4-fold increase in transcription was observed. These experiments demonstrate that it is possible to modulate IFN-beta transcription in vitro but indicate that additional proteins may be required to fully activate IFN-beta transcription.
[ "Stimulation", "of", "interferon", "beta", "gene", "transcription", "in", "vitro", "by", "purified", "NF", "-", "kappa", "B", "and", "a", "novel", "TH", "protein", ".", "\n", "The", "human", "interferon", "beta", "(", "IFN", "-", "beta", ")", "regulatory", "element", "consists", "of", "multiple", "enhanson", "domains", "which", "are", "targets", "for", "transcription", "factors", "involved", "in", "inducible", "expression", "of", "the", "promoter", ".", "To", "further", "characterize", "the", "protein", "-", "DNA", "interactions", "mediating", "IFN", "-", "beta", "induction", ",", "positive", "regulatory", "domain", "(", "PRD", ")", "II", "binding", "proteins", "were", "purified", "from", "phorbol", "ester", "induced", "Jurkat", "T", "-", "cells", "and", "from", "IFN", "primed", ",", "cycloheximide", "/", "polyinosinic", "-", "polycytidylic", "acid", "treated", "HeLa", "S3", "cells", ".", "From", "HeLa", "cells", ",", "two", "major", "proteins", "of", "52", "and", "45", "kilodaltons", "(", "kD", ")", "copurified", "with", "DNA", "binding", "activity", ",", "whereas", "from", "T", "-", "cells", ",", "four", "proteins", "--", "a", "major", "protein", "of", "52", "kD", "and", "three", "minor", "proteins", "of", "82", ",", "67", ",", "and", "43", "-", "47", "kD", "--", "were", "purified", ".", "Also", ",", "an", "induction", "specific", "DNA", "binding", "protein", "was", "purified", "from", "HeLa", "cells", "that", "interacted", "with", "the", "(", "AAGTGA)4", "tetrahexamer", "sequence", "and", "the", "PRDI", "domain", ".", "This", "protein", "is", "immunologically", "distinct", "from", "IRF-1", "/", "ISGF2", ".", "Uninduced", "or", "Sendai", "virus", "induced", "HeLa", "extracts", "were", "used", "to", "examine", "transcription", "in", "vitro", "using", "a", "series", "of", "IFN", "beta", "promoter", "deletions", ".", "Deletions", "upstream", "of", "the", "PRDII", "element", "increased", "transcription", "in", "the", "uninduced", "extract", ",", "indicating", "predominantly", "negative", "regulation", "of", "the", "promoter", ".", "A", "2", "-", "4-fold", "increase", "in", "IFN", "-", "beta", "promoter", "transcription", "was", "observed", "in", "Sendai", "virus", "induced", "extracts", ",", "and", "deletion", "of", "PRDI", "and", "PRDII", "elements", "decreased", "this", "induced", "level", "of", "transcription", ".", "When", "purified", "PRDII", "and", "tetrahexamer", "binding", "proteins", "were", "added", "to", "the", "induced", "extract", ",", "a", "4-fold", "increase", "in", "transcription", "was", "observed", ".", "These", "experiments", "demonstrate", "that", "it", "is", "possible", "to", "modulate", "IFN", "-", "beta", "transcription", "in", "vitro", "but", "indicate", "that", "additional", "proteins", "may", "be", "required", "to", "fully", "activate", "IFN", "-", "beta", "transcription", ".", "\n" ]
[ "Entity", "Protein" ]
bone tumor is an umlsterm, forecast is an umlsterm, behaviour is an umlsterm, diagnosis is an umlsterm, malignant is an umlsterm, benign tumor is an umlsterm, attention is an umlsterm, future is an umlsterm, role is an umlsterm, behaviour is an umlsterm
DerOrthopaede.00290677.eng.abstr_task0
Sentence: The GCT is a primary bone tumor of intermedier dignity , whereby the forecast of the biological behaviour and outcome is impossible on the base of the conventional histological diagnosis . The authors observed in one of their GCT-patients a malignant transformation of the formerly benign tumor . Through announcement of their case the authors want to call the attention to the importance of the DNA-Cytophotometry and to their possible future additional role in the diagnostics of the GCT and in the prediction of their biological behaviour . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]
The GCT is a primary bone tumor of intermedier dignity , whereby the forecast of the biological behaviour and outcome is impossible on the base of the conventional histological diagnosis . The authors observed in one of their GCT-patients a malignant transformation of the formerly benign tumor . Through announcement of their case the authors want to call the attention to the importance of the DNA-Cytophotometry and to their possible future additional role in the diagnostics of the GCT and in the prediction of their biological behaviour .
[ "The", "GCT", "is", "a", "primary", "bone", "tumor", "of", "intermedier", "dignity", ",", "whereby", "the", "forecast", "of", "the", "biological", "behaviour", "and", "outcome", "is", "impossible", "on", "the", "base", "of", "the", "conventional", "histological", "diagnosis", ".", "The", "authors", "observed", "in", "one", "of", "their", "GCT", "-", "patients", "a", "malignant", "transformation", "of", "the", "formerly", "benign", "tumor", ".", "Through", "announcement", "of", "their", "case", "the", "authors", "want", "to", "call", "the", "attention", "to", "the", "importance", "of", "the", "DNA", "-", "Cytophotometry", "and", "to", "their", "possible", "future", "additional", "role", "in", "the", "diagnostics", "of", "the", "GCT", "and", "in", "the", "prediction", "of", "their", "biological", "behaviour", "." ]
[ "umlsterm" ]
bone tumor is an umlsterm, forecast is an umlsterm, behaviour is an umlsterm, diagnosis is an umlsterm, malignant is an umlsterm, benign tumor is an umlsterm, attention is an umlsterm, future is an umlsterm, role is an umlsterm, behaviour is an umlsterm
DerOrthopaede.00290677.eng.abstr_task1
Sentence: The GCT is a primary bone tumor of intermedier dignity , whereby the forecast of the biological behaviour and outcome is impossible on the base of the conventional histological diagnosis . The authors observed in one of their GCT-patients a malignant transformation of the formerly benign tumor . Through announcement of their case the authors want to call the attention to the importance of the DNA-Cytophotometry and to their possible future additional role in the diagnostics of the GCT and in the prediction of their biological behaviour . Instructions: please typing these entity words according to sentence: bone tumor, forecast, behaviour, diagnosis, malignant, benign tumor, attention, future, role, behaviour Options: umlsterm
[ "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]
The GCT is a primary bone tumor of intermedier dignity , whereby the forecast of the biological behaviour and outcome is impossible on the base of the conventional histological diagnosis . The authors observed in one of their GCT-patients a malignant transformation of the formerly benign tumor . Through announcement of their case the authors want to call the attention to the importance of the DNA-Cytophotometry and to their possible future additional role in the diagnostics of the GCT and in the prediction of their biological behaviour .
[ "The", "GCT", "is", "a", "primary", "bone", "tumor", "of", "intermedier", "dignity", ",", "whereby", "the", "forecast", "of", "the", "biological", "behaviour", "and", "outcome", "is", "impossible", "on", "the", "base", "of", "the", "conventional", "histological", "diagnosis", ".", "The", "authors", "observed", "in", "one", "of", "their", "GCT", "-", "patients", "a", "malignant", "transformation", "of", "the", "formerly", "benign", "tumor", ".", "Through", "announcement", "of", "their", "case", "the", "authors", "want", "to", "call", "the", "attention", "to", "the", "importance", "of", "the", "DNA", "-", "Cytophotometry", "and", "to", "their", "possible", "future", "additional", "role", "in", "the", "diagnostics", "of", "the", "GCT", "and", "in", "the", "prediction", "of", "their", "biological", "behaviour", "." ]
[ "umlsterm" ]
bone tumor, forecast, behaviour, diagnosis, malignant, benign tumor, attention, future, role, behaviour
DerOrthopaede.00290677.eng.abstr_task2
Sentence: The GCT is a primary bone tumor of intermedier dignity , whereby the forecast of the biological behaviour and outcome is impossible on the base of the conventional histological diagnosis . The authors observed in one of their GCT-patients a malignant transformation of the formerly benign tumor . Through announcement of their case the authors want to call the attention to the importance of the DNA-Cytophotometry and to their possible future additional role in the diagnostics of the GCT and in the prediction of their biological behaviour . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]
The GCT is a primary bone tumor of intermedier dignity , whereby the forecast of the biological behaviour and outcome is impossible on the base of the conventional histological diagnosis . The authors observed in one of their GCT-patients a malignant transformation of the formerly benign tumor . Through announcement of their case the authors want to call the attention to the importance of the DNA-Cytophotometry and to their possible future additional role in the diagnostics of the GCT and in the prediction of their biological behaviour .
[ "The", "GCT", "is", "a", "primary", "bone", "tumor", "of", "intermedier", "dignity", ",", "whereby", "the", "forecast", "of", "the", "biological", "behaviour", "and", "outcome", "is", "impossible", "on", "the", "base", "of", "the", "conventional", "histological", "diagnosis", ".", "The", "authors", "observed", "in", "one", "of", "their", "GCT", "-", "patients", "a", "malignant", "transformation", "of", "the", "formerly", "benign", "tumor", ".", "Through", "announcement", "of", "their", "case", "the", "authors", "want", "to", "call", "the", "attention", "to", "the", "importance", "of", "the", "DNA", "-", "Cytophotometry", "and", "to", "their", "possible", "future", "additional", "role", "in", "the", "diagnostics", "of", "the", "GCT", "and", "in", "the", "prediction", "of", "their", "biological", "behaviour", "." ]
[ "umlsterm" ]
structure is a MolecularStructure, DNA - binding domain is a DNABindingDomainOfProtein, interleukin enhancer binding factor 1 is a Protein, FOXK1a is a Protein, Interleukin enhancer binding factor is a Protein, ILF is a Protein, interleukin-2 is a Gene, IL-2 is a Gene, promoter is a Promoter, IL-2 is a Gene, 3D structure is a ThreeDimensionalMolecularStructure, DNA - binding domain is a DNABindingDomainOfProtein, ILF is a Protein, DNA - binding domain is a DNABindingDomainOfProtein, ILF is a Protein, winged helix / forkhead family is a ForkheadWingedHelixTF, wing 2 is a ProteinDomain, alpha - helix is a MolecularStructure, alpha - helix is a MolecularStructure, wing 2 is a ProteinDomain, this family is a Protein, DNA is a DNA, ILF is a Protein, winged helix / forkhead proteins is a ForkheadWingedHelixTF, ILF is a Protein, DNA is a DNA
63_task0
Sentence: Solution structure of the DNA-binding domain of interleukin enhancer binding factor 1 (FOXK1a). Interleukin enhancer binding factor (ILF) binds to the interleukin-2 (IL-2) promoter and regulates IL-2 gene expression. In this study, the 3D structure of the DNA-binding domain of ILF was determined by multidimensional NMR spectroscopy. NMR structure analysis revealed that the DNA-binding domain of ILF is a new member of the winged helix/forkhead family, and that its wing 2 contains an extra alpha-helix. This is the first study to report the presence of a C-terminal alpha-helix in place of a typical wing 2 in a member of this family. This structural difference may be responsible for the different DNA-binding specificity of ILF compared to other winged helix/forkhead proteins. Our deletion studies of the fragments of ILF also suggest that the C-terminal region plays a regulatory role in DNA binding. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: DNA, DNABindingDomainOfProtein, Promoter, ThreeDimensionalMolecularStructure, Gene, MolecularStructure, ForkheadWingedHelixTF, ProteinDomain, Protein
[ "O", "B-MolecularStructure", "O", "O", "B-DNABindingDomainOfProtein", "I-DNABindingDomainOfProtein", "I-DNABindingDomainOfProtein", "I-DNABindingDomainOfProtein", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "B-Gene", "O", "B-Gene", "O", "B-Promoter", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "B-ThreeDimensionalMolecularStructure", "I-ThreeDimensionalMolecularStructure", "O", "O", "B-DNABindingDomainOfProtein", "I-DNABindingDomainOfProtein", "I-DNABindingDomainOfProtein", "I-DNABindingDomainOfProtein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DNABindingDomainOfProtein", "I-DNABindingDomainOfProtein", "I-DNABindingDomainOfProtein", "I-DNABindingDomainOfProtein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-ForkheadWingedHelixTF", "I-ForkheadWingedHelixTF", "I-ForkheadWingedHelixTF", "I-ForkheadWingedHelixTF", "I-ForkheadWingedHelixTF", "O", "O", "O", "O", "B-ProteinDomain", "I-ProteinDomain", "O", "O", "O", "B-MolecularStructure", "I-MolecularStructure", "I-MolecularStructure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MolecularStructure", "I-MolecularStructure", "I-MolecularStructure", "O", "O", "O", "O", "O", "B-ProteinDomain", "I-ProteinDomain", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DNA", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-ForkheadWingedHelixTF", "I-ForkheadWingedHelixTF", "I-ForkheadWingedHelixTF", "I-ForkheadWingedHelixTF", "I-ForkheadWingedHelixTF", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DNA", "O", "O", "O" ]
Solution structure of the DNA-binding domain of interleukin enhancer binding factor 1 (FOXK1a). Interleukin enhancer binding factor (ILF) binds to the interleukin-2 (IL-2) promoter and regulates IL-2 gene expression. In this study, the 3D structure of the DNA-binding domain of ILF was determined by multidimensional NMR spectroscopy. NMR structure analysis revealed that the DNA-binding domain of ILF is a new member of the winged helix/forkhead family, and that its wing 2 contains an extra alpha-helix. This is the first study to report the presence of a C-terminal alpha-helix in place of a typical wing 2 in a member of this family. This structural difference may be responsible for the different DNA-binding specificity of ILF compared to other winged helix/forkhead proteins. Our deletion studies of the fragments of ILF also suggest that the C-terminal region plays a regulatory role in DNA binding.
[ "Solution", "structure", "of", "the", "DNA", "-", "binding", "domain", "of", "interleukin", "enhancer", "binding", "factor", "1", "(", "FOXK1a", ")", ".", "Interleukin", "enhancer", "binding", "factor", "(", "ILF", ")", "binds", "to", "the", "interleukin-2", "(", "IL-2", ")", "promoter", "and", "regulates", "IL-2", "gene", "expression", ".", "In", "this", "study", ",", "the", "3D", "structure", "of", "the", "DNA", "-", "binding", "domain", "of", "ILF", "was", "determined", "by", "multidimensional", "NMR", "spectroscopy", ".", "NMR", "structure", "analysis", "revealed", "that", "the", "DNA", "-", "binding", "domain", "of", "ILF", "is", "a", "new", "member", "of", "the", "winged", "helix", "/", "forkhead", "family", ",", "and", "that", "its", "wing", "2", "contains", "an", "extra", "alpha", "-", "helix", ".", "This", "is", "the", "first", "study", "to", "report", "the", "presence", "of", "a", "C", "-", "terminal", "alpha", "-", "helix", "in", "place", "of", "a", "typical", "wing", "2", "in", "a", "member", "of", "this", "family", ".", "This", "structural", "difference", "may", "be", "responsible", "for", "the", "different", "DNA", "-", "binding", "specificity", "of", "ILF", "compared", "to", "other", "winged", "helix", "/", "forkhead", "proteins", ".", "Our", "deletion", "studies", "of", "the", "fragments", "of", "ILF", "also", "suggest", "that", "the", "C", "-", "terminal", "region", "plays", "a", "regulatory", "role", "in", "DNA", "binding", ".", "\n" ]
[ "Protein", "ForkheadWingedHelixTF", "DNABindingDomainOfProtein", "Gene", "ThreeDimensionalMolecularStructure", "MolecularStructure", "Promoter", "ProteinDomain", "DNA" ]
structure is a MolecularStructure, DNA - binding domain is a DNABindingDomainOfProtein, interleukin enhancer binding factor 1 is a Protein, FOXK1a is a Protein, Interleukin enhancer binding factor is a Protein, ILF is a Protein, interleukin-2 is a Gene, IL-2 is a Gene, promoter is a Promoter, IL-2 is a Gene, 3D structure is a ThreeDimensionalMolecularStructure, DNA - binding domain is a DNABindingDomainOfProtein, ILF is a Protein, DNA - binding domain is a DNABindingDomainOfProtein, ILF is a Protein, winged helix / forkhead family is a ForkheadWingedHelixTF, wing 2 is a ProteinDomain, alpha - helix is a MolecularStructure, alpha - helix is a MolecularStructure, wing 2 is a ProteinDomain, this family is a Protein, DNA is a DNA, ILF is a Protein, winged helix / forkhead proteins is a ForkheadWingedHelixTF, ILF is a Protein, DNA is a DNA
63_task1
Sentence: Solution structure of the DNA-binding domain of interleukin enhancer binding factor 1 (FOXK1a). Interleukin enhancer binding factor (ILF) binds to the interleukin-2 (IL-2) promoter and regulates IL-2 gene expression. In this study, the 3D structure of the DNA-binding domain of ILF was determined by multidimensional NMR spectroscopy. NMR structure analysis revealed that the DNA-binding domain of ILF is a new member of the winged helix/forkhead family, and that its wing 2 contains an extra alpha-helix. This is the first study to report the presence of a C-terminal alpha-helix in place of a typical wing 2 in a member of this family. This structural difference may be responsible for the different DNA-binding specificity of ILF compared to other winged helix/forkhead proteins. Our deletion studies of the fragments of ILF also suggest that the C-terminal region plays a regulatory role in DNA binding. Instructions: please typing these entity words according to sentence: structure, DNA - binding domain, interleukin enhancer binding factor 1, FOXK1a, Interleukin enhancer binding factor, ILF, interleukin-2, IL-2, promoter, IL-2, 3D structure, DNA - binding domain, ILF, DNA - binding domain, ILF, winged helix / forkhead family, wing 2, alpha - helix, alpha - helix, wing 2, this family, DNA, ILF, winged helix / forkhead proteins, ILF, DNA Options: DNA, DNABindingDomainOfProtein, Promoter, ThreeDimensionalMolecularStructure, Gene, MolecularStructure, ForkheadWingedHelixTF, ProteinDomain, Protein
[ "O", "B-MolecularStructure", "O", "O", "B-DNABindingDomainOfProtein", "I-DNABindingDomainOfProtein", "I-DNABindingDomainOfProtein", "I-DNABindingDomainOfProtein", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "B-Gene", "O", "B-Gene", "O", "B-Promoter", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "B-ThreeDimensionalMolecularStructure", "I-ThreeDimensionalMolecularStructure", "O", "O", "B-DNABindingDomainOfProtein", "I-DNABindingDomainOfProtein", "I-DNABindingDomainOfProtein", "I-DNABindingDomainOfProtein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DNABindingDomainOfProtein", "I-DNABindingDomainOfProtein", "I-DNABindingDomainOfProtein", "I-DNABindingDomainOfProtein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-ForkheadWingedHelixTF", "I-ForkheadWingedHelixTF", "I-ForkheadWingedHelixTF", "I-ForkheadWingedHelixTF", "I-ForkheadWingedHelixTF", "O", "O", "O", "O", "B-ProteinDomain", "I-ProteinDomain", "O", "O", "O", "B-MolecularStructure", "I-MolecularStructure", "I-MolecularStructure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MolecularStructure", "I-MolecularStructure", "I-MolecularStructure", "O", "O", "O", "O", "O", "B-ProteinDomain", "I-ProteinDomain", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DNA", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-ForkheadWingedHelixTF", "I-ForkheadWingedHelixTF", "I-ForkheadWingedHelixTF", "I-ForkheadWingedHelixTF", "I-ForkheadWingedHelixTF", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DNA", "O", "O", "O" ]
Solution structure of the DNA-binding domain of interleukin enhancer binding factor 1 (FOXK1a). Interleukin enhancer binding factor (ILF) binds to the interleukin-2 (IL-2) promoter and regulates IL-2 gene expression. In this study, the 3D structure of the DNA-binding domain of ILF was determined by multidimensional NMR spectroscopy. NMR structure analysis revealed that the DNA-binding domain of ILF is a new member of the winged helix/forkhead family, and that its wing 2 contains an extra alpha-helix. This is the first study to report the presence of a C-terminal alpha-helix in place of a typical wing 2 in a member of this family. This structural difference may be responsible for the different DNA-binding specificity of ILF compared to other winged helix/forkhead proteins. Our deletion studies of the fragments of ILF also suggest that the C-terminal region plays a regulatory role in DNA binding.
[ "Solution", "structure", "of", "the", "DNA", "-", "binding", "domain", "of", "interleukin", "enhancer", "binding", "factor", "1", "(", "FOXK1a", ")", ".", "Interleukin", "enhancer", "binding", "factor", "(", "ILF", ")", "binds", "to", "the", "interleukin-2", "(", "IL-2", ")", "promoter", "and", "regulates", "IL-2", "gene", "expression", ".", "In", "this", "study", ",", "the", "3D", "structure", "of", "the", "DNA", "-", "binding", "domain", "of", "ILF", "was", "determined", "by", "multidimensional", "NMR", "spectroscopy", ".", "NMR", "structure", "analysis", "revealed", "that", "the", "DNA", "-", "binding", "domain", "of", "ILF", "is", "a", "new", "member", "of", "the", "winged", "helix", "/", "forkhead", "family", ",", "and", "that", "its", "wing", "2", "contains", "an", "extra", "alpha", "-", "helix", ".", "This", "is", "the", "first", "study", "to", "report", "the", "presence", "of", "a", "C", "-", "terminal", "alpha", "-", "helix", "in", "place", "of", "a", "typical", "wing", "2", "in", "a", "member", "of", "this", "family", ".", "This", "structural", "difference", "may", "be", "responsible", "for", "the", "different", "DNA", "-", "binding", "specificity", "of", "ILF", "compared", "to", "other", "winged", "helix", "/", "forkhead", "proteins", ".", "Our", "deletion", "studies", "of", "the", "fragments", "of", "ILF", "also", "suggest", "that", "the", "C", "-", "terminal", "region", "plays", "a", "regulatory", "role", "in", "DNA", "binding", ".", "\n" ]
[ "Protein", "ForkheadWingedHelixTF", "DNABindingDomainOfProtein", "Gene", "ThreeDimensionalMolecularStructure", "MolecularStructure", "Promoter", "ProteinDomain", "DNA" ]
structure, DNA - binding domain, interleukin enhancer binding factor 1, FOXK1a, Interleukin enhancer binding factor, ILF, interleukin-2, IL-2, promoter, IL-2, 3D structure, DNA - binding domain, ILF, DNA - binding domain, ILF, winged helix / forkhead family, wing 2, alpha - helix, alpha - helix, wing 2, this family, DNA, ILF, winged helix / forkhead proteins, ILF, DNA
63_task2
Sentence: Solution structure of the DNA-binding domain of interleukin enhancer binding factor 1 (FOXK1a). Interleukin enhancer binding factor (ILF) binds to the interleukin-2 (IL-2) promoter and regulates IL-2 gene expression. In this study, the 3D structure of the DNA-binding domain of ILF was determined by multidimensional NMR spectroscopy. NMR structure analysis revealed that the DNA-binding domain of ILF is a new member of the winged helix/forkhead family, and that its wing 2 contains an extra alpha-helix. This is the first study to report the presence of a C-terminal alpha-helix in place of a typical wing 2 in a member of this family. This structural difference may be responsible for the different DNA-binding specificity of ILF compared to other winged helix/forkhead proteins. Our deletion studies of the fragments of ILF also suggest that the C-terminal region plays a regulatory role in DNA binding. Instructions: please extract entity words from the input sentence
[ "O", "B-MolecularStructure", "O", "O", "B-DNABindingDomainOfProtein", "I-DNABindingDomainOfProtein", "I-DNABindingDomainOfProtein", "I-DNABindingDomainOfProtein", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "B-Gene", "O", "B-Gene", "O", "B-Promoter", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "O", "O", "B-ThreeDimensionalMolecularStructure", "I-ThreeDimensionalMolecularStructure", "O", "O", "B-DNABindingDomainOfProtein", "I-DNABindingDomainOfProtein", "I-DNABindingDomainOfProtein", "I-DNABindingDomainOfProtein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DNABindingDomainOfProtein", "I-DNABindingDomainOfProtein", "I-DNABindingDomainOfProtein", "I-DNABindingDomainOfProtein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "B-ForkheadWingedHelixTF", "I-ForkheadWingedHelixTF", "I-ForkheadWingedHelixTF", "I-ForkheadWingedHelixTF", "I-ForkheadWingedHelixTF", "O", "O", "O", "O", "B-ProteinDomain", "I-ProteinDomain", "O", "O", "O", "B-MolecularStructure", "I-MolecularStructure", "I-MolecularStructure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MolecularStructure", "I-MolecularStructure", "I-MolecularStructure", "O", "O", "O", "O", "O", "B-ProteinDomain", "I-ProteinDomain", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DNA", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-ForkheadWingedHelixTF", "I-ForkheadWingedHelixTF", "I-ForkheadWingedHelixTF", "I-ForkheadWingedHelixTF", "I-ForkheadWingedHelixTF", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DNA", "O", "O", "O" ]
Solution structure of the DNA-binding domain of interleukin enhancer binding factor 1 (FOXK1a). Interleukin enhancer binding factor (ILF) binds to the interleukin-2 (IL-2) promoter and regulates IL-2 gene expression. In this study, the 3D structure of the DNA-binding domain of ILF was determined by multidimensional NMR spectroscopy. NMR structure analysis revealed that the DNA-binding domain of ILF is a new member of the winged helix/forkhead family, and that its wing 2 contains an extra alpha-helix. This is the first study to report the presence of a C-terminal alpha-helix in place of a typical wing 2 in a member of this family. This structural difference may be responsible for the different DNA-binding specificity of ILF compared to other winged helix/forkhead proteins. Our deletion studies of the fragments of ILF also suggest that the C-terminal region plays a regulatory role in DNA binding.
[ "Solution", "structure", "of", "the", "DNA", "-", "binding", "domain", "of", "interleukin", "enhancer", "binding", "factor", "1", "(", "FOXK1a", ")", ".", "Interleukin", "enhancer", "binding", "factor", "(", "ILF", ")", "binds", "to", "the", "interleukin-2", "(", "IL-2", ")", "promoter", "and", "regulates", "IL-2", "gene", "expression", ".", "In", "this", "study", ",", "the", "3D", "structure", "of", "the", "DNA", "-", "binding", "domain", "of", "ILF", "was", "determined", "by", "multidimensional", "NMR", "spectroscopy", ".", "NMR", "structure", "analysis", "revealed", "that", "the", "DNA", "-", "binding", "domain", "of", "ILF", "is", "a", "new", "member", "of", "the", "winged", "helix", "/", "forkhead", "family", ",", "and", "that", "its", "wing", "2", "contains", "an", "extra", "alpha", "-", "helix", ".", "This", "is", "the", "first", "study", "to", "report", "the", "presence", "of", "a", "C", "-", "terminal", "alpha", "-", "helix", "in", "place", "of", "a", "typical", "wing", "2", "in", "a", "member", "of", "this", "family", ".", "This", "structural", "difference", "may", "be", "responsible", "for", "the", "different", "DNA", "-", "binding", "specificity", "of", "ILF", "compared", "to", "other", "winged", "helix", "/", "forkhead", "proteins", ".", "Our", "deletion", "studies", "of", "the", "fragments", "of", "ILF", "also", "suggest", "that", "the", "C", "-", "terminal", "region", "plays", "a", "regulatory", "role", "in", "DNA", "binding", ".", "\n" ]
[ "Protein", "ForkheadWingedHelixTF", "DNABindingDomainOfProtein", "Gene", "ThreeDimensionalMolecularStructure", "MolecularStructure", "Promoter", "ProteinDomain", "DNA" ]
Literatur is an umlsterm, Patienten is an umlsterm, Patientengruppen is an umlsterm, Aetiologie is an umlsterm, steroidinduzierten is an umlsterm, Knochenalteration is an umlsterm, Osteopathie is an umlsterm, Sichelzellanaemie is an umlsterm, Immunsuppression is an umlsterm, Sichelzellanaemie is an umlsterm, Infektionsraten is an umlsterm, Hueftprothesen is an umlsterm, Aetiologie is an umlsterm, Rolle is an umlsterm, Langzeitergebnisse is an umlsterm, zementlose is an umlsterm, Prothesenmodelle is an umlsterm, Druckscheibenprothesen is an umlsterm, Patienten is an umlsterm, Osteopathie is an umlsterm, Alkoholismus is an umlsterm, Infektionen is an umlsterm, Alkoholismus is an umlsterm, Osteopathie is an umlsterm, Prothesen is an umlsterm, Prothesenmodell is an umlsterm, Stielprothesen is an umlsterm
DerOrthopaede.00290449.ger.abstr_task0
Sentence: In der Literatur finden sich sehr unterschiedliche Komplikations- und Lockerungsraten von Hueftendoprothesen bei Patienten mit Hueftkopfnekrose ( HKN ) . Diese Schwankungen sind v. a. durch die inhomogene Zusammensetzung der Patientengruppen hinsichtlich der Aetiologie der Hueftkopfnekrose bedingt . Untersucht man die Ergebnisse der Hueftendoprothesen fuer die verschiedenen HKN-Aetiologien gesondert , so kristallisiert sich eine hoehere Lockerungsrate bei steroidinduzierten Hueftkopfnekrosen und bei Hueftkopfnekrosen mit einer biologischen und biomechanischen Knochenalteration ( z . B. der renalen Osteopathie oder der Sichelzellanaemie ) heraus . Grunderkrankungen , die einer Immunsuppression beduerfen und die Sichelzellanaemie weisen hoehere Infektionsraten von Hueftprothesen auf . Somit spielt die Aetiologie der Hueftkopfnekrose eine entscheidende Rolle fuer Langzeitergebnisse von Hueftendoprothesen . Moderne Zementiertechniken der 2. Generation und zementlose Huefttotalendoprothesen scheinen bessere Ergebnisse zu liefern als frueher verwendete Prothesenmodelle bzw. Zementiertechniken . In einer prospektiven Studie konnten wir bisher 52 Druckscheibenprothesen bei 45 Patienten mit Hueftkopfnekrosen und einem Mindestnachuntersuchungszeitraum von 2 ( 3,7 +/- 1,6 Jahren ) postoperativ verfolgen . Es ergab sich eine Versagerquote von 9,6 % ( je eine aseptische Lockerung bei renaler Osteopathie und Alkoholismus sowie 3 Infektionen bei Alkoholismus und renaler Osteopathie ) . Zusaetzlich zeigten 5 Prothesen ( 9,6 % ) Roentgensaeume von mindestens 2 mm Breite . Inwieweit dieses Prothesenmodell mit metaphysaerer Fixierung gegenueber den herkoemmlichen Stielprothesen bei den jungen Hueftkopfnekrosepatienten Vorteile erbringen , muessen zukuenftige Studien mit laengeren Beobachtungszeiten zeigen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
In der Literatur finden sich sehr unterschiedliche Komplikations- und Lockerungsraten von Hueftendoprothesen bei Patienten mit Hueftkopfnekrose ( HKN ) . Diese Schwankungen sind v. a. durch die inhomogene Zusammensetzung der Patientengruppen hinsichtlich der Aetiologie der Hueftkopfnekrose bedingt . Untersucht man die Ergebnisse der Hueftendoprothesen fuer die verschiedenen HKN-Aetiologien gesondert , so kristallisiert sich eine hoehere Lockerungsrate bei steroidinduzierten Hueftkopfnekrosen und bei Hueftkopfnekrosen mit einer biologischen und biomechanischen Knochenalteration ( z . B. der renalen Osteopathie oder der Sichelzellanaemie ) heraus . Grunderkrankungen , die einer Immunsuppression beduerfen und die Sichelzellanaemie weisen hoehere Infektionsraten von Hueftprothesen auf . Somit spielt die Aetiologie der Hueftkopfnekrose eine entscheidende Rolle fuer Langzeitergebnisse von Hueftendoprothesen . Moderne Zementiertechniken der 2. Generation und zementlose Huefttotalendoprothesen scheinen bessere Ergebnisse zu liefern als frueher verwendete Prothesenmodelle bzw. Zementiertechniken . In einer prospektiven Studie konnten wir bisher 52 Druckscheibenprothesen bei 45 Patienten mit Hueftkopfnekrosen und einem Mindestnachuntersuchungszeitraum von 2 ( 3,7 +/- 1,6 Jahren ) postoperativ verfolgen . Es ergab sich eine Versagerquote von 9,6 % ( je eine aseptische Lockerung bei renaler Osteopathie und Alkoholismus sowie 3 Infektionen bei Alkoholismus und renaler Osteopathie ) . Zusaetzlich zeigten 5 Prothesen ( 9,6 % ) Roentgensaeume von mindestens 2 mm Breite . Inwieweit dieses Prothesenmodell mit metaphysaerer Fixierung gegenueber den herkoemmlichen Stielprothesen bei den jungen Hueftkopfnekrosepatienten Vorteile erbringen , muessen zukuenftige Studien mit laengeren Beobachtungszeiten zeigen .
[ "In", "der", "Literatur", "finden", "sich", "sehr", "unterschiedliche", "Komplikations-", "und", "Lockerungsraten", "von", "Hueftendoprothesen", "bei", "Patienten", "mit", "Hueftkopfnekrose", "(", "HKN", ")", ".", "Diese", "Schwankungen", "sind", "v.", "a.", "durch", "die", "inhomogene", "Zusammensetzung", "der", "Patientengruppen", "hinsichtlich", "der", "Aetiologie", "der", "Hueftkopfnekrose", "bedingt", ".", "Untersucht", "man", "die", "Ergebnisse", "der", "Hueftendoprothesen", "fuer", "die", "verschiedenen", "HKN", "-", "Aetiologien", "gesondert", ",", "so", "kristallisiert", "sich", "eine", "hoehere", "Lockerungsrate", "bei", "steroidinduzierten", "Hueftkopfnekrosen", "und", "bei", "Hueftkopfnekrosen", "mit", "einer", "biologischen", "und", "biomechanischen", "Knochenalteration", "(", "z", ".", "B.", "der", "renalen", "Osteopathie", "oder", "der", "Sichelzellanaemie", ")", "heraus", ".", "Grunderkrankungen", ",", "die", "einer", "Immunsuppression", "beduerfen", "und", "die", "Sichelzellanaemie", "weisen", "hoehere", "Infektionsraten", "von", "Hueftprothesen", "auf", ".", "Somit", "spielt", "die", "Aetiologie", "der", "Hueftkopfnekrose", "eine", "entscheidende", "Rolle", "fuer", "Langzeitergebnisse", "von", "Hueftendoprothesen", ".", "Moderne", "Zementiertechniken", "der", "2", ".", "Generation", "und", "zementlose", "Huefttotalendoprothesen", "scheinen", "bessere", "Ergebnisse", "zu", "liefern", "als", "frueher", "verwendete", "Prothesenmodelle", "bzw", ".", "Zementiertechniken", ".", "In", "einer", "prospektiven", "Studie", "konnten", "wir", "bisher", "52", "Druckscheibenprothesen", "bei", "45", "Patienten", "mit", "Hueftkopfnekrosen", "und", "einem", "Mindestnachuntersuchungszeitraum", "von", "2", "(", "3,7", "+", "/-", "1,6", "Jahren", ")", "postoperativ", "verfolgen", ".", "Es", "ergab", "sich", "eine", "Versagerquote", "von", "9,6", "%", "(", "je", "eine", "aseptische", "Lockerung", "bei", "renaler", "Osteopathie", "und", "Alkoholismus", "sowie", "3", "Infektionen", "bei", "Alkoholismus", "und", "renaler", "Osteopathie", ")", ".", "Zusaetzlich", "zeigten", "5", "Prothesen", "(", "9,6", "%", ")", "Roentgensaeume", "von", "mindestens", "2", "mm", "Breite", ".", "Inwieweit", "dieses", "Prothesenmodell", "mit", "metaphysaerer", "Fixierung", "gegenueber", "den", "herkoemmlichen", "Stielprothesen", "bei", "den", "jungen", "Hueftkopfnekrosepatienten", "Vorteile", "erbringen", ",", "muessen", "zukuenftige", "Studien", "mit", "laengeren", "Beobachtungszeiten", "zeigen", "." ]
[ "umlsterm" ]
Literatur is an umlsterm, Patienten is an umlsterm, Patientengruppen is an umlsterm, Aetiologie is an umlsterm, steroidinduzierten is an umlsterm, Knochenalteration is an umlsterm, Osteopathie is an umlsterm, Sichelzellanaemie is an umlsterm, Immunsuppression is an umlsterm, Sichelzellanaemie is an umlsterm, Infektionsraten is an umlsterm, Hueftprothesen is an umlsterm, Aetiologie is an umlsterm, Rolle is an umlsterm, Langzeitergebnisse is an umlsterm, zementlose is an umlsterm, Prothesenmodelle is an umlsterm, Druckscheibenprothesen is an umlsterm, Patienten is an umlsterm, Osteopathie is an umlsterm, Alkoholismus is an umlsterm, Infektionen is an umlsterm, Alkoholismus is an umlsterm, Osteopathie is an umlsterm, Prothesen is an umlsterm, Prothesenmodell is an umlsterm, Stielprothesen is an umlsterm
DerOrthopaede.00290449.ger.abstr_task1
Sentence: In der Literatur finden sich sehr unterschiedliche Komplikations- und Lockerungsraten von Hueftendoprothesen bei Patienten mit Hueftkopfnekrose ( HKN ) . Diese Schwankungen sind v. a. durch die inhomogene Zusammensetzung der Patientengruppen hinsichtlich der Aetiologie der Hueftkopfnekrose bedingt . Untersucht man die Ergebnisse der Hueftendoprothesen fuer die verschiedenen HKN-Aetiologien gesondert , so kristallisiert sich eine hoehere Lockerungsrate bei steroidinduzierten Hueftkopfnekrosen und bei Hueftkopfnekrosen mit einer biologischen und biomechanischen Knochenalteration ( z . B. der renalen Osteopathie oder der Sichelzellanaemie ) heraus . Grunderkrankungen , die einer Immunsuppression beduerfen und die Sichelzellanaemie weisen hoehere Infektionsraten von Hueftprothesen auf . Somit spielt die Aetiologie der Hueftkopfnekrose eine entscheidende Rolle fuer Langzeitergebnisse von Hueftendoprothesen . Moderne Zementiertechniken der 2. Generation und zementlose Huefttotalendoprothesen scheinen bessere Ergebnisse zu liefern als frueher verwendete Prothesenmodelle bzw. Zementiertechniken . In einer prospektiven Studie konnten wir bisher 52 Druckscheibenprothesen bei 45 Patienten mit Hueftkopfnekrosen und einem Mindestnachuntersuchungszeitraum von 2 ( 3,7 +/- 1,6 Jahren ) postoperativ verfolgen . Es ergab sich eine Versagerquote von 9,6 % ( je eine aseptische Lockerung bei renaler Osteopathie und Alkoholismus sowie 3 Infektionen bei Alkoholismus und renaler Osteopathie ) . Zusaetzlich zeigten 5 Prothesen ( 9,6 % ) Roentgensaeume von mindestens 2 mm Breite . Inwieweit dieses Prothesenmodell mit metaphysaerer Fixierung gegenueber den herkoemmlichen Stielprothesen bei den jungen Hueftkopfnekrosepatienten Vorteile erbringen , muessen zukuenftige Studien mit laengeren Beobachtungszeiten zeigen . Instructions: please typing these entity words according to sentence: Literatur, Patienten, Patientengruppen, Aetiologie, steroidinduzierten, Knochenalteration, Osteopathie, Sichelzellanaemie, Immunsuppression, Sichelzellanaemie, Infektionsraten, Hueftprothesen, Aetiologie, Rolle, Langzeitergebnisse, zementlose, Prothesenmodelle, Druckscheibenprothesen, Patienten, Osteopathie, Alkoholismus, Infektionen, Alkoholismus, Osteopathie, Prothesen, Prothesenmodell, Stielprothesen Options: umlsterm
[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
In der Literatur finden sich sehr unterschiedliche Komplikations- und Lockerungsraten von Hueftendoprothesen bei Patienten mit Hueftkopfnekrose ( HKN ) . Diese Schwankungen sind v. a. durch die inhomogene Zusammensetzung der Patientengruppen hinsichtlich der Aetiologie der Hueftkopfnekrose bedingt . Untersucht man die Ergebnisse der Hueftendoprothesen fuer die verschiedenen HKN-Aetiologien gesondert , so kristallisiert sich eine hoehere Lockerungsrate bei steroidinduzierten Hueftkopfnekrosen und bei Hueftkopfnekrosen mit einer biologischen und biomechanischen Knochenalteration ( z . B. der renalen Osteopathie oder der Sichelzellanaemie ) heraus . Grunderkrankungen , die einer Immunsuppression beduerfen und die Sichelzellanaemie weisen hoehere Infektionsraten von Hueftprothesen auf . Somit spielt die Aetiologie der Hueftkopfnekrose eine entscheidende Rolle fuer Langzeitergebnisse von Hueftendoprothesen . Moderne Zementiertechniken der 2. Generation und zementlose Huefttotalendoprothesen scheinen bessere Ergebnisse zu liefern als frueher verwendete Prothesenmodelle bzw. Zementiertechniken . In einer prospektiven Studie konnten wir bisher 52 Druckscheibenprothesen bei 45 Patienten mit Hueftkopfnekrosen und einem Mindestnachuntersuchungszeitraum von 2 ( 3,7 +/- 1,6 Jahren ) postoperativ verfolgen . Es ergab sich eine Versagerquote von 9,6 % ( je eine aseptische Lockerung bei renaler Osteopathie und Alkoholismus sowie 3 Infektionen bei Alkoholismus und renaler Osteopathie ) . Zusaetzlich zeigten 5 Prothesen ( 9,6 % ) Roentgensaeume von mindestens 2 mm Breite . Inwieweit dieses Prothesenmodell mit metaphysaerer Fixierung gegenueber den herkoemmlichen Stielprothesen bei den jungen Hueftkopfnekrosepatienten Vorteile erbringen , muessen zukuenftige Studien mit laengeren Beobachtungszeiten zeigen .
[ "In", "der", "Literatur", "finden", "sich", "sehr", "unterschiedliche", "Komplikations-", "und", "Lockerungsraten", "von", "Hueftendoprothesen", "bei", "Patienten", "mit", "Hueftkopfnekrose", "(", "HKN", ")", ".", "Diese", "Schwankungen", "sind", "v.", "a.", "durch", "die", "inhomogene", "Zusammensetzung", "der", "Patientengruppen", "hinsichtlich", "der", "Aetiologie", "der", "Hueftkopfnekrose", "bedingt", ".", "Untersucht", "man", "die", "Ergebnisse", "der", "Hueftendoprothesen", "fuer", "die", "verschiedenen", "HKN", "-", "Aetiologien", "gesondert", ",", "so", "kristallisiert", "sich", "eine", "hoehere", "Lockerungsrate", "bei", "steroidinduzierten", "Hueftkopfnekrosen", "und", "bei", "Hueftkopfnekrosen", "mit", "einer", "biologischen", "und", "biomechanischen", "Knochenalteration", "(", "z", ".", "B.", "der", "renalen", "Osteopathie", "oder", "der", "Sichelzellanaemie", ")", "heraus", ".", "Grunderkrankungen", ",", "die", "einer", "Immunsuppression", "beduerfen", "und", "die", "Sichelzellanaemie", "weisen", "hoehere", "Infektionsraten", "von", "Hueftprothesen", "auf", ".", "Somit", "spielt", "die", "Aetiologie", "der", "Hueftkopfnekrose", "eine", "entscheidende", "Rolle", "fuer", "Langzeitergebnisse", "von", "Hueftendoprothesen", ".", "Moderne", "Zementiertechniken", "der", "2", ".", "Generation", "und", "zementlose", "Huefttotalendoprothesen", "scheinen", "bessere", "Ergebnisse", "zu", "liefern", "als", "frueher", "verwendete", "Prothesenmodelle", "bzw", ".", "Zementiertechniken", ".", "In", "einer", "prospektiven", "Studie", "konnten", "wir", "bisher", "52", "Druckscheibenprothesen", "bei", "45", "Patienten", "mit", "Hueftkopfnekrosen", "und", "einem", "Mindestnachuntersuchungszeitraum", "von", "2", "(", "3,7", "+", "/-", "1,6", "Jahren", ")", "postoperativ", "verfolgen", ".", "Es", "ergab", "sich", "eine", "Versagerquote", "von", "9,6", "%", "(", "je", "eine", "aseptische", "Lockerung", "bei", "renaler", "Osteopathie", "und", "Alkoholismus", "sowie", "3", "Infektionen", "bei", "Alkoholismus", "und", "renaler", "Osteopathie", ")", ".", "Zusaetzlich", "zeigten", "5", "Prothesen", "(", "9,6", "%", ")", "Roentgensaeume", "von", "mindestens", "2", "mm", "Breite", ".", "Inwieweit", "dieses", "Prothesenmodell", "mit", "metaphysaerer", "Fixierung", "gegenueber", "den", "herkoemmlichen", "Stielprothesen", "bei", "den", "jungen", "Hueftkopfnekrosepatienten", "Vorteile", "erbringen", ",", "muessen", "zukuenftige", "Studien", "mit", "laengeren", "Beobachtungszeiten", "zeigen", "." ]
[ "umlsterm" ]
Literatur, Patienten, Patientengruppen, Aetiologie, steroidinduzierten, Knochenalteration, Osteopathie, Sichelzellanaemie, Immunsuppression, Sichelzellanaemie, Infektionsraten, Hueftprothesen, Aetiologie, Rolle, Langzeitergebnisse, zementlose, Prothesenmodelle, Druckscheibenprothesen, Patienten, Osteopathie, Alkoholismus, Infektionen, Alkoholismus, Osteopathie, Prothesen, Prothesenmodell, Stielprothesen
DerOrthopaede.00290449.ger.abstr_task2
Sentence: In der Literatur finden sich sehr unterschiedliche Komplikations- und Lockerungsraten von Hueftendoprothesen bei Patienten mit Hueftkopfnekrose ( HKN ) . Diese Schwankungen sind v. a. durch die inhomogene Zusammensetzung der Patientengruppen hinsichtlich der Aetiologie der Hueftkopfnekrose bedingt . Untersucht man die Ergebnisse der Hueftendoprothesen fuer die verschiedenen HKN-Aetiologien gesondert , so kristallisiert sich eine hoehere Lockerungsrate bei steroidinduzierten Hueftkopfnekrosen und bei Hueftkopfnekrosen mit einer biologischen und biomechanischen Knochenalteration ( z . B. der renalen Osteopathie oder der Sichelzellanaemie ) heraus . Grunderkrankungen , die einer Immunsuppression beduerfen und die Sichelzellanaemie weisen hoehere Infektionsraten von Hueftprothesen auf . Somit spielt die Aetiologie der Hueftkopfnekrose eine entscheidende Rolle fuer Langzeitergebnisse von Hueftendoprothesen . Moderne Zementiertechniken der 2. Generation und zementlose Huefttotalendoprothesen scheinen bessere Ergebnisse zu liefern als frueher verwendete Prothesenmodelle bzw. Zementiertechniken . In einer prospektiven Studie konnten wir bisher 52 Druckscheibenprothesen bei 45 Patienten mit Hueftkopfnekrosen und einem Mindestnachuntersuchungszeitraum von 2 ( 3,7 +/- 1,6 Jahren ) postoperativ verfolgen . Es ergab sich eine Versagerquote von 9,6 % ( je eine aseptische Lockerung bei renaler Osteopathie und Alkoholismus sowie 3 Infektionen bei Alkoholismus und renaler Osteopathie ) . Zusaetzlich zeigten 5 Prothesen ( 9,6 % ) Roentgensaeume von mindestens 2 mm Breite . Inwieweit dieses Prothesenmodell mit metaphysaerer Fixierung gegenueber den herkoemmlichen Stielprothesen bei den jungen Hueftkopfnekrosepatienten Vorteile erbringen , muessen zukuenftige Studien mit laengeren Beobachtungszeiten zeigen . Instructions: please extract entity words from the input sentence
[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
In der Literatur finden sich sehr unterschiedliche Komplikations- und Lockerungsraten von Hueftendoprothesen bei Patienten mit Hueftkopfnekrose ( HKN ) . Diese Schwankungen sind v. a. durch die inhomogene Zusammensetzung der Patientengruppen hinsichtlich der Aetiologie der Hueftkopfnekrose bedingt . Untersucht man die Ergebnisse der Hueftendoprothesen fuer die verschiedenen HKN-Aetiologien gesondert , so kristallisiert sich eine hoehere Lockerungsrate bei steroidinduzierten Hueftkopfnekrosen und bei Hueftkopfnekrosen mit einer biologischen und biomechanischen Knochenalteration ( z . B. der renalen Osteopathie oder der Sichelzellanaemie ) heraus . Grunderkrankungen , die einer Immunsuppression beduerfen und die Sichelzellanaemie weisen hoehere Infektionsraten von Hueftprothesen auf . Somit spielt die Aetiologie der Hueftkopfnekrose eine entscheidende Rolle fuer Langzeitergebnisse von Hueftendoprothesen . Moderne Zementiertechniken der 2. Generation und zementlose Huefttotalendoprothesen scheinen bessere Ergebnisse zu liefern als frueher verwendete Prothesenmodelle bzw. Zementiertechniken . In einer prospektiven Studie konnten wir bisher 52 Druckscheibenprothesen bei 45 Patienten mit Hueftkopfnekrosen und einem Mindestnachuntersuchungszeitraum von 2 ( 3,7 +/- 1,6 Jahren ) postoperativ verfolgen . Es ergab sich eine Versagerquote von 9,6 % ( je eine aseptische Lockerung bei renaler Osteopathie und Alkoholismus sowie 3 Infektionen bei Alkoholismus und renaler Osteopathie ) . Zusaetzlich zeigten 5 Prothesen ( 9,6 % ) Roentgensaeume von mindestens 2 mm Breite . Inwieweit dieses Prothesenmodell mit metaphysaerer Fixierung gegenueber den herkoemmlichen Stielprothesen bei den jungen Hueftkopfnekrosepatienten Vorteile erbringen , muessen zukuenftige Studien mit laengeren Beobachtungszeiten zeigen .
[ "In", "der", "Literatur", "finden", "sich", "sehr", "unterschiedliche", "Komplikations-", "und", "Lockerungsraten", "von", "Hueftendoprothesen", "bei", "Patienten", "mit", "Hueftkopfnekrose", "(", "HKN", ")", ".", "Diese", "Schwankungen", "sind", "v.", "a.", "durch", "die", "inhomogene", "Zusammensetzung", "der", "Patientengruppen", "hinsichtlich", "der", "Aetiologie", "der", "Hueftkopfnekrose", "bedingt", ".", "Untersucht", "man", "die", "Ergebnisse", "der", "Hueftendoprothesen", "fuer", "die", "verschiedenen", "HKN", "-", "Aetiologien", "gesondert", ",", "so", "kristallisiert", "sich", "eine", "hoehere", "Lockerungsrate", "bei", "steroidinduzierten", "Hueftkopfnekrosen", "und", "bei", "Hueftkopfnekrosen", "mit", "einer", "biologischen", "und", "biomechanischen", "Knochenalteration", "(", "z", ".", "B.", "der", "renalen", "Osteopathie", "oder", "der", "Sichelzellanaemie", ")", "heraus", ".", "Grunderkrankungen", ",", "die", "einer", "Immunsuppression", "beduerfen", "und", "die", "Sichelzellanaemie", "weisen", "hoehere", "Infektionsraten", "von", "Hueftprothesen", "auf", ".", "Somit", "spielt", "die", "Aetiologie", "der", "Hueftkopfnekrose", "eine", "entscheidende", "Rolle", "fuer", "Langzeitergebnisse", "von", "Hueftendoprothesen", ".", "Moderne", "Zementiertechniken", "der", "2", ".", "Generation", "und", "zementlose", "Huefttotalendoprothesen", "scheinen", "bessere", "Ergebnisse", "zu", "liefern", "als", "frueher", "verwendete", "Prothesenmodelle", "bzw", ".", "Zementiertechniken", ".", "In", "einer", "prospektiven", "Studie", "konnten", "wir", "bisher", "52", "Druckscheibenprothesen", "bei", "45", "Patienten", "mit", "Hueftkopfnekrosen", "und", "einem", "Mindestnachuntersuchungszeitraum", "von", "2", "(", "3,7", "+", "/-", "1,6", "Jahren", ")", "postoperativ", "verfolgen", ".", "Es", "ergab", "sich", "eine", "Versagerquote", "von", "9,6", "%", "(", "je", "eine", "aseptische", "Lockerung", "bei", "renaler", "Osteopathie", "und", "Alkoholismus", "sowie", "3", "Infektionen", "bei", "Alkoholismus", "und", "renaler", "Osteopathie", ")", ".", "Zusaetzlich", "zeigten", "5", "Prothesen", "(", "9,6", "%", ")", "Roentgensaeume", "von", "mindestens", "2", "mm", "Breite", ".", "Inwieweit", "dieses", "Prothesenmodell", "mit", "metaphysaerer", "Fixierung", "gegenueber", "den", "herkoemmlichen", "Stielprothesen", "bei", "den", "jungen", "Hueftkopfnekrosepatienten", "Vorteile", "erbringen", ",", "muessen", "zukuenftige", "Studien", "mit", "laengeren", "Beobachtungszeiten", "zeigen", "." ]
[ "umlsterm" ]
salicylate is a Intervention_Pharmacological, Acetylsalicylic acid is a Intervention_Pharmacological, ASA is a Intervention_Pharmacological, 12 is a Participant_Sample-size, male is a Participant_Sex, enteric - coated ASA is a Intervention_Pharmacological, ecASA is a Intervention_Pharmacological, compressed ASA tablets ( cASA ) is a Intervention_Pharmacological, sodium salicylate is a Intervention_Pharmacological, maximum effect is a Outcome_Other, plasma ASA level and the maximum effect is a Outcome_Physical
79778_task0
Sentence: Human platelet response to three salicylate dosage forms . Acetylsalicylic acid ( ASA ) inhibition of platelet aggregation as evaluated by collagen-induced 14C-serotonin release , has been measured in 12 healthy male subjects . Each subject received a single oral dose ( 650 mg ) of enteric-coated ASA ( ecASA ) and compressed ASA tablets ( cASA ) , or ecASA and sodium salicylate ( 578 mg ) separated by a minimum of 5 weeks . The platelet response was related to plasma ASA and salicyclic acid determined by high-pressure liquid chromatography . Both ecASA and cASA inhibited 14C-serotonin release ; no significant difference was observed in the maximum effect between these two products ( p less than 0.05 ) . No relationship was found between the maximum observed plasma ASA level and the maximum effect . Further , no correlation was found between the maximum inhibition of 14C-serotonin release in vivo and the release predicted from in vitro experiments wherein the effect was measured after incubating plasma containing specified ASA concentrations . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Participant_Sex, Outcome_Physical, Participant_Sample-size, Outcome_Other
[ "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "B-Participant_Sex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Human platelet response to three salicylate dosage forms . Acetylsalicylic acid ( ASA ) inhibition of platelet aggregation as evaluated by collagen-induced 14C-serotonin release , has been measured in 12 healthy male subjects . Each subject received a single oral dose ( 650 mg ) of enteric-coated ASA ( ecASA ) and compressed ASA tablets ( cASA ) , or ecASA and sodium salicylate ( 578 mg ) separated by a minimum of 5 weeks . The platelet response was related to plasma ASA and salicyclic acid determined by high-pressure liquid chromatography . Both ecASA and cASA inhibited 14C-serotonin release ; no significant difference was observed in the maximum effect between these two products ( p less than 0.05 ) . No relationship was found between the maximum observed plasma ASA level and the maximum effect . Further , no correlation was found between the maximum inhibition of 14C-serotonin release in vivo and the release predicted from in vitro experiments wherein the effect was measured after incubating plasma containing specified ASA concentrations .
[ "Human", "platelet", "response", "to", "three", "salicylate", "dosage", "forms", ".", "Acetylsalicylic", "acid", "(", "ASA", ")", "inhibition", "of", "platelet", "aggregation", "as", "evaluated", "by", "collagen", "-", "induced", "14C", "-", "serotonin", "release", ",", "has", "been", "measured", "in", "12", "healthy", "male", "subjects", ".", "Each", "subject", "received", "a", "single", "oral", "dose", "(", "650", "mg", ")", "of", "enteric", "-", "coated", "ASA", "(", "ecASA", ")", "and", "compressed", "ASA", "tablets", "(", "cASA", ")", ",", "or", "ecASA", "and", "sodium", "salicylate", "(", "578", "mg", ")", "separated", "by", "a", "minimum", "of", "5", "weeks", ".", "The", "platelet", "response", "was", "related", "to", "plasma", "ASA", "and", "salicyclic", "acid", "determined", "by", "high", "-", "pressure", "liquid", "chromatography", ".", "Both", "ecASA", "and", "cASA", "inhibited", "14C", "-", "serotonin", "release", ";", "no", "significant", "difference", "was", "observed", "in", "the", "maximum", "effect", "between", "these", "two", "products", "(", "p", "less", "than", "0.05", ")", ".", "No", "relationship", "was", "found", "between", "the", "maximum", "observed", "plasma", "ASA", "level", "and", "the", "maximum", "effect", ".", "Further", ",", "no", "correlation", "was", "found", "between", "the", "maximum", "inhibition", "of", "14C", "-", "serotonin", "release", "in", "vivo", "and", "the", "release", "predicted", "from", "in", "vitro", "experiments", "wherein", "the", "effect", "was", "measured", "after", "incubating", "plasma", "containing", "specified", "ASA", "concentrations", "." ]
[ "Outcome_Physical", "Intervention_Pharmacological", "Outcome_Other", "Participant_Sex", "Participant_Sample-size" ]
salicylate is a Intervention_Pharmacological, Acetylsalicylic acid is a Intervention_Pharmacological, ASA is a Intervention_Pharmacological, 12 is a Participant_Sample-size, male is a Participant_Sex, enteric - coated ASA is a Intervention_Pharmacological, ecASA is a Intervention_Pharmacological, compressed ASA tablets ( cASA ) is a Intervention_Pharmacological, sodium salicylate is a Intervention_Pharmacological, maximum effect is a Outcome_Other, plasma ASA level and the maximum effect is a Outcome_Physical
79778_task1
Sentence: Human platelet response to three salicylate dosage forms . Acetylsalicylic acid ( ASA ) inhibition of platelet aggregation as evaluated by collagen-induced 14C-serotonin release , has been measured in 12 healthy male subjects . Each subject received a single oral dose ( 650 mg ) of enteric-coated ASA ( ecASA ) and compressed ASA tablets ( cASA ) , or ecASA and sodium salicylate ( 578 mg ) separated by a minimum of 5 weeks . The platelet response was related to plasma ASA and salicyclic acid determined by high-pressure liquid chromatography . Both ecASA and cASA inhibited 14C-serotonin release ; no significant difference was observed in the maximum effect between these two products ( p less than 0.05 ) . No relationship was found between the maximum observed plasma ASA level and the maximum effect . Further , no correlation was found between the maximum inhibition of 14C-serotonin release in vivo and the release predicted from in vitro experiments wherein the effect was measured after incubating plasma containing specified ASA concentrations . Instructions: please typing these entity words according to sentence: salicylate, Acetylsalicylic acid, ASA, 12, male, enteric - coated ASA, ecASA, compressed ASA tablets ( cASA ), sodium salicylate, maximum effect, plasma ASA level and the maximum effect Options: Intervention_Pharmacological, Participant_Sex, Outcome_Physical, Participant_Sample-size, Outcome_Other
[ "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "B-Participant_Sex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Human platelet response to three salicylate dosage forms . Acetylsalicylic acid ( ASA ) inhibition of platelet aggregation as evaluated by collagen-induced 14C-serotonin release , has been measured in 12 healthy male subjects . Each subject received a single oral dose ( 650 mg ) of enteric-coated ASA ( ecASA ) and compressed ASA tablets ( cASA ) , or ecASA and sodium salicylate ( 578 mg ) separated by a minimum of 5 weeks . The platelet response was related to plasma ASA and salicyclic acid determined by high-pressure liquid chromatography . Both ecASA and cASA inhibited 14C-serotonin release ; no significant difference was observed in the maximum effect between these two products ( p less than 0.05 ) . No relationship was found between the maximum observed plasma ASA level and the maximum effect . Further , no correlation was found between the maximum inhibition of 14C-serotonin release in vivo and the release predicted from in vitro experiments wherein the effect was measured after incubating plasma containing specified ASA concentrations .
[ "Human", "platelet", "response", "to", "three", "salicylate", "dosage", "forms", ".", "Acetylsalicylic", "acid", "(", "ASA", ")", "inhibition", "of", "platelet", "aggregation", "as", "evaluated", "by", "collagen", "-", "induced", "14C", "-", "serotonin", "release", ",", "has", "been", "measured", "in", "12", "healthy", "male", "subjects", ".", "Each", "subject", "received", "a", "single", "oral", "dose", "(", "650", "mg", ")", "of", "enteric", "-", "coated", "ASA", "(", "ecASA", ")", "and", "compressed", "ASA", "tablets", "(", "cASA", ")", ",", "or", "ecASA", "and", "sodium", "salicylate", "(", "578", "mg", ")", "separated", "by", "a", "minimum", "of", "5", "weeks", ".", "The", "platelet", "response", "was", "related", "to", "plasma", "ASA", "and", "salicyclic", "acid", "determined", "by", "high", "-", "pressure", "liquid", "chromatography", ".", "Both", "ecASA", "and", "cASA", "inhibited", "14C", "-", "serotonin", "release", ";", "no", "significant", "difference", "was", "observed", "in", "the", "maximum", "effect", "between", "these", "two", "products", "(", "p", "less", "than", "0.05", ")", ".", "No", "relationship", "was", "found", "between", "the", "maximum", "observed", "plasma", "ASA", "level", "and", "the", "maximum", "effect", ".", "Further", ",", "no", "correlation", "was", "found", "between", "the", "maximum", "inhibition", "of", "14C", "-", "serotonin", "release", "in", "vivo", "and", "the", "release", "predicted", "from", "in", "vitro", "experiments", "wherein", "the", "effect", "was", "measured", "after", "incubating", "plasma", "containing", "specified", "ASA", "concentrations", "." ]
[ "Outcome_Physical", "Intervention_Pharmacological", "Outcome_Other", "Participant_Sex", "Participant_Sample-size" ]
salicylate, Acetylsalicylic acid, ASA, 12, male, enteric - coated ASA, ecASA, compressed ASA tablets ( cASA ), sodium salicylate, maximum effect, plasma ASA level and the maximum effect
79778_task2
Sentence: Human platelet response to three salicylate dosage forms . Acetylsalicylic acid ( ASA ) inhibition of platelet aggregation as evaluated by collagen-induced 14C-serotonin release , has been measured in 12 healthy male subjects . Each subject received a single oral dose ( 650 mg ) of enteric-coated ASA ( ecASA ) and compressed ASA tablets ( cASA ) , or ecASA and sodium salicylate ( 578 mg ) separated by a minimum of 5 weeks . The platelet response was related to plasma ASA and salicyclic acid determined by high-pressure liquid chromatography . Both ecASA and cASA inhibited 14C-serotonin release ; no significant difference was observed in the maximum effect between these two products ( p less than 0.05 ) . No relationship was found between the maximum observed plasma ASA level and the maximum effect . Further , no correlation was found between the maximum inhibition of 14C-serotonin release in vivo and the release predicted from in vitro experiments wherein the effect was measured after incubating plasma containing specified ASA concentrations . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "B-Participant_Sex", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Human platelet response to three salicylate dosage forms . Acetylsalicylic acid ( ASA ) inhibition of platelet aggregation as evaluated by collagen-induced 14C-serotonin release , has been measured in 12 healthy male subjects . Each subject received a single oral dose ( 650 mg ) of enteric-coated ASA ( ecASA ) and compressed ASA tablets ( cASA ) , or ecASA and sodium salicylate ( 578 mg ) separated by a minimum of 5 weeks . The platelet response was related to plasma ASA and salicyclic acid determined by high-pressure liquid chromatography . Both ecASA and cASA inhibited 14C-serotonin release ; no significant difference was observed in the maximum effect between these two products ( p less than 0.05 ) . No relationship was found between the maximum observed plasma ASA level and the maximum effect . Further , no correlation was found between the maximum inhibition of 14C-serotonin release in vivo and the release predicted from in vitro experiments wherein the effect was measured after incubating plasma containing specified ASA concentrations .
[ "Human", "platelet", "response", "to", "three", "salicylate", "dosage", "forms", ".", "Acetylsalicylic", "acid", "(", "ASA", ")", "inhibition", "of", "platelet", "aggregation", "as", "evaluated", "by", "collagen", "-", "induced", "14C", "-", "serotonin", "release", ",", "has", "been", "measured", "in", "12", "healthy", "male", "subjects", ".", "Each", "subject", "received", "a", "single", "oral", "dose", "(", "650", "mg", ")", "of", "enteric", "-", "coated", "ASA", "(", "ecASA", ")", "and", "compressed", "ASA", "tablets", "(", "cASA", ")", ",", "or", "ecASA", "and", "sodium", "salicylate", "(", "578", "mg", ")", "separated", "by", "a", "minimum", "of", "5", "weeks", ".", "The", "platelet", "response", "was", "related", "to", "plasma", "ASA", "and", "salicyclic", "acid", "determined", "by", "high", "-", "pressure", "liquid", "chromatography", ".", "Both", "ecASA", "and", "cASA", "inhibited", "14C", "-", "serotonin", "release", ";", "no", "significant", "difference", "was", "observed", "in", "the", "maximum", "effect", "between", "these", "two", "products", "(", "p", "less", "than", "0.05", ")", ".", "No", "relationship", "was", "found", "between", "the", "maximum", "observed", "plasma", "ASA", "level", "and", "the", "maximum", "effect", ".", "Further", ",", "no", "correlation", "was", "found", "between", "the", "maximum", "inhibition", "of", "14C", "-", "serotonin", "release", "in", "vivo", "and", "the", "release", "predicted", "from", "in", "vitro", "experiments", "wherein", "the", "effect", "was", "measured", "after", "incubating", "plasma", "containing", "specified", "ASA", "concentrations", "." ]
[ "Outcome_Physical", "Intervention_Pharmacological", "Outcome_Other", "Participant_Sex", "Participant_Sample-size" ]
pseudarthrosis is an umlsterm, traumatology is an umlsterm, treatment is an umlsterm, treatment is an umlsterm, immobilisation is an umlsterm, bone is an umlsterm, plate is an umlsterm, pseudarthrosis is an umlsterm, bone is an umlsterm, scintigraphy is an umlsterm, X - ray is an umlsterm, treatment is an umlsterm, Osteoporosis is an umlsterm, dislocation is an umlsterm, complications is an umlsterm, treatment is an umlsterm, pseudarthrosis is an umlsterm, defect is an umlsterm, bone is an umlsterm, defects is an umlsterm, transfer is an umlsterm, fibula - to - tibia is an umlsterm, operation is an umlsterm, lithotripsy is an umlsterm, method is an umlsterm, treatment is an umlsterm, contraindication is an umlsterm, immobilisation is an umlsterm, Treatment is an umlsterm, low - frequency is an umlsterm, magnetic is an umlsterm, attention is an umlsterm, bone is an umlsterm, asepsis is an umlsterm, development is an umlsterm, pseudarthrosis is an umlsterm
DerOrthopaede.60250394.eng.abstr_task0
Sentence: Aseptic pseudarthrosis may occur after all kinds of traumatology treatment . Following conservative treatment , incomplete immobilisation or an unattached bone fragment can be causal . After plate osteosynthesis the biomechanical principles are not efficient or the circulatory damage delays healing . There are two broad types of pseudarthrosis : vascular and nonvascular . The extent of vascularisation can be demonstrated by bone scintigraphy as well as X-ray . The treatment of vascular nonunions is very common . Mechanical stability is required , therefore a new osteosynthesis is desirable . Osteoporosis caused by inactivity and dislocation increases the rate of complications . Much more difficult problems are encountered in treatment of unreactive and avital pseudarthrosis , particularly in cases with a defect of bone substance . These defects can be treated with a segment transfer and a fibula-to-tibia operation . Extracorporal lithotripsy has been established as a new method in treatment of active and vascular nonunions . Former osteosynthesis is not a contraindication . Stability and immobilisation are necessary . Treatment in the low-frequency magnetic field shows no effect . Correct biomechanical and biological osteosynthesis with proper attention paid to location , quality of bone and asepsis can avoid the development of a pseudarthrosis . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]
Aseptic pseudarthrosis may occur after all kinds of traumatology treatment . Following conservative treatment , incomplete immobilisation or an unattached bone fragment can be causal . After plate osteosynthesis the biomechanical principles are not efficient or the circulatory damage delays healing . There are two broad types of pseudarthrosis : vascular and nonvascular . The extent of vascularisation can be demonstrated by bone scintigraphy as well as X-ray . The treatment of vascular nonunions is very common . Mechanical stability is required , therefore a new osteosynthesis is desirable . Osteoporosis caused by inactivity and dislocation increases the rate of complications . Much more difficult problems are encountered in treatment of unreactive and avital pseudarthrosis , particularly in cases with a defect of bone substance . These defects can be treated with a segment transfer and a fibula-to-tibia operation . Extracorporal lithotripsy has been established as a new method in treatment of active and vascular nonunions . Former osteosynthesis is not a contraindication . Stability and immobilisation are necessary . Treatment in the low-frequency magnetic field shows no effect . Correct biomechanical and biological osteosynthesis with proper attention paid to location , quality of bone and asepsis can avoid the development of a pseudarthrosis .
[ "Aseptic", "pseudarthrosis", "may", "occur", "after", "all", "kinds", "of", "traumatology", "treatment", ".", "Following", "conservative", "treatment", ",", "incomplete", "immobilisation", "or", "an", "unattached", "bone", "fragment", "can", "be", "causal", ".", "After", "plate", "osteosynthesis", "the", "biomechanical", "principles", "are", "not", "efficient", "or", "the", "circulatory", "damage", "delays", "healing", ".", "There", "are", "two", "broad", "types", "of", "pseudarthrosis", ":", "vascular", "and", "nonvascular", ".", "The", "extent", "of", "vascularisation", "can", "be", "demonstrated", "by", "bone", "scintigraphy", "as", "well", "as", "X", "-", "ray", ".", "The", "treatment", "of", "vascular", "nonunions", "is", "very", "common", ".", "Mechanical", "stability", "is", "required", ",", "therefore", "a", "new", "osteosynthesis", "is", "desirable", ".", "Osteoporosis", "caused", "by", "inactivity", "and", "dislocation", "increases", "the", "rate", "of", "complications", ".", "Much", "more", "difficult", "problems", "are", "encountered", "in", "treatment", "of", "unreactive", "and", "avital", "pseudarthrosis", ",", "particularly", "in", "cases", "with", "a", "defect", "of", "bone", "substance", ".", "These", "defects", "can", "be", "treated", "with", "a", "segment", "transfer", "and", "a", "fibula", "-", "to", "-", "tibia", "operation", ".", "Extracorporal", "lithotripsy", "has", "been", "established", "as", "a", "new", "method", "in", "treatment", "of", "active", "and", "vascular", "nonunions", ".", "Former", "osteosynthesis", "is", "not", "a", "contraindication", ".", "Stability", "and", "immobilisation", "are", "necessary", ".", "Treatment", "in", "the", "low", "-", "frequency", "magnetic", "field", "shows", "no", "effect", ".", "Correct", "biomechanical", "and", "biological", "osteosynthesis", "with", "proper", "attention", "paid", "to", "location", ",", "quality", "of", "bone", "and", "asepsis", "can", "avoid", "the", "development", "of", "a", "pseudarthrosis", "." ]
[ "umlsterm" ]
pseudarthrosis is an umlsterm, traumatology is an umlsterm, treatment is an umlsterm, treatment is an umlsterm, immobilisation is an umlsterm, bone is an umlsterm, plate is an umlsterm, pseudarthrosis is an umlsterm, bone is an umlsterm, scintigraphy is an umlsterm, X - ray is an umlsterm, treatment is an umlsterm, Osteoporosis is an umlsterm, dislocation is an umlsterm, complications is an umlsterm, treatment is an umlsterm, pseudarthrosis is an umlsterm, defect is an umlsterm, bone is an umlsterm, defects is an umlsterm, transfer is an umlsterm, fibula - to - tibia is an umlsterm, operation is an umlsterm, lithotripsy is an umlsterm, method is an umlsterm, treatment is an umlsterm, contraindication is an umlsterm, immobilisation is an umlsterm, Treatment is an umlsterm, low - frequency is an umlsterm, magnetic is an umlsterm, attention is an umlsterm, bone is an umlsterm, asepsis is an umlsterm, development is an umlsterm, pseudarthrosis is an umlsterm
DerOrthopaede.60250394.eng.abstr_task1
Sentence: Aseptic pseudarthrosis may occur after all kinds of traumatology treatment . Following conservative treatment , incomplete immobilisation or an unattached bone fragment can be causal . After plate osteosynthesis the biomechanical principles are not efficient or the circulatory damage delays healing . There are two broad types of pseudarthrosis : vascular and nonvascular . The extent of vascularisation can be demonstrated by bone scintigraphy as well as X-ray . The treatment of vascular nonunions is very common . Mechanical stability is required , therefore a new osteosynthesis is desirable . Osteoporosis caused by inactivity and dislocation increases the rate of complications . Much more difficult problems are encountered in treatment of unreactive and avital pseudarthrosis , particularly in cases with a defect of bone substance . These defects can be treated with a segment transfer and a fibula-to-tibia operation . Extracorporal lithotripsy has been established as a new method in treatment of active and vascular nonunions . Former osteosynthesis is not a contraindication . Stability and immobilisation are necessary . Treatment in the low-frequency magnetic field shows no effect . Correct biomechanical and biological osteosynthesis with proper attention paid to location , quality of bone and asepsis can avoid the development of a pseudarthrosis . Instructions: please typing these entity words according to sentence: pseudarthrosis, traumatology, treatment, treatment, immobilisation, bone, plate, pseudarthrosis, bone, scintigraphy, X - ray, treatment, Osteoporosis, dislocation, complications, treatment, pseudarthrosis, defect, bone, defects, transfer, fibula - to - tibia, operation, lithotripsy, method, treatment, contraindication, immobilisation, Treatment, low - frequency, magnetic, attention, bone, asepsis, development, pseudarthrosis Options: umlsterm
[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]
Aseptic pseudarthrosis may occur after all kinds of traumatology treatment . Following conservative treatment , incomplete immobilisation or an unattached bone fragment can be causal . After plate osteosynthesis the biomechanical principles are not efficient or the circulatory damage delays healing . There are two broad types of pseudarthrosis : vascular and nonvascular . The extent of vascularisation can be demonstrated by bone scintigraphy as well as X-ray . The treatment of vascular nonunions is very common . Mechanical stability is required , therefore a new osteosynthesis is desirable . Osteoporosis caused by inactivity and dislocation increases the rate of complications . Much more difficult problems are encountered in treatment of unreactive and avital pseudarthrosis , particularly in cases with a defect of bone substance . These defects can be treated with a segment transfer and a fibula-to-tibia operation . Extracorporal lithotripsy has been established as a new method in treatment of active and vascular nonunions . Former osteosynthesis is not a contraindication . Stability and immobilisation are necessary . Treatment in the low-frequency magnetic field shows no effect . Correct biomechanical and biological osteosynthesis with proper attention paid to location , quality of bone and asepsis can avoid the development of a pseudarthrosis .
[ "Aseptic", "pseudarthrosis", "may", "occur", "after", "all", "kinds", "of", "traumatology", "treatment", ".", "Following", "conservative", "treatment", ",", "incomplete", "immobilisation", "or", "an", "unattached", "bone", "fragment", "can", "be", "causal", ".", "After", "plate", "osteosynthesis", "the", "biomechanical", "principles", "are", "not", "efficient", "or", "the", "circulatory", "damage", "delays", "healing", ".", "There", "are", "two", "broad", "types", "of", "pseudarthrosis", ":", "vascular", "and", "nonvascular", ".", "The", "extent", "of", "vascularisation", "can", "be", "demonstrated", "by", "bone", "scintigraphy", "as", "well", "as", "X", "-", "ray", ".", "The", "treatment", "of", "vascular", "nonunions", "is", "very", "common", ".", "Mechanical", "stability", "is", "required", ",", "therefore", "a", "new", "osteosynthesis", "is", "desirable", ".", "Osteoporosis", "caused", "by", "inactivity", "and", "dislocation", "increases", "the", "rate", "of", "complications", ".", "Much", "more", "difficult", "problems", "are", "encountered", "in", "treatment", "of", "unreactive", "and", "avital", "pseudarthrosis", ",", "particularly", "in", "cases", "with", "a", "defect", "of", "bone", "substance", ".", "These", "defects", "can", "be", "treated", "with", "a", "segment", "transfer", "and", "a", "fibula", "-", "to", "-", "tibia", "operation", ".", "Extracorporal", "lithotripsy", "has", "been", "established", "as", "a", "new", "method", "in", "treatment", "of", "active", "and", "vascular", "nonunions", ".", "Former", "osteosynthesis", "is", "not", "a", "contraindication", ".", "Stability", "and", "immobilisation", "are", "necessary", ".", "Treatment", "in", "the", "low", "-", "frequency", "magnetic", "field", "shows", "no", "effect", ".", "Correct", "biomechanical", "and", "biological", "osteosynthesis", "with", "proper", "attention", "paid", "to", "location", ",", "quality", "of", "bone", "and", "asepsis", "can", "avoid", "the", "development", "of", "a", "pseudarthrosis", "." ]
[ "umlsterm" ]
pseudarthrosis, traumatology, treatment, treatment, immobilisation, bone, plate, pseudarthrosis, bone, scintigraphy, X - ray, treatment, Osteoporosis, dislocation, complications, treatment, pseudarthrosis, defect, bone, defects, transfer, fibula - to - tibia, operation, lithotripsy, method, treatment, contraindication, immobilisation, Treatment, low - frequency, magnetic, attention, bone, asepsis, development, pseudarthrosis
DerOrthopaede.60250394.eng.abstr_task2
Sentence: Aseptic pseudarthrosis may occur after all kinds of traumatology treatment . Following conservative treatment , incomplete immobilisation or an unattached bone fragment can be causal . After plate osteosynthesis the biomechanical principles are not efficient or the circulatory damage delays healing . There are two broad types of pseudarthrosis : vascular and nonvascular . The extent of vascularisation can be demonstrated by bone scintigraphy as well as X-ray . The treatment of vascular nonunions is very common . Mechanical stability is required , therefore a new osteosynthesis is desirable . Osteoporosis caused by inactivity and dislocation increases the rate of complications . Much more difficult problems are encountered in treatment of unreactive and avital pseudarthrosis , particularly in cases with a defect of bone substance . These defects can be treated with a segment transfer and a fibula-to-tibia operation . Extracorporal lithotripsy has been established as a new method in treatment of active and vascular nonunions . Former osteosynthesis is not a contraindication . Stability and immobilisation are necessary . Treatment in the low-frequency magnetic field shows no effect . Correct biomechanical and biological osteosynthesis with proper attention paid to location , quality of bone and asepsis can avoid the development of a pseudarthrosis . Instructions: please extract entity words from the input sentence
[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]
Aseptic pseudarthrosis may occur after all kinds of traumatology treatment . Following conservative treatment , incomplete immobilisation or an unattached bone fragment can be causal . After plate osteosynthesis the biomechanical principles are not efficient or the circulatory damage delays healing . There are two broad types of pseudarthrosis : vascular and nonvascular . The extent of vascularisation can be demonstrated by bone scintigraphy as well as X-ray . The treatment of vascular nonunions is very common . Mechanical stability is required , therefore a new osteosynthesis is desirable . Osteoporosis caused by inactivity and dislocation increases the rate of complications . Much more difficult problems are encountered in treatment of unreactive and avital pseudarthrosis , particularly in cases with a defect of bone substance . These defects can be treated with a segment transfer and a fibula-to-tibia operation . Extracorporal lithotripsy has been established as a new method in treatment of active and vascular nonunions . Former osteosynthesis is not a contraindication . Stability and immobilisation are necessary . Treatment in the low-frequency magnetic field shows no effect . Correct biomechanical and biological osteosynthesis with proper attention paid to location , quality of bone and asepsis can avoid the development of a pseudarthrosis .
[ "Aseptic", "pseudarthrosis", "may", "occur", "after", "all", "kinds", "of", "traumatology", "treatment", ".", "Following", "conservative", "treatment", ",", "incomplete", "immobilisation", "or", "an", "unattached", "bone", "fragment", "can", "be", "causal", ".", "After", "plate", "osteosynthesis", "the", "biomechanical", "principles", "are", "not", "efficient", "or", "the", "circulatory", "damage", "delays", "healing", ".", "There", "are", "two", "broad", "types", "of", "pseudarthrosis", ":", "vascular", "and", "nonvascular", ".", "The", "extent", "of", "vascularisation", "can", "be", "demonstrated", "by", "bone", "scintigraphy", "as", "well", "as", "X", "-", "ray", ".", "The", "treatment", "of", "vascular", "nonunions", "is", "very", "common", ".", "Mechanical", "stability", "is", "required", ",", "therefore", "a", "new", "osteosynthesis", "is", "desirable", ".", "Osteoporosis", "caused", "by", "inactivity", "and", "dislocation", "increases", "the", "rate", "of", "complications", ".", "Much", "more", "difficult", "problems", "are", "encountered", "in", "treatment", "of", "unreactive", "and", "avital", "pseudarthrosis", ",", "particularly", "in", "cases", "with", "a", "defect", "of", "bone", "substance", ".", "These", "defects", "can", "be", "treated", "with", "a", "segment", "transfer", "and", "a", "fibula", "-", "to", "-", "tibia", "operation", ".", "Extracorporal", "lithotripsy", "has", "been", "established", "as", "a", "new", "method", "in", "treatment", "of", "active", "and", "vascular", "nonunions", ".", "Former", "osteosynthesis", "is", "not", "a", "contraindication", ".", "Stability", "and", "immobilisation", "are", "necessary", ".", "Treatment", "in", "the", "low", "-", "frequency", "magnetic", "field", "shows", "no", "effect", ".", "Correct", "biomechanical", "and", "biological", "osteosynthesis", "with", "proper", "attention", "paid", "to", "location", ",", "quality", "of", "bone", "and", "asepsis", "can", "avoid", "the", "development", "of", "a", "pseudarthrosis", "." ]
[ "umlsterm" ]
allergy is a Condition, opioid is a Drug, contraindications is a Condition, epidural analgesia is a Procedure, coagulopathies is a Condition, platelet count of less than 100,000 is a Scope, spine surgery is a Procedure, in past is a Temporal
NCT03344042_exc_task0
Sentence: no consent known allergy to administered opioid contraindications to epidural analgesia coagulopathies including platelet count of less than 100,000 spine surgery in past Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Temporal, Condition, Procedure, Scope, Drug
[ "O", "O", "O", "O", "B-Condition", "O", "O", "B-Drug", "O", "B-Condition", "O", "B-Procedure", "I-Procedure", "O", "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Procedure", "I-Procedure", "B-Temporal", "I-Temporal", "O" ]
no consent known allergy to administered opioid contraindications to epidural analgesia coagulopathies including platelet count of less than 100,000 spine surgery in past
[ "no", "consent", "\n", "known", "allergy", "to", "administered", "opioid", "\n", "contraindications", "to", "epidural", "analgesia", "\n", "coagulopathies", "including", "platelet", "count", "of", "less", "than", "100,000", "\n", "spine", "surgery", "in", "past", "\n" ]
[ "Scope", "Procedure", "Condition", "Value", "Measurement", "Temporal", "Drug" ]
allergy is a Condition, opioid is a Drug, contraindications is a Condition, epidural analgesia is a Procedure, coagulopathies is a Condition, platelet count of less than 100,000 is a Scope, spine surgery is a Procedure, in past is a Temporal
NCT03344042_exc_task1
Sentence: no consent known allergy to administered opioid contraindications to epidural analgesia coagulopathies including platelet count of less than 100,000 spine surgery in past Instructions: please typing these entity words according to sentence: allergy, opioid, contraindications, epidural analgesia, coagulopathies, platelet count of less than 100,000, spine surgery, in past Options: Temporal, Condition, Procedure, Scope, Drug
[ "O", "O", "O", "O", "B-Condition", "O", "O", "B-Drug", "O", "B-Condition", "O", "B-Procedure", "I-Procedure", "O", "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Procedure", "I-Procedure", "B-Temporal", "I-Temporal", "O" ]
no consent known allergy to administered opioid contraindications to epidural analgesia coagulopathies including platelet count of less than 100,000 spine surgery in past
[ "no", "consent", "\n", "known", "allergy", "to", "administered", "opioid", "\n", "contraindications", "to", "epidural", "analgesia", "\n", "coagulopathies", "including", "platelet", "count", "of", "less", "than", "100,000", "\n", "spine", "surgery", "in", "past", "\n" ]
[ "Scope", "Procedure", "Condition", "Value", "Measurement", "Temporal", "Drug" ]
allergy, opioid, contraindications, epidural analgesia, coagulopathies, platelet count of less than 100,000, spine surgery, in past
NCT03344042_exc_task2
Sentence: no consent known allergy to administered opioid contraindications to epidural analgesia coagulopathies including platelet count of less than 100,000 spine surgery in past Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "B-Condition", "O", "O", "B-Drug", "O", "B-Condition", "O", "B-Procedure", "I-Procedure", "O", "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Procedure", "I-Procedure", "B-Temporal", "I-Temporal", "O" ]
no consent known allergy to administered opioid contraindications to epidural analgesia coagulopathies including platelet count of less than 100,000 spine surgery in past
[ "no", "consent", "\n", "known", "allergy", "to", "administered", "opioid", "\n", "contraindications", "to", "epidural", "analgesia", "\n", "coagulopathies", "including", "platelet", "count", "of", "less", "than", "100,000", "\n", "spine", "surgery", "in", "past", "\n" ]
[ "Scope", "Procedure", "Condition", "Value", "Measurement", "Temporal", "Drug" ]
physical activity intervention is a Intervention_Physical, 3 - 5 year old children attending long day care services : is a Participant_Condition, Young children is a Participant_Condition, wait list control is a Intervention_Control, physical activity intervention will consist of a number of strategies including is a Intervention_Physical, delivering structured fundamental movement skill activities , increasing physical activity opportunities , increasing staff role modelling , providing children with a physical activity promoting indoor and outdoor environment and limiting children ' s small screen recreation and sedentary behaviours is a Intervention_Physical, child physical activity levels is a Outcome_Physical, during attendance at long day care is a Outcome_Mental, acceptability and extent of implementation of the intervention by services is a Outcome_Other
47380_task0
Sentence: A cluster randomised trial to evaluate a physical activity intervention among 3-5 year old children attending long day care services : study protocol . BACKGROUND Young children are not participating in recommended levels of physical activity and exhibit high levels of sedentary behaviour . Childcare services provide access to large numbers of young children for prolonged periods , yet there is limited experimental evidence regarding the effectiveness of physical activity interventions implemented in this setting . The aim of this study is to assess the effectiveness and acceptability of a multi-component physical activity intervention , delivered by childcare service staff , in increasing the physical activity levels of children attending long day care services . METHODS/DESIGN The study will employ a cluster randomised controlled trial design . Three hundred children aged between 3-5 years from twenty randomly selected long day care services in the Hunter Region of New South Wales , Australia will be invited to participate in the trial . Ten of the 20 long day care services will be randomly allocated to deliver the intervention with the remaining ten services allocated to a wait list control group . The physical activity intervention will consist of a number of strategies including : delivering structured fundamental movement skill activities , increasing physical activity opportunities , increasing staff role modelling , providing children with a physical activity promoting indoor and outdoor environment and limiting children 's small screen recreation and sedentary behaviours . Intervention effectiveness will be measured via child physical activity levels during attendance at long day care . The study also seeks to determine the acceptability and extent of implementation of the intervention by services and their staff participating in the study . DISCUSSION The trial will address current gaps in the research evidence base and contribute to the design and delivery of future interventions promoting physical activity for young children in long day care settings . TRIAL REGISTRATION Australian New Zealand Clinical Trials Registry ACTRN12610000087055 . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Physical, Intervention_Control, Participant_Condition, Outcome_Physical, Outcome_Other, Outcome_Mental
[ "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
A cluster randomised trial to evaluate a physical activity intervention among 3-5 year old children attending long day care services : study protocol . BACKGROUND Young children are not participating in recommended levels of physical activity and exhibit high levels of sedentary behaviour . Childcare services provide access to large numbers of young children for prolonged periods , yet there is limited experimental evidence regarding the effectiveness of physical activity interventions implemented in this setting . The aim of this study is to assess the effectiveness and acceptability of a multi-component physical activity intervention , delivered by childcare service staff , in increasing the physical activity levels of children attending long day care services . METHODS/DESIGN The study will employ a cluster randomised controlled trial design . Three hundred children aged between 3-5 years from twenty randomly selected long day care services in the Hunter Region of New South Wales , Australia will be invited to participate in the trial . Ten of the 20 long day care services will be randomly allocated to deliver the intervention with the remaining ten services allocated to a wait list control group . The physical activity intervention will consist of a number of strategies including : delivering structured fundamental movement skill activities , increasing physical activity opportunities , increasing staff role modelling , providing children with a physical activity promoting indoor and outdoor environment and limiting children 's small screen recreation and sedentary behaviours . Intervention effectiveness will be measured via child physical activity levels during attendance at long day care . The study also seeks to determine the acceptability and extent of implementation of the intervention by services and their staff participating in the study . DISCUSSION The trial will address current gaps in the research evidence base and contribute to the design and delivery of future interventions promoting physical activity for young children in long day care settings . TRIAL REGISTRATION Australian New Zealand Clinical Trials Registry ACTRN12610000087055 .
[ "A", "cluster", "randomised", "trial", "to", "evaluate", "a", "physical", "activity", "intervention", "among", "3", "-", "5", "year", "old", "children", "attending", "long", "day", "care", "services", ":", "study", "protocol", ".", "BACKGROUND", "Young", "children", "are", "not", "participating", "in", "recommended", "levels", "of", "physical", "activity", "and", "exhibit", "high", "levels", "of", "sedentary", "behaviour", ".", "Childcare", "services", "provide", "access", "to", "large", "numbers", "of", "young", "children", "for", "prolonged", "periods", ",", "yet", "there", "is", "limited", "experimental", "evidence", "regarding", "the", "effectiveness", "of", "physical", "activity", "interventions", "implemented", "in", "this", "setting", ".", "The", "aim", "of", "this", "study", "is", "to", "assess", "the", "effectiveness", "and", "acceptability", "of", "a", "multi", "-", "component", "physical", "activity", "intervention", ",", "delivered", "by", "childcare", "service", "staff", ",", "in", "increasing", "the", "physical", "activity", "levels", "of", "children", "attending", "long", "day", "care", "services", ".", "METHODS", "/", "DESIGN", "The", "study", "will", "employ", "a", "cluster", "randomised", "controlled", "trial", "design", ".", "Three", "hundred", "children", "aged", "between", "3", "-", "5", "years", "from", "twenty", "randomly", "selected", "long", "day", "care", "services", "in", "the", "Hunter", "Region", "of", "New", "South", "Wales", ",", "Australia", "will", "be", "invited", "to", "participate", "in", "the", "trial", ".", "Ten", "of", "the", "20", "long", "day", "care", "services", "will", "be", "randomly", "allocated", "to", "deliver", "the", "intervention", "with", "the", "remaining", "ten", "services", "allocated", "to", "a", "wait", "list", "control", "group", ".", "The", "physical", "activity", "intervention", "will", "consist", "of", "a", "number", "of", "strategies", "including", ":", "delivering", "structured", "fundamental", "movement", "skill", "activities", ",", "increasing", "physical", "activity", "opportunities", ",", "increasing", "staff", "role", "modelling", ",", "providing", "children", "with", "a", "physical", "activity", "promoting", "indoor", "and", "outdoor", "environment", "and", "limiting", "children", "'", "s", "small", "screen", "recreation", "and", "sedentary", "behaviours", ".", "Intervention", "effectiveness", "will", "be", "measured", "via", "child", "physical", "activity", "levels", "during", "attendance", "at", "long", "day", "care", ".", "The", "study", "also", "seeks", "to", "determine", "the", "acceptability", "and", "extent", "of", "implementation", "of", "the", "intervention", "by", "services", "and", "their", "staff", "participating", "in", "the", "study", ".", "DISCUSSION", "The", "trial", "will", "address", "current", "gaps", "in", "the", "research", "evidence", "base", "and", "contribute", "to", "the", "design", "and", "delivery", "of", "future", "interventions", "promoting", "physical", "activity", "for", "young", "children", "in", "long", "day", "care", "settings", ".", "TRIAL", "REGISTRATION", "Australian", "New", "Zealand", "Clinical", "Trials", "Registry", "ACTRN12610000087055", "." ]
[ "Intervention_Physical", "Outcome_Other", "Participant_Condition", "Outcome_Mental", "Outcome_Physical", "Intervention_Control" ]
physical activity intervention is a Intervention_Physical, 3 - 5 year old children attending long day care services : is a Participant_Condition, Young children is a Participant_Condition, wait list control is a Intervention_Control, physical activity intervention will consist of a number of strategies including is a Intervention_Physical, delivering structured fundamental movement skill activities , increasing physical activity opportunities , increasing staff role modelling , providing children with a physical activity promoting indoor and outdoor environment and limiting children ' s small screen recreation and sedentary behaviours is a Intervention_Physical, child physical activity levels is a Outcome_Physical, during attendance at long day care is a Outcome_Mental, acceptability and extent of implementation of the intervention by services is a Outcome_Other
47380_task1
Sentence: A cluster randomised trial to evaluate a physical activity intervention among 3-5 year old children attending long day care services : study protocol . BACKGROUND Young children are not participating in recommended levels of physical activity and exhibit high levels of sedentary behaviour . Childcare services provide access to large numbers of young children for prolonged periods , yet there is limited experimental evidence regarding the effectiveness of physical activity interventions implemented in this setting . The aim of this study is to assess the effectiveness and acceptability of a multi-component physical activity intervention , delivered by childcare service staff , in increasing the physical activity levels of children attending long day care services . METHODS/DESIGN The study will employ a cluster randomised controlled trial design . Three hundred children aged between 3-5 years from twenty randomly selected long day care services in the Hunter Region of New South Wales , Australia will be invited to participate in the trial . Ten of the 20 long day care services will be randomly allocated to deliver the intervention with the remaining ten services allocated to a wait list control group . The physical activity intervention will consist of a number of strategies including : delivering structured fundamental movement skill activities , increasing physical activity opportunities , increasing staff role modelling , providing children with a physical activity promoting indoor and outdoor environment and limiting children 's small screen recreation and sedentary behaviours . Intervention effectiveness will be measured via child physical activity levels during attendance at long day care . The study also seeks to determine the acceptability and extent of implementation of the intervention by services and their staff participating in the study . DISCUSSION The trial will address current gaps in the research evidence base and contribute to the design and delivery of future interventions promoting physical activity for young children in long day care settings . TRIAL REGISTRATION Australian New Zealand Clinical Trials Registry ACTRN12610000087055 . Instructions: please typing these entity words according to sentence: physical activity intervention, 3 - 5 year old children attending long day care services :, Young children, wait list control, physical activity intervention will consist of a number of strategies including, delivering structured fundamental movement skill activities , increasing physical activity opportunities , increasing staff role modelling , providing children with a physical activity promoting indoor and outdoor environment and limiting children ' s small screen recreation and sedentary behaviours, child physical activity levels, during attendance at long day care, acceptability and extent of implementation of the intervention by services Options: Intervention_Physical, Intervention_Control, Participant_Condition, Outcome_Physical, Outcome_Other, Outcome_Mental
[ "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
A cluster randomised trial to evaluate a physical activity intervention among 3-5 year old children attending long day care services : study protocol . BACKGROUND Young children are not participating in recommended levels of physical activity and exhibit high levels of sedentary behaviour . Childcare services provide access to large numbers of young children for prolonged periods , yet there is limited experimental evidence regarding the effectiveness of physical activity interventions implemented in this setting . The aim of this study is to assess the effectiveness and acceptability of a multi-component physical activity intervention , delivered by childcare service staff , in increasing the physical activity levels of children attending long day care services . METHODS/DESIGN The study will employ a cluster randomised controlled trial design . Three hundred children aged between 3-5 years from twenty randomly selected long day care services in the Hunter Region of New South Wales , Australia will be invited to participate in the trial . Ten of the 20 long day care services will be randomly allocated to deliver the intervention with the remaining ten services allocated to a wait list control group . The physical activity intervention will consist of a number of strategies including : delivering structured fundamental movement skill activities , increasing physical activity opportunities , increasing staff role modelling , providing children with a physical activity promoting indoor and outdoor environment and limiting children 's small screen recreation and sedentary behaviours . Intervention effectiveness will be measured via child physical activity levels during attendance at long day care . The study also seeks to determine the acceptability and extent of implementation of the intervention by services and their staff participating in the study . DISCUSSION The trial will address current gaps in the research evidence base and contribute to the design and delivery of future interventions promoting physical activity for young children in long day care settings . TRIAL REGISTRATION Australian New Zealand Clinical Trials Registry ACTRN12610000087055 .
[ "A", "cluster", "randomised", "trial", "to", "evaluate", "a", "physical", "activity", "intervention", "among", "3", "-", "5", "year", "old", "children", "attending", "long", "day", "care", "services", ":", "study", "protocol", ".", "BACKGROUND", "Young", "children", "are", "not", "participating", "in", "recommended", "levels", "of", "physical", "activity", "and", "exhibit", "high", "levels", "of", "sedentary", "behaviour", ".", "Childcare", "services", "provide", "access", "to", "large", "numbers", "of", "young", "children", "for", "prolonged", "periods", ",", "yet", "there", "is", "limited", "experimental", "evidence", "regarding", "the", "effectiveness", "of", "physical", "activity", "interventions", "implemented", "in", "this", "setting", ".", "The", "aim", "of", "this", "study", "is", "to", "assess", "the", "effectiveness", "and", "acceptability", "of", "a", "multi", "-", "component", "physical", "activity", "intervention", ",", "delivered", "by", "childcare", "service", "staff", ",", "in", "increasing", "the", "physical", "activity", "levels", "of", "children", "attending", "long", "day", "care", "services", ".", "METHODS", "/", "DESIGN", "The", "study", "will", "employ", "a", "cluster", "randomised", "controlled", "trial", "design", ".", "Three", "hundred", "children", "aged", "between", "3", "-", "5", "years", "from", "twenty", "randomly", "selected", "long", "day", "care", "services", "in", "the", "Hunter", "Region", "of", "New", "South", "Wales", ",", "Australia", "will", "be", "invited", "to", "participate", "in", "the", "trial", ".", "Ten", "of", "the", "20", "long", "day", "care", "services", "will", "be", "randomly", "allocated", "to", "deliver", "the", "intervention", "with", "the", "remaining", "ten", "services", "allocated", "to", "a", "wait", "list", "control", "group", ".", "The", "physical", "activity", "intervention", "will", "consist", "of", "a", "number", "of", "strategies", "including", ":", "delivering", "structured", "fundamental", "movement", "skill", "activities", ",", "increasing", "physical", "activity", "opportunities", ",", "increasing", "staff", "role", "modelling", ",", "providing", "children", "with", "a", "physical", "activity", "promoting", "indoor", "and", "outdoor", "environment", "and", "limiting", "children", "'", "s", "small", "screen", "recreation", "and", "sedentary", "behaviours", ".", "Intervention", "effectiveness", "will", "be", "measured", "via", "child", "physical", "activity", "levels", "during", "attendance", "at", "long", "day", "care", ".", "The", "study", "also", "seeks", "to", "determine", "the", "acceptability", "and", "extent", "of", "implementation", "of", "the", "intervention", "by", "services", "and", "their", "staff", "participating", "in", "the", "study", ".", "DISCUSSION", "The", "trial", "will", "address", "current", "gaps", "in", "the", "research", "evidence", "base", "and", "contribute", "to", "the", "design", "and", "delivery", "of", "future", "interventions", "promoting", "physical", "activity", "for", "young", "children", "in", "long", "day", "care", "settings", ".", "TRIAL", "REGISTRATION", "Australian", "New", "Zealand", "Clinical", "Trials", "Registry", "ACTRN12610000087055", "." ]
[ "Intervention_Physical", "Outcome_Other", "Participant_Condition", "Outcome_Mental", "Outcome_Physical", "Intervention_Control" ]
physical activity intervention, 3 - 5 year old children attending long day care services :, Young children, wait list control, physical activity intervention will consist of a number of strategies including, delivering structured fundamental movement skill activities , increasing physical activity opportunities , increasing staff role modelling , providing children with a physical activity promoting indoor and outdoor environment and limiting children ' s small screen recreation and sedentary behaviours, child physical activity levels, during attendance at long day care, acceptability and extent of implementation of the intervention by services
47380_task2
Sentence: A cluster randomised trial to evaluate a physical activity intervention among 3-5 year old children attending long day care services : study protocol . BACKGROUND Young children are not participating in recommended levels of physical activity and exhibit high levels of sedentary behaviour . Childcare services provide access to large numbers of young children for prolonged periods , yet there is limited experimental evidence regarding the effectiveness of physical activity interventions implemented in this setting . The aim of this study is to assess the effectiveness and acceptability of a multi-component physical activity intervention , delivered by childcare service staff , in increasing the physical activity levels of children attending long day care services . METHODS/DESIGN The study will employ a cluster randomised controlled trial design . Three hundred children aged between 3-5 years from twenty randomly selected long day care services in the Hunter Region of New South Wales , Australia will be invited to participate in the trial . Ten of the 20 long day care services will be randomly allocated to deliver the intervention with the remaining ten services allocated to a wait list control group . The physical activity intervention will consist of a number of strategies including : delivering structured fundamental movement skill activities , increasing physical activity opportunities , increasing staff role modelling , providing children with a physical activity promoting indoor and outdoor environment and limiting children 's small screen recreation and sedentary behaviours . Intervention effectiveness will be measured via child physical activity levels during attendance at long day care . The study also seeks to determine the acceptability and extent of implementation of the intervention by services and their staff participating in the study . DISCUSSION The trial will address current gaps in the research evidence base and contribute to the design and delivery of future interventions promoting physical activity for young children in long day care settings . TRIAL REGISTRATION Australian New Zealand Clinical Trials Registry ACTRN12610000087055 . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "B-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "I-Outcome_Mental", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
A cluster randomised trial to evaluate a physical activity intervention among 3-5 year old children attending long day care services : study protocol . BACKGROUND Young children are not participating in recommended levels of physical activity and exhibit high levels of sedentary behaviour . Childcare services provide access to large numbers of young children for prolonged periods , yet there is limited experimental evidence regarding the effectiveness of physical activity interventions implemented in this setting . The aim of this study is to assess the effectiveness and acceptability of a multi-component physical activity intervention , delivered by childcare service staff , in increasing the physical activity levels of children attending long day care services . METHODS/DESIGN The study will employ a cluster randomised controlled trial design . Three hundred children aged between 3-5 years from twenty randomly selected long day care services in the Hunter Region of New South Wales , Australia will be invited to participate in the trial . Ten of the 20 long day care services will be randomly allocated to deliver the intervention with the remaining ten services allocated to a wait list control group . The physical activity intervention will consist of a number of strategies including : delivering structured fundamental movement skill activities , increasing physical activity opportunities , increasing staff role modelling , providing children with a physical activity promoting indoor and outdoor environment and limiting children 's small screen recreation and sedentary behaviours . Intervention effectiveness will be measured via child physical activity levels during attendance at long day care . The study also seeks to determine the acceptability and extent of implementation of the intervention by services and their staff participating in the study . DISCUSSION The trial will address current gaps in the research evidence base and contribute to the design and delivery of future interventions promoting physical activity for young children in long day care settings . TRIAL REGISTRATION Australian New Zealand Clinical Trials Registry ACTRN12610000087055 .
[ "A", "cluster", "randomised", "trial", "to", "evaluate", "a", "physical", "activity", "intervention", "among", "3", "-", "5", "year", "old", "children", "attending", "long", "day", "care", "services", ":", "study", "protocol", ".", "BACKGROUND", "Young", "children", "are", "not", "participating", "in", "recommended", "levels", "of", "physical", "activity", "and", "exhibit", "high", "levels", "of", "sedentary", "behaviour", ".", "Childcare", "services", "provide", "access", "to", "large", "numbers", "of", "young", "children", "for", "prolonged", "periods", ",", "yet", "there", "is", "limited", "experimental", "evidence", "regarding", "the", "effectiveness", "of", "physical", "activity", "interventions", "implemented", "in", "this", "setting", ".", "The", "aim", "of", "this", "study", "is", "to", "assess", "the", "effectiveness", "and", "acceptability", "of", "a", "multi", "-", "component", "physical", "activity", "intervention", ",", "delivered", "by", "childcare", "service", "staff", ",", "in", "increasing", "the", "physical", "activity", "levels", "of", "children", "attending", "long", "day", "care", "services", ".", "METHODS", "/", "DESIGN", "The", "study", "will", "employ", "a", "cluster", "randomised", "controlled", "trial", "design", ".", "Three", "hundred", "children", "aged", "between", "3", "-", "5", "years", "from", "twenty", "randomly", "selected", "long", "day", "care", "services", "in", "the", "Hunter", "Region", "of", "New", "South", "Wales", ",", "Australia", "will", "be", "invited", "to", "participate", "in", "the", "trial", ".", "Ten", "of", "the", "20", "long", "day", "care", "services", "will", "be", "randomly", "allocated", "to", "deliver", "the", "intervention", "with", "the", "remaining", "ten", "services", "allocated", "to", "a", "wait", "list", "control", "group", ".", "The", "physical", "activity", "intervention", "will", "consist", "of", "a", "number", "of", "strategies", "including", ":", "delivering", "structured", "fundamental", "movement", "skill", "activities", ",", "increasing", "physical", "activity", "opportunities", ",", "increasing", "staff", "role", "modelling", ",", "providing", "children", "with", "a", "physical", "activity", "promoting", "indoor", "and", "outdoor", "environment", "and", "limiting", "children", "'", "s", "small", "screen", "recreation", "and", "sedentary", "behaviours", ".", "Intervention", "effectiveness", "will", "be", "measured", "via", "child", "physical", "activity", "levels", "during", "attendance", "at", "long", "day", "care", ".", "The", "study", "also", "seeks", "to", "determine", "the", "acceptability", "and", "extent", "of", "implementation", "of", "the", "intervention", "by", "services", "and", "their", "staff", "participating", "in", "the", "study", ".", "DISCUSSION", "The", "trial", "will", "address", "current", "gaps", "in", "the", "research", "evidence", "base", "and", "contribute", "to", "the", "design", "and", "delivery", "of", "future", "interventions", "promoting", "physical", "activity", "for", "young", "children", "in", "long", "day", "care", "settings", ".", "TRIAL", "REGISTRATION", "Australian", "New", "Zealand", "Clinical", "Trials", "Registry", "ACTRN12610000087055", "." ]
[ "Intervention_Physical", "Outcome_Other", "Participant_Condition", "Outcome_Mental", "Outcome_Physical", "Intervention_Control" ]
Chondroblastom is an umlsterm, Knochentumor is an umlsterm, Epiphyse is an umlsterm, Patella is an umlsterm, Patienten is an umlsterm, Chondroblastom is an umlsterm, Patella is an umlsterm, Spontanfraktur is an umlsterm, Patella is an umlsterm, Literatur is an umlsterm, Chondroblastoms is an umlsterm, Patella is an umlsterm, Fraktur is an umlsterm
DerUnfallchirurg.01030898.ger.abstr_task0
Sentence: Das Chondroblastom ist ein seltener gutartiger , chondrogener Knochentumor . Die typische Lokalisation ist die Epiphyse im Bereich der langen Roehrenknochen . Der Befall der Patella ist ein seltenes Ereignis und wird mit einer Haeufigkeit von 2% angegeben . Wir berichten ueber einen Fall eines 16-jaehrigen Patienten mit einem Chondroblastom der Patella , bei dem es zu einer Spontanfraktur gekommen ist . Therapeutisch wurde eine Teilresektion der Patella durchgefuehrt . In der Literatur ist dies der sechste beschriebene Fall eines Chondroblastoms der Patella mit Eintreten einer spontanen ( pathologischen ) Fraktur . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]
Das Chondroblastom ist ein seltener gutartiger , chondrogener Knochentumor . Die typische Lokalisation ist die Epiphyse im Bereich der langen Roehrenknochen . Der Befall der Patella ist ein seltenes Ereignis und wird mit einer Haeufigkeit von 2% angegeben . Wir berichten ueber einen Fall eines 16-jaehrigen Patienten mit einem Chondroblastom der Patella , bei dem es zu einer Spontanfraktur gekommen ist . Therapeutisch wurde eine Teilresektion der Patella durchgefuehrt . In der Literatur ist dies der sechste beschriebene Fall eines Chondroblastoms der Patella mit Eintreten einer spontanen ( pathologischen ) Fraktur .
[ "Das", "Chondroblastom", "ist", "ein", "seltener", "gutartiger", ",", "chondrogener", "Knochentumor", ".", "Die", "typische", "Lokalisation", "ist", "die", "Epiphyse", "im", "Bereich", "der", "langen", "Roehrenknochen", ".", "Der", "Befall", "der", "Patella", "ist", "ein", "seltenes", "Ereignis", "und", "wird", "mit", "einer", "Haeufigkeit", "von", "2", "%", "angegeben", ".", "Wir", "berichten", "ueber", "einen", "Fall", "eines", "16-jaehrigen", "Patienten", "mit", "einem", "Chondroblastom", "der", "Patella", ",", "bei", "dem", "es", "zu", "einer", "Spontanfraktur", "gekommen", "ist", ".", "Therapeutisch", "wurde", "eine", "Teilresektion", "der", "Patella", "durchgefuehrt", ".", "In", "der", "Literatur", "ist", "dies", "der", "sechste", "beschriebene", "Fall", "eines", "Chondroblastoms", "der", "Patella", "mit", "Eintreten", "einer", "spontanen", "(", "pathologischen", ")", "Fraktur", "." ]
[ "umlsterm" ]
Chondroblastom is an umlsterm, Knochentumor is an umlsterm, Epiphyse is an umlsterm, Patella is an umlsterm, Patienten is an umlsterm, Chondroblastom is an umlsterm, Patella is an umlsterm, Spontanfraktur is an umlsterm, Patella is an umlsterm, Literatur is an umlsterm, Chondroblastoms is an umlsterm, Patella is an umlsterm, Fraktur is an umlsterm
DerUnfallchirurg.01030898.ger.abstr_task1
Sentence: Das Chondroblastom ist ein seltener gutartiger , chondrogener Knochentumor . Die typische Lokalisation ist die Epiphyse im Bereich der langen Roehrenknochen . Der Befall der Patella ist ein seltenes Ereignis und wird mit einer Haeufigkeit von 2% angegeben . Wir berichten ueber einen Fall eines 16-jaehrigen Patienten mit einem Chondroblastom der Patella , bei dem es zu einer Spontanfraktur gekommen ist . Therapeutisch wurde eine Teilresektion der Patella durchgefuehrt . In der Literatur ist dies der sechste beschriebene Fall eines Chondroblastoms der Patella mit Eintreten einer spontanen ( pathologischen ) Fraktur . Instructions: please typing these entity words according to sentence: Chondroblastom, Knochentumor, Epiphyse, Patella, Patienten, Chondroblastom, Patella, Spontanfraktur, Patella, Literatur, Chondroblastoms, Patella, Fraktur Options: umlsterm
[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]
Das Chondroblastom ist ein seltener gutartiger , chondrogener Knochentumor . Die typische Lokalisation ist die Epiphyse im Bereich der langen Roehrenknochen . Der Befall der Patella ist ein seltenes Ereignis und wird mit einer Haeufigkeit von 2% angegeben . Wir berichten ueber einen Fall eines 16-jaehrigen Patienten mit einem Chondroblastom der Patella , bei dem es zu einer Spontanfraktur gekommen ist . Therapeutisch wurde eine Teilresektion der Patella durchgefuehrt . In der Literatur ist dies der sechste beschriebene Fall eines Chondroblastoms der Patella mit Eintreten einer spontanen ( pathologischen ) Fraktur .
[ "Das", "Chondroblastom", "ist", "ein", "seltener", "gutartiger", ",", "chondrogener", "Knochentumor", ".", "Die", "typische", "Lokalisation", "ist", "die", "Epiphyse", "im", "Bereich", "der", "langen", "Roehrenknochen", ".", "Der", "Befall", "der", "Patella", "ist", "ein", "seltenes", "Ereignis", "und", "wird", "mit", "einer", "Haeufigkeit", "von", "2", "%", "angegeben", ".", "Wir", "berichten", "ueber", "einen", "Fall", "eines", "16-jaehrigen", "Patienten", "mit", "einem", "Chondroblastom", "der", "Patella", ",", "bei", "dem", "es", "zu", "einer", "Spontanfraktur", "gekommen", "ist", ".", "Therapeutisch", "wurde", "eine", "Teilresektion", "der", "Patella", "durchgefuehrt", ".", "In", "der", "Literatur", "ist", "dies", "der", "sechste", "beschriebene", "Fall", "eines", "Chondroblastoms", "der", "Patella", "mit", "Eintreten", "einer", "spontanen", "(", "pathologischen", ")", "Fraktur", "." ]
[ "umlsterm" ]
Chondroblastom, Knochentumor, Epiphyse, Patella, Patienten, Chondroblastom, Patella, Spontanfraktur, Patella, Literatur, Chondroblastoms, Patella, Fraktur
DerUnfallchirurg.01030898.ger.abstr_task2
Sentence: Das Chondroblastom ist ein seltener gutartiger , chondrogener Knochentumor . Die typische Lokalisation ist die Epiphyse im Bereich der langen Roehrenknochen . Der Befall der Patella ist ein seltenes Ereignis und wird mit einer Haeufigkeit von 2% angegeben . Wir berichten ueber einen Fall eines 16-jaehrigen Patienten mit einem Chondroblastom der Patella , bei dem es zu einer Spontanfraktur gekommen ist . Therapeutisch wurde eine Teilresektion der Patella durchgefuehrt . In der Literatur ist dies der sechste beschriebene Fall eines Chondroblastoms der Patella mit Eintreten einer spontanen ( pathologischen ) Fraktur . Instructions: please extract entity words from the input sentence
[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]
Das Chondroblastom ist ein seltener gutartiger , chondrogener Knochentumor . Die typische Lokalisation ist die Epiphyse im Bereich der langen Roehrenknochen . Der Befall der Patella ist ein seltenes Ereignis und wird mit einer Haeufigkeit von 2% angegeben . Wir berichten ueber einen Fall eines 16-jaehrigen Patienten mit einem Chondroblastom der Patella , bei dem es zu einer Spontanfraktur gekommen ist . Therapeutisch wurde eine Teilresektion der Patella durchgefuehrt . In der Literatur ist dies der sechste beschriebene Fall eines Chondroblastoms der Patella mit Eintreten einer spontanen ( pathologischen ) Fraktur .
[ "Das", "Chondroblastom", "ist", "ein", "seltener", "gutartiger", ",", "chondrogener", "Knochentumor", ".", "Die", "typische", "Lokalisation", "ist", "die", "Epiphyse", "im", "Bereich", "der", "langen", "Roehrenknochen", ".", "Der", "Befall", "der", "Patella", "ist", "ein", "seltenes", "Ereignis", "und", "wird", "mit", "einer", "Haeufigkeit", "von", "2", "%", "angegeben", ".", "Wir", "berichten", "ueber", "einen", "Fall", "eines", "16-jaehrigen", "Patienten", "mit", "einem", "Chondroblastom", "der", "Patella", ",", "bei", "dem", "es", "zu", "einer", "Spontanfraktur", "gekommen", "ist", ".", "Therapeutisch", "wurde", "eine", "Teilresektion", "der", "Patella", "durchgefuehrt", ".", "In", "der", "Literatur", "ist", "dies", "der", "sechste", "beschriebene", "Fall", "eines", "Chondroblastoms", "der", "Patella", "mit", "Eintreten", "einer", "spontanen", "(", "pathologischen", ")", "Fraktur", "." ]
[ "umlsterm" ]
chronic hepatitis B is a Condition, hepatitis B surface antigen test is a Measurement, active hepatitis C is a Condition, hepatitis C virus [ HCV ] Ab test is a Measurement, positive is a Value, HCV ribonucleic acid [ RNA ] PCR test is a Measurement, active is a Qualifier, syphilis infection is a Condition, chlamydia is a Condition, gonorrhea is a Condition, trichomonas is a Condition, Active is a Qualifier, syphilis is a Condition, serology is a Measurement, unless is a Negation, positive is a Value, serology is a Measurement, treated infection is a Condition, thyroidectomy is a Procedure, active is a Qualifier, thyroid disease is a Condition, medication is a Drug, during the last 12 months is a Temporal, not excluded is a Negation, stable is a Qualifier, thyroid supplementation is a Drug, major psychiatric illness and / or substance abuse is a Scope, during the past 12 months is a Temporal, hospitalization or periods of work disability is a Scope, licensed vaccine is a Drug, within 14 days prior to the first dose of study vaccine / placebo , plans to receive within 14 days after the first study vaccination , or plans to receive within 14 days before or after the second , third or fourth vaccination is a Scope, prophylactic or therapeutic is a Scope, HIV vaccine candidate is a Drug, at any time is a Temporal, other experimental vaccine(s ) is a Drug, within the last 12 months is a Temporal, experimental vaccine is a Drug, except is a Negation, HIV vaccine is a Drug, more than 12 months ago is a Temporal
NCT02788045_exc_task0
Sentence: Has chronic hepatitis B (measured by hepatitis B surface antigen test) or active hepatitis C (measured by hepatitis C virus [HCV] Ab test; if positive, HCV ribonucleic acid [RNA] PCR test will be used to confirm active versus past HCV infection), active syphilis infection, chlamydia, gonorrhea, or trichomonas . Active syphilis documented by serology unless positive serology is due to past treated infection Has had a thyroidectomy or active thyroid disease requiring medication during the last 12 months (not excluded: a stable thyroid supplementation) Has had major psychiatric illness and/or substance abuse problems during the past 12 months (including hospitalization or periods of work disability) that in the opinion of the investigator would preclude participation Has been in receipt of any licensed vaccine within 14 days prior to the first dose of study vaccine/placebo, plans to receive within 14 days after the first study vaccination, or plans to receive within 14 days before or after the second, third or fourth vaccination Is a recipient of a prophylactic or therapeutic HIV vaccine candidate at any time, or a recipient of other experimental vaccine(s) within the last 12 months. For participants who received an experimental vaccine (except HIV vaccine) more than 12 months ago, documentation of the identity of the experimental vaccine must be provided to the sponsor, who will determine eligibility on a case-by-case basis Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Temporal, Condition, Qualifier, Value, Procedure, Negation, Scope, Measurement, Drug
[ "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "O", "B-Value", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Qualifier", "B-Condition", "I-Condition", "O", "B-Condition", "O", "B-Condition", "O", "O", "B-Condition", "O", "B-Qualifier", "B-Condition", "O", "O", "B-Measurement", "B-Negation", "B-Value", "B-Measurement", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "O", "O", "O", "B-Procedure", "O", "B-Qualifier", "B-Condition", "I-Condition", "O", "B-Drug", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Negation", "I-Negation", "O", "O", "B-Qualifier", "B-Drug", "I-Drug", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Drug", "I-Drug", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "B-Drug", "I-Drug", "I-Drug", "B-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "B-Drug", "I-Drug", "I-Drug", "I-Drug", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "B-Drug", "I-Drug", "O", "B-Negation", "B-Drug", "I-Drug", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Has chronic hepatitis B (measured by hepatitis B surface antigen test) or active hepatitis C (measured by hepatitis C virus [HCV] Ab test; if positive, HCV ribonucleic acid [RNA] PCR test will be used to confirm active versus past HCV infection), active syphilis infection, chlamydia, gonorrhea, or trichomonas . Active syphilis documented by serology unless positive serology is due to past treated infection Has had a thyroidectomy or active thyroid disease requiring medication during the last 12 months (not excluded: a stable thyroid supplementation) Has had major psychiatric illness and/or substance abuse problems during the past 12 months (including hospitalization or periods of work disability) that in the opinion of the investigator would preclude participation Has been in receipt of any licensed vaccine within 14 days prior to the first dose of study vaccine/placebo, plans to receive within 14 days after the first study vaccination, or plans to receive within 14 days before or after the second, third or fourth vaccination Is a recipient of a prophylactic or therapeutic HIV vaccine candidate at any time, or a recipient of other experimental vaccine(s) within the last 12 months. For participants who received an experimental vaccine (except HIV vaccine) more than 12 months ago, documentation of the identity of the experimental vaccine must be provided to the sponsor, who will determine eligibility on a case-by-case basis
[ "Has", "chronic", "hepatitis", "B", "(", "measured", "by", "hepatitis", "B", "surface", "antigen", "test", ")", "or", "active", "hepatitis", "C", "(", "measured", "by", "hepatitis", "C", "virus", "[", "HCV", "]", "Ab", "test", ";", "if", "positive", ",", "HCV", "ribonucleic", "acid", "[", "RNA", "]", "PCR", "test", "will", "be", "used", "to", "confirm", "active", "versus", "past", "HCV", "infection", ")", ",", "active", "syphilis", "infection", ",", "chlamydia", ",", "gonorrhea", ",", "or", "trichomonas", ".", "Active", "syphilis", "documented", "by", "serology", "unless", "positive", "serology", "is", "due", "to", "past", "treated", "infection", "\n", "Has", "had", "a", "thyroidectomy", "or", "active", "thyroid", "disease", "requiring", "medication", "during", "the", "last", "12", "months", "(", "not", "excluded", ":", "a", "stable", "thyroid", "supplementation", ")", "\n", "Has", "had", "major", "psychiatric", "illness", "and", "/", "or", "substance", "abuse", "problems", "during", "the", "past", "12", "months", "(", "including", "hospitalization", "or", "periods", "of", "work", "disability", ")", "that", "in", "the", "opinion", "of", "the", "investigator", "would", "preclude", "participation", "\n", "Has", "been", "in", "receipt", "of", "any", "licensed", "vaccine", "within", "14", "days", "prior", "to", "the", "first", "dose", "of", "study", "vaccine", "/", "placebo", ",", "plans", "to", "receive", "within", "14", "days", "after", "the", "first", "study", "vaccination", ",", "or", "plans", "to", "receive", "within", "14", "days", "before", "or", "after", "the", "second", ",", "third", "or", "fourth", "vaccination", "\n", "Is", "a", "recipient", "of", "a", "prophylactic", "or", "therapeutic", "HIV", "vaccine", "candidate", "at", "any", "time", ",", "or", "a", "recipient", "of", "other", "experimental", "vaccine(s", ")", "within", "the", "last", "12", "months", ".", "For", "participants", "who", "received", "an", "experimental", "vaccine", "(", "except", "HIV", "vaccine", ")", "more", "than", "12", "months", "ago", ",", "documentation", "of", "the", "identity", "of", "the", "experimental", "vaccine", "must", "be", "provided", "to", "the", "sponsor", ",", "who", "will", "determine", "eligibility", "on", "a", "case", "-", "by", "-", "case", "basis", " \n \n" ]
[ "Scope", "Reference_point", "Measurement", "Temporal", "Drug", "Condition", "Procedure", "Qualifier", "Negation", "Value" ]
chronic hepatitis B is a Condition, hepatitis B surface antigen test is a Measurement, active hepatitis C is a Condition, hepatitis C virus [ HCV ] Ab test is a Measurement, positive is a Value, HCV ribonucleic acid [ RNA ] PCR test is a Measurement, active is a Qualifier, syphilis infection is a Condition, chlamydia is a Condition, gonorrhea is a Condition, trichomonas is a Condition, Active is a Qualifier, syphilis is a Condition, serology is a Measurement, unless is a Negation, positive is a Value, serology is a Measurement, treated infection is a Condition, thyroidectomy is a Procedure, active is a Qualifier, thyroid disease is a Condition, medication is a Drug, during the last 12 months is a Temporal, not excluded is a Negation, stable is a Qualifier, thyroid supplementation is a Drug, major psychiatric illness and / or substance abuse is a Scope, during the past 12 months is a Temporal, hospitalization or periods of work disability is a Scope, licensed vaccine is a Drug, within 14 days prior to the first dose of study vaccine / placebo , plans to receive within 14 days after the first study vaccination , or plans to receive within 14 days before or after the second , third or fourth vaccination is a Scope, prophylactic or therapeutic is a Scope, HIV vaccine candidate is a Drug, at any time is a Temporal, other experimental vaccine(s ) is a Drug, within the last 12 months is a Temporal, experimental vaccine is a Drug, except is a Negation, HIV vaccine is a Drug, more than 12 months ago is a Temporal
NCT02788045_exc_task1
Sentence: Has chronic hepatitis B (measured by hepatitis B surface antigen test) or active hepatitis C (measured by hepatitis C virus [HCV] Ab test; if positive, HCV ribonucleic acid [RNA] PCR test will be used to confirm active versus past HCV infection), active syphilis infection, chlamydia, gonorrhea, or trichomonas . Active syphilis documented by serology unless positive serology is due to past treated infection Has had a thyroidectomy or active thyroid disease requiring medication during the last 12 months (not excluded: a stable thyroid supplementation) Has had major psychiatric illness and/or substance abuse problems during the past 12 months (including hospitalization or periods of work disability) that in the opinion of the investigator would preclude participation Has been in receipt of any licensed vaccine within 14 days prior to the first dose of study vaccine/placebo, plans to receive within 14 days after the first study vaccination, or plans to receive within 14 days before or after the second, third or fourth vaccination Is a recipient of a prophylactic or therapeutic HIV vaccine candidate at any time, or a recipient of other experimental vaccine(s) within the last 12 months. For participants who received an experimental vaccine (except HIV vaccine) more than 12 months ago, documentation of the identity of the experimental vaccine must be provided to the sponsor, who will determine eligibility on a case-by-case basis Instructions: please typing these entity words according to sentence: chronic hepatitis B, hepatitis B surface antigen test, active hepatitis C, hepatitis C virus [ HCV ] Ab test, positive, HCV ribonucleic acid [ RNA ] PCR test, active, syphilis infection, chlamydia, gonorrhea, trichomonas, Active, syphilis, serology, unless, positive, serology, treated infection, thyroidectomy, active, thyroid disease, medication, during the last 12 months, not excluded, stable, thyroid supplementation, major psychiatric illness and / or substance abuse, during the past 12 months, hospitalization or periods of work disability, licensed vaccine, within 14 days prior to the first dose of study vaccine / placebo , plans to receive within 14 days after the first study vaccination , or plans to receive within 14 days before or after the second , third or fourth vaccination, prophylactic or therapeutic, HIV vaccine candidate, at any time, other experimental vaccine(s ), within the last 12 months, experimental vaccine, except, HIV vaccine, more than 12 months ago Options: Temporal, Condition, Qualifier, Value, Procedure, Negation, Scope, Measurement, Drug
[ "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "O", "B-Value", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Qualifier", "B-Condition", "I-Condition", "O", "B-Condition", "O", "B-Condition", "O", "O", "B-Condition", "O", "B-Qualifier", "B-Condition", "O", "O", "B-Measurement", "B-Negation", "B-Value", "B-Measurement", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "O", "O", "O", "B-Procedure", "O", "B-Qualifier", "B-Condition", "I-Condition", "O", "B-Drug", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Negation", "I-Negation", "O", "O", "B-Qualifier", "B-Drug", "I-Drug", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Drug", "I-Drug", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "B-Drug", "I-Drug", "I-Drug", "B-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "B-Drug", "I-Drug", "I-Drug", "I-Drug", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "B-Drug", "I-Drug", "O", "B-Negation", "B-Drug", "I-Drug", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Has chronic hepatitis B (measured by hepatitis B surface antigen test) or active hepatitis C (measured by hepatitis C virus [HCV] Ab test; if positive, HCV ribonucleic acid [RNA] PCR test will be used to confirm active versus past HCV infection), active syphilis infection, chlamydia, gonorrhea, or trichomonas . Active syphilis documented by serology unless positive serology is due to past treated infection Has had a thyroidectomy or active thyroid disease requiring medication during the last 12 months (not excluded: a stable thyroid supplementation) Has had major psychiatric illness and/or substance abuse problems during the past 12 months (including hospitalization or periods of work disability) that in the opinion of the investigator would preclude participation Has been in receipt of any licensed vaccine within 14 days prior to the first dose of study vaccine/placebo, plans to receive within 14 days after the first study vaccination, or plans to receive within 14 days before or after the second, third or fourth vaccination Is a recipient of a prophylactic or therapeutic HIV vaccine candidate at any time, or a recipient of other experimental vaccine(s) within the last 12 months. For participants who received an experimental vaccine (except HIV vaccine) more than 12 months ago, documentation of the identity of the experimental vaccine must be provided to the sponsor, who will determine eligibility on a case-by-case basis
[ "Has", "chronic", "hepatitis", "B", "(", "measured", "by", "hepatitis", "B", "surface", "antigen", "test", ")", "or", "active", "hepatitis", "C", "(", "measured", "by", "hepatitis", "C", "virus", "[", "HCV", "]", "Ab", "test", ";", "if", "positive", ",", "HCV", "ribonucleic", "acid", "[", "RNA", "]", "PCR", "test", "will", "be", "used", "to", "confirm", "active", "versus", "past", "HCV", "infection", ")", ",", "active", "syphilis", "infection", ",", "chlamydia", ",", "gonorrhea", ",", "or", "trichomonas", ".", "Active", "syphilis", "documented", "by", "serology", "unless", "positive", "serology", "is", "due", "to", "past", "treated", "infection", "\n", "Has", "had", "a", "thyroidectomy", "or", "active", "thyroid", "disease", "requiring", "medication", "during", "the", "last", "12", "months", "(", "not", "excluded", ":", "a", "stable", "thyroid", "supplementation", ")", "\n", "Has", "had", "major", "psychiatric", "illness", "and", "/", "or", "substance", "abuse", "problems", "during", "the", "past", "12", "months", "(", "including", "hospitalization", "or", "periods", "of", "work", "disability", ")", "that", "in", "the", "opinion", "of", "the", "investigator", "would", "preclude", "participation", "\n", "Has", "been", "in", "receipt", "of", "any", "licensed", "vaccine", "within", "14", "days", "prior", "to", "the", "first", "dose", "of", "study", "vaccine", "/", "placebo", ",", "plans", "to", "receive", "within", "14", "days", "after", "the", "first", "study", "vaccination", ",", "or", "plans", "to", "receive", "within", "14", "days", "before", "or", "after", "the", "second", ",", "third", "or", "fourth", "vaccination", "\n", "Is", "a", "recipient", "of", "a", "prophylactic", "or", "therapeutic", "HIV", "vaccine", "candidate", "at", "any", "time", ",", "or", "a", "recipient", "of", "other", "experimental", "vaccine(s", ")", "within", "the", "last", "12", "months", ".", "For", "participants", "who", "received", "an", "experimental", "vaccine", "(", "except", "HIV", "vaccine", ")", "more", "than", "12", "months", "ago", ",", "documentation", "of", "the", "identity", "of", "the", "experimental", "vaccine", "must", "be", "provided", "to", "the", "sponsor", ",", "who", "will", "determine", "eligibility", "on", "a", "case", "-", "by", "-", "case", "basis", " \n \n" ]
[ "Scope", "Reference_point", "Measurement", "Temporal", "Drug", "Condition", "Procedure", "Qualifier", "Negation", "Value" ]
chronic hepatitis B, hepatitis B surface antigen test, active hepatitis C, hepatitis C virus [ HCV ] Ab test, positive, HCV ribonucleic acid [ RNA ] PCR test, active, syphilis infection, chlamydia, gonorrhea, trichomonas, Active, syphilis, serology, unless, positive, serology, treated infection, thyroidectomy, active, thyroid disease, medication, during the last 12 months, not excluded, stable, thyroid supplementation, major psychiatric illness and / or substance abuse, during the past 12 months, hospitalization or periods of work disability, licensed vaccine, within 14 days prior to the first dose of study vaccine / placebo , plans to receive within 14 days after the first study vaccination , or plans to receive within 14 days before or after the second , third or fourth vaccination, prophylactic or therapeutic, HIV vaccine candidate, at any time, other experimental vaccine(s ), within the last 12 months, experimental vaccine, except, HIV vaccine, more than 12 months ago
NCT02788045_exc_task2
Sentence: Has chronic hepatitis B (measured by hepatitis B surface antigen test) or active hepatitis C (measured by hepatitis C virus [HCV] Ab test; if positive, HCV ribonucleic acid [RNA] PCR test will be used to confirm active versus past HCV infection), active syphilis infection, chlamydia, gonorrhea, or trichomonas . Active syphilis documented by serology unless positive serology is due to past treated infection Has had a thyroidectomy or active thyroid disease requiring medication during the last 12 months (not excluded: a stable thyroid supplementation) Has had major psychiatric illness and/or substance abuse problems during the past 12 months (including hospitalization or periods of work disability) that in the opinion of the investigator would preclude participation Has been in receipt of any licensed vaccine within 14 days prior to the first dose of study vaccine/placebo, plans to receive within 14 days after the first study vaccination, or plans to receive within 14 days before or after the second, third or fourth vaccination Is a recipient of a prophylactic or therapeutic HIV vaccine candidate at any time, or a recipient of other experimental vaccine(s) within the last 12 months. For participants who received an experimental vaccine (except HIV vaccine) more than 12 months ago, documentation of the identity of the experimental vaccine must be provided to the sponsor, who will determine eligibility on a case-by-case basis Instructions: please extract entity words from the input sentence
[ "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "O", "B-Value", "O", "B-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "I-Measurement", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Qualifier", "B-Condition", "I-Condition", "O", "B-Condition", "O", "B-Condition", "O", "O", "B-Condition", "O", "B-Qualifier", "B-Condition", "O", "O", "B-Measurement", "B-Negation", "B-Value", "B-Measurement", "O", "O", "O", "O", "B-Condition", "I-Condition", "O", "O", "O", "O", "B-Procedure", "O", "B-Qualifier", "B-Condition", "I-Condition", "O", "B-Drug", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "B-Negation", "I-Negation", "O", "O", "B-Qualifier", "B-Drug", "I-Drug", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Drug", "I-Drug", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "B-Drug", "I-Drug", "I-Drug", "B-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "B-Drug", "I-Drug", "I-Drug", "I-Drug", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "B-Drug", "I-Drug", "O", "B-Negation", "B-Drug", "I-Drug", "O", "B-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Has chronic hepatitis B (measured by hepatitis B surface antigen test) or active hepatitis C (measured by hepatitis C virus [HCV] Ab test; if positive, HCV ribonucleic acid [RNA] PCR test will be used to confirm active versus past HCV infection), active syphilis infection, chlamydia, gonorrhea, or trichomonas . Active syphilis documented by serology unless positive serology is due to past treated infection Has had a thyroidectomy or active thyroid disease requiring medication during the last 12 months (not excluded: a stable thyroid supplementation) Has had major psychiatric illness and/or substance abuse problems during the past 12 months (including hospitalization or periods of work disability) that in the opinion of the investigator would preclude participation Has been in receipt of any licensed vaccine within 14 days prior to the first dose of study vaccine/placebo, plans to receive within 14 days after the first study vaccination, or plans to receive within 14 days before or after the second, third or fourth vaccination Is a recipient of a prophylactic or therapeutic HIV vaccine candidate at any time, or a recipient of other experimental vaccine(s) within the last 12 months. For participants who received an experimental vaccine (except HIV vaccine) more than 12 months ago, documentation of the identity of the experimental vaccine must be provided to the sponsor, who will determine eligibility on a case-by-case basis
[ "Has", "chronic", "hepatitis", "B", "(", "measured", "by", "hepatitis", "B", "surface", "antigen", "test", ")", "or", "active", "hepatitis", "C", "(", "measured", "by", "hepatitis", "C", "virus", "[", "HCV", "]", "Ab", "test", ";", "if", "positive", ",", "HCV", "ribonucleic", "acid", "[", "RNA", "]", "PCR", "test", "will", "be", "used", "to", "confirm", "active", "versus", "past", "HCV", "infection", ")", ",", "active", "syphilis", "infection", ",", "chlamydia", ",", "gonorrhea", ",", "or", "trichomonas", ".", "Active", "syphilis", "documented", "by", "serology", "unless", "positive", "serology", "is", "due", "to", "past", "treated", "infection", "\n", "Has", "had", "a", "thyroidectomy", "or", "active", "thyroid", "disease", "requiring", "medication", "during", "the", "last", "12", "months", "(", "not", "excluded", ":", "a", "stable", "thyroid", "supplementation", ")", "\n", "Has", "had", "major", "psychiatric", "illness", "and", "/", "or", "substance", "abuse", "problems", "during", "the", "past", "12", "months", "(", "including", "hospitalization", "or", "periods", "of", "work", "disability", ")", "that", "in", "the", "opinion", "of", "the", "investigator", "would", "preclude", "participation", "\n", "Has", "been", "in", "receipt", "of", "any", "licensed", "vaccine", "within", "14", "days", "prior", "to", "the", "first", "dose", "of", "study", "vaccine", "/", "placebo", ",", "plans", "to", "receive", "within", "14", "days", "after", "the", "first", "study", "vaccination", ",", "or", "plans", "to", "receive", "within", "14", "days", "before", "or", "after", "the", "second", ",", "third", "or", "fourth", "vaccination", "\n", "Is", "a", "recipient", "of", "a", "prophylactic", "or", "therapeutic", "HIV", "vaccine", "candidate", "at", "any", "time", ",", "or", "a", "recipient", "of", "other", "experimental", "vaccine(s", ")", "within", "the", "last", "12", "months", ".", "For", "participants", "who", "received", "an", "experimental", "vaccine", "(", "except", "HIV", "vaccine", ")", "more", "than", "12", "months", "ago", ",", "documentation", "of", "the", "identity", "of", "the", "experimental", "vaccine", "must", "be", "provided", "to", "the", "sponsor", ",", "who", "will", "determine", "eligibility", "on", "a", "case", "-", "by", "-", "case", "basis", " \n \n" ]
[ "Scope", "Reference_point", "Measurement", "Temporal", "Drug", "Condition", "Procedure", "Qualifier", "Negation", "Value" ]
test is an umlsterm, screening is an umlsterm, test is an umlsterm, tests is an umlsterm, odor is an umlsterm, odor is an umlsterm, discrimination is an umlsterm, odor is an umlsterm, identification is an umlsterm, test is an umlsterm, values is an umlsterm
HNO.90470629.eng.abstr_task0
Sentence: Introduction : The Sniffin'Sticks test battery consists of a short screening test and tests for odor detection thresholds ( using n-butanol ) , odor discrimination and odor identification . We evaluated the usefulness of this new test in clinical practice and propose normative values . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]
Introduction : The Sniffin'Sticks test battery consists of a short screening test and tests for odor detection thresholds ( using n-butanol ) , odor discrimination and odor identification . We evaluated the usefulness of this new test in clinical practice and propose normative values .
[ "Introduction", ":", "The", "Sniffin'Sticks", "test", "battery", "consists", "of", "a", "short", "screening", "test", "and", "tests", "for", "odor", "detection", "thresholds", "(", "using", "n", "-", "butanol", ")", ",", "odor", "discrimination", "and", "odor", "identification", ".", "We", "evaluated", "the", "usefulness", "of", "this", "new", "test", "in", "clinical", "practice", "and", "propose", "normative", "values", "." ]
[ "umlsterm" ]
test is an umlsterm, screening is an umlsterm, test is an umlsterm, tests is an umlsterm, odor is an umlsterm, odor is an umlsterm, discrimination is an umlsterm, odor is an umlsterm, identification is an umlsterm, test is an umlsterm, values is an umlsterm
HNO.90470629.eng.abstr_task1
Sentence: Introduction : The Sniffin'Sticks test battery consists of a short screening test and tests for odor detection thresholds ( using n-butanol ) , odor discrimination and odor identification . We evaluated the usefulness of this new test in clinical practice and propose normative values . Instructions: please typing these entity words according to sentence: test, screening, test, tests, odor, odor, discrimination, odor, identification, test, values Options: umlsterm
[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]
Introduction : The Sniffin'Sticks test battery consists of a short screening test and tests for odor detection thresholds ( using n-butanol ) , odor discrimination and odor identification . We evaluated the usefulness of this new test in clinical practice and propose normative values .
[ "Introduction", ":", "The", "Sniffin'Sticks", "test", "battery", "consists", "of", "a", "short", "screening", "test", "and", "tests", "for", "odor", "detection", "thresholds", "(", "using", "n", "-", "butanol", ")", ",", "odor", "discrimination", "and", "odor", "identification", ".", "We", "evaluated", "the", "usefulness", "of", "this", "new", "test", "in", "clinical", "practice", "and", "propose", "normative", "values", "." ]
[ "umlsterm" ]
test, screening, test, tests, odor, odor, discrimination, odor, identification, test, values
HNO.90470629.eng.abstr_task2
Sentence: Introduction : The Sniffin'Sticks test battery consists of a short screening test and tests for odor detection thresholds ( using n-butanol ) , odor discrimination and odor identification . We evaluated the usefulness of this new test in clinical practice and propose normative values . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]
Introduction : The Sniffin'Sticks test battery consists of a short screening test and tests for odor detection thresholds ( using n-butanol ) , odor discrimination and odor identification . We evaluated the usefulness of this new test in clinical practice and propose normative values .
[ "Introduction", ":", "The", "Sniffin'Sticks", "test", "battery", "consists", "of", "a", "short", "screening", "test", "and", "tests", "for", "odor", "detection", "thresholds", "(", "using", "n", "-", "butanol", ")", ",", "odor", "discrimination", "and", "odor", "identification", ".", "We", "evaluated", "the", "usefulness", "of", "this", "new", "test", "in", "clinical", "practice", "and", "propose", "normative", "values", "." ]
[ "umlsterm" ]
Salzwasserbaedern is an umlsterm, Behandlung is an umlsterm, Psoriasis is an umlsterm, Dermatitis is an umlsterm, Salz is an umlsterm, Meer is an umlsterm, Kochsalz is an umlsterm, Unterarmbeugeseiten is an umlsterm, Konzentrationen is an umlsterm, Erythemstaerke is an umlsterm, Erythem is an umlsterm, Pigmentierung is an umlsterm, Haut is an umlsterm, Erythembildung is an umlsterm, Erythem is an umlsterm, Suesswasser is an umlsterm, Salze is an umlsterm, Bades is an umlsterm, Pigmentierung is an umlsterm, Erythemwirksamkeit is an umlsterm, Photosole - Therapie is an umlsterm, Sonne is an umlsterm
DerHautarzt.80490482.ger.abstr_task0
Sentence: Die Kombination von Salzwasserbaedern mit anschliessender UV-Bestrahlung wird seit langem bei der Behandlung der Psoriasis und der atopischen Dermatitis eingesetzt . Ziel der vorliegenden Studie war es , die photosensibilisierenden Eigenschaften von 2 handelsueblichen Badesalzen , Salz aus dem Toten Meer und Kochsalz zu untersuchen . Testareale der Unterarmbeugeseiten von 10 Probanden wurden fuer 15 min mit Salzloesungen in Konzentrationen von 1% , 3% , 5% und 15% inkubiert und anschliessend mit einer erythematogenen UV-B-Dosis bestrahlt . Zum Vergleich diente Leitungswasser+UVB und UVB allein . Die Erythemstaerke wurde visuell abgelesen , zusaetzlich wurden Erythem und Pigmentierung photometrisch bestimmt . Jedes Baden der Haut verstaerkte die UV-B-induzierte Erythembildung . Das staerkste Erythem wurde in den mit Suesswasser behandelten Arealen beobachtet . Die verwendeten Salze unterschieden sich in ihren photosensibilisierenden Eigenschaften , wobei die 5%igen Salzloesungen die staerkste photosensibilisierende Wirkung aufwiesen . Der Einfluss eines der Bestrahlung vorausgehenden Bades in den verschiedenen Salzloesungen oder in Leitungswasser auf die verzoegerte Pigmentierung war gering . Die Ergebnisse zeigen , dass Baden in Salzloesungen oder Leitungswasser die Erythemwirksamkeit einer nachfolgenden UV-B-Bestrahlung erhoeht . Dies ist moeglicherweise von Bedeutung fuer die therapeutische Wirkung einer Photosole-Therapie , aber auch fuer das erhoehte Sonnenbrandrisiko beim Baden in der Sonne . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]
Die Kombination von Salzwasserbaedern mit anschliessender UV-Bestrahlung wird seit langem bei der Behandlung der Psoriasis und der atopischen Dermatitis eingesetzt . Ziel der vorliegenden Studie war es , die photosensibilisierenden Eigenschaften von 2 handelsueblichen Badesalzen , Salz aus dem Toten Meer und Kochsalz zu untersuchen . Testareale der Unterarmbeugeseiten von 10 Probanden wurden fuer 15 min mit Salzloesungen in Konzentrationen von 1% , 3% , 5% und 15% inkubiert und anschliessend mit einer erythematogenen UV-B-Dosis bestrahlt . Zum Vergleich diente Leitungswasser+UVB und UVB allein . Die Erythemstaerke wurde visuell abgelesen , zusaetzlich wurden Erythem und Pigmentierung photometrisch bestimmt . Jedes Baden der Haut verstaerkte die UV-B-induzierte Erythembildung . Das staerkste Erythem wurde in den mit Suesswasser behandelten Arealen beobachtet . Die verwendeten Salze unterschieden sich in ihren photosensibilisierenden Eigenschaften , wobei die 5%igen Salzloesungen die staerkste photosensibilisierende Wirkung aufwiesen . Der Einfluss eines der Bestrahlung vorausgehenden Bades in den verschiedenen Salzloesungen oder in Leitungswasser auf die verzoegerte Pigmentierung war gering . Die Ergebnisse zeigen , dass Baden in Salzloesungen oder Leitungswasser die Erythemwirksamkeit einer nachfolgenden UV-B-Bestrahlung erhoeht . Dies ist moeglicherweise von Bedeutung fuer die therapeutische Wirkung einer Photosole-Therapie , aber auch fuer das erhoehte Sonnenbrandrisiko beim Baden in der Sonne .
[ "Die", "Kombination", "von", "Salzwasserbaedern", "mit", "anschliessender", "UV", "-", "Bestrahlung", "wird", "seit", "langem", "bei", "der", "Behandlung", "der", "Psoriasis", "und", "der", "atopischen", "Dermatitis", "eingesetzt", ".", "Ziel", "der", "vorliegenden", "Studie", "war", "es", ",", "die", "photosensibilisierenden", "Eigenschaften", "von", "2", "handelsueblichen", "Badesalzen", ",", "Salz", "aus", "dem", "Toten", "Meer", "und", "Kochsalz", "zu", "untersuchen", ".", "Testareale", "der", "Unterarmbeugeseiten", "von", "10", "Probanden", "wurden", "fuer", "15", "min", "mit", "Salzloesungen", "in", "Konzentrationen", "von", "1", "%", ",", "3", "%", ",", "5", "%", "und", "15", "%", "inkubiert", "und", "anschliessend", "mit", "einer", "erythematogenen", "UV", "-", "B", "-", "Dosis", "bestrahlt", ".", "Zum", "Vergleich", "diente", "Leitungswasser+UVB", "und", "UVB", "allein", ".", "Die", "Erythemstaerke", "wurde", "visuell", "abgelesen", ",", "zusaetzlich", "wurden", "Erythem", "und", "Pigmentierung", "photometrisch", "bestimmt", ".", "Jedes", "Baden", "der", "Haut", "verstaerkte", "die", "UV", "-", "B", "-", "induzierte", "Erythembildung", ".", "Das", "staerkste", "Erythem", "wurde", "in", "den", "mit", "Suesswasser", "behandelten", "Arealen", "beobachtet", ".", "Die", "verwendeten", "Salze", "unterschieden", "sich", "in", "ihren", "photosensibilisierenden", "Eigenschaften", ",", "wobei", "die", "5%igen", "Salzloesungen", "die", "staerkste", "photosensibilisierende", "Wirkung", "aufwiesen", ".", "Der", "Einfluss", "eines", "der", "Bestrahlung", "vorausgehenden", "Bades", "in", "den", "verschiedenen", "Salzloesungen", "oder", "in", "Leitungswasser", "auf", "die", "verzoegerte", "Pigmentierung", "war", "gering", ".", "Die", "Ergebnisse", "zeigen", ",", "dass", "Baden", "in", "Salzloesungen", "oder", "Leitungswasser", "die", "Erythemwirksamkeit", "einer", "nachfolgenden", "UV", "-", "B", "-", "Bestrahlung", "erhoeht", ".", "Dies", "ist", "moeglicherweise", "von", "Bedeutung", "fuer", "die", "therapeutische", "Wirkung", "einer", "Photosole", "-", "Therapie", ",", "aber", "auch", "fuer", "das", "erhoehte", "Sonnenbrandrisiko", "beim", "Baden", "in", "der", "Sonne", "." ]
[ "umlsterm" ]
Salzwasserbaedern is an umlsterm, Behandlung is an umlsterm, Psoriasis is an umlsterm, Dermatitis is an umlsterm, Salz is an umlsterm, Meer is an umlsterm, Kochsalz is an umlsterm, Unterarmbeugeseiten is an umlsterm, Konzentrationen is an umlsterm, Erythemstaerke is an umlsterm, Erythem is an umlsterm, Pigmentierung is an umlsterm, Haut is an umlsterm, Erythembildung is an umlsterm, Erythem is an umlsterm, Suesswasser is an umlsterm, Salze is an umlsterm, Bades is an umlsterm, Pigmentierung is an umlsterm, Erythemwirksamkeit is an umlsterm, Photosole - Therapie is an umlsterm, Sonne is an umlsterm
DerHautarzt.80490482.ger.abstr_task1
Sentence: Die Kombination von Salzwasserbaedern mit anschliessender UV-Bestrahlung wird seit langem bei der Behandlung der Psoriasis und der atopischen Dermatitis eingesetzt . Ziel der vorliegenden Studie war es , die photosensibilisierenden Eigenschaften von 2 handelsueblichen Badesalzen , Salz aus dem Toten Meer und Kochsalz zu untersuchen . Testareale der Unterarmbeugeseiten von 10 Probanden wurden fuer 15 min mit Salzloesungen in Konzentrationen von 1% , 3% , 5% und 15% inkubiert und anschliessend mit einer erythematogenen UV-B-Dosis bestrahlt . Zum Vergleich diente Leitungswasser+UVB und UVB allein . Die Erythemstaerke wurde visuell abgelesen , zusaetzlich wurden Erythem und Pigmentierung photometrisch bestimmt . Jedes Baden der Haut verstaerkte die UV-B-induzierte Erythembildung . Das staerkste Erythem wurde in den mit Suesswasser behandelten Arealen beobachtet . Die verwendeten Salze unterschieden sich in ihren photosensibilisierenden Eigenschaften , wobei die 5%igen Salzloesungen die staerkste photosensibilisierende Wirkung aufwiesen . Der Einfluss eines der Bestrahlung vorausgehenden Bades in den verschiedenen Salzloesungen oder in Leitungswasser auf die verzoegerte Pigmentierung war gering . Die Ergebnisse zeigen , dass Baden in Salzloesungen oder Leitungswasser die Erythemwirksamkeit einer nachfolgenden UV-B-Bestrahlung erhoeht . Dies ist moeglicherweise von Bedeutung fuer die therapeutische Wirkung einer Photosole-Therapie , aber auch fuer das erhoehte Sonnenbrandrisiko beim Baden in der Sonne . Instructions: please typing these entity words according to sentence: Salzwasserbaedern, Behandlung, Psoriasis, Dermatitis, Salz, Meer, Kochsalz, Unterarmbeugeseiten, Konzentrationen, Erythemstaerke, Erythem, Pigmentierung, Haut, Erythembildung, Erythem, Suesswasser, Salze, Bades, Pigmentierung, Erythemwirksamkeit, Photosole - Therapie, Sonne Options: umlsterm
[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]
Die Kombination von Salzwasserbaedern mit anschliessender UV-Bestrahlung wird seit langem bei der Behandlung der Psoriasis und der atopischen Dermatitis eingesetzt . Ziel der vorliegenden Studie war es , die photosensibilisierenden Eigenschaften von 2 handelsueblichen Badesalzen , Salz aus dem Toten Meer und Kochsalz zu untersuchen . Testareale der Unterarmbeugeseiten von 10 Probanden wurden fuer 15 min mit Salzloesungen in Konzentrationen von 1% , 3% , 5% und 15% inkubiert und anschliessend mit einer erythematogenen UV-B-Dosis bestrahlt . Zum Vergleich diente Leitungswasser+UVB und UVB allein . Die Erythemstaerke wurde visuell abgelesen , zusaetzlich wurden Erythem und Pigmentierung photometrisch bestimmt . Jedes Baden der Haut verstaerkte die UV-B-induzierte Erythembildung . Das staerkste Erythem wurde in den mit Suesswasser behandelten Arealen beobachtet . Die verwendeten Salze unterschieden sich in ihren photosensibilisierenden Eigenschaften , wobei die 5%igen Salzloesungen die staerkste photosensibilisierende Wirkung aufwiesen . Der Einfluss eines der Bestrahlung vorausgehenden Bades in den verschiedenen Salzloesungen oder in Leitungswasser auf die verzoegerte Pigmentierung war gering . Die Ergebnisse zeigen , dass Baden in Salzloesungen oder Leitungswasser die Erythemwirksamkeit einer nachfolgenden UV-B-Bestrahlung erhoeht . Dies ist moeglicherweise von Bedeutung fuer die therapeutische Wirkung einer Photosole-Therapie , aber auch fuer das erhoehte Sonnenbrandrisiko beim Baden in der Sonne .
[ "Die", "Kombination", "von", "Salzwasserbaedern", "mit", "anschliessender", "UV", "-", "Bestrahlung", "wird", "seit", "langem", "bei", "der", "Behandlung", "der", "Psoriasis", "und", "der", "atopischen", "Dermatitis", "eingesetzt", ".", "Ziel", "der", "vorliegenden", "Studie", "war", "es", ",", "die", "photosensibilisierenden", "Eigenschaften", "von", "2", "handelsueblichen", "Badesalzen", ",", "Salz", "aus", "dem", "Toten", "Meer", "und", "Kochsalz", "zu", "untersuchen", ".", "Testareale", "der", "Unterarmbeugeseiten", "von", "10", "Probanden", "wurden", "fuer", "15", "min", "mit", "Salzloesungen", "in", "Konzentrationen", "von", "1", "%", ",", "3", "%", ",", "5", "%", "und", "15", "%", "inkubiert", "und", "anschliessend", "mit", "einer", "erythematogenen", "UV", "-", "B", "-", "Dosis", "bestrahlt", ".", "Zum", "Vergleich", "diente", "Leitungswasser+UVB", "und", "UVB", "allein", ".", "Die", "Erythemstaerke", "wurde", "visuell", "abgelesen", ",", "zusaetzlich", "wurden", "Erythem", "und", "Pigmentierung", "photometrisch", "bestimmt", ".", "Jedes", "Baden", "der", "Haut", "verstaerkte", "die", "UV", "-", "B", "-", "induzierte", "Erythembildung", ".", "Das", "staerkste", "Erythem", "wurde", "in", "den", "mit", "Suesswasser", "behandelten", "Arealen", "beobachtet", ".", "Die", "verwendeten", "Salze", "unterschieden", "sich", "in", "ihren", "photosensibilisierenden", "Eigenschaften", ",", "wobei", "die", "5%igen", "Salzloesungen", "die", "staerkste", "photosensibilisierende", "Wirkung", "aufwiesen", ".", "Der", "Einfluss", "eines", "der", "Bestrahlung", "vorausgehenden", "Bades", "in", "den", "verschiedenen", "Salzloesungen", "oder", "in", "Leitungswasser", "auf", "die", "verzoegerte", "Pigmentierung", "war", "gering", ".", "Die", "Ergebnisse", "zeigen", ",", "dass", "Baden", "in", "Salzloesungen", "oder", "Leitungswasser", "die", "Erythemwirksamkeit", "einer", "nachfolgenden", "UV", "-", "B", "-", "Bestrahlung", "erhoeht", ".", "Dies", "ist", "moeglicherweise", "von", "Bedeutung", "fuer", "die", "therapeutische", "Wirkung", "einer", "Photosole", "-", "Therapie", ",", "aber", "auch", "fuer", "das", "erhoehte", "Sonnenbrandrisiko", "beim", "Baden", "in", "der", "Sonne", "." ]
[ "umlsterm" ]
Salzwasserbaedern, Behandlung, Psoriasis, Dermatitis, Salz, Meer, Kochsalz, Unterarmbeugeseiten, Konzentrationen, Erythemstaerke, Erythem, Pigmentierung, Haut, Erythembildung, Erythem, Suesswasser, Salze, Bades, Pigmentierung, Erythemwirksamkeit, Photosole - Therapie, Sonne
DerHautarzt.80490482.ger.abstr_task2
Sentence: Die Kombination von Salzwasserbaedern mit anschliessender UV-Bestrahlung wird seit langem bei der Behandlung der Psoriasis und der atopischen Dermatitis eingesetzt . Ziel der vorliegenden Studie war es , die photosensibilisierenden Eigenschaften von 2 handelsueblichen Badesalzen , Salz aus dem Toten Meer und Kochsalz zu untersuchen . Testareale der Unterarmbeugeseiten von 10 Probanden wurden fuer 15 min mit Salzloesungen in Konzentrationen von 1% , 3% , 5% und 15% inkubiert und anschliessend mit einer erythematogenen UV-B-Dosis bestrahlt . Zum Vergleich diente Leitungswasser+UVB und UVB allein . Die Erythemstaerke wurde visuell abgelesen , zusaetzlich wurden Erythem und Pigmentierung photometrisch bestimmt . Jedes Baden der Haut verstaerkte die UV-B-induzierte Erythembildung . Das staerkste Erythem wurde in den mit Suesswasser behandelten Arealen beobachtet . Die verwendeten Salze unterschieden sich in ihren photosensibilisierenden Eigenschaften , wobei die 5%igen Salzloesungen die staerkste photosensibilisierende Wirkung aufwiesen . Der Einfluss eines der Bestrahlung vorausgehenden Bades in den verschiedenen Salzloesungen oder in Leitungswasser auf die verzoegerte Pigmentierung war gering . Die Ergebnisse zeigen , dass Baden in Salzloesungen oder Leitungswasser die Erythemwirksamkeit einer nachfolgenden UV-B-Bestrahlung erhoeht . Dies ist moeglicherweise von Bedeutung fuer die therapeutische Wirkung einer Photosole-Therapie , aber auch fuer das erhoehte Sonnenbrandrisiko beim Baden in der Sonne . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]
Die Kombination von Salzwasserbaedern mit anschliessender UV-Bestrahlung wird seit langem bei der Behandlung der Psoriasis und der atopischen Dermatitis eingesetzt . Ziel der vorliegenden Studie war es , die photosensibilisierenden Eigenschaften von 2 handelsueblichen Badesalzen , Salz aus dem Toten Meer und Kochsalz zu untersuchen . Testareale der Unterarmbeugeseiten von 10 Probanden wurden fuer 15 min mit Salzloesungen in Konzentrationen von 1% , 3% , 5% und 15% inkubiert und anschliessend mit einer erythematogenen UV-B-Dosis bestrahlt . Zum Vergleich diente Leitungswasser+UVB und UVB allein . Die Erythemstaerke wurde visuell abgelesen , zusaetzlich wurden Erythem und Pigmentierung photometrisch bestimmt . Jedes Baden der Haut verstaerkte die UV-B-induzierte Erythembildung . Das staerkste Erythem wurde in den mit Suesswasser behandelten Arealen beobachtet . Die verwendeten Salze unterschieden sich in ihren photosensibilisierenden Eigenschaften , wobei die 5%igen Salzloesungen die staerkste photosensibilisierende Wirkung aufwiesen . Der Einfluss eines der Bestrahlung vorausgehenden Bades in den verschiedenen Salzloesungen oder in Leitungswasser auf die verzoegerte Pigmentierung war gering . Die Ergebnisse zeigen , dass Baden in Salzloesungen oder Leitungswasser die Erythemwirksamkeit einer nachfolgenden UV-B-Bestrahlung erhoeht . Dies ist moeglicherweise von Bedeutung fuer die therapeutische Wirkung einer Photosole-Therapie , aber auch fuer das erhoehte Sonnenbrandrisiko beim Baden in der Sonne .
[ "Die", "Kombination", "von", "Salzwasserbaedern", "mit", "anschliessender", "UV", "-", "Bestrahlung", "wird", "seit", "langem", "bei", "der", "Behandlung", "der", "Psoriasis", "und", "der", "atopischen", "Dermatitis", "eingesetzt", ".", "Ziel", "der", "vorliegenden", "Studie", "war", "es", ",", "die", "photosensibilisierenden", "Eigenschaften", "von", "2", "handelsueblichen", "Badesalzen", ",", "Salz", "aus", "dem", "Toten", "Meer", "und", "Kochsalz", "zu", "untersuchen", ".", "Testareale", "der", "Unterarmbeugeseiten", "von", "10", "Probanden", "wurden", "fuer", "15", "min", "mit", "Salzloesungen", "in", "Konzentrationen", "von", "1", "%", ",", "3", "%", ",", "5", "%", "und", "15", "%", "inkubiert", "und", "anschliessend", "mit", "einer", "erythematogenen", "UV", "-", "B", "-", "Dosis", "bestrahlt", ".", "Zum", "Vergleich", "diente", "Leitungswasser+UVB", "und", "UVB", "allein", ".", "Die", "Erythemstaerke", "wurde", "visuell", "abgelesen", ",", "zusaetzlich", "wurden", "Erythem", "und", "Pigmentierung", "photometrisch", "bestimmt", ".", "Jedes", "Baden", "der", "Haut", "verstaerkte", "die", "UV", "-", "B", "-", "induzierte", "Erythembildung", ".", "Das", "staerkste", "Erythem", "wurde", "in", "den", "mit", "Suesswasser", "behandelten", "Arealen", "beobachtet", ".", "Die", "verwendeten", "Salze", "unterschieden", "sich", "in", "ihren", "photosensibilisierenden", "Eigenschaften", ",", "wobei", "die", "5%igen", "Salzloesungen", "die", "staerkste", "photosensibilisierende", "Wirkung", "aufwiesen", ".", "Der", "Einfluss", "eines", "der", "Bestrahlung", "vorausgehenden", "Bades", "in", "den", "verschiedenen", "Salzloesungen", "oder", "in", "Leitungswasser", "auf", "die", "verzoegerte", "Pigmentierung", "war", "gering", ".", "Die", "Ergebnisse", "zeigen", ",", "dass", "Baden", "in", "Salzloesungen", "oder", "Leitungswasser", "die", "Erythemwirksamkeit", "einer", "nachfolgenden", "UV", "-", "B", "-", "Bestrahlung", "erhoeht", ".", "Dies", "ist", "moeglicherweise", "von", "Bedeutung", "fuer", "die", "therapeutische", "Wirkung", "einer", "Photosole", "-", "Therapie", ",", "aber", "auch", "fuer", "das", "erhoehte", "Sonnenbrandrisiko", "beim", "Baden", "in", "der", "Sonne", "." ]
[ "umlsterm" ]
Asn residues 554 is a Entity, 566 is a Entity, E - cadherin is a Protein, E - cadherin is a Protein, E - cadherin is a Protein, E - cadherin is a Protein, N - glycosylation sites is a Entity, E - cadherin is a Protein, N - glycan is a Entity, Asn633 is a Entity, E - cadherin is a Protein, E - cadherin is a Protein, E - cadherin is a Protein, N - glycans is a Entity, Asn554 is a Entity, Asn566 is a Entity, E - cadherin is a Protein, E - cadherin is a Protein, E - cadherin is a Protein, E - cadherin is a Protein
298_task0
Sentence: N-glycosylation at Asn residues 554 and 566 of E-cadherin affects cell cycle progression through extracellular signal-regulated protein kinase signaling pathway. E-cadherin, which has a widely acknowledged role in mediating calcium-dependent cell-cell adhesion between epithelial cells, also functions as a tumor suppressor. The ectodomain of human E-cadherin contains four potential N-glycosylation sites at Asn residues 554, 566, 618, and 633. We investigated the role of E-cadherin N-glycosylation in cell cycle progression by site-directed mutagenesis. We showed previously that all four potential N-glycosylation sites of E-cadherin were N-glycosylated in human breast carcinoma MDA-MB-435 cells. Removal of N-glycan at Asn633 dramatically affected E-cadherin stability. In this study we showed that E-cadherin mutant missing N-glycans at Asn554, Asn566 and Asn618 failed to induce cell cycle arrest in G1 phase and to suppress cell proliferation in comparison with wild-type E-cadherin. Moreover, N-glycans at Asn554 and Asn566, but not at Asn618, seemed to be indispensable for E-cadherin-mediated suppression of cell cycle progression. Removal of N-glycans at either Asn554 or Asn566 of E-cadherin was accompanied with the activation of the extracellular signal-regulated protein kinase signaling pathway. After treatment with PD98059, an inhibitor of the extracellular signal-regulated protein kinase signaling pathway, wild-type E-cadherin transfected MDA-MB-435 and E-cadherin N-glycosylation-deficient mutant transfected MDA-MB-435 cells had equivalent numbers of cells in G1 phase. These findings implied that N-glycosylation might be crucial for E-cadherin-mediated suppression of cell cycle progression. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein
[ "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "B-Entity", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "B-Entity", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "B-Entity", "O", "B-Entity", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
N-glycosylation at Asn residues 554 and 566 of E-cadherin affects cell cycle progression through extracellular signal-regulated protein kinase signaling pathway. E-cadherin, which has a widely acknowledged role in mediating calcium-dependent cell-cell adhesion between epithelial cells, also functions as a tumor suppressor. The ectodomain of human E-cadherin contains four potential N-glycosylation sites at Asn residues 554, 566, 618, and 633. We investigated the role of E-cadherin N-glycosylation in cell cycle progression by site-directed mutagenesis. We showed previously that all four potential N-glycosylation sites of E-cadherin were N-glycosylated in human breast carcinoma MDA-MB-435 cells. Removal of N-glycan at Asn633 dramatically affected E-cadherin stability. In this study we showed that E-cadherin mutant missing N-glycans at Asn554, Asn566 and Asn618 failed to induce cell cycle arrest in G1 phase and to suppress cell proliferation in comparison with wild-type E-cadherin. Moreover, N-glycans at Asn554 and Asn566, but not at Asn618, seemed to be indispensable for E-cadherin-mediated suppression of cell cycle progression. Removal of N-glycans at either Asn554 or Asn566 of E-cadherin was accompanied with the activation of the extracellular signal-regulated protein kinase signaling pathway. After treatment with PD98059, an inhibitor of the extracellular signal-regulated protein kinase signaling pathway, wild-type E-cadherin transfected MDA-MB-435 and E-cadherin N-glycosylation-deficient mutant transfected MDA-MB-435 cells had equivalent numbers of cells in G1 phase. These findings implied that N-glycosylation might be crucial for E-cadherin-mediated suppression of cell cycle progression.
[ "N", "-", "glycosylation", "at", "Asn", "residues", "554", "and", "566", "of", "E", "-", "cadherin", "affects", "cell", "cycle", "progression", "through", "extracellular", "signal", "-", "regulated", "protein", "kinase", "signaling", "pathway", ".", "\n", "E", "-", "cadherin", ",", "which", "has", "a", "widely", "acknowledged", "role", "in", "mediating", "calcium", "-", "dependent", "cell", "-", "cell", "adhesion", "between", "epithelial", "cells", ",", "also", "functions", "as", "a", "tumor", "suppressor", ".", "The", "ectodomain", "of", "human", "E", "-", "cadherin", "contains", "four", "potential", "N", "-", "glycosylation", "sites", "at", "Asn", "residues", "554", ",", "566", ",", "618", ",", "and", "633", ".", "We", "investigated", "the", "role", "of", "E", "-", "cadherin", "N", "-", "glycosylation", "in", "cell", "cycle", "progression", "by", "site", "-", "directed", "mutagenesis", ".", "We", "showed", "previously", "that", "all", "four", "potential", "N", "-", "glycosylation", "sites", "of", "E", "-", "cadherin", "were", "N", "-", "glycosylated", "in", "human", "breast", "carcinoma", "MDA", "-", "MB-435", "cells", ".", "Removal", "of", "N", "-", "glycan", "at", "Asn633", "dramatically", "affected", "E", "-", "cadherin", "stability", ".", "In", "this", "study", "we", "showed", "that", "E", "-", "cadherin", "mutant", "missing", "N", "-", "glycans", "at", "Asn554", ",", "Asn566", "and", "Asn618", "failed", "to", "induce", "cell", "cycle", "arrest", "in", "G1", "phase", "and", "to", "suppress", "cell", "proliferation", "in", "comparison", "with", "wild", "-", "type", "E", "-", "cadherin", ".", "Moreover", ",", "N", "-", "glycans", "at", "Asn554", "and", "Asn566", ",", "but", "not", "at", "Asn618", ",", "seemed", "to", "be", "indispensable", "for", "E", "-", "cadherin", "-", "mediated", "suppression", "of", "cell", "cycle", "progression", ".", "Removal", "of", "N", "-", "glycans", "at", "either", "Asn554", "or", "Asn566", "of", "E", "-", "cadherin", "was", "accompanied", "with", "the", "activation", "of", "the", "extracellular", "signal", "-", "regulated", "protein", "kinase", "signaling", "pathway", ".", "After", "treatment", "with", "PD98059", ",", "an", "inhibitor", "of", "the", "extracellular", "signal", "-", "regulated", "protein", "kinase", "signaling", "pathway", ",", "wild", "-", "type", "E", "-", "cadherin", "transfected", "MDA", "-", "MB-435", "and", "E", "-", "cadherin", "N", "-", "glycosylation", "-", "deficient", "mutant", "transfected", "MDA", "-", "MB-435", "cells", "had", "equivalent", "numbers", "of", "cells", "in", "G1", "phase", ".", "These", "findings", "implied", "that", "N", "-", "glycosylation", "might", "be", "crucial", "for", "E", "-", "cadherin", "-", "mediated", "suppression", "of", "cell", "cycle", "progression", ".", "\n" ]
[ "Entity", "Protein" ]
Asn residues 554 is a Entity, 566 is a Entity, E - cadherin is a Protein, E - cadherin is a Protein, E - cadherin is a Protein, E - cadherin is a Protein, N - glycosylation sites is a Entity, E - cadherin is a Protein, N - glycan is a Entity, Asn633 is a Entity, E - cadherin is a Protein, E - cadherin is a Protein, E - cadherin is a Protein, N - glycans is a Entity, Asn554 is a Entity, Asn566 is a Entity, E - cadherin is a Protein, E - cadherin is a Protein, E - cadherin is a Protein, E - cadherin is a Protein
298_task1
Sentence: N-glycosylation at Asn residues 554 and 566 of E-cadherin affects cell cycle progression through extracellular signal-regulated protein kinase signaling pathway. E-cadherin, which has a widely acknowledged role in mediating calcium-dependent cell-cell adhesion between epithelial cells, also functions as a tumor suppressor. The ectodomain of human E-cadherin contains four potential N-glycosylation sites at Asn residues 554, 566, 618, and 633. We investigated the role of E-cadherin N-glycosylation in cell cycle progression by site-directed mutagenesis. We showed previously that all four potential N-glycosylation sites of E-cadherin were N-glycosylated in human breast carcinoma MDA-MB-435 cells. Removal of N-glycan at Asn633 dramatically affected E-cadherin stability. In this study we showed that E-cadherin mutant missing N-glycans at Asn554, Asn566 and Asn618 failed to induce cell cycle arrest in G1 phase and to suppress cell proliferation in comparison with wild-type E-cadherin. Moreover, N-glycans at Asn554 and Asn566, but not at Asn618, seemed to be indispensable for E-cadherin-mediated suppression of cell cycle progression. Removal of N-glycans at either Asn554 or Asn566 of E-cadherin was accompanied with the activation of the extracellular signal-regulated protein kinase signaling pathway. After treatment with PD98059, an inhibitor of the extracellular signal-regulated protein kinase signaling pathway, wild-type E-cadherin transfected MDA-MB-435 and E-cadherin N-glycosylation-deficient mutant transfected MDA-MB-435 cells had equivalent numbers of cells in G1 phase. These findings implied that N-glycosylation might be crucial for E-cadherin-mediated suppression of cell cycle progression. Instructions: please typing these entity words according to sentence: Asn residues 554, 566, E - cadherin, E - cadherin, E - cadherin, E - cadherin, N - glycosylation sites, E - cadherin, N - glycan, Asn633, E - cadherin, E - cadherin, E - cadherin, N - glycans, Asn554, Asn566, E - cadherin, E - cadherin, E - cadherin, E - cadherin Options: Entity, Protein
[ "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "B-Entity", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "B-Entity", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "B-Entity", "O", "B-Entity", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
N-glycosylation at Asn residues 554 and 566 of E-cadherin affects cell cycle progression through extracellular signal-regulated protein kinase signaling pathway. E-cadherin, which has a widely acknowledged role in mediating calcium-dependent cell-cell adhesion between epithelial cells, also functions as a tumor suppressor. The ectodomain of human E-cadherin contains four potential N-glycosylation sites at Asn residues 554, 566, 618, and 633. We investigated the role of E-cadherin N-glycosylation in cell cycle progression by site-directed mutagenesis. We showed previously that all four potential N-glycosylation sites of E-cadherin were N-glycosylated in human breast carcinoma MDA-MB-435 cells. Removal of N-glycan at Asn633 dramatically affected E-cadherin stability. In this study we showed that E-cadherin mutant missing N-glycans at Asn554, Asn566 and Asn618 failed to induce cell cycle arrest in G1 phase and to suppress cell proliferation in comparison with wild-type E-cadherin. Moreover, N-glycans at Asn554 and Asn566, but not at Asn618, seemed to be indispensable for E-cadherin-mediated suppression of cell cycle progression. Removal of N-glycans at either Asn554 or Asn566 of E-cadherin was accompanied with the activation of the extracellular signal-regulated protein kinase signaling pathway. After treatment with PD98059, an inhibitor of the extracellular signal-regulated protein kinase signaling pathway, wild-type E-cadherin transfected MDA-MB-435 and E-cadherin N-glycosylation-deficient mutant transfected MDA-MB-435 cells had equivalent numbers of cells in G1 phase. These findings implied that N-glycosylation might be crucial for E-cadherin-mediated suppression of cell cycle progression.
[ "N", "-", "glycosylation", "at", "Asn", "residues", "554", "and", "566", "of", "E", "-", "cadherin", "affects", "cell", "cycle", "progression", "through", "extracellular", "signal", "-", "regulated", "protein", "kinase", "signaling", "pathway", ".", "\n", "E", "-", "cadherin", ",", "which", "has", "a", "widely", "acknowledged", "role", "in", "mediating", "calcium", "-", "dependent", "cell", "-", "cell", "adhesion", "between", "epithelial", "cells", ",", "also", "functions", "as", "a", "tumor", "suppressor", ".", "The", "ectodomain", "of", "human", "E", "-", "cadherin", "contains", "four", "potential", "N", "-", "glycosylation", "sites", "at", "Asn", "residues", "554", ",", "566", ",", "618", ",", "and", "633", ".", "We", "investigated", "the", "role", "of", "E", "-", "cadherin", "N", "-", "glycosylation", "in", "cell", "cycle", "progression", "by", "site", "-", "directed", "mutagenesis", ".", "We", "showed", "previously", "that", "all", "four", "potential", "N", "-", "glycosylation", "sites", "of", "E", "-", "cadherin", "were", "N", "-", "glycosylated", "in", "human", "breast", "carcinoma", "MDA", "-", "MB-435", "cells", ".", "Removal", "of", "N", "-", "glycan", "at", "Asn633", "dramatically", "affected", "E", "-", "cadherin", "stability", ".", "In", "this", "study", "we", "showed", "that", "E", "-", "cadherin", "mutant", "missing", "N", "-", "glycans", "at", "Asn554", ",", "Asn566", "and", "Asn618", "failed", "to", "induce", "cell", "cycle", "arrest", "in", "G1", "phase", "and", "to", "suppress", "cell", "proliferation", "in", "comparison", "with", "wild", "-", "type", "E", "-", "cadherin", ".", "Moreover", ",", "N", "-", "glycans", "at", "Asn554", "and", "Asn566", ",", "but", "not", "at", "Asn618", ",", "seemed", "to", "be", "indispensable", "for", "E", "-", "cadherin", "-", "mediated", "suppression", "of", "cell", "cycle", "progression", ".", "Removal", "of", "N", "-", "glycans", "at", "either", "Asn554", "or", "Asn566", "of", "E", "-", "cadherin", "was", "accompanied", "with", "the", "activation", "of", "the", "extracellular", "signal", "-", "regulated", "protein", "kinase", "signaling", "pathway", ".", "After", "treatment", "with", "PD98059", ",", "an", "inhibitor", "of", "the", "extracellular", "signal", "-", "regulated", "protein", "kinase", "signaling", "pathway", ",", "wild", "-", "type", "E", "-", "cadherin", "transfected", "MDA", "-", "MB-435", "and", "E", "-", "cadherin", "N", "-", "glycosylation", "-", "deficient", "mutant", "transfected", "MDA", "-", "MB-435", "cells", "had", "equivalent", "numbers", "of", "cells", "in", "G1", "phase", ".", "These", "findings", "implied", "that", "N", "-", "glycosylation", "might", "be", "crucial", "for", "E", "-", "cadherin", "-", "mediated", "suppression", "of", "cell", "cycle", "progression", ".", "\n" ]
[ "Entity", "Protein" ]
Asn residues 554, 566, E - cadherin, E - cadherin, E - cadherin, E - cadherin, N - glycosylation sites, E - cadherin, N - glycan, Asn633, E - cadherin, E - cadherin, E - cadherin, N - glycans, Asn554, Asn566, E - cadherin, E - cadherin, E - cadherin, E - cadherin
298_task2
Sentence: N-glycosylation at Asn residues 554 and 566 of E-cadherin affects cell cycle progression through extracellular signal-regulated protein kinase signaling pathway. E-cadherin, which has a widely acknowledged role in mediating calcium-dependent cell-cell adhesion between epithelial cells, also functions as a tumor suppressor. The ectodomain of human E-cadherin contains four potential N-glycosylation sites at Asn residues 554, 566, 618, and 633. We investigated the role of E-cadherin N-glycosylation in cell cycle progression by site-directed mutagenesis. We showed previously that all four potential N-glycosylation sites of E-cadherin were N-glycosylated in human breast carcinoma MDA-MB-435 cells. Removal of N-glycan at Asn633 dramatically affected E-cadherin stability. In this study we showed that E-cadherin mutant missing N-glycans at Asn554, Asn566 and Asn618 failed to induce cell cycle arrest in G1 phase and to suppress cell proliferation in comparison with wild-type E-cadherin. Moreover, N-glycans at Asn554 and Asn566, but not at Asn618, seemed to be indispensable for E-cadherin-mediated suppression of cell cycle progression. Removal of N-glycans at either Asn554 or Asn566 of E-cadherin was accompanied with the activation of the extracellular signal-regulated protein kinase signaling pathway. After treatment with PD98059, an inhibitor of the extracellular signal-regulated protein kinase signaling pathway, wild-type E-cadherin transfected MDA-MB-435 and E-cadherin N-glycosylation-deficient mutant transfected MDA-MB-435 cells had equivalent numbers of cells in G1 phase. These findings implied that N-glycosylation might be crucial for E-cadherin-mediated suppression of cell cycle progression. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "B-Entity", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "B-Entity", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "O", "O", "B-Entity", "O", "B-Entity", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
N-glycosylation at Asn residues 554 and 566 of E-cadherin affects cell cycle progression through extracellular signal-regulated protein kinase signaling pathway. E-cadherin, which has a widely acknowledged role in mediating calcium-dependent cell-cell adhesion between epithelial cells, also functions as a tumor suppressor. The ectodomain of human E-cadherin contains four potential N-glycosylation sites at Asn residues 554, 566, 618, and 633. We investigated the role of E-cadherin N-glycosylation in cell cycle progression by site-directed mutagenesis. We showed previously that all four potential N-glycosylation sites of E-cadherin were N-glycosylated in human breast carcinoma MDA-MB-435 cells. Removal of N-glycan at Asn633 dramatically affected E-cadherin stability. In this study we showed that E-cadherin mutant missing N-glycans at Asn554, Asn566 and Asn618 failed to induce cell cycle arrest in G1 phase and to suppress cell proliferation in comparison with wild-type E-cadherin. Moreover, N-glycans at Asn554 and Asn566, but not at Asn618, seemed to be indispensable for E-cadherin-mediated suppression of cell cycle progression. Removal of N-glycans at either Asn554 or Asn566 of E-cadherin was accompanied with the activation of the extracellular signal-regulated protein kinase signaling pathway. After treatment with PD98059, an inhibitor of the extracellular signal-regulated protein kinase signaling pathway, wild-type E-cadherin transfected MDA-MB-435 and E-cadherin N-glycosylation-deficient mutant transfected MDA-MB-435 cells had equivalent numbers of cells in G1 phase. These findings implied that N-glycosylation might be crucial for E-cadherin-mediated suppression of cell cycle progression.
[ "N", "-", "glycosylation", "at", "Asn", "residues", "554", "and", "566", "of", "E", "-", "cadherin", "affects", "cell", "cycle", "progression", "through", "extracellular", "signal", "-", "regulated", "protein", "kinase", "signaling", "pathway", ".", "\n", "E", "-", "cadherin", ",", "which", "has", "a", "widely", "acknowledged", "role", "in", "mediating", "calcium", "-", "dependent", "cell", "-", "cell", "adhesion", "between", "epithelial", "cells", ",", "also", "functions", "as", "a", "tumor", "suppressor", ".", "The", "ectodomain", "of", "human", "E", "-", "cadherin", "contains", "four", "potential", "N", "-", "glycosylation", "sites", "at", "Asn", "residues", "554", ",", "566", ",", "618", ",", "and", "633", ".", "We", "investigated", "the", "role", "of", "E", "-", "cadherin", "N", "-", "glycosylation", "in", "cell", "cycle", "progression", "by", "site", "-", "directed", "mutagenesis", ".", "We", "showed", "previously", "that", "all", "four", "potential", "N", "-", "glycosylation", "sites", "of", "E", "-", "cadherin", "were", "N", "-", "glycosylated", "in", "human", "breast", "carcinoma", "MDA", "-", "MB-435", "cells", ".", "Removal", "of", "N", "-", "glycan", "at", "Asn633", "dramatically", "affected", "E", "-", "cadherin", "stability", ".", "In", "this", "study", "we", "showed", "that", "E", "-", "cadherin", "mutant", "missing", "N", "-", "glycans", "at", "Asn554", ",", "Asn566", "and", "Asn618", "failed", "to", "induce", "cell", "cycle", "arrest", "in", "G1", "phase", "and", "to", "suppress", "cell", "proliferation", "in", "comparison", "with", "wild", "-", "type", "E", "-", "cadherin", ".", "Moreover", ",", "N", "-", "glycans", "at", "Asn554", "and", "Asn566", ",", "but", "not", "at", "Asn618", ",", "seemed", "to", "be", "indispensable", "for", "E", "-", "cadherin", "-", "mediated", "suppression", "of", "cell", "cycle", "progression", ".", "Removal", "of", "N", "-", "glycans", "at", "either", "Asn554", "or", "Asn566", "of", "E", "-", "cadherin", "was", "accompanied", "with", "the", "activation", "of", "the", "extracellular", "signal", "-", "regulated", "protein", "kinase", "signaling", "pathway", ".", "After", "treatment", "with", "PD98059", ",", "an", "inhibitor", "of", "the", "extracellular", "signal", "-", "regulated", "protein", "kinase", "signaling", "pathway", ",", "wild", "-", "type", "E", "-", "cadherin", "transfected", "MDA", "-", "MB-435", "and", "E", "-", "cadherin", "N", "-", "glycosylation", "-", "deficient", "mutant", "transfected", "MDA", "-", "MB-435", "cells", "had", "equivalent", "numbers", "of", "cells", "in", "G1", "phase", ".", "These", "findings", "implied", "that", "N", "-", "glycosylation", "might", "be", "crucial", "for", "E", "-", "cadherin", "-", "mediated", "suppression", "of", "cell", "cycle", "progression", ".", "\n" ]
[ "Entity", "Protein" ]
Tumoren is an umlsterm, Genen is an umlsterm, Prostatakarzinom is an umlsterm, Tumoren is an umlsterm, Tumor is an umlsterm, Gene is an umlsterm, Y - Chromosom is an umlsterm, Prostatakarzinom is an umlsterm, Tumorsuppressorgene is an umlsterm, DNS - Sequenzvermehrungen is an umlsterm, Chromosom is an umlsterm, Prognoserelevanz is an umlsterm, Prognose is an umlsterm, Androgenrezeptors is an umlsterm, Tumor is an umlsterm, Androgenblockade is an umlsterm, Gene is an umlsterm, Patienten is an umlsterm, Prostatakarzinom is an umlsterm
DerPathologe.80190063.ger.abstr_task0
Sentence: Entstehung und Progression von Tumoren werden durch Funktionsstoerungen von spezifischen Genen gesteuert . Obwohl das Prostatakarzinom zu den haeufigsten Tumoren gehoert , ist ueber die bei diesem Tumor involvierten Gene wenig bekannt . Zytogenetische und molekulare Untersuchungen haben gezeigt , dass chromosomale Deletionen besonders haeufig das Y-Chromosom , 7q , 8p , 10q , 13q , 16q und 17p betreffen . Diese Loci duerften fuer das Prostatakarzinom relevante Tumorsuppressorgene enthalten . Haeufige DNS-Sequenzvermehrungen von Chromosom 7 , 8q und 11q deuten auf die Lokalisation von moeglichen Onkogenen hin . Bereits heute bestehen Anhaltspunkte fuer eine Prognoserelevanz genetischer Veraenderungen . Der Nachweis von Polysomien in Primaertumoren deuten auf eine unguenstige Prognose hin . Eine Amplifikation des Androgenrezeptors spricht fuer einen Hormontherapie-resistenten Tumor , welcher moeglicherweise besonders gut auf eine totale Androgenblockade ansprechen wird . Die Identifikation der alterierten Gene und die Entschluesselung ihrer Funktion koennte in Zukunft zu deutlich verbesserten Behandlungsstretegien fuer Patienten mit Prostatakarzinom fuehrten . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O" ]
Entstehung und Progression von Tumoren werden durch Funktionsstoerungen von spezifischen Genen gesteuert . Obwohl das Prostatakarzinom zu den haeufigsten Tumoren gehoert , ist ueber die bei diesem Tumor involvierten Gene wenig bekannt . Zytogenetische und molekulare Untersuchungen haben gezeigt , dass chromosomale Deletionen besonders haeufig das Y-Chromosom , 7q , 8p , 10q , 13q , 16q und 17p betreffen . Diese Loci duerften fuer das Prostatakarzinom relevante Tumorsuppressorgene enthalten . Haeufige DNS-Sequenzvermehrungen von Chromosom 7 , 8q und 11q deuten auf die Lokalisation von moeglichen Onkogenen hin . Bereits heute bestehen Anhaltspunkte fuer eine Prognoserelevanz genetischer Veraenderungen . Der Nachweis von Polysomien in Primaertumoren deuten auf eine unguenstige Prognose hin . Eine Amplifikation des Androgenrezeptors spricht fuer einen Hormontherapie-resistenten Tumor , welcher moeglicherweise besonders gut auf eine totale Androgenblockade ansprechen wird . Die Identifikation der alterierten Gene und die Entschluesselung ihrer Funktion koennte in Zukunft zu deutlich verbesserten Behandlungsstretegien fuer Patienten mit Prostatakarzinom fuehrten .
[ "Entstehung", "und", "Progression", "von", "Tumoren", "werden", "durch", "Funktionsstoerungen", "von", "spezifischen", "Genen", "gesteuert", ".", "Obwohl", "das", "Prostatakarzinom", "zu", "den", "haeufigsten", "Tumoren", "gehoert", ",", "ist", "ueber", "die", "bei", "diesem", "Tumor", "involvierten", "Gene", "wenig", "bekannt", ".", "Zytogenetische", "und", "molekulare", "Untersuchungen", "haben", "gezeigt", ",", "dass", "chromosomale", "Deletionen", "besonders", "haeufig", "das", "Y", "-", "Chromosom", ",", "7q", ",", "8p", ",", "10q", ",", "13q", ",", "16q", "und", "17p", "betreffen", ".", "Diese", "Loci", "duerften", "fuer", "das", "Prostatakarzinom", "relevante", "Tumorsuppressorgene", "enthalten", ".", "Haeufige", "DNS", "-", "Sequenzvermehrungen", "von", "Chromosom", "7", ",", "8q", "und", "11q", "deuten", "auf", "die", "Lokalisation", "von", "moeglichen", "Onkogenen", "hin", ".", "Bereits", "heute", "bestehen", "Anhaltspunkte", "fuer", "eine", "Prognoserelevanz", "genetischer", "Veraenderungen", ".", "Der", "Nachweis", "von", "Polysomien", "in", "Primaertumoren", "deuten", "auf", "eine", "unguenstige", "Prognose", "hin", ".", "Eine", "Amplifikation", "des", "Androgenrezeptors", "spricht", "fuer", "einen", "Hormontherapie", "-", "resistenten", "Tumor", ",", "welcher", "moeglicherweise", "besonders", "gut", "auf", "eine", "totale", "Androgenblockade", "ansprechen", "wird", ".", "Die", "Identifikation", "der", "alterierten", "Gene", "und", "die", "Entschluesselung", "ihrer", "Funktion", "koennte", "in", "Zukunft", "zu", "deutlich", "verbesserten", "Behandlungsstretegien", "fuer", "Patienten", "mit", "Prostatakarzinom", "fuehrten", "." ]
[ "umlsterm" ]
Tumoren is an umlsterm, Genen is an umlsterm, Prostatakarzinom is an umlsterm, Tumoren is an umlsterm, Tumor is an umlsterm, Gene is an umlsterm, Y - Chromosom is an umlsterm, Prostatakarzinom is an umlsterm, Tumorsuppressorgene is an umlsterm, DNS - Sequenzvermehrungen is an umlsterm, Chromosom is an umlsterm, Prognoserelevanz is an umlsterm, Prognose is an umlsterm, Androgenrezeptors is an umlsterm, Tumor is an umlsterm, Androgenblockade is an umlsterm, Gene is an umlsterm, Patienten is an umlsterm, Prostatakarzinom is an umlsterm
DerPathologe.80190063.ger.abstr_task1
Sentence: Entstehung und Progression von Tumoren werden durch Funktionsstoerungen von spezifischen Genen gesteuert . Obwohl das Prostatakarzinom zu den haeufigsten Tumoren gehoert , ist ueber die bei diesem Tumor involvierten Gene wenig bekannt . Zytogenetische und molekulare Untersuchungen haben gezeigt , dass chromosomale Deletionen besonders haeufig das Y-Chromosom , 7q , 8p , 10q , 13q , 16q und 17p betreffen . Diese Loci duerften fuer das Prostatakarzinom relevante Tumorsuppressorgene enthalten . Haeufige DNS-Sequenzvermehrungen von Chromosom 7 , 8q und 11q deuten auf die Lokalisation von moeglichen Onkogenen hin . Bereits heute bestehen Anhaltspunkte fuer eine Prognoserelevanz genetischer Veraenderungen . Der Nachweis von Polysomien in Primaertumoren deuten auf eine unguenstige Prognose hin . Eine Amplifikation des Androgenrezeptors spricht fuer einen Hormontherapie-resistenten Tumor , welcher moeglicherweise besonders gut auf eine totale Androgenblockade ansprechen wird . Die Identifikation der alterierten Gene und die Entschluesselung ihrer Funktion koennte in Zukunft zu deutlich verbesserten Behandlungsstretegien fuer Patienten mit Prostatakarzinom fuehrten . Instructions: please typing these entity words according to sentence: Tumoren, Genen, Prostatakarzinom, Tumoren, Tumor, Gene, Y - Chromosom, Prostatakarzinom, Tumorsuppressorgene, DNS - Sequenzvermehrungen, Chromosom, Prognoserelevanz, Prognose, Androgenrezeptors, Tumor, Androgenblockade, Gene, Patienten, Prostatakarzinom Options: umlsterm
[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O" ]
Entstehung und Progression von Tumoren werden durch Funktionsstoerungen von spezifischen Genen gesteuert . Obwohl das Prostatakarzinom zu den haeufigsten Tumoren gehoert , ist ueber die bei diesem Tumor involvierten Gene wenig bekannt . Zytogenetische und molekulare Untersuchungen haben gezeigt , dass chromosomale Deletionen besonders haeufig das Y-Chromosom , 7q , 8p , 10q , 13q , 16q und 17p betreffen . Diese Loci duerften fuer das Prostatakarzinom relevante Tumorsuppressorgene enthalten . Haeufige DNS-Sequenzvermehrungen von Chromosom 7 , 8q und 11q deuten auf die Lokalisation von moeglichen Onkogenen hin . Bereits heute bestehen Anhaltspunkte fuer eine Prognoserelevanz genetischer Veraenderungen . Der Nachweis von Polysomien in Primaertumoren deuten auf eine unguenstige Prognose hin . Eine Amplifikation des Androgenrezeptors spricht fuer einen Hormontherapie-resistenten Tumor , welcher moeglicherweise besonders gut auf eine totale Androgenblockade ansprechen wird . Die Identifikation der alterierten Gene und die Entschluesselung ihrer Funktion koennte in Zukunft zu deutlich verbesserten Behandlungsstretegien fuer Patienten mit Prostatakarzinom fuehrten .
[ "Entstehung", "und", "Progression", "von", "Tumoren", "werden", "durch", "Funktionsstoerungen", "von", "spezifischen", "Genen", "gesteuert", ".", "Obwohl", "das", "Prostatakarzinom", "zu", "den", "haeufigsten", "Tumoren", "gehoert", ",", "ist", "ueber", "die", "bei", "diesem", "Tumor", "involvierten", "Gene", "wenig", "bekannt", ".", "Zytogenetische", "und", "molekulare", "Untersuchungen", "haben", "gezeigt", ",", "dass", "chromosomale", "Deletionen", "besonders", "haeufig", "das", "Y", "-", "Chromosom", ",", "7q", ",", "8p", ",", "10q", ",", "13q", ",", "16q", "und", "17p", "betreffen", ".", "Diese", "Loci", "duerften", "fuer", "das", "Prostatakarzinom", "relevante", "Tumorsuppressorgene", "enthalten", ".", "Haeufige", "DNS", "-", "Sequenzvermehrungen", "von", "Chromosom", "7", ",", "8q", "und", "11q", "deuten", "auf", "die", "Lokalisation", "von", "moeglichen", "Onkogenen", "hin", ".", "Bereits", "heute", "bestehen", "Anhaltspunkte", "fuer", "eine", "Prognoserelevanz", "genetischer", "Veraenderungen", ".", "Der", "Nachweis", "von", "Polysomien", "in", "Primaertumoren", "deuten", "auf", "eine", "unguenstige", "Prognose", "hin", ".", "Eine", "Amplifikation", "des", "Androgenrezeptors", "spricht", "fuer", "einen", "Hormontherapie", "-", "resistenten", "Tumor", ",", "welcher", "moeglicherweise", "besonders", "gut", "auf", "eine", "totale", "Androgenblockade", "ansprechen", "wird", ".", "Die", "Identifikation", "der", "alterierten", "Gene", "und", "die", "Entschluesselung", "ihrer", "Funktion", "koennte", "in", "Zukunft", "zu", "deutlich", "verbesserten", "Behandlungsstretegien", "fuer", "Patienten", "mit", "Prostatakarzinom", "fuehrten", "." ]
[ "umlsterm" ]
Tumoren, Genen, Prostatakarzinom, Tumoren, Tumor, Gene, Y - Chromosom, Prostatakarzinom, Tumorsuppressorgene, DNS - Sequenzvermehrungen, Chromosom, Prognoserelevanz, Prognose, Androgenrezeptors, Tumor, Androgenblockade, Gene, Patienten, Prostatakarzinom
DerPathologe.80190063.ger.abstr_task2
Sentence: Entstehung und Progression von Tumoren werden durch Funktionsstoerungen von spezifischen Genen gesteuert . Obwohl das Prostatakarzinom zu den haeufigsten Tumoren gehoert , ist ueber die bei diesem Tumor involvierten Gene wenig bekannt . Zytogenetische und molekulare Untersuchungen haben gezeigt , dass chromosomale Deletionen besonders haeufig das Y-Chromosom , 7q , 8p , 10q , 13q , 16q und 17p betreffen . Diese Loci duerften fuer das Prostatakarzinom relevante Tumorsuppressorgene enthalten . Haeufige DNS-Sequenzvermehrungen von Chromosom 7 , 8q und 11q deuten auf die Lokalisation von moeglichen Onkogenen hin . Bereits heute bestehen Anhaltspunkte fuer eine Prognoserelevanz genetischer Veraenderungen . Der Nachweis von Polysomien in Primaertumoren deuten auf eine unguenstige Prognose hin . Eine Amplifikation des Androgenrezeptors spricht fuer einen Hormontherapie-resistenten Tumor , welcher moeglicherweise besonders gut auf eine totale Androgenblockade ansprechen wird . Die Identifikation der alterierten Gene und die Entschluesselung ihrer Funktion koennte in Zukunft zu deutlich verbesserten Behandlungsstretegien fuer Patienten mit Prostatakarzinom fuehrten . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O" ]
Entstehung und Progression von Tumoren werden durch Funktionsstoerungen von spezifischen Genen gesteuert . Obwohl das Prostatakarzinom zu den haeufigsten Tumoren gehoert , ist ueber die bei diesem Tumor involvierten Gene wenig bekannt . Zytogenetische und molekulare Untersuchungen haben gezeigt , dass chromosomale Deletionen besonders haeufig das Y-Chromosom , 7q , 8p , 10q , 13q , 16q und 17p betreffen . Diese Loci duerften fuer das Prostatakarzinom relevante Tumorsuppressorgene enthalten . Haeufige DNS-Sequenzvermehrungen von Chromosom 7 , 8q und 11q deuten auf die Lokalisation von moeglichen Onkogenen hin . Bereits heute bestehen Anhaltspunkte fuer eine Prognoserelevanz genetischer Veraenderungen . Der Nachweis von Polysomien in Primaertumoren deuten auf eine unguenstige Prognose hin . Eine Amplifikation des Androgenrezeptors spricht fuer einen Hormontherapie-resistenten Tumor , welcher moeglicherweise besonders gut auf eine totale Androgenblockade ansprechen wird . Die Identifikation der alterierten Gene und die Entschluesselung ihrer Funktion koennte in Zukunft zu deutlich verbesserten Behandlungsstretegien fuer Patienten mit Prostatakarzinom fuehrten .
[ "Entstehung", "und", "Progression", "von", "Tumoren", "werden", "durch", "Funktionsstoerungen", "von", "spezifischen", "Genen", "gesteuert", ".", "Obwohl", "das", "Prostatakarzinom", "zu", "den", "haeufigsten", "Tumoren", "gehoert", ",", "ist", "ueber", "die", "bei", "diesem", "Tumor", "involvierten", "Gene", "wenig", "bekannt", ".", "Zytogenetische", "und", "molekulare", "Untersuchungen", "haben", "gezeigt", ",", "dass", "chromosomale", "Deletionen", "besonders", "haeufig", "das", "Y", "-", "Chromosom", ",", "7q", ",", "8p", ",", "10q", ",", "13q", ",", "16q", "und", "17p", "betreffen", ".", "Diese", "Loci", "duerften", "fuer", "das", "Prostatakarzinom", "relevante", "Tumorsuppressorgene", "enthalten", ".", "Haeufige", "DNS", "-", "Sequenzvermehrungen", "von", "Chromosom", "7", ",", "8q", "und", "11q", "deuten", "auf", "die", "Lokalisation", "von", "moeglichen", "Onkogenen", "hin", ".", "Bereits", "heute", "bestehen", "Anhaltspunkte", "fuer", "eine", "Prognoserelevanz", "genetischer", "Veraenderungen", ".", "Der", "Nachweis", "von", "Polysomien", "in", "Primaertumoren", "deuten", "auf", "eine", "unguenstige", "Prognose", "hin", ".", "Eine", "Amplifikation", "des", "Androgenrezeptors", "spricht", "fuer", "einen", "Hormontherapie", "-", "resistenten", "Tumor", ",", "welcher", "moeglicherweise", "besonders", "gut", "auf", "eine", "totale", "Androgenblockade", "ansprechen", "wird", ".", "Die", "Identifikation", "der", "alterierten", "Gene", "und", "die", "Entschluesselung", "ihrer", "Funktion", "koennte", "in", "Zukunft", "zu", "deutlich", "verbesserten", "Behandlungsstretegien", "fuer", "Patienten", "mit", "Prostatakarzinom", "fuehrten", "." ]
[ "umlsterm" ]
amiloride is a Intervention_Pharmacological, carbenoxolone is a Intervention_Pharmacological, patients with gastric ulcer . is a Participant_Condition, Patients with benign gastric ulcer is a Participant_Condition, carbenoxolone sodium as Biogastrone tablets 100 mg three times a day is a Intervention_Pharmacological, Fifty two patients entered the trial , and 12 were withdrawn . is a Participant_Condition, dummy tablets is a Intervention_Control, weight gain is a Outcome_Physical, oedema is a Outcome_Physical, hypertension , hypokalaemia and hypernatraemia is a Outcome_Physical, serum carbenoxolone levels is a Outcome_Physical, spironolactone is a Intervention_Pharmacological, ulcer - healing is a Outcome_Physical, metabolic side - effects is a Outcome_Adverse-effects, peptic ulcer . is a Participant_Condition
80095_task0
Sentence: The influence of amiloride on the therapeutic and metabolic effects of carbenoxolone in patients with gastric ulcer . A double-blind controlled trial . Patients with benign gastric ulcer were treated for four weeks with carbenoxolone sodium as Biogastrone tablets 100 mg three times a day , and if the ulcers were not healed at 4 weeks treatment was continued for a further 4 weeks . Fifty two patients entered the trial , and 12 were withdrawn . In 17 patients who were randomly allotted double-blind additional dummy tablets 16 of their ulcer healed completely endoscopically , whereas of the 23 patients given additional amiloride 5 mg three times a day only 14 ulcers healed , a significant reduction in ulcer healing . The clinical ( weight gain and oedema ) and metabolic ( hypertension , hypokalaemia and hypernatraemia ) side-effects were reduced by the active amiloride therapy , but serum carbenoxolone levels were not affected . Thus the potassium-retaining diuretic amiloride , like the aldosterone antagonist spironolactone , markedly reduces both the ulcer-healing and the metabolic side-effects of carbenoxolone sodium , and should not be used together with it in the treatment of peptic ulcer . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Outcome_Adverse-effects, Intervention_Control, Participant_Condition, Outcome_Physical
[ "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition" ]
The influence of amiloride on the therapeutic and metabolic effects of carbenoxolone in patients with gastric ulcer . A double-blind controlled trial . Patients with benign gastric ulcer were treated for four weeks with carbenoxolone sodium as Biogastrone tablets 100 mg three times a day , and if the ulcers were not healed at 4 weeks treatment was continued for a further 4 weeks . Fifty two patients entered the trial , and 12 were withdrawn . In 17 patients who were randomly allotted double-blind additional dummy tablets 16 of their ulcer healed completely endoscopically , whereas of the 23 patients given additional amiloride 5 mg three times a day only 14 ulcers healed , a significant reduction in ulcer healing . The clinical ( weight gain and oedema ) and metabolic ( hypertension , hypokalaemia and hypernatraemia ) side-effects were reduced by the active amiloride therapy , but serum carbenoxolone levels were not affected . Thus the potassium-retaining diuretic amiloride , like the aldosterone antagonist spironolactone , markedly reduces both the ulcer-healing and the metabolic side-effects of carbenoxolone sodium , and should not be used together with it in the treatment of peptic ulcer .
[ "The", "influence", "of", "amiloride", "on", "the", "therapeutic", "and", "metabolic", "effects", "of", "carbenoxolone", "in", "patients", "with", "gastric", "ulcer", ".", "A", "double", "-", "blind", "controlled", "trial", ".", "Patients", "with", "benign", "gastric", "ulcer", "were", "treated", "for", "four", "weeks", "with", "carbenoxolone", "sodium", "as", "Biogastrone", "tablets", "100", "mg", "three", "times", "a", "day", ",", "and", "if", "the", "ulcers", "were", "not", "healed", "at", "4", "weeks", "treatment", "was", "continued", "for", "a", "further", "4", "weeks", ".", "Fifty", "two", "patients", "entered", "the", "trial", ",", "and", "12", "were", "withdrawn", ".", "In", "17", "patients", "who", "were", "randomly", "allotted", "double", "-", "blind", "additional", "dummy", "tablets", "16", "of", "their", "ulcer", "healed", "completely", "endoscopically", ",", "whereas", "of", "the", "23", "patients", "given", "additional", "amiloride", "5", "mg", "three", "times", "a", "day", "only", "14", "ulcers", "healed", ",", "a", "significant", "reduction", "in", "ulcer", "healing", ".", "The", "clinical", "(", "weight", "gain", "and", "oedema", ")", "and", "metabolic", "(", "hypertension", ",", "hypokalaemia", "and", "hypernatraemia", ")", "side", "-", "effects", "were", "reduced", "by", "the", "active", "amiloride", "therapy", ",", "but", "serum", "carbenoxolone", "levels", "were", "not", "affected", ".", "Thus", "the", "potassium", "-", "retaining", "diuretic", "amiloride", ",", "like", "the", "aldosterone", "antagonist", "spironolactone", ",", "markedly", "reduces", "both", "the", "ulcer", "-", "healing", "and", "the", "metabolic", "side", "-", "effects", "of", "carbenoxolone", "sodium", ",", "and", "should", "not", "be", "used", "together", "with", "it", "in", "the", "treatment", "of", "peptic", "ulcer", "." ]
[ "Intervention_Pharmacological", "Participant_Condition", "Outcome_Physical", "Outcome_Adverse-effects", "Intervention_Control" ]
amiloride is a Intervention_Pharmacological, carbenoxolone is a Intervention_Pharmacological, patients with gastric ulcer . is a Participant_Condition, Patients with benign gastric ulcer is a Participant_Condition, carbenoxolone sodium as Biogastrone tablets 100 mg three times a day is a Intervention_Pharmacological, Fifty two patients entered the trial , and 12 were withdrawn . is a Participant_Condition, dummy tablets is a Intervention_Control, weight gain is a Outcome_Physical, oedema is a Outcome_Physical, hypertension , hypokalaemia and hypernatraemia is a Outcome_Physical, serum carbenoxolone levels is a Outcome_Physical, spironolactone is a Intervention_Pharmacological, ulcer - healing is a Outcome_Physical, metabolic side - effects is a Outcome_Adverse-effects, peptic ulcer . is a Participant_Condition
80095_task1
Sentence: The influence of amiloride on the therapeutic and metabolic effects of carbenoxolone in patients with gastric ulcer . A double-blind controlled trial . Patients with benign gastric ulcer were treated for four weeks with carbenoxolone sodium as Biogastrone tablets 100 mg three times a day , and if the ulcers were not healed at 4 weeks treatment was continued for a further 4 weeks . Fifty two patients entered the trial , and 12 were withdrawn . In 17 patients who were randomly allotted double-blind additional dummy tablets 16 of their ulcer healed completely endoscopically , whereas of the 23 patients given additional amiloride 5 mg three times a day only 14 ulcers healed , a significant reduction in ulcer healing . The clinical ( weight gain and oedema ) and metabolic ( hypertension , hypokalaemia and hypernatraemia ) side-effects were reduced by the active amiloride therapy , but serum carbenoxolone levels were not affected . Thus the potassium-retaining diuretic amiloride , like the aldosterone antagonist spironolactone , markedly reduces both the ulcer-healing and the metabolic side-effects of carbenoxolone sodium , and should not be used together with it in the treatment of peptic ulcer . Instructions: please typing these entity words according to sentence: amiloride, carbenoxolone, patients with gastric ulcer ., Patients with benign gastric ulcer, carbenoxolone sodium as Biogastrone tablets 100 mg three times a day, Fifty two patients entered the trial , and 12 were withdrawn ., dummy tablets, weight gain, oedema, hypertension , hypokalaemia and hypernatraemia, serum carbenoxolone levels, spironolactone, ulcer - healing, metabolic side - effects, peptic ulcer . Options: Intervention_Pharmacological, Outcome_Adverse-effects, Intervention_Control, Participant_Condition, Outcome_Physical
[ "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition" ]
The influence of amiloride on the therapeutic and metabolic effects of carbenoxolone in patients with gastric ulcer . A double-blind controlled trial . Patients with benign gastric ulcer were treated for four weeks with carbenoxolone sodium as Biogastrone tablets 100 mg three times a day , and if the ulcers were not healed at 4 weeks treatment was continued for a further 4 weeks . Fifty two patients entered the trial , and 12 were withdrawn . In 17 patients who were randomly allotted double-blind additional dummy tablets 16 of their ulcer healed completely endoscopically , whereas of the 23 patients given additional amiloride 5 mg three times a day only 14 ulcers healed , a significant reduction in ulcer healing . The clinical ( weight gain and oedema ) and metabolic ( hypertension , hypokalaemia and hypernatraemia ) side-effects were reduced by the active amiloride therapy , but serum carbenoxolone levels were not affected . Thus the potassium-retaining diuretic amiloride , like the aldosterone antagonist spironolactone , markedly reduces both the ulcer-healing and the metabolic side-effects of carbenoxolone sodium , and should not be used together with it in the treatment of peptic ulcer .
[ "The", "influence", "of", "amiloride", "on", "the", "therapeutic", "and", "metabolic", "effects", "of", "carbenoxolone", "in", "patients", "with", "gastric", "ulcer", ".", "A", "double", "-", "blind", "controlled", "trial", ".", "Patients", "with", "benign", "gastric", "ulcer", "were", "treated", "for", "four", "weeks", "with", "carbenoxolone", "sodium", "as", "Biogastrone", "tablets", "100", "mg", "three", "times", "a", "day", ",", "and", "if", "the", "ulcers", "were", "not", "healed", "at", "4", "weeks", "treatment", "was", "continued", "for", "a", "further", "4", "weeks", ".", "Fifty", "two", "patients", "entered", "the", "trial", ",", "and", "12", "were", "withdrawn", ".", "In", "17", "patients", "who", "were", "randomly", "allotted", "double", "-", "blind", "additional", "dummy", "tablets", "16", "of", "their", "ulcer", "healed", "completely", "endoscopically", ",", "whereas", "of", "the", "23", "patients", "given", "additional", "amiloride", "5", "mg", "three", "times", "a", "day", "only", "14", "ulcers", "healed", ",", "a", "significant", "reduction", "in", "ulcer", "healing", ".", "The", "clinical", "(", "weight", "gain", "and", "oedema", ")", "and", "metabolic", "(", "hypertension", ",", "hypokalaemia", "and", "hypernatraemia", ")", "side", "-", "effects", "were", "reduced", "by", "the", "active", "amiloride", "therapy", ",", "but", "serum", "carbenoxolone", "levels", "were", "not", "affected", ".", "Thus", "the", "potassium", "-", "retaining", "diuretic", "amiloride", ",", "like", "the", "aldosterone", "antagonist", "spironolactone", ",", "markedly", "reduces", "both", "the", "ulcer", "-", "healing", "and", "the", "metabolic", "side", "-", "effects", "of", "carbenoxolone", "sodium", ",", "and", "should", "not", "be", "used", "together", "with", "it", "in", "the", "treatment", "of", "peptic", "ulcer", "." ]
[ "Intervention_Pharmacological", "Participant_Condition", "Outcome_Physical", "Outcome_Adverse-effects", "Intervention_Control" ]
amiloride, carbenoxolone, patients with gastric ulcer ., Patients with benign gastric ulcer, carbenoxolone sodium as Biogastrone tablets 100 mg three times a day, Fifty two patients entered the trial , and 12 were withdrawn ., dummy tablets, weight gain, oedema, hypertension , hypokalaemia and hypernatraemia, serum carbenoxolone levels, spironolactone, ulcer - healing, metabolic side - effects, peptic ulcer .
80095_task2
Sentence: The influence of amiloride on the therapeutic and metabolic effects of carbenoxolone in patients with gastric ulcer . A double-blind controlled trial . Patients with benign gastric ulcer were treated for four weeks with carbenoxolone sodium as Biogastrone tablets 100 mg three times a day , and if the ulcers were not healed at 4 weeks treatment was continued for a further 4 weeks . Fifty two patients entered the trial , and 12 were withdrawn . In 17 patients who were randomly allotted double-blind additional dummy tablets 16 of their ulcer healed completely endoscopically , whereas of the 23 patients given additional amiloride 5 mg three times a day only 14 ulcers healed , a significant reduction in ulcer healing . The clinical ( weight gain and oedema ) and metabolic ( hypertension , hypokalaemia and hypernatraemia ) side-effects were reduced by the active amiloride therapy , but serum carbenoxolone levels were not affected . Thus the potassium-retaining diuretic amiloride , like the aldosterone antagonist spironolactone , markedly reduces both the ulcer-healing and the metabolic side-effects of carbenoxolone sodium , and should not be used together with it in the treatment of peptic ulcer . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "B-Outcome_Physical", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition" ]
The influence of amiloride on the therapeutic and metabolic effects of carbenoxolone in patients with gastric ulcer . A double-blind controlled trial . Patients with benign gastric ulcer were treated for four weeks with carbenoxolone sodium as Biogastrone tablets 100 mg three times a day , and if the ulcers were not healed at 4 weeks treatment was continued for a further 4 weeks . Fifty two patients entered the trial , and 12 were withdrawn . In 17 patients who were randomly allotted double-blind additional dummy tablets 16 of their ulcer healed completely endoscopically , whereas of the 23 patients given additional amiloride 5 mg three times a day only 14 ulcers healed , a significant reduction in ulcer healing . The clinical ( weight gain and oedema ) and metabolic ( hypertension , hypokalaemia and hypernatraemia ) side-effects were reduced by the active amiloride therapy , but serum carbenoxolone levels were not affected . Thus the potassium-retaining diuretic amiloride , like the aldosterone antagonist spironolactone , markedly reduces both the ulcer-healing and the metabolic side-effects of carbenoxolone sodium , and should not be used together with it in the treatment of peptic ulcer .
[ "The", "influence", "of", "amiloride", "on", "the", "therapeutic", "and", "metabolic", "effects", "of", "carbenoxolone", "in", "patients", "with", "gastric", "ulcer", ".", "A", "double", "-", "blind", "controlled", "trial", ".", "Patients", "with", "benign", "gastric", "ulcer", "were", "treated", "for", "four", "weeks", "with", "carbenoxolone", "sodium", "as", "Biogastrone", "tablets", "100", "mg", "three", "times", "a", "day", ",", "and", "if", "the", "ulcers", "were", "not", "healed", "at", "4", "weeks", "treatment", "was", "continued", "for", "a", "further", "4", "weeks", ".", "Fifty", "two", "patients", "entered", "the", "trial", ",", "and", "12", "were", "withdrawn", ".", "In", "17", "patients", "who", "were", "randomly", "allotted", "double", "-", "blind", "additional", "dummy", "tablets", "16", "of", "their", "ulcer", "healed", "completely", "endoscopically", ",", "whereas", "of", "the", "23", "patients", "given", "additional", "amiloride", "5", "mg", "three", "times", "a", "day", "only", "14", "ulcers", "healed", ",", "a", "significant", "reduction", "in", "ulcer", "healing", ".", "The", "clinical", "(", "weight", "gain", "and", "oedema", ")", "and", "metabolic", "(", "hypertension", ",", "hypokalaemia", "and", "hypernatraemia", ")", "side", "-", "effects", "were", "reduced", "by", "the", "active", "amiloride", "therapy", ",", "but", "serum", "carbenoxolone", "levels", "were", "not", "affected", ".", "Thus", "the", "potassium", "-", "retaining", "diuretic", "amiloride", ",", "like", "the", "aldosterone", "antagonist", "spironolactone", ",", "markedly", "reduces", "both", "the", "ulcer", "-", "healing", "and", "the", "metabolic", "side", "-", "effects", "of", "carbenoxolone", "sodium", ",", "and", "should", "not", "be", "used", "together", "with", "it", "in", "the", "treatment", "of", "peptic", "ulcer", "." ]
[ "Intervention_Pharmacological", "Participant_Condition", "Outcome_Physical", "Outcome_Adverse-effects", "Intervention_Control" ]
heme is a chemical, RFABG is a protein
1.0alpha7.train.663_task0
Sentence: The aim of the present study was to characterize the heme-binding properties of RFABG. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: chemical, protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-chemical", "O", "O", "O", "O", "O", "B-protein", "O" ]
The aim of the present study was to characterize the heme-binding properties of RFABG.
[ "The", "aim", "of", "the", "present", "study", "was", "to", "characterize", "the", " ", "heme", "-", "binding", "properties", "of", " ", "RFABG", "." ]
[ "protein", "chemical" ]
heme is a chemical, RFABG is a protein
1.0alpha7.train.663_task1
Sentence: The aim of the present study was to characterize the heme-binding properties of RFABG. Instructions: please typing these entity words according to sentence: heme, RFABG Options: chemical, protein
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-chemical", "O", "O", "O", "O", "O", "B-protein", "O" ]
The aim of the present study was to characterize the heme-binding properties of RFABG.
[ "The", "aim", "of", "the", "present", "study", "was", "to", "characterize", "the", " ", "heme", "-", "binding", "properties", "of", " ", "RFABG", "." ]
[ "protein", "chemical" ]
heme, RFABG
1.0alpha7.train.663_task2
Sentence: The aim of the present study was to characterize the heme-binding properties of RFABG. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-chemical", "O", "O", "O", "O", "O", "B-protein", "O" ]
The aim of the present study was to characterize the heme-binding properties of RFABG.
[ "The", "aim", "of", "the", "present", "study", "was", "to", "characterize", "the", " ", "heme", "-", "binding", "properties", "of", " ", "RFABG", "." ]
[ "protein", "chemical" ]
liver surgery II -- regional chemotherapy is a Intervention_Pharmacological, 657 is a Participant_Sample-size, Adjuvant portal therapy of the liver with resection of the colorectal primary malignancy is a Intervention_Surgical, survival is a Outcome_Mortality, curative resection of colorectal liver metastases is a Intervention_Surgical, median survival time ( FUDR , pump ) is a Outcome_Mortality, palliative local chemotherapy is a Intervention_Pharmacological
70505_task0
Sentence: [ European topic : liver surgery II -- regional chemotherapy ] . The most important methods of regional chemotherapy are exemplified by 657 cases of primary and secondary liver only malignancies . I . Adjuvant portal therapy of the liver with resection of the colorectal primary malignancy seems to be advantageous for advanced tumors . II . It is still unresolved whether survival is prolonged by adjuvant treatment of the liver following curative resection of colorectal liver metastases . III . The median survival time ( FUDR , pump ) is 17 months for palliative local chemotherapy of unresectable colorectal liver metastases . IV . Primary non-resectable liver malignancies show the best results after chemoembolisation ( Frankfurt method ) . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Intervention_Surgical, Outcome_Mortality, Participant_Sample-size
[ "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
[ European topic : liver surgery II -- regional chemotherapy ] . The most important methods of regional chemotherapy are exemplified by 657 cases of primary and secondary liver only malignancies . I . Adjuvant portal therapy of the liver with resection of the colorectal primary malignancy seems to be advantageous for advanced tumors . II . It is still unresolved whether survival is prolonged by adjuvant treatment of the liver following curative resection of colorectal liver metastases . III . The median survival time ( FUDR , pump ) is 17 months for palliative local chemotherapy of unresectable colorectal liver metastases . IV . Primary non-resectable liver malignancies show the best results after chemoembolisation ( Frankfurt method ) .
[ "[", "European", "topic", ":", "liver", "surgery", "II", "--", "regional", "chemotherapy", "]", ".", "The", "most", "important", "methods", "of", "regional", "chemotherapy", "are", "exemplified", "by", "657", "cases", "of", "primary", "and", "secondary", "liver", "only", "malignancies", ".", "I", ".", "Adjuvant", "portal", "therapy", "of", "the", "liver", "with", "resection", "of", "the", "colorectal", "primary", "malignancy", "seems", "to", "be", "advantageous", "for", "advanced", "tumors", ".", "II", ".", "It", "is", "still", "unresolved", "whether", "survival", "is", "prolonged", "by", "adjuvant", "treatment", "of", "the", "liver", "following", "curative", "resection", "of", "colorectal", "liver", "metastases", ".", "III", ".", "The", "median", "survival", "time", "(", "FUDR", ",", "pump", ")", "is", "17", "months", "for", "palliative", "local", "chemotherapy", "of", "unresectable", "colorectal", "liver", "metastases", ".", "IV", ".", "Primary", "non", "-", "resectable", "liver", "malignancies", "show", "the", "best", "results", "after", "chemoembolisation", "(", "Frankfurt", "method", ")", "." ]
[ "Intervention_Surgical", "Intervention_Pharmacological", "Outcome_Mortality", "Participant_Sample-size" ]
liver surgery II -- regional chemotherapy is a Intervention_Pharmacological, 657 is a Participant_Sample-size, Adjuvant portal therapy of the liver with resection of the colorectal primary malignancy is a Intervention_Surgical, survival is a Outcome_Mortality, curative resection of colorectal liver metastases is a Intervention_Surgical, median survival time ( FUDR , pump ) is a Outcome_Mortality, palliative local chemotherapy is a Intervention_Pharmacological
70505_task1
Sentence: [ European topic : liver surgery II -- regional chemotherapy ] . The most important methods of regional chemotherapy are exemplified by 657 cases of primary and secondary liver only malignancies . I . Adjuvant portal therapy of the liver with resection of the colorectal primary malignancy seems to be advantageous for advanced tumors . II . It is still unresolved whether survival is prolonged by adjuvant treatment of the liver following curative resection of colorectal liver metastases . III . The median survival time ( FUDR , pump ) is 17 months for palliative local chemotherapy of unresectable colorectal liver metastases . IV . Primary non-resectable liver malignancies show the best results after chemoembolisation ( Frankfurt method ) . Instructions: please typing these entity words according to sentence: liver surgery II -- regional chemotherapy, 657, Adjuvant portal therapy of the liver with resection of the colorectal primary malignancy, survival, curative resection of colorectal liver metastases, median survival time ( FUDR , pump ), palliative local chemotherapy Options: Intervention_Pharmacological, Intervention_Surgical, Outcome_Mortality, Participant_Sample-size
[ "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
[ European topic : liver surgery II -- regional chemotherapy ] . The most important methods of regional chemotherapy are exemplified by 657 cases of primary and secondary liver only malignancies . I . Adjuvant portal therapy of the liver with resection of the colorectal primary malignancy seems to be advantageous for advanced tumors . II . It is still unresolved whether survival is prolonged by adjuvant treatment of the liver following curative resection of colorectal liver metastases . III . The median survival time ( FUDR , pump ) is 17 months for palliative local chemotherapy of unresectable colorectal liver metastases . IV . Primary non-resectable liver malignancies show the best results after chemoembolisation ( Frankfurt method ) .
[ "[", "European", "topic", ":", "liver", "surgery", "II", "--", "regional", "chemotherapy", "]", ".", "The", "most", "important", "methods", "of", "regional", "chemotherapy", "are", "exemplified", "by", "657", "cases", "of", "primary", "and", "secondary", "liver", "only", "malignancies", ".", "I", ".", "Adjuvant", "portal", "therapy", "of", "the", "liver", "with", "resection", "of", "the", "colorectal", "primary", "malignancy", "seems", "to", "be", "advantageous", "for", "advanced", "tumors", ".", "II", ".", "It", "is", "still", "unresolved", "whether", "survival", "is", "prolonged", "by", "adjuvant", "treatment", "of", "the", "liver", "following", "curative", "resection", "of", "colorectal", "liver", "metastases", ".", "III", ".", "The", "median", "survival", "time", "(", "FUDR", ",", "pump", ")", "is", "17", "months", "for", "palliative", "local", "chemotherapy", "of", "unresectable", "colorectal", "liver", "metastases", ".", "IV", ".", "Primary", "non", "-", "resectable", "liver", "malignancies", "show", "the", "best", "results", "after", "chemoembolisation", "(", "Frankfurt", "method", ")", "." ]
[ "Intervention_Surgical", "Intervention_Pharmacological", "Outcome_Mortality", "Participant_Sample-size" ]
liver surgery II -- regional chemotherapy, 657, Adjuvant portal therapy of the liver with resection of the colorectal primary malignancy, survival, curative resection of colorectal liver metastases, median survival time ( FUDR , pump ), palliative local chemotherapy
70505_task2
Sentence: [ European topic : liver surgery II -- regional chemotherapy ] . The most important methods of regional chemotherapy are exemplified by 657 cases of primary and secondary liver only malignancies . I . Adjuvant portal therapy of the liver with resection of the colorectal primary malignancy seems to be advantageous for advanced tumors . II . It is still unresolved whether survival is prolonged by adjuvant treatment of the liver following curative resection of colorectal liver metastases . III . The median survival time ( FUDR , pump ) is 17 months for palliative local chemotherapy of unresectable colorectal liver metastases . IV . Primary non-resectable liver malignancies show the best results after chemoembolisation ( Frankfurt method ) . Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Mortality", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
[ European topic : liver surgery II -- regional chemotherapy ] . The most important methods of regional chemotherapy are exemplified by 657 cases of primary and secondary liver only malignancies . I . Adjuvant portal therapy of the liver with resection of the colorectal primary malignancy seems to be advantageous for advanced tumors . II . It is still unresolved whether survival is prolonged by adjuvant treatment of the liver following curative resection of colorectal liver metastases . III . The median survival time ( FUDR , pump ) is 17 months for palliative local chemotherapy of unresectable colorectal liver metastases . IV . Primary non-resectable liver malignancies show the best results after chemoembolisation ( Frankfurt method ) .
[ "[", "European", "topic", ":", "liver", "surgery", "II", "--", "regional", "chemotherapy", "]", ".", "The", "most", "important", "methods", "of", "regional", "chemotherapy", "are", "exemplified", "by", "657", "cases", "of", "primary", "and", "secondary", "liver", "only", "malignancies", ".", "I", ".", "Adjuvant", "portal", "therapy", "of", "the", "liver", "with", "resection", "of", "the", "colorectal", "primary", "malignancy", "seems", "to", "be", "advantageous", "for", "advanced", "tumors", ".", "II", ".", "It", "is", "still", "unresolved", "whether", "survival", "is", "prolonged", "by", "adjuvant", "treatment", "of", "the", "liver", "following", "curative", "resection", "of", "colorectal", "liver", "metastases", ".", "III", ".", "The", "median", "survival", "time", "(", "FUDR", ",", "pump", ")", "is", "17", "months", "for", "palliative", "local", "chemotherapy", "of", "unresectable", "colorectal", "liver", "metastases", ".", "IV", ".", "Primary", "non", "-", "resectable", "liver", "malignancies", "show", "the", "best", "results", "after", "chemoembolisation", "(", "Frankfurt", "method", ")", "." ]
[ "Intervention_Surgical", "Intervention_Pharmacological", "Outcome_Mortality", "Participant_Sample-size" ]
c - Fos is a protein_molecule, v - Fos is a protein_molecule, phosphorylation - dependent signal is a protein_substructure, c - Jun is a protein_molecule
86424_task0
Sentence: Targeted degradation of c-Fos, but not v-Fos, by a phosphorylation-dependent signal on c-Jun. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein_substructure, protein_molecule
[ "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "O", "O", "B-protein_substructure", "I-protein_substructure", "I-protein_substructure", "I-protein_substructure", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O" ]
Targeted degradation of c-Fos, but not v-Fos, by a phosphorylation-dependent signal on c-Jun.
[ "Targeted", "degradation", "of", "c", "-", "Fos", ",", "but", "not", "v", "-", "Fos", ",", "by", "a", "phosphorylation", "-", "dependent", "signal", "on", "c", "-", "Jun", "." ]
[ "other_name", "protein_substructure", "cell_line", "protein_molecule", "protein_family_or_group" ]
c - Fos is a protein_molecule, v - Fos is a protein_molecule, phosphorylation - dependent signal is a protein_substructure, c - Jun is a protein_molecule
86424_task1
Sentence: Targeted degradation of c-Fos, but not v-Fos, by a phosphorylation-dependent signal on c-Jun. Instructions: please typing these entity words according to sentence: c - Fos, v - Fos, phosphorylation - dependent signal, c - Jun Options: protein_substructure, protein_molecule
[ "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "O", "O", "B-protein_substructure", "I-protein_substructure", "I-protein_substructure", "I-protein_substructure", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O" ]
Targeted degradation of c-Fos, but not v-Fos, by a phosphorylation-dependent signal on c-Jun.
[ "Targeted", "degradation", "of", "c", "-", "Fos", ",", "but", "not", "v", "-", "Fos", ",", "by", "a", "phosphorylation", "-", "dependent", "signal", "on", "c", "-", "Jun", "." ]
[ "other_name", "protein_substructure", "cell_line", "protein_molecule", "protein_family_or_group" ]
c - Fos, v - Fos, phosphorylation - dependent signal, c - Jun
86424_task2
Sentence: Targeted degradation of c-Fos, but not v-Fos, by a phosphorylation-dependent signal on c-Jun. Instructions: please extract entity words from the input sentence
[ "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "O", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O", "O", "O", "B-protein_substructure", "I-protein_substructure", "I-protein_substructure", "I-protein_substructure", "O", "B-protein_molecule", "I-protein_molecule", "I-protein_molecule", "O" ]
Targeted degradation of c-Fos, but not v-Fos, by a phosphorylation-dependent signal on c-Jun.
[ "Targeted", "degradation", "of", "c", "-", "Fos", ",", "but", "not", "v", "-", "Fos", ",", "by", "a", "phosphorylation", "-", "dependent", "signal", "on", "c", "-", "Jun", "." ]
[ "other_name", "protein_substructure", "cell_line", "protein_molecule", "protein_family_or_group" ]
type 1 cannabinoid receptor is a GENE-Y
23602984_task0
Sentence: Cannabinoids increase type 1 cannabinoid receptor expression in a cell culture model of striatal neurons: Implications for Huntington's disease. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y
[ "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Cannabinoids increase type 1 cannabinoid receptor expression in a cell culture model of striatal neurons: Implications for Huntington's disease.
[ "Cannabinoids", "increase", "type", "1", "cannabinoid", "receptor", "expression", "in", "a", "cell", "culture", "model", "of", "striatal", "neurons", ":", "Implications", "for", "Huntington", "'s", "disease", "." ]
[ "GENE-Y", "GENE-N", "CHEMICAL" ]
type 1 cannabinoid receptor is a GENE-Y
23602984_task1
Sentence: Cannabinoids increase type 1 cannabinoid receptor expression in a cell culture model of striatal neurons: Implications for Huntington's disease. Instructions: please typing these entity words according to sentence: type 1 cannabinoid receptor Options: GENE-Y
[ "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Cannabinoids increase type 1 cannabinoid receptor expression in a cell culture model of striatal neurons: Implications for Huntington's disease.
[ "Cannabinoids", "increase", "type", "1", "cannabinoid", "receptor", "expression", "in", "a", "cell", "culture", "model", "of", "striatal", "neurons", ":", "Implications", "for", "Huntington", "'s", "disease", "." ]
[ "GENE-Y", "GENE-N", "CHEMICAL" ]
type 1 cannabinoid receptor
23602984_task2
Sentence: Cannabinoids increase type 1 cannabinoid receptor expression in a cell culture model of striatal neurons: Implications for Huntington's disease. Instructions: please extract entity words from the input sentence
[ "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Cannabinoids increase type 1 cannabinoid receptor expression in a cell culture model of striatal neurons: Implications for Huntington's disease.
[ "Cannabinoids", "increase", "type", "1", "cannabinoid", "receptor", "expression", "in", "a", "cell", "culture", "model", "of", "striatal", "neurons", ":", "Implications", "for", "Huntington", "'s", "disease", "." ]
[ "GENE-Y", "GENE-N", "CHEMICAL" ]
Mycobacterium gordonae is an umlsterm, atypical mycobacterium is an umlsterm, soil is an umlsterm, water is an umlsterm, mucous membranes is an umlsterm, persons is an umlsterm, infections is an umlsterm, immunocompromised patients is an umlsterm, contrast is an umlsterm, skin infections is an umlsterm, patients is an umlsterm, patient is an umlsterm, immunodeficiency is an umlsterm, mycobacteriosis is an umlsterm, thorn is an umlsterm, injury is an umlsterm, tissue culture is an umlsterm, skin is an umlsterm, after treatment is an umlsterm, doxycycline is an umlsterm
DerHautarzt.60470771.eng.abstr_task0
Sentence: Mycobacterium gordonae is an atypical mycobacterium of very low pathogenic potential . It is widely distributed in soil and water and often detected on the mucous membranes of healthy persons . In recent years , there have been numerous reports of infections by M. gordonae in immunocompromised patients . In contrast , only four cases of skin infections by M. gordonae in immunocompetent patients have been published . We report on another patient without evidence of immunodeficiency who developed an atypical mycobacteriosis after a thorn injury during gardening . M. gordonae was isolated by tissue culture . The skin lesion cleared completely after treatment with doxycycline for three months . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O" ]
Mycobacterium gordonae is an atypical mycobacterium of very low pathogenic potential . It is widely distributed in soil and water and often detected on the mucous membranes of healthy persons . In recent years , there have been numerous reports of infections by M. gordonae in immunocompromised patients . In contrast , only four cases of skin infections by M. gordonae in immunocompetent patients have been published . We report on another patient without evidence of immunodeficiency who developed an atypical mycobacteriosis after a thorn injury during gardening . M. gordonae was isolated by tissue culture . The skin lesion cleared completely after treatment with doxycycline for three months .
[ "Mycobacterium", "gordonae", "is", "an", "atypical", "mycobacterium", "of", "very", "low", "pathogenic", "potential", ".", "It", "is", "widely", "distributed", "in", "soil", "and", "water", "and", "often", "detected", "on", "the", "mucous", "membranes", "of", "healthy", "persons", ".", "In", "recent", "years", ",", "there", "have", "been", "numerous", "reports", "of", "infections", "by", "M.", "gordonae", "in", "immunocompromised", "patients", ".", "In", "contrast", ",", "only", "four", "cases", "of", "skin", "infections", "by", "M.", "gordonae", "in", "immunocompetent", "patients", "have", "been", "published", ".", "We", "report", "on", "another", "patient", "without", "evidence", "of", "immunodeficiency", "who", "developed", "an", "atypical", "mycobacteriosis", "after", "a", "thorn", "injury", "during", "gardening", ".", "M.", "gordonae", "was", "isolated", "by", "tissue", "culture", ".", "The", "skin", "lesion", "cleared", "completely", "after", "treatment", "with", "doxycycline", "for", "three", "months", "." ]
[ "umlsterm" ]
Mycobacterium gordonae is an umlsterm, atypical mycobacterium is an umlsterm, soil is an umlsterm, water is an umlsterm, mucous membranes is an umlsterm, persons is an umlsterm, infections is an umlsterm, immunocompromised patients is an umlsterm, contrast is an umlsterm, skin infections is an umlsterm, patients is an umlsterm, patient is an umlsterm, immunodeficiency is an umlsterm, mycobacteriosis is an umlsterm, thorn is an umlsterm, injury is an umlsterm, tissue culture is an umlsterm, skin is an umlsterm, after treatment is an umlsterm, doxycycline is an umlsterm
DerHautarzt.60470771.eng.abstr_task1
Sentence: Mycobacterium gordonae is an atypical mycobacterium of very low pathogenic potential . It is widely distributed in soil and water and often detected on the mucous membranes of healthy persons . In recent years , there have been numerous reports of infections by M. gordonae in immunocompromised patients . In contrast , only four cases of skin infections by M. gordonae in immunocompetent patients have been published . We report on another patient without evidence of immunodeficiency who developed an atypical mycobacteriosis after a thorn injury during gardening . M. gordonae was isolated by tissue culture . The skin lesion cleared completely after treatment with doxycycline for three months . Instructions: please typing these entity words according to sentence: Mycobacterium gordonae, atypical mycobacterium, soil, water, mucous membranes, persons, infections, immunocompromised patients, contrast, skin infections, patients, patient, immunodeficiency, mycobacteriosis, thorn, injury, tissue culture, skin, after treatment, doxycycline Options: umlsterm
[ "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O" ]
Mycobacterium gordonae is an atypical mycobacterium of very low pathogenic potential . It is widely distributed in soil and water and often detected on the mucous membranes of healthy persons . In recent years , there have been numerous reports of infections by M. gordonae in immunocompromised patients . In contrast , only four cases of skin infections by M. gordonae in immunocompetent patients have been published . We report on another patient without evidence of immunodeficiency who developed an atypical mycobacteriosis after a thorn injury during gardening . M. gordonae was isolated by tissue culture . The skin lesion cleared completely after treatment with doxycycline for three months .
[ "Mycobacterium", "gordonae", "is", "an", "atypical", "mycobacterium", "of", "very", "low", "pathogenic", "potential", ".", "It", "is", "widely", "distributed", "in", "soil", "and", "water", "and", "often", "detected", "on", "the", "mucous", "membranes", "of", "healthy", "persons", ".", "In", "recent", "years", ",", "there", "have", "been", "numerous", "reports", "of", "infections", "by", "M.", "gordonae", "in", "immunocompromised", "patients", ".", "In", "contrast", ",", "only", "four", "cases", "of", "skin", "infections", "by", "M.", "gordonae", "in", "immunocompetent", "patients", "have", "been", "published", ".", "We", "report", "on", "another", "patient", "without", "evidence", "of", "immunodeficiency", "who", "developed", "an", "atypical", "mycobacteriosis", "after", "a", "thorn", "injury", "during", "gardening", ".", "M.", "gordonae", "was", "isolated", "by", "tissue", "culture", ".", "The", "skin", "lesion", "cleared", "completely", "after", "treatment", "with", "doxycycline", "for", "three", "months", "." ]
[ "umlsterm" ]
Mycobacterium gordonae, atypical mycobacterium, soil, water, mucous membranes, persons, infections, immunocompromised patients, contrast, skin infections, patients, patient, immunodeficiency, mycobacteriosis, thorn, injury, tissue culture, skin, after treatment, doxycycline
DerHautarzt.60470771.eng.abstr_task2
Sentence: Mycobacterium gordonae is an atypical mycobacterium of very low pathogenic potential . It is widely distributed in soil and water and often detected on the mucous membranes of healthy persons . In recent years , there have been numerous reports of infections by M. gordonae in immunocompromised patients . In contrast , only four cases of skin infections by M. gordonae in immunocompetent patients have been published . We report on another patient without evidence of immunodeficiency who developed an atypical mycobacteriosis after a thorn injury during gardening . M. gordonae was isolated by tissue culture . The skin lesion cleared completely after treatment with doxycycline for three months . Instructions: please extract entity words from the input sentence
[ "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O" ]
Mycobacterium gordonae is an atypical mycobacterium of very low pathogenic potential . It is widely distributed in soil and water and often detected on the mucous membranes of healthy persons . In recent years , there have been numerous reports of infections by M. gordonae in immunocompromised patients . In contrast , only four cases of skin infections by M. gordonae in immunocompetent patients have been published . We report on another patient without evidence of immunodeficiency who developed an atypical mycobacteriosis after a thorn injury during gardening . M. gordonae was isolated by tissue culture . The skin lesion cleared completely after treatment with doxycycline for three months .
[ "Mycobacterium", "gordonae", "is", "an", "atypical", "mycobacterium", "of", "very", "low", "pathogenic", "potential", ".", "It", "is", "widely", "distributed", "in", "soil", "and", "water", "and", "often", "detected", "on", "the", "mucous", "membranes", "of", "healthy", "persons", ".", "In", "recent", "years", ",", "there", "have", "been", "numerous", "reports", "of", "infections", "by", "M.", "gordonae", "in", "immunocompromised", "patients", ".", "In", "contrast", ",", "only", "four", "cases", "of", "skin", "infections", "by", "M.", "gordonae", "in", "immunocompetent", "patients", "have", "been", "published", ".", "We", "report", "on", "another", "patient", "without", "evidence", "of", "immunodeficiency", "who", "developed", "an", "atypical", "mycobacteriosis", "after", "a", "thorn", "injury", "during", "gardening", ".", "M.", "gordonae", "was", "isolated", "by", "tissue", "culture", ".", "The", "skin", "lesion", "cleared", "completely", "after", "treatment", "with", "doxycycline", "for", "three", "months", "." ]
[ "umlsterm" ]
malignen Melanom is an umlsterm, Haut is an umlsterm, Aerzten is an umlsterm, Anstrengungen is an umlsterm, malignen Melanoms is an umlsterm, Australien is an umlsterm, Melanominzidenz is an umlsterm, Wissen is an umlsterm, Hautkrebs is an umlsterm, Verhalten is an umlsterm, Bevoelkerung is an umlsterm, Sonne is an umlsterm, USA is an umlsterm, Grossbritannien is an umlsterm, Deutschland is an umlsterm, Melanoms is an umlsterm, Gesellschaft is an umlsterm, Analyse is an umlsterm, Wissen is an umlsterm, Bevoelkerung is an umlsterm, Hautkrebs is an umlsterm, Verhalten is an umlsterm, Textilien is an umlsterm, Aerzte is an umlsterm
DerHautarzt.80490826.ger.abstr_task0
Sentence: Beim malignen Melanom der Haut wurden insbesondere im letzten Jahrzehnt von Dermatologen und Aerzten anderer Fachrichtungen sowie weiteren Angehoerigen von Gesundheitsberufen grosse Anstrengungen unternommen , die Aufklaerung ( primaere Praevention ) und Frueherkennung ( sekundaere Praevention ) zu verbessern . Die erste oeffentlichkeitswirksame Kampagne zur Praevention des malignen Melanoms wurde bereits in den 60er Jahren in Australien , dem Land mit der weltweit hoechsten Melanominzidenz , durchgefuehrt . Durch Aufklaerung vermehrte sich das Wissen ueber Hautkrebs , und Einstellung und Verhalten der Bevoelkerung in bezug auf die Sonne aenderten sich . Auch in den USA und in Grossbritannien wurden zahlreiche oeffentlichkeitswirksame Aktivitaeten durchgefuehrt und umfangreiche Erfahrungen gesammelt . In Deutschland wurden Aufklaerungsaktionen zunaechst auf regionaler Ebene durchgefuehrt . 1989 initiierte die Kommission zur Frueherkennung und Praevention des Melanoms der Deutschen Dermatologischen Gesellschaft bundesweite Kampagnen . Regionale Aktionen ergaenzten diese Aktivitaeten in den 90er Jahren . Die Analyse bisheriger Aktionen zeigt , dass einmalige Aktivitaeten wenig wirksam und dass Wiederholungen von oeffentlichkeitswirksamen Praeventionskampagnen notwendig sind , um das Wissen in der Bevoelkerung ueber Hautkrebs zu verbessern und Einstellungen und Verhalten gegenueber der UV-Exposition zu aendern . Ergaenzend hierzu sollten die Entwicklung von Textilien mit hohem Lichtschutzfaktor und strukturelle Veraenderungen , z.B. Schaffung von Schattenplaetzen in Schwimmbaedern , angestrebt werden . In Praeventionskampagnen sollten auch vermehrt Aerzte anderer Disziplinen sowie weitere Gesundheitsberufe mit einbezogen werden . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm
[ "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Beim malignen Melanom der Haut wurden insbesondere im letzten Jahrzehnt von Dermatologen und Aerzten anderer Fachrichtungen sowie weiteren Angehoerigen von Gesundheitsberufen grosse Anstrengungen unternommen , die Aufklaerung ( primaere Praevention ) und Frueherkennung ( sekundaere Praevention ) zu verbessern . Die erste oeffentlichkeitswirksame Kampagne zur Praevention des malignen Melanoms wurde bereits in den 60er Jahren in Australien , dem Land mit der weltweit hoechsten Melanominzidenz , durchgefuehrt . Durch Aufklaerung vermehrte sich das Wissen ueber Hautkrebs , und Einstellung und Verhalten der Bevoelkerung in bezug auf die Sonne aenderten sich . Auch in den USA und in Grossbritannien wurden zahlreiche oeffentlichkeitswirksame Aktivitaeten durchgefuehrt und umfangreiche Erfahrungen gesammelt . In Deutschland wurden Aufklaerungsaktionen zunaechst auf regionaler Ebene durchgefuehrt . 1989 initiierte die Kommission zur Frueherkennung und Praevention des Melanoms der Deutschen Dermatologischen Gesellschaft bundesweite Kampagnen . Regionale Aktionen ergaenzten diese Aktivitaeten in den 90er Jahren . Die Analyse bisheriger Aktionen zeigt , dass einmalige Aktivitaeten wenig wirksam und dass Wiederholungen von oeffentlichkeitswirksamen Praeventionskampagnen notwendig sind , um das Wissen in der Bevoelkerung ueber Hautkrebs zu verbessern und Einstellungen und Verhalten gegenueber der UV-Exposition zu aendern . Ergaenzend hierzu sollten die Entwicklung von Textilien mit hohem Lichtschutzfaktor und strukturelle Veraenderungen , z.B. Schaffung von Schattenplaetzen in Schwimmbaedern , angestrebt werden . In Praeventionskampagnen sollten auch vermehrt Aerzte anderer Disziplinen sowie weitere Gesundheitsberufe mit einbezogen werden .
[ "Beim", "malignen", "Melanom", "der", "Haut", "wurden", "insbesondere", "im", "letzten", "Jahrzehnt", "von", "Dermatologen", "und", "Aerzten", "anderer", "Fachrichtungen", "sowie", "weiteren", "Angehoerigen", "von", "Gesundheitsberufen", "grosse", "Anstrengungen", "unternommen", ",", "die", "Aufklaerung", "(", "primaere", "Praevention", ")", "und", "Frueherkennung", "(", "sekundaere", "Praevention", ")", "zu", "verbessern", ".", "Die", "erste", "oeffentlichkeitswirksame", "Kampagne", "zur", "Praevention", "des", "malignen", "Melanoms", "wurde", "bereits", "in", "den", "60er", "Jahren", "in", "Australien", ",", "dem", "Land", "mit", "der", "weltweit", "hoechsten", "Melanominzidenz", ",", "durchgefuehrt", ".", "Durch", "Aufklaerung", "vermehrte", "sich", "das", "Wissen", "ueber", "Hautkrebs", ",", "und", "Einstellung", "und", "Verhalten", "der", "Bevoelkerung", "in", "bezug", "auf", "die", "Sonne", "aenderten", "sich", ".", "Auch", "in", "den", "USA", "und", "in", "Grossbritannien", "wurden", "zahlreiche", "oeffentlichkeitswirksame", "Aktivitaeten", "durchgefuehrt", "und", "umfangreiche", "Erfahrungen", "gesammelt", ".", "In", "Deutschland", "wurden", "Aufklaerungsaktionen", "zunaechst", "auf", "regionaler", "Ebene", "durchgefuehrt", ".", "1989", "initiierte", "die", "Kommission", "zur", "Frueherkennung", "und", "Praevention", "des", "Melanoms", "der", "Deutschen", "Dermatologischen", "Gesellschaft", "bundesweite", "Kampagnen", ".", "Regionale", "Aktionen", "ergaenzten", "diese", "Aktivitaeten", "in", "den", "90er", "Jahren", ".", "Die", "Analyse", "bisheriger", "Aktionen", "zeigt", ",", "dass", "einmalige", "Aktivitaeten", "wenig", "wirksam", "und", "dass", "Wiederholungen", "von", "oeffentlichkeitswirksamen", "Praeventionskampagnen", "notwendig", "sind", ",", "um", "das", "Wissen", "in", "der", "Bevoelkerung", "ueber", "Hautkrebs", "zu", "verbessern", "und", "Einstellungen", "und", "Verhalten", "gegenueber", "der", "UV", "-", "Exposition", "zu", "aendern", ".", "Ergaenzend", "hierzu", "sollten", "die", "Entwicklung", "von", "Textilien", "mit", "hohem", "Lichtschutzfaktor", "und", "strukturelle", "Veraenderungen", ",", "z.", "B.", "Schaffung", "von", "Schattenplaetzen", "in", "Schwimmbaedern", ",", "angestrebt", "werden", ".", "In", "Praeventionskampagnen", "sollten", "auch", "vermehrt", "Aerzte", "anderer", "Disziplinen", "sowie", "weitere", "Gesundheitsberufe", "mit", "einbezogen", "werden", "." ]
[ "umlsterm" ]
malignen Melanom is an umlsterm, Haut is an umlsterm, Aerzten is an umlsterm, Anstrengungen is an umlsterm, malignen Melanoms is an umlsterm, Australien is an umlsterm, Melanominzidenz is an umlsterm, Wissen is an umlsterm, Hautkrebs is an umlsterm, Verhalten is an umlsterm, Bevoelkerung is an umlsterm, Sonne is an umlsterm, USA is an umlsterm, Grossbritannien is an umlsterm, Deutschland is an umlsterm, Melanoms is an umlsterm, Gesellschaft is an umlsterm, Analyse is an umlsterm, Wissen is an umlsterm, Bevoelkerung is an umlsterm, Hautkrebs is an umlsterm, Verhalten is an umlsterm, Textilien is an umlsterm, Aerzte is an umlsterm
DerHautarzt.80490826.ger.abstr_task1
Sentence: Beim malignen Melanom der Haut wurden insbesondere im letzten Jahrzehnt von Dermatologen und Aerzten anderer Fachrichtungen sowie weiteren Angehoerigen von Gesundheitsberufen grosse Anstrengungen unternommen , die Aufklaerung ( primaere Praevention ) und Frueherkennung ( sekundaere Praevention ) zu verbessern . Die erste oeffentlichkeitswirksame Kampagne zur Praevention des malignen Melanoms wurde bereits in den 60er Jahren in Australien , dem Land mit der weltweit hoechsten Melanominzidenz , durchgefuehrt . Durch Aufklaerung vermehrte sich das Wissen ueber Hautkrebs , und Einstellung und Verhalten der Bevoelkerung in bezug auf die Sonne aenderten sich . Auch in den USA und in Grossbritannien wurden zahlreiche oeffentlichkeitswirksame Aktivitaeten durchgefuehrt und umfangreiche Erfahrungen gesammelt . In Deutschland wurden Aufklaerungsaktionen zunaechst auf regionaler Ebene durchgefuehrt . 1989 initiierte die Kommission zur Frueherkennung und Praevention des Melanoms der Deutschen Dermatologischen Gesellschaft bundesweite Kampagnen . Regionale Aktionen ergaenzten diese Aktivitaeten in den 90er Jahren . Die Analyse bisheriger Aktionen zeigt , dass einmalige Aktivitaeten wenig wirksam und dass Wiederholungen von oeffentlichkeitswirksamen Praeventionskampagnen notwendig sind , um das Wissen in der Bevoelkerung ueber Hautkrebs zu verbessern und Einstellungen und Verhalten gegenueber der UV-Exposition zu aendern . Ergaenzend hierzu sollten die Entwicklung von Textilien mit hohem Lichtschutzfaktor und strukturelle Veraenderungen , z.B. Schaffung von Schattenplaetzen in Schwimmbaedern , angestrebt werden . In Praeventionskampagnen sollten auch vermehrt Aerzte anderer Disziplinen sowie weitere Gesundheitsberufe mit einbezogen werden . Instructions: please typing these entity words according to sentence: malignen Melanom, Haut, Aerzten, Anstrengungen, malignen Melanoms, Australien, Melanominzidenz, Wissen, Hautkrebs, Verhalten, Bevoelkerung, Sonne, USA, Grossbritannien, Deutschland, Melanoms, Gesellschaft, Analyse, Wissen, Bevoelkerung, Hautkrebs, Verhalten, Textilien, Aerzte Options: umlsterm
[ "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Beim malignen Melanom der Haut wurden insbesondere im letzten Jahrzehnt von Dermatologen und Aerzten anderer Fachrichtungen sowie weiteren Angehoerigen von Gesundheitsberufen grosse Anstrengungen unternommen , die Aufklaerung ( primaere Praevention ) und Frueherkennung ( sekundaere Praevention ) zu verbessern . Die erste oeffentlichkeitswirksame Kampagne zur Praevention des malignen Melanoms wurde bereits in den 60er Jahren in Australien , dem Land mit der weltweit hoechsten Melanominzidenz , durchgefuehrt . Durch Aufklaerung vermehrte sich das Wissen ueber Hautkrebs , und Einstellung und Verhalten der Bevoelkerung in bezug auf die Sonne aenderten sich . Auch in den USA und in Grossbritannien wurden zahlreiche oeffentlichkeitswirksame Aktivitaeten durchgefuehrt und umfangreiche Erfahrungen gesammelt . In Deutschland wurden Aufklaerungsaktionen zunaechst auf regionaler Ebene durchgefuehrt . 1989 initiierte die Kommission zur Frueherkennung und Praevention des Melanoms der Deutschen Dermatologischen Gesellschaft bundesweite Kampagnen . Regionale Aktionen ergaenzten diese Aktivitaeten in den 90er Jahren . Die Analyse bisheriger Aktionen zeigt , dass einmalige Aktivitaeten wenig wirksam und dass Wiederholungen von oeffentlichkeitswirksamen Praeventionskampagnen notwendig sind , um das Wissen in der Bevoelkerung ueber Hautkrebs zu verbessern und Einstellungen und Verhalten gegenueber der UV-Exposition zu aendern . Ergaenzend hierzu sollten die Entwicklung von Textilien mit hohem Lichtschutzfaktor und strukturelle Veraenderungen , z.B. Schaffung von Schattenplaetzen in Schwimmbaedern , angestrebt werden . In Praeventionskampagnen sollten auch vermehrt Aerzte anderer Disziplinen sowie weitere Gesundheitsberufe mit einbezogen werden .
[ "Beim", "malignen", "Melanom", "der", "Haut", "wurden", "insbesondere", "im", "letzten", "Jahrzehnt", "von", "Dermatologen", "und", "Aerzten", "anderer", "Fachrichtungen", "sowie", "weiteren", "Angehoerigen", "von", "Gesundheitsberufen", "grosse", "Anstrengungen", "unternommen", ",", "die", "Aufklaerung", "(", "primaere", "Praevention", ")", "und", "Frueherkennung", "(", "sekundaere", "Praevention", ")", "zu", "verbessern", ".", "Die", "erste", "oeffentlichkeitswirksame", "Kampagne", "zur", "Praevention", "des", "malignen", "Melanoms", "wurde", "bereits", "in", "den", "60er", "Jahren", "in", "Australien", ",", "dem", "Land", "mit", "der", "weltweit", "hoechsten", "Melanominzidenz", ",", "durchgefuehrt", ".", "Durch", "Aufklaerung", "vermehrte", "sich", "das", "Wissen", "ueber", "Hautkrebs", ",", "und", "Einstellung", "und", "Verhalten", "der", "Bevoelkerung", "in", "bezug", "auf", "die", "Sonne", "aenderten", "sich", ".", "Auch", "in", "den", "USA", "und", "in", "Grossbritannien", "wurden", "zahlreiche", "oeffentlichkeitswirksame", "Aktivitaeten", "durchgefuehrt", "und", "umfangreiche", "Erfahrungen", "gesammelt", ".", "In", "Deutschland", "wurden", "Aufklaerungsaktionen", "zunaechst", "auf", "regionaler", "Ebene", "durchgefuehrt", ".", "1989", "initiierte", "die", "Kommission", "zur", "Frueherkennung", "und", "Praevention", "des", "Melanoms", "der", "Deutschen", "Dermatologischen", "Gesellschaft", "bundesweite", "Kampagnen", ".", "Regionale", "Aktionen", "ergaenzten", "diese", "Aktivitaeten", "in", "den", "90er", "Jahren", ".", "Die", "Analyse", "bisheriger", "Aktionen", "zeigt", ",", "dass", "einmalige", "Aktivitaeten", "wenig", "wirksam", "und", "dass", "Wiederholungen", "von", "oeffentlichkeitswirksamen", "Praeventionskampagnen", "notwendig", "sind", ",", "um", "das", "Wissen", "in", "der", "Bevoelkerung", "ueber", "Hautkrebs", "zu", "verbessern", "und", "Einstellungen", "und", "Verhalten", "gegenueber", "der", "UV", "-", "Exposition", "zu", "aendern", ".", "Ergaenzend", "hierzu", "sollten", "die", "Entwicklung", "von", "Textilien", "mit", "hohem", "Lichtschutzfaktor", "und", "strukturelle", "Veraenderungen", ",", "z.", "B.", "Schaffung", "von", "Schattenplaetzen", "in", "Schwimmbaedern", ",", "angestrebt", "werden", ".", "In", "Praeventionskampagnen", "sollten", "auch", "vermehrt", "Aerzte", "anderer", "Disziplinen", "sowie", "weitere", "Gesundheitsberufe", "mit", "einbezogen", "werden", "." ]
[ "umlsterm" ]
malignen Melanom, Haut, Aerzten, Anstrengungen, malignen Melanoms, Australien, Melanominzidenz, Wissen, Hautkrebs, Verhalten, Bevoelkerung, Sonne, USA, Grossbritannien, Deutschland, Melanoms, Gesellschaft, Analyse, Wissen, Bevoelkerung, Hautkrebs, Verhalten, Textilien, Aerzte
DerHautarzt.80490826.ger.abstr_task2
Sentence: Beim malignen Melanom der Haut wurden insbesondere im letzten Jahrzehnt von Dermatologen und Aerzten anderer Fachrichtungen sowie weiteren Angehoerigen von Gesundheitsberufen grosse Anstrengungen unternommen , die Aufklaerung ( primaere Praevention ) und Frueherkennung ( sekundaere Praevention ) zu verbessern . Die erste oeffentlichkeitswirksame Kampagne zur Praevention des malignen Melanoms wurde bereits in den 60er Jahren in Australien , dem Land mit der weltweit hoechsten Melanominzidenz , durchgefuehrt . Durch Aufklaerung vermehrte sich das Wissen ueber Hautkrebs , und Einstellung und Verhalten der Bevoelkerung in bezug auf die Sonne aenderten sich . Auch in den USA und in Grossbritannien wurden zahlreiche oeffentlichkeitswirksame Aktivitaeten durchgefuehrt und umfangreiche Erfahrungen gesammelt . In Deutschland wurden Aufklaerungsaktionen zunaechst auf regionaler Ebene durchgefuehrt . 1989 initiierte die Kommission zur Frueherkennung und Praevention des Melanoms der Deutschen Dermatologischen Gesellschaft bundesweite Kampagnen . Regionale Aktionen ergaenzten diese Aktivitaeten in den 90er Jahren . Die Analyse bisheriger Aktionen zeigt , dass einmalige Aktivitaeten wenig wirksam und dass Wiederholungen von oeffentlichkeitswirksamen Praeventionskampagnen notwendig sind , um das Wissen in der Bevoelkerung ueber Hautkrebs zu verbessern und Einstellungen und Verhalten gegenueber der UV-Exposition zu aendern . Ergaenzend hierzu sollten die Entwicklung von Textilien mit hohem Lichtschutzfaktor und strukturelle Veraenderungen , z.B. Schaffung von Schattenplaetzen in Schwimmbaedern , angestrebt werden . In Praeventionskampagnen sollten auch vermehrt Aerzte anderer Disziplinen sowie weitere Gesundheitsberufe mit einbezogen werden . Instructions: please extract entity words from the input sentence
[ "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]
Beim malignen Melanom der Haut wurden insbesondere im letzten Jahrzehnt von Dermatologen und Aerzten anderer Fachrichtungen sowie weiteren Angehoerigen von Gesundheitsberufen grosse Anstrengungen unternommen , die Aufklaerung ( primaere Praevention ) und Frueherkennung ( sekundaere Praevention ) zu verbessern . Die erste oeffentlichkeitswirksame Kampagne zur Praevention des malignen Melanoms wurde bereits in den 60er Jahren in Australien , dem Land mit der weltweit hoechsten Melanominzidenz , durchgefuehrt . Durch Aufklaerung vermehrte sich das Wissen ueber Hautkrebs , und Einstellung und Verhalten der Bevoelkerung in bezug auf die Sonne aenderten sich . Auch in den USA und in Grossbritannien wurden zahlreiche oeffentlichkeitswirksame Aktivitaeten durchgefuehrt und umfangreiche Erfahrungen gesammelt . In Deutschland wurden Aufklaerungsaktionen zunaechst auf regionaler Ebene durchgefuehrt . 1989 initiierte die Kommission zur Frueherkennung und Praevention des Melanoms der Deutschen Dermatologischen Gesellschaft bundesweite Kampagnen . Regionale Aktionen ergaenzten diese Aktivitaeten in den 90er Jahren . Die Analyse bisheriger Aktionen zeigt , dass einmalige Aktivitaeten wenig wirksam und dass Wiederholungen von oeffentlichkeitswirksamen Praeventionskampagnen notwendig sind , um das Wissen in der Bevoelkerung ueber Hautkrebs zu verbessern und Einstellungen und Verhalten gegenueber der UV-Exposition zu aendern . Ergaenzend hierzu sollten die Entwicklung von Textilien mit hohem Lichtschutzfaktor und strukturelle Veraenderungen , z.B. Schaffung von Schattenplaetzen in Schwimmbaedern , angestrebt werden . In Praeventionskampagnen sollten auch vermehrt Aerzte anderer Disziplinen sowie weitere Gesundheitsberufe mit einbezogen werden .
[ "Beim", "malignen", "Melanom", "der", "Haut", "wurden", "insbesondere", "im", "letzten", "Jahrzehnt", "von", "Dermatologen", "und", "Aerzten", "anderer", "Fachrichtungen", "sowie", "weiteren", "Angehoerigen", "von", "Gesundheitsberufen", "grosse", "Anstrengungen", "unternommen", ",", "die", "Aufklaerung", "(", "primaere", "Praevention", ")", "und", "Frueherkennung", "(", "sekundaere", "Praevention", ")", "zu", "verbessern", ".", "Die", "erste", "oeffentlichkeitswirksame", "Kampagne", "zur", "Praevention", "des", "malignen", "Melanoms", "wurde", "bereits", "in", "den", "60er", "Jahren", "in", "Australien", ",", "dem", "Land", "mit", "der", "weltweit", "hoechsten", "Melanominzidenz", ",", "durchgefuehrt", ".", "Durch", "Aufklaerung", "vermehrte", "sich", "das", "Wissen", "ueber", "Hautkrebs", ",", "und", "Einstellung", "und", "Verhalten", "der", "Bevoelkerung", "in", "bezug", "auf", "die", "Sonne", "aenderten", "sich", ".", "Auch", "in", "den", "USA", "und", "in", "Grossbritannien", "wurden", "zahlreiche", "oeffentlichkeitswirksame", "Aktivitaeten", "durchgefuehrt", "und", "umfangreiche", "Erfahrungen", "gesammelt", ".", "In", "Deutschland", "wurden", "Aufklaerungsaktionen", "zunaechst", "auf", "regionaler", "Ebene", "durchgefuehrt", ".", "1989", "initiierte", "die", "Kommission", "zur", "Frueherkennung", "und", "Praevention", "des", "Melanoms", "der", "Deutschen", "Dermatologischen", "Gesellschaft", "bundesweite", "Kampagnen", ".", "Regionale", "Aktionen", "ergaenzten", "diese", "Aktivitaeten", "in", "den", "90er", "Jahren", ".", "Die", "Analyse", "bisheriger", "Aktionen", "zeigt", ",", "dass", "einmalige", "Aktivitaeten", "wenig", "wirksam", "und", "dass", "Wiederholungen", "von", "oeffentlichkeitswirksamen", "Praeventionskampagnen", "notwendig", "sind", ",", "um", "das", "Wissen", "in", "der", "Bevoelkerung", "ueber", "Hautkrebs", "zu", "verbessern", "und", "Einstellungen", "und", "Verhalten", "gegenueber", "der", "UV", "-", "Exposition", "zu", "aendern", ".", "Ergaenzend", "hierzu", "sollten", "die", "Entwicklung", "von", "Textilien", "mit", "hohem", "Lichtschutzfaktor", "und", "strukturelle", "Veraenderungen", ",", "z.", "B.", "Schaffung", "von", "Schattenplaetzen", "in", "Schwimmbaedern", ",", "angestrebt", "werden", ".", "In", "Praeventionskampagnen", "sollten", "auch", "vermehrt", "Aerzte", "anderer", "Disziplinen", "sowie", "weitere", "Gesundheitsberufe", "mit", "einbezogen", "werden", "." ]
[ "umlsterm" ]
endothelial cell is a Cell, vascular permeability factor is a Gene_or_gene_product, vascular endothelial growth factor is a Gene_or_gene_product, alphavbeta3 integrin is a Gene_or_gene_product, osteopontin is a Gene_or_gene_product, thrombin is a Gene_or_gene_product, vascular permeability factor is a Gene_or_gene_product, vascular endothelial growth factor is a Gene_or_gene_product, VPF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, endothelial cells is a Cell, EC is a Cell, VPF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, microvascular EC is a Cell, alphav is a Gene_or_gene_product, beta3 integrin subunits is a Gene_or_gene_product, alphavbeta3 is a Gene_or_gene_product, cell surface is a Cellular_component, VPF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, osteopontin is a Gene_or_gene_product, OPN is a Gene_or_gene_product, alphavbeta3 is a Gene_or_gene_product, OPN is a Gene_or_gene_product, EC is a Cell, VPF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, alphavbeta3 is a Gene_or_gene_product, EC is a Cell, OPN is a Gene_or_gene_product, thrombin is a Gene_or_gene_product, OPN is a Gene_or_gene_product, OPN is a Gene_or_gene_product, VPF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, microvascular is a Tissue, VPF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, thrombin is a Gene_or_gene_product, OPN is a Gene_or_gene_product, VPF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, OPN is a Gene_or_gene_product, OPN is a Gene_or_gene_product, thrombin is a Gene_or_gene_product, OPN is a Gene_or_gene_product, thrombin is a Gene_or_gene_product, OPN is a Gene_or_gene_product, EC is a Cell, alpha v beta 3 is a Gene_or_gene_product, VPF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, EC is a Cell, alphavbeta3 integrin is a Gene_or_gene_product, alphavbeta3 is a Gene_or_gene_product, OPN is a Gene_or_gene_product, thrombin is a Gene_or_gene_product, OPN is a Gene_or_gene_product, VPF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, EC is a Cell, VPF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, microvascular is a Tissue, EC is a Cell
106_task0
Sentence: Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. We have identified several mechanisms by which the angiogenic cytokine vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) likely regulates endothelial cells (EC) migration. VPF/VEGF induced dermal microvascular EC expression of mRNAs encoding the alphav and beta3 integrin subunits resulting in increased levels of the alphavbeta3 heterodimer at the cell surface, and VPF/VEGF also induced mRNA encoding osteopontin (OPN), an alphavbeta3 ligand. OPN promoted EC migration in vitro; and VPF/VEGF induction of alphavbeta3 was accompanied by increased EC migration toward OPN. Because thrombin cleavage of OPN results in substantial enhancement of OPN's adhesive properties, and because VPF/VEGF promotes increased microvascular permeability leading to activation of the extrinsic coagulation pathway, we also investigated whether VPF/VEGF facilitates thrombin cleavage of OPN in vivo. Consistent with this hypothesis, co-injection of VPF/VEGF together with OPN resulted in rapid cleavage of OPN by endogenous thrombin. Furthermore, in comparison with native OPN, thrombin-cleaved OPN stimulated a greater rate of EC migration in vitro, which was additive to the increased migration associated with induction of alpha v beta 3. Thus, these data demonstrate cooperative mechanisms for VPF/VEGF regulation of EC migration involving the alphavbeta3 integrin, the alphavbeta3 ligand OPN, and thrombin cleavage of OPN. These findings also illustrate an operational link between VPF/VEGF induction of EC gene expression and VPF/VEGF enhancement of microvascular permeability, suggesting that these distinct biological activities may act accordingly to stimulate EC migration during angiogenesis. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Cellular_component, Tissue, Gene_or_gene_product, Cell
[ "O", "O", "B-Cell", "I-Cell", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Cell", "I-Cell", "O", "B-Cell", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "B-Cell", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Cell", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Cell", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Cell", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O" ]
Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. We have identified several mechanisms by which the angiogenic cytokine vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) likely regulates endothelial cells (EC) migration. VPF/VEGF induced dermal microvascular EC expression of mRNAs encoding the alphav and beta3 integrin subunits resulting in increased levels of the alphavbeta3 heterodimer at the cell surface, and VPF/VEGF also induced mRNA encoding osteopontin (OPN), an alphavbeta3 ligand. OPN promoted EC migration in vitro; and VPF/VEGF induction of alphavbeta3 was accompanied by increased EC migration toward OPN. Because thrombin cleavage of OPN results in substantial enhancement of OPN's adhesive properties, and because VPF/VEGF promotes increased microvascular permeability leading to activation of the extrinsic coagulation pathway, we also investigated whether VPF/VEGF facilitates thrombin cleavage of OPN in vivo. Consistent with this hypothesis, co-injection of VPF/VEGF together with OPN resulted in rapid cleavage of OPN by endogenous thrombin. Furthermore, in comparison with native OPN, thrombin-cleaved OPN stimulated a greater rate of EC migration in vitro, which was additive to the increased migration associated with induction of alpha v beta 3. Thus, these data demonstrate cooperative mechanisms for VPF/VEGF regulation of EC migration involving the alphavbeta3 integrin, the alphavbeta3 ligand OPN, and thrombin cleavage of OPN. These findings also illustrate an operational link between VPF/VEGF induction of EC gene expression and VPF/VEGF enhancement of microvascular permeability, suggesting that these distinct biological activities may act accordingly to stimulate EC migration during angiogenesis.
[ "Stimulation", "of", "endothelial", "cell", "migration", "by", "vascular", "permeability", "factor", "/", "vascular", "endothelial", "growth", "factor", "through", "cooperative", "mechanisms", "involving", "the", "alphavbeta3", "integrin", ",", "osteopontin", ",", "and", "thrombin", ".", "\n\n", "We", "have", "identified", "several", "mechanisms", "by", "which", "the", "angiogenic", "cytokine", "vascular", "permeability", "factor", "/", "vascular", "endothelial", "growth", "factor", "(", "VPF", "/", "VEGF", ")", "likely", "regulates", "endothelial", "cells", "(", "EC", ")", "migration", ".", "VPF", "/", "VEGF", "induced", "dermal", "microvascular", "EC", "expression", "of", "mRNAs", "encoding", "the", "alphav", "and", "beta3", "integrin", "subunits", "resulting", "in", "increased", "levels", "of", "the", "alphavbeta3", "heterodimer", "at", "the", "cell", "surface", ",", "and", "VPF", "/", "VEGF", "also", "induced", "mRNA", "encoding", "osteopontin", "(", "OPN", ")", ",", "an", "alphavbeta3", "ligand", ".", "OPN", "promoted", "EC", "migration", "in", "vitro", ";", "and", "VPF", "/", "VEGF", "induction", "of", "alphavbeta3", "was", "accompanied", "by", "increased", "EC", "migration", "toward", "OPN", ".", "Because", "thrombin", "cleavage", "of", "OPN", "results", "in", "substantial", "enhancement", "of", "OPN", "'s", "adhesive", "properties", ",", "and", "because", "VPF", "/", "VEGF", "promotes", "increased", "microvascular", "permeability", "leading", "to", "activation", "of", "the", "extrinsic", "coagulation", "pathway", ",", "we", "also", "investigated", "whether", "VPF", "/", "VEGF", "facilitates", "thrombin", "cleavage", "of", "OPN", "in", "vivo", ".", "Consistent", "with", "this", "hypothesis", ",", "co", "-", "injection", "of", "VPF", "/", "VEGF", "together", "with", "OPN", "resulted", "in", "rapid", "cleavage", "of", "OPN", "by", "endogenous", "thrombin", ".", "Furthermore", ",", "in", "comparison", "with", "native", "OPN", ",", "thrombin", "-", "cleaved", "OPN", "stimulated", "a", "greater", "rate", "of", "EC", "migration", "in", "vitro", ",", "which", "was", "additive", "to", "the", "increased", "migration", "associated", "with", "induction", "of", "alpha", "v", "beta", "3", ".", "Thus", ",", "these", "data", "demonstrate", "cooperative", "mechanisms", "for", "VPF", "/", "VEGF", "regulation", "of", "EC", "migration", "involving", "the", "alphavbeta3", "integrin", ",", "the", "alphavbeta3", "ligand", "OPN", ",", "and", "thrombin", "cleavage", "of", "OPN", ".", "These", "findings", "also", "illustrate", "an", "operational", "link", "between", "VPF", "/", "VEGF", "induction", "of", "EC", "gene", "expression", "and", "VPF", "/", "VEGF", "enhancement", "of", "microvascular", "permeability", ",", "suggesting", "that", "these", "distinct", "biological", "activities", "may", "act", "accordingly", "to", "stimulate", "EC", "migration", "during", "angiogenesis", ".", "\n" ]
[ "Gene_or_gene_product", "Cell", "Tissue", "Cellular_component" ]
endothelial cell is a Cell, vascular permeability factor is a Gene_or_gene_product, vascular endothelial growth factor is a Gene_or_gene_product, alphavbeta3 integrin is a Gene_or_gene_product, osteopontin is a Gene_or_gene_product, thrombin is a Gene_or_gene_product, vascular permeability factor is a Gene_or_gene_product, vascular endothelial growth factor is a Gene_or_gene_product, VPF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, endothelial cells is a Cell, EC is a Cell, VPF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, microvascular EC is a Cell, alphav is a Gene_or_gene_product, beta3 integrin subunits is a Gene_or_gene_product, alphavbeta3 is a Gene_or_gene_product, cell surface is a Cellular_component, VPF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, osteopontin is a Gene_or_gene_product, OPN is a Gene_or_gene_product, alphavbeta3 is a Gene_or_gene_product, OPN is a Gene_or_gene_product, EC is a Cell, VPF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, alphavbeta3 is a Gene_or_gene_product, EC is a Cell, OPN is a Gene_or_gene_product, thrombin is a Gene_or_gene_product, OPN is a Gene_or_gene_product, OPN is a Gene_or_gene_product, VPF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, microvascular is a Tissue, VPF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, thrombin is a Gene_or_gene_product, OPN is a Gene_or_gene_product, VPF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, OPN is a Gene_or_gene_product, OPN is a Gene_or_gene_product, thrombin is a Gene_or_gene_product, OPN is a Gene_or_gene_product, thrombin is a Gene_or_gene_product, OPN is a Gene_or_gene_product, EC is a Cell, alpha v beta 3 is a Gene_or_gene_product, VPF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, EC is a Cell, alphavbeta3 integrin is a Gene_or_gene_product, alphavbeta3 is a Gene_or_gene_product, OPN is a Gene_or_gene_product, thrombin is a Gene_or_gene_product, OPN is a Gene_or_gene_product, VPF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, EC is a Cell, VPF is a Gene_or_gene_product, VEGF is a Gene_or_gene_product, microvascular is a Tissue, EC is a Cell
106_task1
Sentence: Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. We have identified several mechanisms by which the angiogenic cytokine vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) likely regulates endothelial cells (EC) migration. VPF/VEGF induced dermal microvascular EC expression of mRNAs encoding the alphav and beta3 integrin subunits resulting in increased levels of the alphavbeta3 heterodimer at the cell surface, and VPF/VEGF also induced mRNA encoding osteopontin (OPN), an alphavbeta3 ligand. OPN promoted EC migration in vitro; and VPF/VEGF induction of alphavbeta3 was accompanied by increased EC migration toward OPN. Because thrombin cleavage of OPN results in substantial enhancement of OPN's adhesive properties, and because VPF/VEGF promotes increased microvascular permeability leading to activation of the extrinsic coagulation pathway, we also investigated whether VPF/VEGF facilitates thrombin cleavage of OPN in vivo. Consistent with this hypothesis, co-injection of VPF/VEGF together with OPN resulted in rapid cleavage of OPN by endogenous thrombin. Furthermore, in comparison with native OPN, thrombin-cleaved OPN stimulated a greater rate of EC migration in vitro, which was additive to the increased migration associated with induction of alpha v beta 3. Thus, these data demonstrate cooperative mechanisms for VPF/VEGF regulation of EC migration involving the alphavbeta3 integrin, the alphavbeta3 ligand OPN, and thrombin cleavage of OPN. These findings also illustrate an operational link between VPF/VEGF induction of EC gene expression and VPF/VEGF enhancement of microvascular permeability, suggesting that these distinct biological activities may act accordingly to stimulate EC migration during angiogenesis. Instructions: please typing these entity words according to sentence: endothelial cell, vascular permeability factor, vascular endothelial growth factor, alphavbeta3 integrin, osteopontin, thrombin, vascular permeability factor, vascular endothelial growth factor, VPF, VEGF, endothelial cells, EC, VPF, VEGF, microvascular EC, alphav, beta3 integrin subunits, alphavbeta3, cell surface, VPF, VEGF, osteopontin, OPN, alphavbeta3, OPN, EC, VPF, VEGF, alphavbeta3, EC, OPN, thrombin, OPN, OPN, VPF, VEGF, microvascular, VPF, VEGF, thrombin, OPN, VPF, VEGF, OPN, OPN, thrombin, OPN, thrombin, OPN, EC, alpha v beta 3, VPF, VEGF, EC, alphavbeta3 integrin, alphavbeta3, OPN, thrombin, OPN, VPF, VEGF, EC, VPF, VEGF, microvascular, EC Options: Cellular_component, Tissue, Gene_or_gene_product, Cell
[ "O", "O", "B-Cell", "I-Cell", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Cell", "I-Cell", "O", "B-Cell", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "B-Cell", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Cell", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Cell", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Cell", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O" ]
Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. We have identified several mechanisms by which the angiogenic cytokine vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) likely regulates endothelial cells (EC) migration. VPF/VEGF induced dermal microvascular EC expression of mRNAs encoding the alphav and beta3 integrin subunits resulting in increased levels of the alphavbeta3 heterodimer at the cell surface, and VPF/VEGF also induced mRNA encoding osteopontin (OPN), an alphavbeta3 ligand. OPN promoted EC migration in vitro; and VPF/VEGF induction of alphavbeta3 was accompanied by increased EC migration toward OPN. Because thrombin cleavage of OPN results in substantial enhancement of OPN's adhesive properties, and because VPF/VEGF promotes increased microvascular permeability leading to activation of the extrinsic coagulation pathway, we also investigated whether VPF/VEGF facilitates thrombin cleavage of OPN in vivo. Consistent with this hypothesis, co-injection of VPF/VEGF together with OPN resulted in rapid cleavage of OPN by endogenous thrombin. Furthermore, in comparison with native OPN, thrombin-cleaved OPN stimulated a greater rate of EC migration in vitro, which was additive to the increased migration associated with induction of alpha v beta 3. Thus, these data demonstrate cooperative mechanisms for VPF/VEGF regulation of EC migration involving the alphavbeta3 integrin, the alphavbeta3 ligand OPN, and thrombin cleavage of OPN. These findings also illustrate an operational link between VPF/VEGF induction of EC gene expression and VPF/VEGF enhancement of microvascular permeability, suggesting that these distinct biological activities may act accordingly to stimulate EC migration during angiogenesis.
[ "Stimulation", "of", "endothelial", "cell", "migration", "by", "vascular", "permeability", "factor", "/", "vascular", "endothelial", "growth", "factor", "through", "cooperative", "mechanisms", "involving", "the", "alphavbeta3", "integrin", ",", "osteopontin", ",", "and", "thrombin", ".", "\n\n", "We", "have", "identified", "several", "mechanisms", "by", "which", "the", "angiogenic", "cytokine", "vascular", "permeability", "factor", "/", "vascular", "endothelial", "growth", "factor", "(", "VPF", "/", "VEGF", ")", "likely", "regulates", "endothelial", "cells", "(", "EC", ")", "migration", ".", "VPF", "/", "VEGF", "induced", "dermal", "microvascular", "EC", "expression", "of", "mRNAs", "encoding", "the", "alphav", "and", "beta3", "integrin", "subunits", "resulting", "in", "increased", "levels", "of", "the", "alphavbeta3", "heterodimer", "at", "the", "cell", "surface", ",", "and", "VPF", "/", "VEGF", "also", "induced", "mRNA", "encoding", "osteopontin", "(", "OPN", ")", ",", "an", "alphavbeta3", "ligand", ".", "OPN", "promoted", "EC", "migration", "in", "vitro", ";", "and", "VPF", "/", "VEGF", "induction", "of", "alphavbeta3", "was", "accompanied", "by", "increased", "EC", "migration", "toward", "OPN", ".", "Because", "thrombin", "cleavage", "of", "OPN", "results", "in", "substantial", "enhancement", "of", "OPN", "'s", "adhesive", "properties", ",", "and", "because", "VPF", "/", "VEGF", "promotes", "increased", "microvascular", "permeability", "leading", "to", "activation", "of", "the", "extrinsic", "coagulation", "pathway", ",", "we", "also", "investigated", "whether", "VPF", "/", "VEGF", "facilitates", "thrombin", "cleavage", "of", "OPN", "in", "vivo", ".", "Consistent", "with", "this", "hypothesis", ",", "co", "-", "injection", "of", "VPF", "/", "VEGF", "together", "with", "OPN", "resulted", "in", "rapid", "cleavage", "of", "OPN", "by", "endogenous", "thrombin", ".", "Furthermore", ",", "in", "comparison", "with", "native", "OPN", ",", "thrombin", "-", "cleaved", "OPN", "stimulated", "a", "greater", "rate", "of", "EC", "migration", "in", "vitro", ",", "which", "was", "additive", "to", "the", "increased", "migration", "associated", "with", "induction", "of", "alpha", "v", "beta", "3", ".", "Thus", ",", "these", "data", "demonstrate", "cooperative", "mechanisms", "for", "VPF", "/", "VEGF", "regulation", "of", "EC", "migration", "involving", "the", "alphavbeta3", "integrin", ",", "the", "alphavbeta3", "ligand", "OPN", ",", "and", "thrombin", "cleavage", "of", "OPN", ".", "These", "findings", "also", "illustrate", "an", "operational", "link", "between", "VPF", "/", "VEGF", "induction", "of", "EC", "gene", "expression", "and", "VPF", "/", "VEGF", "enhancement", "of", "microvascular", "permeability", ",", "suggesting", "that", "these", "distinct", "biological", "activities", "may", "act", "accordingly", "to", "stimulate", "EC", "migration", "during", "angiogenesis", ".", "\n" ]
[ "Gene_or_gene_product", "Cell", "Tissue", "Cellular_component" ]
endothelial cell, vascular permeability factor, vascular endothelial growth factor, alphavbeta3 integrin, osteopontin, thrombin, vascular permeability factor, vascular endothelial growth factor, VPF, VEGF, endothelial cells, EC, VPF, VEGF, microvascular EC, alphav, beta3 integrin subunits, alphavbeta3, cell surface, VPF, VEGF, osteopontin, OPN, alphavbeta3, OPN, EC, VPF, VEGF, alphavbeta3, EC, OPN, thrombin, OPN, OPN, VPF, VEGF, microvascular, VPF, VEGF, thrombin, OPN, VPF, VEGF, OPN, OPN, thrombin, OPN, thrombin, OPN, EC, alpha v beta 3, VPF, VEGF, EC, alphavbeta3 integrin, alphavbeta3, OPN, thrombin, OPN, VPF, VEGF, EC, VPF, VEGF, microvascular, EC
106_task2
Sentence: Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. We have identified several mechanisms by which the angiogenic cytokine vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) likely regulates endothelial cells (EC) migration. VPF/VEGF induced dermal microvascular EC expression of mRNAs encoding the alphav and beta3 integrin subunits resulting in increased levels of the alphavbeta3 heterodimer at the cell surface, and VPF/VEGF also induced mRNA encoding osteopontin (OPN), an alphavbeta3 ligand. OPN promoted EC migration in vitro; and VPF/VEGF induction of alphavbeta3 was accompanied by increased EC migration toward OPN. Because thrombin cleavage of OPN results in substantial enhancement of OPN's adhesive properties, and because VPF/VEGF promotes increased microvascular permeability leading to activation of the extrinsic coagulation pathway, we also investigated whether VPF/VEGF facilitates thrombin cleavage of OPN in vivo. Consistent with this hypothesis, co-injection of VPF/VEGF together with OPN resulted in rapid cleavage of OPN by endogenous thrombin. Furthermore, in comparison with native OPN, thrombin-cleaved OPN stimulated a greater rate of EC migration in vitro, which was additive to the increased migration associated with induction of alpha v beta 3. Thus, these data demonstrate cooperative mechanisms for VPF/VEGF regulation of EC migration involving the alphavbeta3 integrin, the alphavbeta3 ligand OPN, and thrombin cleavage of OPN. These findings also illustrate an operational link between VPF/VEGF induction of EC gene expression and VPF/VEGF enhancement of microvascular permeability, suggesting that these distinct biological activities may act accordingly to stimulate EC migration during angiogenesis. Instructions: please extract entity words from the input sentence
[ "O", "O", "B-Cell", "I-Cell", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Cell", "I-Cell", "O", "B-Cell", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Cell", "I-Cell", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Cellular_component", "I-Cellular_component", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "B-Cell", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "B-Cell", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Cell", "O", "O", "O", "B-Gene_or_gene_product", "I-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "B-Gene_or_gene_product", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Cell", "O", "O", "O", "B-Gene_or_gene_product", "O", "B-Gene_or_gene_product", "O", "O", "B-Tissue", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Cell", "O", "O", "O", "O", "O" ]
Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the alphavbeta3 integrin, osteopontin, and thrombin. We have identified several mechanisms by which the angiogenic cytokine vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) likely regulates endothelial cells (EC) migration. VPF/VEGF induced dermal microvascular EC expression of mRNAs encoding the alphav and beta3 integrin subunits resulting in increased levels of the alphavbeta3 heterodimer at the cell surface, and VPF/VEGF also induced mRNA encoding osteopontin (OPN), an alphavbeta3 ligand. OPN promoted EC migration in vitro; and VPF/VEGF induction of alphavbeta3 was accompanied by increased EC migration toward OPN. Because thrombin cleavage of OPN results in substantial enhancement of OPN's adhesive properties, and because VPF/VEGF promotes increased microvascular permeability leading to activation of the extrinsic coagulation pathway, we also investigated whether VPF/VEGF facilitates thrombin cleavage of OPN in vivo. Consistent with this hypothesis, co-injection of VPF/VEGF together with OPN resulted in rapid cleavage of OPN by endogenous thrombin. Furthermore, in comparison with native OPN, thrombin-cleaved OPN stimulated a greater rate of EC migration in vitro, which was additive to the increased migration associated with induction of alpha v beta 3. Thus, these data demonstrate cooperative mechanisms for VPF/VEGF regulation of EC migration involving the alphavbeta3 integrin, the alphavbeta3 ligand OPN, and thrombin cleavage of OPN. These findings also illustrate an operational link between VPF/VEGF induction of EC gene expression and VPF/VEGF enhancement of microvascular permeability, suggesting that these distinct biological activities may act accordingly to stimulate EC migration during angiogenesis.
[ "Stimulation", "of", "endothelial", "cell", "migration", "by", "vascular", "permeability", "factor", "/", "vascular", "endothelial", "growth", "factor", "through", "cooperative", "mechanisms", "involving", "the", "alphavbeta3", "integrin", ",", "osteopontin", ",", "and", "thrombin", ".", "\n\n", "We", "have", "identified", "several", "mechanisms", "by", "which", "the", "angiogenic", "cytokine", "vascular", "permeability", "factor", "/", "vascular", "endothelial", "growth", "factor", "(", "VPF", "/", "VEGF", ")", "likely", "regulates", "endothelial", "cells", "(", "EC", ")", "migration", ".", "VPF", "/", "VEGF", "induced", "dermal", "microvascular", "EC", "expression", "of", "mRNAs", "encoding", "the", "alphav", "and", "beta3", "integrin", "subunits", "resulting", "in", "increased", "levels", "of", "the", "alphavbeta3", "heterodimer", "at", "the", "cell", "surface", ",", "and", "VPF", "/", "VEGF", "also", "induced", "mRNA", "encoding", "osteopontin", "(", "OPN", ")", ",", "an", "alphavbeta3", "ligand", ".", "OPN", "promoted", "EC", "migration", "in", "vitro", ";", "and", "VPF", "/", "VEGF", "induction", "of", "alphavbeta3", "was", "accompanied", "by", "increased", "EC", "migration", "toward", "OPN", ".", "Because", "thrombin", "cleavage", "of", "OPN", "results", "in", "substantial", "enhancement", "of", "OPN", "'s", "adhesive", "properties", ",", "and", "because", "VPF", "/", "VEGF", "promotes", "increased", "microvascular", "permeability", "leading", "to", "activation", "of", "the", "extrinsic", "coagulation", "pathway", ",", "we", "also", "investigated", "whether", "VPF", "/", "VEGF", "facilitates", "thrombin", "cleavage", "of", "OPN", "in", "vivo", ".", "Consistent", "with", "this", "hypothesis", ",", "co", "-", "injection", "of", "VPF", "/", "VEGF", "together", "with", "OPN", "resulted", "in", "rapid", "cleavage", "of", "OPN", "by", "endogenous", "thrombin", ".", "Furthermore", ",", "in", "comparison", "with", "native", "OPN", ",", "thrombin", "-", "cleaved", "OPN", "stimulated", "a", "greater", "rate", "of", "EC", "migration", "in", "vitro", ",", "which", "was", "additive", "to", "the", "increased", "migration", "associated", "with", "induction", "of", "alpha", "v", "beta", "3", ".", "Thus", ",", "these", "data", "demonstrate", "cooperative", "mechanisms", "for", "VPF", "/", "VEGF", "regulation", "of", "EC", "migration", "involving", "the", "alphavbeta3", "integrin", ",", "the", "alphavbeta3", "ligand", "OPN", ",", "and", "thrombin", "cleavage", "of", "OPN", ".", "These", "findings", "also", "illustrate", "an", "operational", "link", "between", "VPF", "/", "VEGF", "induction", "of", "EC", "gene", "expression", "and", "VPF", "/", "VEGF", "enhancement", "of", "microvascular", "permeability", ",", "suggesting", "that", "these", "distinct", "biological", "activities", "may", "act", "accordingly", "to", "stimulate", "EC", "migration", "during", "angiogenesis", ".", "\n" ]
[ "Gene_or_gene_product", "Cell", "Tissue", "Cellular_component" ]
cDNA is a DNA, fibroblast growth factor is a Protein, human is a Eukaryote, heart is a Tissue, human is a Eukaryote, fibroblast growth factor is a Protein, hFGF is a Protein, fibroblast growth factor-9 is a Protein, human is a Eukaryote, heart is a Tissue, cDNA is a DNA, protein is a Protein, amino acid is a AminoAcid, human is a Eukaryote, heart is a Tissue, cDNA is a DNA, coding region is a ProteinCodingRegion, gene is a Gene, human is a Eukaryote, tissues is a Tissue, gene is a Gene, human is a Eukaryote, heart is a Tissue, human is a Eukaryote, brain is a Tissue, human is a Eukaryote, tissues is a Tissue
37_task0
Sentence: Cloning and characterization of a cDNA encoding a novel fibroblast growth factor preferentially expressed in human heart. A novel human fibroblast growth factor (hFGF), which shows 75% sequence homology with fibroblast growth factor-9, was isolated in random sequencing of a human heart cDNA library. The full-length sequence is 928 bp, the encoded protein is composed of 168 amino acid residues, and its pI value and molecular weight were estimated to be 8.13 and 19.1 kDa, respectively. RT-PCR using Marathon human heart cDNA shows that the coding region is approximately 507 bp. Southern hybridization showed a single band which indicates that this is a single copy gene. Northern hybridization done on a human multiple tissues blot showed that the gene is preferentially expressed in human heart, very weakly detectable in human brain and not detectable in 18 other different human tissues. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: ProteinCodingRegion, AminoAcid, DNA, Tissue, Gene, Eukaryote, Protein
[ "O", "O", "O", "O", "O", "B-DNA", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "B-Eukaryote", "B-Tissue", "O", "O", "O", "B-Eukaryote", "B-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Eukaryote", "B-Tissue", "B-DNA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "B-AminoAcid", "I-AminoAcid", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Eukaryote", "B-Tissue", "B-DNA", "O", "O", "O", "B-ProteinCodingRegion", "I-ProteinCodingRegion", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "O", "O", "B-Eukaryote", "O", "B-Tissue", "O", "O", "O", "O", "B-Gene", "O", "O", "O", "O", "B-Eukaryote", "B-Tissue", "O", "O", "O", "O", "O", "B-Eukaryote", "B-Tissue", "O", "O", "O", "O", "O", "O", "O", "B-Eukaryote", "B-Tissue", "O", "O" ]
Cloning and characterization of a cDNA encoding a novel fibroblast growth factor preferentially expressed in human heart. A novel human fibroblast growth factor (hFGF), which shows 75% sequence homology with fibroblast growth factor-9, was isolated in random sequencing of a human heart cDNA library. The full-length sequence is 928 bp, the encoded protein is composed of 168 amino acid residues, and its pI value and molecular weight were estimated to be 8.13 and 19.1 kDa, respectively. RT-PCR using Marathon human heart cDNA shows that the coding region is approximately 507 bp. Southern hybridization showed a single band which indicates that this is a single copy gene. Northern hybridization done on a human multiple tissues blot showed that the gene is preferentially expressed in human heart, very weakly detectable in human brain and not detectable in 18 other different human tissues.
[ "Cloning", "and", "characterization", "of", "a", "cDNA", "encoding", "a", "novel", "fibroblast", "growth", "factor", "preferentially", "expressed", "in", "human", "heart", ".", "A", "novel", "human", "fibroblast", "growth", "factor", "(", "hFGF", ")", ",", "which", "shows", "75", "%", "sequence", "homology", "with", "fibroblast", "growth", "factor-9", ",", "was", "isolated", "in", "random", "sequencing", "of", "a", "human", "heart", "cDNA", "library", ".", "The", "full", "-", "length", "sequence", "is", "928", "bp", ",", "the", "encoded", "protein", "is", "composed", "of", "168", "amino", "acid", "residues", ",", "and", "its", "pI", "value", "and", "molecular", "weight", "were", "estimated", "to", "be", "8.13", "and", "19.1", "kDa", ",", "respectively", ".", "RT", "-", "PCR", "using", "Marathon", "human", "heart", "cDNA", "shows", "that", "the", "coding", "region", "is", "approximately", "507", "bp", ".", "Southern", "hybridization", "showed", "a", "single", "band", "which", "indicates", "that", "this", "is", "a", "single", "copy", "gene", ".", "Northern", "hybridization", "done", "on", "a", "human", "multiple", "tissues", "blot", "showed", "that", "the", "gene", "is", "preferentially", "expressed", "in", "human", "heart", ",", "very", "weakly", "detectable", "in", "human", "brain", "and", "not", "detectable", "in", "18", "other", "different", "human", "tissues", ".", "\n" ]
[ "Protein", "ProteinCodingRegion", "AminoAcid", "Tissue", "Eukaryote", "DNA", "Gene" ]